0001681622-24-000009.txt : 20240206 0001681622-24-000009.hdr.sgml : 20240206 20240206160921 ACCESSION NUMBER: 0001681622-24-000009 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 101 CONFORMED PERIOD OF REPORT: 20231229 FILED AS OF DATE: 20240206 DATE AS OF CHANGE: 20240206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Varex Imaging Corp CENTRAL INDEX KEY: 0001681622 STANDARD INDUSTRIAL CLASSIFICATION: ELECTRONIC COMPONENTS, NEC [3679] ORGANIZATION NAME: 04 Manufacturing IRS NUMBER: 813434516 STATE OF INCORPORATION: DE FISCAL YEAR END: 0927 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37860 FILM NUMBER: 24600323 BUSINESS ADDRESS: STREET 1: 1678 S. PIONEER ROAD CITY: SALT LAKE CITY STATE: UT ZIP: 84104 BUSINESS PHONE: 801-972-5000 MAIL ADDRESS: STREET 1: 1678 S. PIONEER ROAD CITY: SALT LAKE CITY STATE: UT ZIP: 84104 10-Q 1 var-20231229.htm 10-Q var-20231229
FALSE2024Q1000168162209-27http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Memberhttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#Assetshttp://fasb.org/us-gaap/2023#Liabilitieshttp://fasb.org/us-gaap/2023#Assetshttp://fasb.org/us-gaap/2023#Liabilities0.048084http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense33600016816222023-09-302023-12-2900016816222024-01-30xbrli:sharesiso4217:USD00016816222022-10-012022-12-30iso4217:USDxbrli:shares00016816222023-12-2900016816222023-09-290001681622us-gaap:CommonStockMember2023-09-290001681622us-gaap:AdditionalPaidInCapitalMember2023-09-290001681622us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-290001681622us-gaap:RetainedEarningsMember2023-09-290001681622us-gaap:ParentMember2023-09-290001681622us-gaap:NoncontrollingInterestMember2023-09-290001681622us-gaap:RetainedEarningsMember2023-09-302023-12-290001681622us-gaap:ParentMember2023-09-302023-12-290001681622us-gaap:NoncontrollingInterestMember2023-09-302023-12-290001681622us-gaap:CommonStockMember2023-09-302023-12-290001681622us-gaap:AdditionalPaidInCapitalMember2023-09-302023-12-290001681622us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-302023-12-290001681622us-gaap:CommonStockMember2023-12-290001681622us-gaap:AdditionalPaidInCapitalMember2023-12-290001681622us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-290001681622us-gaap:RetainedEarningsMember2023-12-290001681622us-gaap:ParentMember2023-12-290001681622us-gaap:NoncontrollingInterestMember2023-12-290001681622us-gaap:CommonStockMember2022-09-300001681622us-gaap:AdditionalPaidInCapitalMember2022-09-300001681622us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001681622us-gaap:RetainedEarningsMember2022-09-300001681622us-gaap:ParentMember2022-09-300001681622us-gaap:NoncontrollingInterestMember2022-09-3000016816222022-09-300001681622srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2021-10-022022-09-300001681622srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:AdditionalPaidInCapitalMember2022-09-300001681622srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:RetainedEarningsMember2022-09-300001681622srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:ParentMember2022-09-300001681622srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-09-300001681622us-gaap:RetainedEarningsMember2022-10-012022-12-300001681622us-gaap:ParentMember2022-10-012022-12-300001681622us-gaap:NoncontrollingInterestMember2022-10-012022-12-300001681622us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-300001681622us-gaap:CommonStockMember2022-12-300001681622us-gaap:AdditionalPaidInCapitalMember2022-12-300001681622us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-300001681622us-gaap:RetainedEarningsMember2022-12-300001681622us-gaap:ParentMember2022-12-300001681622us-gaap:NoncontrollingInterestMember2022-12-3000016816222022-12-30var:segment0001681622us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembervar:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember2023-09-302023-12-29xbrli:pure0001681622us-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMembervar:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember2022-10-012022-12-300001681622us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMembervar:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember2023-09-302023-12-290001681622us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMembervar:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember2022-10-012023-09-290001681622var:MeVisBreastcareMember2023-09-302023-12-290001681622srt:MinimumMember2023-09-302023-12-290001681622srt:MaximumMember2023-09-302023-12-290001681622srt:AmericasMember2023-09-302023-12-290001681622srt:AmericasMember2022-10-012022-12-300001681622us-gaap:EMEAMember2023-09-302023-12-290001681622us-gaap:EMEAMember2022-10-012022-12-300001681622srt:AsiaPacificMember2023-09-302023-12-290001681622srt:AsiaPacificMember2022-10-012022-12-300001681622country:US2023-09-302023-12-290001681622country:US2022-10-012022-12-300001681622var:DpiXHoldingMemberus-gaap:EquityMethodInvesteeMember2023-12-290001681622var:DpiXLLCMemberus-gaap:EquityMethodInvesteeMembervar:DpiXHoldingMember2023-12-290001681622var:DpiXHoldingMemberus-gaap:EquityMethodInvesteeMember2023-09-302023-12-290001681622var:DpiXHoldingMemberus-gaap:EquityMethodInvesteeMember2022-10-012022-12-300001681622var:DpiXHoldingMemberus-gaap:EquityMethodInvesteeMember2023-09-290001681622var:DpiXLLCMembervar:PurchasesMember2023-09-302023-12-290001681622var:DpiXLLCMembervar:PurchasesMember2022-10-012022-12-300001681622var:DpiXHoldingMemberus-gaap:EquityMethodInvesteeMember2013-10-012013-10-300001681622var:DpiXHoldingMemberus-gaap:EquityMethodInvesteeMembersrt:ScenarioForecastMembervar:FixedCostCommitmentsMember2024-01-012024-12-310001681622us-gaap:EquityMethodInvesteeMembervar:VECImagingGmbHCo.KGMember2023-09-302023-12-290001681622us-gaap:EquityMethodInvesteeMembervar:VECImagingGmbHCo.KGMember2022-10-012022-12-300001681622us-gaap:EquityMethodInvesteeMembervar:VECImagingGmbHCo.KGMember2023-12-290001681622us-gaap:EquityMethodInvesteeMembervar:VECImagingGmbHCo.KGMember2023-09-290001681622us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:CrossCurrencyInterestRateContractMember2023-12-29var:instrument0001681622us-gaap:CrossCurrencyInterestRateContractMember2023-09-302023-12-290001681622us-gaap:CrossCurrencyInterestRateContractMember2022-10-012022-12-300001681622us-gaap:InterestExpenseMemberus-gaap:CrossCurrencyInterestRateContractMember2023-09-302023-12-290001681622us-gaap:InterestExpenseMemberus-gaap:CrossCurrencyInterestRateContractMember2022-10-012022-12-300001681622us-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:CrossCurrencyInterestRateContractMember2023-12-290001681622us-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:CrossCurrencyInterestRateContractMember2023-09-290001681622us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:CrossCurrencyInterestRateContractMember2023-12-290001681622us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:CrossCurrencyInterestRateContractMember2023-09-290001681622currency:AUDus-gaap:ForeignExchangeContractMemberus-gaap:ShortMember2023-12-290001681622us-gaap:ForeignExchangeContractMemberus-gaap:ShortMembercurrency:CNY2023-12-290001681622currency:EURus-gaap:ForeignExchangeContractMemberus-gaap:ShortMember2023-12-290001681622currency:INRus-gaap:ForeignExchangeContractMemberus-gaap:ShortMember2023-12-290001681622us-gaap:ForeignExchangeContractMemberus-gaap:ShortMember2023-12-290001681622us-gaap:FairValueInputsLevel1Memberus-gaap:ConvertibleDebtMember2023-12-290001681622us-gaap:FairValueInputsLevel1Memberus-gaap:SecuredDebtMember2023-12-290001681622us-gaap:FairValueInputsLevel1Memberus-gaap:ConvertibleDebtMember2023-09-290001681622us-gaap:FairValueInputsLevel1Memberus-gaap:SecuredDebtMember2023-09-290001681622us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-290001681622us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-290001681622us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-12-290001681622us-gaap:FairValueMeasurementsRecurringMember2023-12-290001681622us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001681622us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-290001681622us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-09-290001681622us-gaap:FairValueMeasurementsRecurringMember2023-09-290001681622us-gaap:CommercialPaperMember2023-12-290001681622us-gaap:CorporateBondSecuritiesMember2023-12-290001681622us-gaap:USTreasuryBillSecuritiesMember2023-12-290001681622us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-290001681622us-gaap:CommercialPaperMember2023-09-290001681622us-gaap:CorporateBondSecuritiesMember2023-09-290001681622us-gaap:USTreasuryBillSecuritiesMember2023-09-290001681622us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-290001681622us-gaap:CashAndCashEquivalentsMemberus-gaap:CommercialPaperMember2023-12-290001681622us-gaap:CashAndCashEquivalentsMemberus-gaap:CorporateBondSecuritiesMember2023-12-290001681622us-gaap:CashAndCashEquivalentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-290001681622us-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasuryBillSecuritiesMember2023-12-290001681622us-gaap:CashAndCashEquivalentsMember2023-12-290001681622us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CommercialPaperMember2023-12-290001681622us-gaap:CorporateBondSecuritiesMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-290001681622us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-290001681622us-gaap:USTreasuryBillSecuritiesMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-290001681622us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-290001681622us-gaap:CashAndCashEquivalentsMemberus-gaap:CommercialPaperMember2023-09-290001681622us-gaap:CashAndCashEquivalentsMemberus-gaap:CorporateBondSecuritiesMember2023-09-290001681622us-gaap:CashAndCashEquivalentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-290001681622us-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasuryBillSecuritiesMember2023-09-290001681622us-gaap:CashAndCashEquivalentsMember2023-09-290001681622us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:CommercialPaperMember2023-09-290001681622us-gaap:CorporateBondSecuritiesMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-09-290001681622us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-09-290001681622us-gaap:USTreasuryBillSecuritiesMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-09-290001681622us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-09-290001681622var:MedicalMember2023-09-290001681622var:IndustrialMember2023-09-290001681622var:MedicalMember2023-09-302023-12-290001681622var:IndustrialMember2023-09-302023-12-290001681622var:MedicalMember2023-12-290001681622var:IndustrialMember2023-12-290001681622us-gaap:DevelopedTechnologyRightsMember2023-12-290001681622us-gaap:DevelopedTechnologyRightsMember2023-09-290001681622us-gaap:IntellectualPropertyMember2023-12-290001681622us-gaap:IntellectualPropertyMember2023-09-290001681622var:CustomerContractsandSupplierRelationshipsMember2023-12-290001681622var:CustomerContractsandSupplierRelationshipsMember2023-09-290001681622var:MeVisBreastcareMember2023-10-310001681622var:MeVisBreastcareMembervar:CustomerContractsandSupplierRelationshipsMember2023-10-310001681622us-gaap:DevelopedTechnologyRightsMembervar:MeVisBreastcareMember2023-10-310001681622us-gaap:OtherDebtSecuritiesMember2023-12-290001681622us-gaap:OtherDebtSecuritiesMember2023-09-290001681622us-gaap:ConvertibleDebtMember2023-12-290001681622us-gaap:ConvertibleDebtMember2023-09-290001681622us-gaap:ConvertibleDebtMember2023-09-302023-12-290001681622var:SeniorSecuredNotesMemberus-gaap:SecuredDebtMember2023-12-290001681622var:SeniorSecuredNotesMemberus-gaap:SecuredDebtMember2023-09-290001681622var:SeniorSecuredNotesMemberus-gaap:SecuredDebtMember2023-09-302023-12-290001681622var:ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2020-06-090001681622var:ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2020-06-092020-06-090001681622var:ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2020-06-050001681622var:ConvertibleNotesMemberus-gaap:ConvertibleDebtMembersrt:MaximumMember2020-06-042020-06-050001681622var:ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2020-06-040001681622var:ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2020-06-042020-06-050001681622var:ConvertibleNotesMemberus-gaap:ConvertibleDebtMember2023-09-302023-12-290001681622var:SeniorSecuredNotesMemberus-gaap:SecuredDebtMember2020-09-300001681622var:SeniorSecuredNotesMemberus-gaap:SecuredDebtMember2021-07-150001681622var:SeniorSecuredNotesMemberus-gaap:SecuredDebtMember2022-03-180001681622us-gaap:RevolvingCreditFacilityMembervar:AssetBasedLoanRevolvingCreditFacilityMemberus-gaap:SecuredDebtMember2020-09-300001681622srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembervar:AssetBasedLoanRevolvingCreditFacilityMemberus-gaap:SecuredDebtMember2020-09-302020-09-300001681622us-gaap:RevolvingCreditFacilityMembervar:AssetBasedLoanRevolvingCreditFacilityMemberus-gaap:SecuredDebtMember2023-12-290001681622var:MeVisBreastcareMember2023-09-290001681622var:MeVisBreastcareMember2023-10-310001681622var:MeVisBreastcareMember2023-10-012023-10-310001681622var:JointVentureInSaudiArabiaMember2018-09-300001681622var:MeVisMedicalSolutionsAGMeVisMember2015-04-300001681622var:MeVisMedicalSolutionsAGMeVisMember2017-09-292017-09-290001681622var:MeVisMedicalSolutionsAGMeVisMember2018-09-282018-09-280001681622var:MeVisMedicalSolutionsAGMeVisMember2018-12-310001681622var:MeVisMedicalSolutionsAGMeVisMember2015-08-012015-08-31iso4217:EURxbrli:shares0001681622var:MeVisMedicalSolutionsAGMeVisMember2023-12-290001681622var:MeVisMedicalSolutionsAGMeVisMembervar:MeVisMedicalSolutionsAGMeVisMember2023-12-290001681622us-gaap:RestrictedStockMember2023-09-302023-12-290001681622us-gaap:RestrictedStockMember2022-10-012022-12-300001681622us-gaap:ConvertibleDebtSecuritiesMember2023-09-302023-12-290001681622us-gaap:ConvertibleDebtSecuritiesMember2022-10-012022-12-300001681622us-gaap:WarrantMember2023-09-302023-12-290001681622us-gaap:WarrantMember2022-10-012022-12-300001681622us-gaap:CostOfSalesMember2023-09-302023-12-290001681622us-gaap:CostOfSalesMember2022-10-012022-12-300001681622us-gaap:ResearchAndDevelopmentExpenseMember2023-09-302023-12-290001681622us-gaap:ResearchAndDevelopmentExpenseMember2022-10-012022-12-300001681622us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-09-302023-12-290001681622us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-10-012022-12-300001681622srt:MinimumMember2023-09-290001681622srt:MaximumMember2023-09-2900016816222022-10-012023-09-290001681622srt:MinimumMember2023-12-290001681622srt:MaximumMember2023-12-290001681622var:MedicalSegmentMember2023-09-302023-12-290001681622var:MedicalSegmentMember2022-10-012022-12-300001681622var:IndustrialSegmentMember2023-09-302023-12-290001681622var:IndustrialSegmentMember2022-10-012022-12-300001681622var:KimberleyHoneysettMember2023-09-302023-12-290001681622var:KimberleyHoneysettMember2023-12-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ____________________________________________________________
FORM 10-Q
 ____________________________________________________________
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended December 29, 2023
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 001-37860
 ____________________________________________________________ 
logoa37.jpg
VAREX IMAGING CORPORATION
(Exact name of registrant as specified in its charter)
 ____________________________________________________________ 
Delaware
81-3434516
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
1678 S. Pioneer Road, Salt Lake City, Utah
84104
(Address of principal executive offices)
(Zip Code)
(801) 972-5000
(Registrant’s telephone number, including area code)
 ____________________________________________________________ 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
VREX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes   ☒ No   ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes   ☒     No   ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated filer
☒
Accelerated filer
☐
Non-Accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  ☐  No  ☒
As of January 30, 2024, there were 40.6 million shares of the registrant’s common stock outstanding.


VAREX IMAGING CORPORATION
FORM 10-Q
For the Quarter Ended December 29, 2023
INDEX
 

1
PART I
FINANCIAL INFORMATION

Item 1. Financial Statements

VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS    
(Unaudited)
Three Months Ended
(In millions, except per share amounts)December 29, 2023December 30, 2022
Revenues, net$190.0 $205.6 
Cost of revenues132.9 142.3 
Gross profit57.1 63.3 
Operating expenses:
Research and development20.5 20.0 
Selling, general, and administrative32.4 30.3 
Total operating expenses52.9 50.3 
Operating income4.2 13.0 
Interest income1.9 0.5 
Interest expense(7.3)(7.5)
Other income (expense), net0.6 (0.6)
Interest and other expense, net(4.8)(7.6)
(Loss) income before taxes(0.6)5.4 
Income tax (benefit) expense(0.2)2.2 
Net (loss) income(0.4)3.2 
Less: Net income attributable to noncontrolling interests0.1 0.1 
Net (loss) income attributable to Varex$(0.5)$3.1 
Net (loss) income per common share attributable to Varex
Basic$(0.01)$0.08 
Diluted$(0.01)$0.08 
Weighted average common shares outstanding
Basic40.6 40.1 
Diluted40.6 40.6 
See accompanying Notes to the Condensed Consolidated Financial Statements.
2


VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(Unaudited)
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Net (loss) income$(0.4)$3.2 
Other comprehensive loss
Foreign currency translation adjustments(1.0)— 
Total comprehensive (loss) income(1.4)3.2 
Less: Comprehensive income attributable to noncontrolling interests0.1 0.1 
Comprehensive (loss) income attributable to Varex$(1.5)$3.1 
 See accompanying Notes to the Condensed Consolidated Financial Statements.
3
VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In millions, except share and per share amounts)December 29, 2023September 29, 2023
Assets
Current assets:
Cash and cash equivalents$141.3 $152.6 
Accounts receivable, net of allowance for credit losses of $0.6 million and $0.6 million at December 29, 2023 and September 29, 2023, respectively
139.6 163.6 
Inventories289.7 277.5 
Prepaid expenses and other current assets
75.1 64.6 
Total current assets645.7 658.3 
Property, plant, and equipment, net148.3 143.6 
Goodwill
290.4 288.5 
Intangible assets, net
22.1 22.4 
Investments in privately-held companies
28.3 29.0 
Deferred tax assets
42.0 41.3 
Operating lease assets28.4 29.0 
Other assets
37.1 37.5 
Total assets
$1,242.3 $1,249.6 
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
$73.7 $64.7 
Accrued liabilities and other current liabilities
61.6 82.6 
Current operating lease liabilities
3.8 3.8 
Current maturities of long-term debt
1.6 1.5 
Deferred revenues
9.4 10.2 
Total current liabilities150.1 162.8 
Long-term debt, net
441.4 441.1 
Operating lease liabilities22.9 23.1 
Other long-term liabilities
44.9 41.6 
Total liabilities659.3 668.6 
Stockholders' equity:
Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued
— — 
Common stock, $.01 par value: 150,000,000 shares authorized
Shares issued and outstanding: 40,618,590 and 40,529,573 at December 29, 2023 and September 29, 2023, respectively
0.4 0.4 
Additional paid-in capital453.2 450.4 
Accumulated other comprehensive loss(2.2)(1.2)
Retained earnings117.5 118.1 
Total Varex stockholders' equity568.9 567.7 
Noncontrolling interests14.1 13.3 
Total stockholders' equity583.0 581.0 
Total liabilities and stockholders' equity$1,242.3 $1,249.6 
See accompanying Notes to the Condensed Consolidated Financial Statements.

4


VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY
(Unaudited)

Three Months Ended December 29, 2023
Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive LossRetained EarningsTotal Varex EquityNoncontrolling InterestsTotal Stockholders' Equity
(In millions)SharesAmount
September 29, 202340.5 $0.4 $450.4 $(1.2)$118.1 $567.7 $13.3 $581.0 
Net (loss) income— — — — (0.5)(0.5)0.1 (0.4)
Common stock issued upon vesting of restricted shares0.2 — — — — — — — 
Shares withheld on vesting of restricted stock(0.1)— (1.0)— — (1.0)— (1.0)
Share-based compensation— — 3.7 — — 3.7 — 3.7 
Foreign currency translation adjustments— — — (1.0)— (1.0)— (1.0)
Business acquisitions— — — — — — 0.7 0.7 
Other— — 0.1 — (0.1)— — — 
December 29, 202340.6 $0.4 $453.2 $(2.2)$117.5 $568.9 $14.1 $583.0 


Three Months Ended December 30, 2022
Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive IncomeRetained EarningsTotal Varex EquityNoncontrolling InterestsTotal Stockholders' Equity
(In millions)SharesAmount
September 30, 202240.1 $0.4 $469.1 $0.1 $63.8 $533.4 $13.3 $546.7 
Cumulative effect of accounting changes— — (34.6)— 6.5 (28.1)— (28.1)
Net income— — — — 3.1 3.1 0.1 3.2 
Share-based compensation— — 3.3 — — 3.3 — 3.3 
Other— — 0.1 — (0.1)— (0.1)(0.1)
December 30, 202240.1 $0.4 $437.9 $0.1 $73.3 $511.7 $13.3 $525.0 
See accompanying Notes to the Condensed Consolidated Financial Statements.
5
VAREX IMAGING CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Cash flows from operating activities:
Net (loss) income$(0.4)$3.2 
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Share-based compensation expense3.7 3.3 
Depreciation5.1 4.6 
Amortization of intangible assets3.6 3.4 
Deferred taxes(0.8)(0.2)
Income from equity method investments(0.4)(1.3)
Amortization of deferred loan costs0.7 0.6 
Gain on purchase of business(2.1)— 
Inventory write-down0.9 2.0 
Other, net(0.5)— 
Changes in assets and liabilities:
Accounts receivable25.3 15.6 
Inventories(13.2)(18.8)
Prepaid expenses and other assets2.2 (0.4)
Accounts payable9.0 8.0 
Accrued liabilities and other current and long-term liabilities(22.0)(25.4)
Deferred revenues(0.8)1.7 
Net cash provided by (used in) operating activities10.3 (3.7)
Cash flows from investing activities:
Purchases of property, plant, and equipment(10.4)(5.5)
Loss on settlement of cash flow hedge— (0.3)
Proceeds from maturities of marketable debt securities14.2 4.0 
Purchase of marketable debt securities(24.5)(6.3)
Purchase of marketable equity securities— (2.7)
Settlement of net investment hedge— 7.0 
Acquisitions of businesses, net of cash acquired0.9 — 
Other, net(0.1)0.1 
Net cash used in investing activities(19.9)(3.7)
Cash flows from financing activities:
Taxes related to net share settlement of equity awards
(1.0)— 
Repayments of borrowing under credit agreements
(0.4)(0.5)
Other, net(0.3)0.1 
Net cash used in financing activities(1.7)(0.4)
Net decrease in cash and cash equivalents and restricted cash
(11.3)(7.8)
Cash and cash equivalents and restricted cash at beginning of period
154.0 90.6 
Cash and cash equivalents and restricted cash at end of period
$142.7 $82.8 
Supplemental cash flow information:
Cash paid for interest$13.7 $13.7 
Income taxes paid, net of (refunds)2.7 4.5 
Supplemental non-cash activities:
Purchases of property, plant, and equipment financed through accounts payable$2.5 $2.0 
See accompanying Notes to the Condensed Consolidated Financial Statements.
6
VAREX IMAGING CORPORATION
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business
    Varex Imaging Corporation (the “Company” or “Varex”) designs, manufactures, sells, and services a broad range of medical products, which include X-ray imaging components including X-ray tubes, flat panel and photon counting detectors and accessories, ionization chambers, high voltage connectors, image processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. The Company sells its products to imaging system original equipment manufacturer (“OEM”) customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary equipment, as well as to independent service companies and distributors, and directly to end-users for replacement purposes.
    The Company also designs, manufactures, sells and services industrial products, which include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, coolers, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex’s products into their inspection or irradiation systems and processes. The Company conducts an active research and development program to focus on new technology and applications in both the medical and industrial X-ray imaging markets.
Basis of Presentation
    The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements include all adjustments necessary for a fair presentation of the results for the interim periods. The Company has consolidated all of its majority owned subsidiaries and entities over which it has control. All intercompany balances and transactions have been eliminated as part of the consolidation.
    These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended September 29, 2023 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on November 16, 2023. The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures. Except for the change in certain policies upon adoption of the accounting standards described below, there have been no material changes to the Company's significant accounting policies, compared to the accounting policies described in Note 1, Summary of Significant Accounting Policies, in the Company’s Annual Report on Form 10-K for fiscal year 2023.
Segment Reporting
    The Company has two reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its Chief Executive Officer, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance. See Note 15, Segment Information, for further information on the Company’s segments.
Fiscal Year
    The fiscal years of the Company as reported are the 52 or 53-week periods ending on the Friday nearest September 30. Fiscal year 2024 is the 52-week period ending September 27, 2024. Fiscal year 2023 was the 52-week period that ended on September 29, 2023. The fiscal quarters ended December 29, 2023 and December 30, 2022 were both 13-week periods.
7
Use of Estimates
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, valuation of goodwill and intangible assets, receivables, warranties, refund liabilities, long-lived asset valuations, impairment of investments, valuation of financial instruments, and taxes on income. Actual results could differ from these estimates.
Cash and Cash Equivalents
    The Company considers unrestricted currency on hand, demand deposits, time deposits, and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents.
Restricted Cash
    Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the Company's Condensed Consolidated Balance Sheets. Cash and cash equivalents and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows consisted of the following:
Three Months EndedThree Months Ended
December 29, 2023December 30, 2022
(In millions)Beginning of PeriodEnd of PeriodBeginning of PeriodEnd of Period
Cash and cash equivalents$152.6 $141.3 $89.4 $81.5 
Restricted cash1.4 1.4 1.2 1.3 
Total as presented in the Condensed Consolidated Statements of Cash Flows$154.0 $142.7 $90.6 $82.8 
Concentration of Risk
    Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities, certificates of deposit, and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. To date, the Company has not realized any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases, and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for credit losses based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. When these suppliers are unable to meet the Company's supply needs, the Company's production is negatively impacted.
    Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. In certain circumstances, a customer may be required to prepay all or a portion of the contract price prior to transfer of control. During the periods presented, one of the Company's customers accounted for a significant portion of revenues, as set forth below:
Three Months Ended
December 29, 2023December 30, 2022
Canon Medical Systems Corporation14.7 %20.1 %
    Canon Medical Systems Corporation accounted for 8.2% and 13.8% of the Company’s accounts receivable as of December 29, 2023 and September 29, 2023, respectively.
Equity Method Investments
    The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in, but not control, these investments. The Company records impairment losses on its equity method investments if an impairment exists and is deemed to be other-than-temporary, which is based on various factors, including but not limited to, the length of time the fair value of the investment is below the carrying value, the absence of an ability to recover the carrying amount of the investment, and the inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. There were no impairments recorded during the three months ended December 29, 2023 and December 30, 2022.
8
Marketable Securities
    The Company's marketable securities consist primarily of financial instruments such as United States treasury securities, United States agency obligations, corporate bonds, commercial paper, money market funds, and equity securities.
Marketable Debt Securities
    The Company's marketable debt securities are classified as available-for-sale. Classification of marketable debt securities is determined at the time of purchase, and the Company reevaluates such classification as of each balance sheet date. Marketable debt securities are recorded at estimated fair value and included in cash and cash equivalents, prepaid expenses and other current assets, and other assets within the Condensed Consolidated Balance Sheets. Any unrealized gains or losses are included in accumulated other comprehensive loss within the Condensed Consolidated Balance Sheets. When the fair value of a marketable debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in the Condensed Consolidated Statements of Operations. When the fair value of a marketable debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss, and are recognized in the Condensed Consolidated Statements of Operations only if the Company sells or intends to sell the security before recovery of its cost basis. There were no impairments related to marketable debt securities recorded during the three months ended December 29, 2023 and December 30, 2022.
Marketable Equity Securities
    Marketable equity securities are stated at fair value as determined by the most recently traded price of each security at the balance sheet date and included in other assets within the Condensed Consolidated Balance Sheets. All unrealized gains and losses on marketable equity securities are recorded as part of other income (expense), net in the Company's Condensed Consolidated Statements of Operations. See Note 6, Fair Value, for further details.
Loss Contingencies
    From time to time, the Company is involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, and other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. When a loss contingency is probable but not reasonably estimable the nature of the contingency and the fact that an estimate cannot be made is disclosed.
Supplier Finance Programs
    The Company participates in voluntary supply chain finance programs with a financial intermediary which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. As part of participating in these arrangements, the Company generally receives more favorable payment terms from its suppliers. The Company does not receive fees, payments, extended payment terms, or other direct economic benefits from the intermediary. The total amounts due to the financial intermediary to settle supplier invoices under supply chain finance programs as of December 29, 2023 and September 29, 2023 were $2.3 million and $4.2 million, respectively. These amounts are included within accounts payable in the Condensed Consolidated Balance Sheets.
9
Environmental Obligations
    The Company's operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport, and disposal of hazardous substances. Certain of those laws impose cleanup liabilities under certain circumstances. In connection with those laws and certain of our past and present operations and facilities, the Company is obligated to indemnify Varian Medical Systems, Inc. ("Varian") for the cleanup liabilities related to prior corporate restructuring activities. The Company anticipates that it will be obligated to reimburse Varian for 20% of the liabilities of Varian related to these sites (after adjusting for any insurance proceeds or tax benefits received by Varian). As of December 29, 2023, our estimated environmental liability for these sites was $2.6 million, net of expected insurance proceeds. As of September 29, 2023, our estimated liability for these sites was $2.8 million, net of expected insurance proceeds.
Product Warranty
    The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.
    The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience of product failures, adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.
    The following table reflects the changes in the Company’s accrued product warranty:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Accrued product warranty, at beginning of period$7.7 $7.9 
New accruals charged to cost of revenues3.7 2.8 
Product warranty expenditures(3.4)(3.0)
Accrued product warranty, at end of period$8.0 $7.7 
Leases
    The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represent the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate. The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its Condensed Consolidated Balance Sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its Condensed Consolidated Balance Sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option.
Revenue Recognition
    The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts.
    The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray imaging components including X-ray tubes, digital detectors and image-processing tools, and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X-ray imaging and sells its Linatron® X-ray linear accelerators together with its image processing software and image detection products to OEM customers that incorporate them into their inspection or irradiation systems and processes. Service contracts are often sold with certain security and inspection products and computer-aided detection products.
    The Company determines revenue recognition through the following steps:
•Identification of the contract, or contracts, with a customer
10
•Identification of the performance obligations in the contract
•Determination of the transaction price
•Allocation of the transaction price to the performance obligations in the contract
•Recognition of revenue when, or as, a performance obligation is satisfied
Contracts and Performance Obligations
    The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.
Transaction Price and Allocation to Performance Obligations
    Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current, and forecasted) that is reasonably available.
    The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. For sales with a right of return, revenue is reduced and a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding refund liability and right of return asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.
    If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation could be sold separately.
Recognition of Revenue
    Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.
    Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
    Service revenue is generally recognized over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract, and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.
Disaggregation of Revenue
    Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note 15, Segment Information, included in this report, for the disaggregation of the Company’s revenue based on reportable operating segments and Note 2, Revenue Recognition, for the disaggregation of revenue by geographic region.
Contract Balances
    Contract liabilities are included within the deferred revenues, and other long-term liabilities balances in the Condensed Consolidated Balance Sheets. The Company does not have any material contract assets.
11
    Deferred revenue represents the Company's obligation to transfer goods or services to its customers for which it has already received consideration (or the amount is due) from the customer. The Company's deferred revenue balance primarily relates to contract advances and billings for warranty contracts.
    Deferred revenue that is estimated to be recognized during the following twelve-month period is recorded as deferred revenues and the remaining portion is recorded as other long-term liabilities in the Condensed Consolidated Balance Sheets.
Costs to Obtain or Fulfill a Customer Contract
    The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.
Recently Adopted Accounting Pronouncements
    In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The Company adopted this ASU on October 1, 2022, using the modified retrospective method. For further details, refer to Note 1, Summary of Significant Accounting Policies, of the Notes to the Condensed Consolidated Financial Statements of our Annual Report on Form 10-K for the fiscal year ended September 29, 2023 filed with the SEC on November 16, 2023.
    In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs, which requires entities to provide qualitative and quantitative disclosures about their supplier finance programs, including a rollforward of related obligations. The adoption of ASU 2022-04 did not affect the Company’s financial condition, results of operations, or cash flows as the guidance only requires additional disclosures. We adopted this ASU effective September 30, 2023 on a retrospective basis, except for the amendment on rollforward information, which has been adopted on a prospective basis.
Recent Accounting Standards or Updates Not Yet Effective
    There are no new accounting standards not yet adopted or effective that are expected to have a material impact on the Company's Condensed Consolidated Financial Statements.
2. REVENUE RECOGNITION
Disaggregation of Revenue
    Revenue is disaggregated from contracts by geographic region and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors.
    The following table disaggregates the Company’s revenue by geographic region:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Americas$62.4 $66.6 
EMEA66.0 65.3 
APAC61.6 73.7 
$190.0 $205.6 
    Revenue in the United States was $60.6 million and $65.4 million for the three months ended December 29, 2023 and December 30, 2022, respectively.
    Our products are sold in three geographic regions: the Americas, EMEA, and APAC. The Americas includes North America (primarily the United States) and Latin America. EMEA includes Europe, the Middle East, India, and Africa. APAC includes Asia (other than India) and Australia. Revenues by region are based on the known final destination of products sold.
    Refer to Note 15, Segment Information, for the disaggregation of the Company’s revenue based on reportable operating segments.
12
Right of Return Assets and Refund Liabilities
    Right of return assets are included within the prepaid expenses and other current assets, and other assets balances in the Condensed Consolidated Balance Sheets. Refund liabilities are included within the accrued liabilities and other current liabilities and other long-term liabilities balances in the Condensed Consolidated Balance Sheets. The following table summarizes the changes in the right of return assets and refund liabilities for the three months ended December 29, 2023 and December 30, 2022:
Right of Return Assets
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Balance at beginning of period$26.0 $25.4 
Costs recovered from product returns during the period(1.9)(1.5)
Right of return assets from shipments of products subject to return during the period1.4 1.5 
Balance at end of period$25.5 $25.4 
Refund Liabilities
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Balance at beginning of period$28.9 $28.2 
Release of refund liability included in beginning of year refund liability(2.1)(1.6)
Additions to refund liabilities1.5 1.7 
Balance at end of period$28.3 $28.3 
Contract Balances
    During the three months ended December 29, 2023, the Company recognized revenue of $6.8 million related to deferred revenues which existed at September 29, 2023. During the three months ended December 30, 2022, the Company recognized revenue of $4.2 million related to deferred revenues that existed at September 30, 2022.
3. LEASES
    The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles, and equipment. The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
(In millions)Balance Sheet LocationDecember 29, 2023September 29, 2023
Assets
Operating lease right-of-use assetsOperating lease assets$28.4 $29.0 
Finance lease right-of-use assetsProperty, plant, and equipment, net1.0 0.3 
Liabilities
Operating lease liabilities (current) Current operating lease liabilities3.8 3.8 
Finance lease liabilities (current) Accrued liabilities and other current liabilities0.2 0.1 
Operating lease liabilities (non-current)Operating lease liabilities22.9 23.1 
Finance lease liabilities (non-current)Other long-term liabilities$0.6 $0.2 
13
    The following table provides information related to the Company’s operating and finance leases:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Total operating lease costs(1)
$1.5 $1.5 
Total finance lease costs$0.1 $0.1 
Operating cash flows from operating leases$1.4 $1.6 
Financing cash flows from finance leases0.3 0.1 
Total cash paid for amounts included in the measurement of lease liabilities$1.7 $1.7 
Noncash operating right-of-use assets obtained in exchange for new lease liabilities$1.5 $— 
Noncash finance right-of-use assets obtained in exchange for new lease liabilities0.7 — 
Total right-of-use assets obtained in exchange for new lease liabilities$2.2 $— 
(1) Includes variable and short-term lease expense, which were immaterial for the three months ended December 29, 2023 and December 30, 2022.
4. RELATED-PARTY TRANSACTIONS
Investments in Privately-Held Companies
    The Company has a 40% ownership interest in dpiX Holding LLC (“dpiX Holding”), a holding company that has a 100% ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon-based thin film transistor arrays for flat panels used in the Company's digital image detectors. In accordance with the dpiX Holding operating agreement, net profits or losses are allocated to the members in accordance with their ownership interests.
    The investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are also eliminated. During the three months ended December 29, 2023 and December 30, 2022, the Company recorded income on the equity investment in dpiX Holding of $0.5 million and $2.0 million, respectively. The income and loss on the equity investment in dpiX Holding are included in other income (expense), net in the Condensed Consolidated Statements of Operations. The carrying value of the equity investment in dpiX Holding was $26.3 million and $25.8 million at December 29, 2023 and September 29, 2023, respectively.
    During the three months ended December 29, 2023 and December 30, 2022, the Company purchased glass transistor arrays from dpiX totaling $5.0 million and $5.0 million, respectively. These purchases of glass transistor arrays are included as a component of inventories on the Condensed Consolidated Balance Sheets or cost of revenues in the Condensed Consolidated Statements of Operations.
    As of December 29, 2023 and September 29, 2023, the Company had accounts payable to dpiX totaling $2.8 million and $2.7 million, respectively.
     In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides it with the right to 50% of dpiX’s total manufacturing capacity. In addition, the Company is required to pay for 50% of dpiX's fixed costs, as determined at the beginning of each calendar year. In January 2024, the Company's fixed cost commitment was determined and approved by the dpiX board of directors to be $12.4 million for calendar year 2024. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).
    The Company has determined that dpiX Holding is a variable interest entity because the at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to unilaterally direct the activities of dpiX Holding, and therefore, is not the primary beneficiary of dpiX Holding. The Company’s exposure to loss as a result of its involvement with dpiX Holding is limited to the carrying value of the Company’s investment of $26.3 million and fixed cost commitments.
14
    In November 2018, the Company (through one of its wholly-owned subsidiaries) and CETTEEN GmbH (“CETTEEN”), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging GmbH & Co. KG (“VEC”), a joint venture formed to develop technology for use in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method of accounting. The Company has determined that VEC is a variable interest entity.
    During the three months ended December 29, 2023 and December 30, 2022, the Company recorded a loss on the equity investment in VEC of $0.1 million and $0.3 million, respectively. The Company's investment in VEC was $2.0 million and $2.1 million at December 29, 2023 and September 29, 2023, respectively. As of December 29, 2023 and September 29, 2023, the Company had loans and other receivables outstanding from VEC of $0.7 million, and $0.7 million, respectively, which are recorded in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.

5. FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES
    As part of the Company’s overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates.
    The Company records all derivatives on the Condensed Consolidated Balance Sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective, in which case the Company would test for effectiveness on a more frequent basis. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period income. The Company does not offset fair value amounts recognized for derivative instruments in its Condensed Consolidated Balance Sheets for presentation purposes.
    Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions that meet certain minimum credit ratings to help mitigate counterparty credit risk.
Derivatives Designated as Hedging Instruments - Net Investment Hedges
    The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in wholly-owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive loss along with the foreign currency translation adjustments on those investments.
    As of December 29, 2023, the Company had the following outstanding derivatives designated as net investment hedging instruments:
(In millions, except number of instruments)Number of InstrumentsNotional Value
Cross currency swap contracts2$58.7 
    The following table summarizes the amount of pre-tax income recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:
Amount of Loss Recognized in OCI on Derivative
Three Months Ended		Location of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
Three Months Ended
(In millions)December 29, 2023December 30, 2022December 29, 2023December 30, 2022
Cross currency swap contracts$(2.7)$(4.0)Interest expense$0.3 $0.2 
15
    These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying Condensed Consolidated Balance Sheets where the instruments are recorded:
(In millions)Derivative Assets and Liabilities
Derivatives Designated as Net Investment HedgesBalance Sheet LocationDecember 29, 2023September 29, 2023
Cross currency swap contractsPrepaid expenses and other current assets$0.8 $0.7 
Cross currency swap contractsOther long-term liabilities$7.7 $4.9 
Balance Sheet Hedges
    The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency-denominated monetary assets and liabilities, primarily cash, lease contracts, third-party accounts receivable and payable, and intercompany accounts receivable and payable. These forward contracts are generally entered into at the end of one fiscal period and expire by the end of the next fiscal period. These forward contracts are not designated for hedge accounting treatment; therefore, the change in fair value of these derivatives is recorded as a component of other income (expense), net in the Condensed Consolidated Statements of Operations and offsets the change in fair value of the foreign currency-denominated assets and liabilities, which are also recorded as a component of other income (expense), net. The Company has not and does not intend to use derivative financial instruments for speculative or trading purposes.
    The following table shows the notional amounts of outstanding foreign currency contracts as of December 29, 2023:
Notional Value of Derivatives not Designated as Hedging Instruments:
(In millions of equivalent USD)Sell contracts
Australian Dollar$3.8 
Chinese Renminbi10.2 
Euro13.3 
Indian Rupee5.0 
$32.3 
6. FAIR VALUE
Assets and Liabilities Measured at Fair Value on a Recurring Basis
    The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable, net and accounts payable, approximate their fair values due to their short maturities. As of December 29, 2023, the fair values of the Company’s Convertible Notes and Senior Secured Notes, as defined in Note 9, Borrowings and measured using Level 1 inputs, were $234.0 million and $244.4 million, respectively. As of September 29, 2023, the fair values of the Company’s Convertible Notes and Senior Secured Notes, measured using Level 1 inputs, were $228.4 million and $243.6 million, respectively. The Company has elected to use the income approach to value its derivative instruments using standard valuation techniques and Level 2 inputs, such as currency spot rates, forward points and credit default swap spreads.
16
    In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
Fair Value at December 29, 2023
(In millions)
Quoted Prices in Active Markets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Total
Assets:
Money market funds$— $20.5 $— $20.5 
Commercial paper— 8.3 — 8.3 
Corporate notes/bonds— 10.3 — 10.3 
Government agencies— 20.1 — 20.1 
U.S. Treasury bills— 21.8 — 21.8 
Derivative assets
— 0.8 — 0.8 
Deferred compensation plan(1)
6.9 — — 6.9 
Marketable equity securities3.6 — — 3.6 
Total assets measured at fair value$10.5 $81.8 $— $92.3 
Liabilities:
Derivative liabilities
$— $7.7 $— $7.7 
Total liabilities measured at fair value$— $7.7 $— $7.7 
(1) The assets held under the Company’s deferred compensation plan are classified in Level 1, as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.
Fair Value at September 29, 2023
(In millions)
Quoted Prices in Active Markets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Total
Assets:
Money market funds$— $45.4 $— $45.4 
Commercial paper— 6.0 — 6.0 
Corporate notes/bonds— 8.3 — 8.3 
Government agencies— 6.6 — 6.6 
U.S. Treasury bills— 28.6 — 28.6 
Derivative assets— 0.7 — 0.7 
Deferred compensation plan(1)
6.3 — — 6.3 
Marketable equity securities4.1 — — 4.1 
Total assets measured at fair value$10.4 $95.6 $— $106.0 
Liabilities:
Derivative liabilities$— $4.9 $— $4.9 
Total liabilities measured at fair value$— $4.9 $— $4.9 
(1) The assets held under the Company’s deferred compensation plan are classified in Level 1 as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.
17
Marketable Debt Securities
    The following is a summary of marketable debt securities, which are included within the cash and cash equivalents, prepaid expenses and other current assets, and other assets balances on the Condensed Consolidated Balance Sheets.
December 29, 2023
(In millions)Amortized CostsFair Value
Commercial paper$8.3 $8.3 
Corporate notes/bonds10.3 10.3 
U.S. Treasury bills21.8 21.8 
Government agencies20.120.1
Total marketable debt securities$60.5 $60.5 
September 29, 2023
(In millions)Amortized CostsFair Value
Commercial paper$6.0 $6.0 
Corporate notes/bonds8.3 8.3 
U.S. Treasury bills28.6 28.6 
Government agencies6.66.6
Total marketable debt securities$49.5 $49.5 
    The contractual maturities of marketable debt securities as of December 29, 2023, are shown in the table below. Actual maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations.
December 29, 2023
(In millions)Amortized CostsFair Value
Contractual maturities:
Due within one year$60.5 $60.5 
Due after one year through five years— — 
Total marketable debt securities$60.5 $60.5 
    During the three months ended December 29, 2023, there were no gross realized gains or losses from the sale of certain marketable debt securities that were reclassified out of accumulated other comprehensive loss.
    The following tables summarize the balance sheet locations for marketable debt securities:
December 29, 2023
(In millions)Commercial paperCorporate notes/bondsGovernment agenciesTreasury billsTotal
Cash and cash equivalents$8.3 $— $— $— $8.3 
Prepaid expenses and other current assets— 10.3 20.1 21.8 52.2 
Total marketable debt securities$8.3 $10.3 $20.1 $21.8 $60.5 
September 29, 2023
(In millions)Commercial paperCorporate notes/bondsGovernment agenciesTreasury billsTotal
Cash and cash equivalents$6.0 $— $— $2.2 $8.2 
Prepaid expenses and other current assets— 8.3 6.6 26.4 41.3 
Total marketable debt securities$6.0 $8.3 $6.6 $28.6 $49.5 
18
7. INVENTORIES
    The following table summarizes the Company’s inventories:
(In millions)December 29, 2023September 29, 2023
Raw materials and parts$223.5 $217.5 
Work-in-process19.5 20.0 
Finished goods46.7 40.0 
Total inventories$289.7 $277.5 
8. GOODWILL AND INTANGIBLE ASSETS
    The following table reflects goodwill by reportable operating segment:
(In millions)MedicalIndustrialTotal
Balance at September 29, 2023$171.5 $117.0 $288.5 
Foreign currency translation adjustments1.1 0.8 1.9 
Balance at December 29, 2023$172.6 $117.8 $290.4 
    The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the Condensed Consolidated Balance Sheets:
December 29, 2023September 29, 2023
(In millions)
Gross Carrying Amount
Accumulated Amortization
Net Carrying AmountGross Carrying Amount
Accumulated Amortization
Net Carrying Amount
Acquired existing technology
$73.5 $(59.9)$13.6 $72.3 $(57.8)$14.5 
Patents, licenses and other
12.6 (12.4)0.2 12.5 (12.2)0.3 
Customer contracts and supplier relationship
52.7 (44.4)8.3 50.3 (42.7)7.6 
Total intangible assets
$138.8 $(116.7)$22.1 $135.1 $(112.7)$22.4 
    Amortization expense for intangible assets was $3.6 million and $3.4 million for the three months ended December 29, 2023 and December 30, 2022, respectively. In connection with the business combination discussed in Note 10. Business Combinations, the Company recorded additional intangible assets of $2.6 million, of which $2.1 million related to customer contracts and supplier relationships and $0.5 million related to acquired existing technology.
19
9. BORROWINGS
    The following table summarizes the Company’s short-term and long-term debt:
December 29, 2023September 29, 2023
(In millions, except for percentages)AmountAmountContractual Interest RateEffective Interest Rate
Current maturities of long-term debt
Other debt$1.6 $1.5 
Total current maturities of long-term debt$1.6 $1.5 
Non-current maturities of long-term debt:
Convertible Senior Unsecured Notes$200.0 $200.0 4.0%4.8%
Senior Secured Notes243.0 243.0 7.9%8.2%
Other debt3.2 3.5 
Total non-current maturities of long-term debt:$446.2 $446.5 
Unamortized issuance costs
Unamortized issuance costs - Convertible Notes$(2.1)$(2.5)
Unamortized issuance costs - Senior Secured Notes(2.7)(2.9)
Total(4.8)(5.4)
Total debt outstanding, net$443.0 $442.6 
    The following table summarizes the Company’s interest expense:
Three Months Ended
December 29, 2023December 30, 2022
Contractual interest coupon and other$6.6 $6.9 
Amortization of debt issuance costs0.7 0.6 
Total interest expense$7.3 $7.5 
Convertible Senior Unsecured Notes
    On June 9, 2020, Varex issued $200.0 million in aggregate principal amount of 4.00% Convertible Senior Unsecured Notes due 2025 (“Convertible Notes”). The net proceeds from the issuance of the Convertible Notes, after deducting transaction fees and offering expense payable by the Company, were approximately $193.1 million. The Convertible Notes bear interest at the annual rate of 4.00%, payable semiannually on June 1 and December 1 of each year, beginning on December 1, 2020, and will mature on June 1, 2025, unless earlier converted or repurchased by Varex.
    The Convertible Notes are convertible into cash, shares of Varex common stock or a combination thereof, at Varex’s election, at an initial conversion rate of 48.048 shares of common stock per $1,000 principal amount of Convertible Notes, which is equivalent to an initial conversion price of approximately $20.81 per share, subject to adjustment pursuant to the terms of the indenture governing the Convertible Notes. The Convertible Notes may be converted at any time after, and including, December 15, 2024, until the close of business on the second scheduled trading day immediately before the maturity date. The maximum number of shares issuable upon conversion of the Convertible Notes is 9.6 million.
20
Call Spread
    On June 4, 2020 and June 5, 2020, in connection with the offering of the Convertible Notes, Varex entered into privately negotiated convertible note hedge transactions (collectively, the “Hedge Transactions”). The Hedge Transactions cover, subject to customary anti-dilution adjustments, the number of shares of Varex common stock that initially underlie the Convertible Notes. The Hedge Transactions are expected generally to reduce the potential dilution and/or offset any cash payments Varex is required to make in excess of the principal amount due upon conversion of the Convertible Notes in the event that the market price of Varex common stock is greater than the strike price of the Hedge Transactions, which was initially $20.81 per share (subject to adjustment under the terms of the Hedge Transactions). The strike price of $20.81 corresponds to the initial conversion price of the Convertible Notes. The number of shares underlying the Hedge Transactions is 9.6 million.
    On June 4, 2020 and June 5, 2020, Varex also entered into privately negotiated warrant transactions (collectively, the “Warrant Transactions” and, together with the Hedge Transactions, the “Call Spread Transactions”), whereby the Company sold warrants at a higher strike price relating to the same number of shares of Varex common stock that initially underlie the Convertible Notes, subject to customary anti-dilution adjustments. The initial strike price of the warrants is $24.975 per share (subject to adjustment under the terms of the Warrant Transactions), which was 50% above the last reported sale price of Varex common stock on June 4, 2020. The Warrant Transactions could have a dilutive effect to the Company's stockholders to the extent that the market price per share of Varex common stock, as measured under the terms of the Warrant Transactions, exceeds the applicable strike price of the warrants. The number of shares underlying the Warrant Transactions is 9.6 million. The number of warrants outstanding as of December 29, 2023 was 9.6 million.
Senior Secured Notes
    Varex issued $300.0 million aggregate principal amount of 7.875% Senior Secured Notes due 2027 (the "Senior Secured Notes") pursuant to an indenture dated September 30, 2020. Interest payments are paid semiannually on April 15 and October 15 of each year, beginning on April 15, 2021. The Senior Secured Notes will mature on October 15, 2027, unless earlier redeemed or repurchased by Varex. On July 15, 2021, we redeemed $30.0 million, and on March 18, 2022, we redeemed $27.0 million of the Senior Secured Notes. As of December 29, 2023, the aggregate principal amount of the outstanding Senior Secured Notes was $243.0 million.
    The Senior Secured Notes are secured by a first priority lien on substantially all of the assets of Varex and the assets and capital stock of its subsidiary guarantors (subject to exceptions), except for assets for which a first priority security interest is pledged for the ABL Facility (defined below), in which the Senior Secured Notes have a second lien security interest. The Senior Secured Notes include negative covenants, subject to certain exceptions, restricting or limiting Varex's ability and the ability of its restricted subsidiaries to, among other things, incur liens on collateral; sell certain assets; incur additional indebtedness; pay dividends; issue preferred shares; consolidate, merge, or sell all or substantially all of its assets; and enter into certain transactions with their affiliates.
Asset-Based Loan
    On September 30, 2020, the Company entered into a revolving credit agreement consisting of a $100.0 million asset-based loan revolving credit facility (the “Asset-Based Loan” or "ABL Facility"). Borrowings under the Asset-Based Loan bear interest at floating rates based on the Secured Overnight Financing Rate ("SOFR"), or a comparable rate, or a base rate, and an applicable margin based on Average Daily Excess Availability (as defined in the Asset-Based Loan Agreement). In addition, the Company is required to pay a quarterly commitment fee of 0.25% annualized, based on the aggregate unused commitments under the Asset-Based Loan.
    The ABL Facility matures on the earlier of September 30, 2025 or 91 days prior to the maturity of the Convertible Notes, at which time all outstanding amounts under the ABL Facility will be due and payable. The maximum availability under the ABL Facility is $100.0 million; however, the borrowing base under the ABL Facility fluctuates from month-to-month depending on the amount of eligible accounts receivable, inventory, and real estate. As of December 29, 2023, the amount available under the ABL Facility was $71.9 million and the ABL Facility remains undrawn.
    The ABL Facility includes various restrictive covenants that limit our ability to engage in certain transactions, including the incurrence of debt, payment of dividends and other restrictive payments, existence of restrictions affecting subsidiaries, sales of stock and assets, certain affiliate transactions, modifications of debt documents and organizational documents, changes to line of business and fiscal year, incurrence of liens, making fundamental changes, prepayments of junior indebtedness, and certain other transactions.
21
10. BUSINESS COMBINATIONS
    As of September 29, 2023, the Company, through two of its consolidated subsidiaries, Varex Imaging Deutschland AG and MeVis Medical Solutions AG ("MeVis Medical"), held a combined ownership interest in MeVis BreastCare GmbH and MeVis BreastCare Gmbh & Co KG (referred to in combination as "MeVis Breastcare") of 37.6%. Because the Company had the ability to exercise significant influence in, but not control, over MeVis Breastcare, it was historically accounted for as an equity method investment.
    In October 2023, the Company increased its ownership in MeVis Breastcare to 87.1% for a purchase price of $0.9 million, resulting in the Company now holding a controlling interest in MeVis Breastcare. The purchase of this additional ownership interest was accounted for as a business combination achieved in stages, or step acquisition. As a result, the previously held equity interest was remeasured to its acquisition-date fair value, with a gain of $0.9 million recognized in other income (expense), net in the Condensed Consolidated Statements of Operations. The assets and liabilities of MeVis Breastcare were then recorded on the Company's balance sheet at their fair values in accordance with ASC 805, and a gain on bargain purchase of $1.2 million was recorded in other income (expense), net in the Condensed Consolidated Statements of Operations. Because the purchase price did not give consideration to the other assets of the business, the fair value of the ownership interest acquired exceeded the price paid to the third party partial owner and this resulted in a gain on bargain purchase.
    The following table summarizes the consideration paid for MeVis Breastcare and the amounts of the assets acquired and liabilities assumed recognized at their estimated acquisition date fair values, as well as the estimated fair value at the acquisition date of the noncontrolling interest in MeVis Breastcare.
USD
(in millions)
Consideration paid
Cash$0.9 
Fair value of total consideration transferred0.9 
Remeasurement of previous equity interest
Carrying value of previous equity interest before acquisition1.1 
Fair value of previous equity interest at acquisition date2.0 
Remeasurement gain recorded on previous equity interest0.9 
Total of consideration paid and fair value of previous equity interest$2.9 
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash and cash equivalents$1.8 
Accounts receivable, net 1.2 
Intangible assets, net2.6 
Accounts payable(0.1)
Accrued liabilities and other current liabilities(0.6)
Other long-term liabilities(0.1)
Total identifiable net assets4.8 
Noncontrolling interest in MeVis Breastcare(0.7)
Bargain purchase gain(1.2)
Total$2.9 
22
11. NONCONTROLLING INTERESTS
    In September 2018, the Company entered into a partnership in Saudi Arabia. The Company has majority voting rights with an approximate 75% interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in its Condensed Consolidated Financial Statements and recorded the noncontrolling interests. The noncontrolling interest related to the partner’s 25% interest is included in noncontrolling interests in the equity section of the Company’s Condensed Consolidated Balance Sheets. Income representing the noncontrolling partner's share of income from operations is included in the Company's Condensed Consolidated Statements of Operations.
    In April 2015, the Company acquired 73.5% of the then outstanding shares of MeVis Medical, a publicly traded company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a Domination and Profit and Loss Transfer Agreement (the “DPLTA”) with MeVis Medical. In fiscal years 2017 and 2018, the Company purchased an additional 0.2% of outstanding shares such that the Company now owns 73.7% of the outstanding shares of common stock of MeVis Medical. Under the DPLTA, MeVis Medical subordinates its management to the Company and undertakes to transfer all its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis Medical, an annual recurring net compensation of €0.95 per MeVis Medical share. At December 29, 2023, noncontrolling shareholders together held approximately 0.5 million shares of MeVis Medical, representing 26.3% of the outstanding shares.
    During the first quarter of fiscal year 2024, the Company acquired a controlling interest in MeVis Breastcare, in which the Company now holds an 87.1% ownership interest. In association with this acquisition, the Company recorded an associated noncontrolling interest of $0.7 million.
    Changes in noncontrolling interests were as follows:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Noncontrolling interests, at beginning of period$13.3 $13.3 
Net income attributable to noncontrolling interests0.1 0.1 
Business acquisitions0.7 — 
Other— (0.1)
Noncontrolling interests, at end of period$14.1 $13.3 
23
12. NET (LOSS) INCOME PER SHARE
    Basic net (loss) income per common share is computed by dividing the net (loss) income for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted net (loss) income per common share reflects the effects of potentially dilutive securities, which is computed by dividing the sum of net (loss) income and any adjustments to net income by the sum of the weighted average number of common shares outstanding and dilutive common shares.
    A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:
Three Months Ended
(In millions, except per share amounts)
December 29, 2023December 30, 2022
Net (loss) income per share - basic
Net (loss) income attributable to Varex$(0.5)$3.1 
Basic weighted average shares outstanding
40.6 40.1 
Basic net (loss) income per share attributable to Varex$(0.01)$0.08 
Net (loss) income per share - diluted
Net (loss) income attributable to Varex$(0.5)$3.1 
Basic weighted average shares outstanding40.6 40.1 
Dilutive effect of share-based awards and other— 0.5 
Diluted weighted average shares outstanding
40.6 40.6 
Diluted net (loss) income per share attributable to Varex$(0.01)$0.08 
Anti-dilutive share summary
Share-based awards and other
3.6 3.0 
Convertible notes9.6 9.6 
Warrants9.6 1.9 
Total anti-dilutive shares22.8 14.5 
    Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying stock options, unvested stock awards, purchase rights granted under the employee stock purchase plan, warrants, and Convertible Notes using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net (loss) income per share attributable to Varex when their effect is dilutive. In connection with the offering of the Convertible Notes, the Company entered into convertible note hedges and warrants (see Note 9, Borrowings). However, the Company's convertible note hedges are not included when calculating potentially dilutive shares since their effect is always anti-dilutive.
13. EMPLOYEE STOCK PLANS
Share-Based Compensation Expense
    Share-based compensation expense recognized in the Condensed Consolidated Statements of Operations is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company’s direct employees.
24
    The table below summarizes the effect of recording share-based compensation expense and the option value of the employee stock purchase plan shares:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Cost of revenues$0.5 $0.4 
Research and development0.9 0.8 
Selling, general, and administrative
2.3 2.1 
Total share-based compensation expense$3.7 $3.3 
Stock Option Activity
    The following table summarizes the activity for stock options under Varex’s employee incentive plans for the Company's employees:
(In thousands, except per share amounts and the remaining term)OptionsPrice Range
Weighted Average Exercise Price
Weighted Average Remaining Term (in years)
Aggregate Intrinsic Value(1)
Outstanding at September 29, 20232,862 
$13.61 - $37.60
$28.08 4.8$871.4 
Granted— 
$0.00 - $0.00
— 
Canceled, expired or forfeited— 
$0.00 - $0.00
— 
Outstanding at December 29, 20232,862 
$13.61 - $37.60
$28.08 4.6$1,159.0 
Exercisable at December 29, 20232,249 
$13.61 - $37.60
$29.01 3.6$937.8 
(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $20.50 as of December 29, 2023, the last trading date of the Company's first quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their in-the-money options and sold the shares received upon exercise as of that date.
Restricted Stock Units, Performance Stock Units, Restricted Stock Awards, and Deferred Stock Units
    In the first quarter of fiscal year 2024, the Company issued performance stock units ("PSUs"). PSUs are awarded to certain officers and key employees in connection with our long-term incentive program. Each PSU represents the right to receive one share of our common stock, provided that the applicable performance and vesting conditions are satisfied. The fair value of certain PSUs are linked to the achievement of performance goals based on Adjusted EBITDA margin. Share-based compensation expense for these PSUs are recognized over the performance period based on the probability of achieving the performance targets. Certain PSUs include a performance objective based on our relative total shareholder return over the performance period compared to a predetermined peer group. The fair value of these awards is determined using a Monte Carlo simulation as of the date of the grant and share-based compensation expense will not be adjusted should the target awards vary from actual awards.
    The following table summarizes the activity for restricted stock units, performance stock units, restricted stock awards, and deferred stock units under the 2020 Omnibus Stock Plan:
(In thousands, except per share amounts)Number of SharesWeighted Average Grant-Date Fair Value
Outstanding at September 29, 20231,277 $22.30 
Granted785 20.17 
Vested(142)28.04 
Canceled or expired(16)21.91 
Outstanding at December 29, 20231,904 $21.00 
25
14. TAXES ON (LOSS) INCOME
    For the three months ended December 29, 2023, the Company recognized income tax benefit of $0.2 million on $0.6 million of pre-tax loss. For the three months ended December 30, 2022, the Company recognized income tax expense of $2.2 million on $5.4 million of pre-tax income. The Company is unable to recognize a tax benefit for pre-tax book losses in certain foreign jurisdictions but has recognized tax expense for profitable foreign jurisdictions.
    The Company's tax expense for the three months ended December 29, 2023 decreased, primarily due to decreased pre-tax income in certain jurisdictions and losses in certain foreign jurisdictions for which no benefit can be recorded.
    The Company is maintaining its reinvestment assertion with respect to foreign earnings for the three months ended December 29, 2023, which is that all earnings prior to fiscal year 2018 are permanently reinvested for all countries, and that all earnings for Varex Imaging Sweden and Oy Varex Imaging Finland are also indefinitely reinvested in those countries, but post fiscal year 2017 earnings in all other countries are not permanently reinvested. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable United States tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately $0.1 million. This estimated liability is for United States state income taxes and foreign withholding taxes that would apply if the foreign earnings were repatriated in the form of a dividend.
15. SEGMENT INFORMATION
    The Company has two reportable operating segments: Medical and Industrial, which aligns with how the CODM reviews the Company’s performance. The segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s CEO evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross profit. The operating and reportable segment structure provides alignment between business strategies and operating results.
Description of Segments
    The Medical segment designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. These components are used in a range of medical imaging applications including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses.
    The Industrial segment designs, develops, manufactures, sells and services X-ray imaging products for use in a number of markets, including security applications for cargo screening at ports and borders, baggage screening at airports, and nondestructive testing, irradiation, and inspection applications used in a number of other vertical markets. The Company's industrial products include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, and coolers. In addition, the Company licenses proprietary image-processing and detection software designed to work with other Varex products to provide packaged sub-assembly solutions to industrial customers.
    Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.
26
    Information related to the Company’s segments is as follows:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Revenues, net
Medical$139.9 $160.1 
Industrial50.1 45.5 
Total revenues190.0 205.6 
Gross profit
Medical38.9 46.3 
Industrial18.2 17.0 
Total gross profit57.1 63.3 
Total operating expenses52.9 50.3 
Interest and other expense, net(4.8)(7.6)
(Loss) income before taxes(0.6)5.4 
Income tax (benefit) expense(0.2)2.2 
Net (loss) income(0.4)3.2 
Less: Net income attributable to noncontrolling interests0.1 0.1 
Net (loss) income attributable to Varex$(0.5)$3.1 
    The Company does not disclose total assets by segment as this information is not provided to the CODM.
27
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
    The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and notes thereto that are contained in this Quarterly Report on Form 10-Q (this "Quarterly Report") as well as our Annual Report on Form 10-K for the fiscal year ended September 29, 2023 ("Annual Report") and our other filings, including the Current Reports on Form 8-K, that have been filed with the Securities and Exchange Commission (" SEC") through the date of this report.
    In this Quarterly Report, unless otherwise specified or the context otherwise requires, the "Company," "Varex," "we," "us," and "our" refer to Varex Imaging Corporation.
Forward-Looking Statements
    This Quarterly Report contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, which provides a “safe harbor” for statements about future events, products, and future financial performance that are based on the beliefs of, estimates made by, and information currently available to the management of Varex. Actual results and the outcome or timing of certain events described in these forward-looking statements are subject to risk and uncertainties and may differ significantly from those described. Important factors that could cause our actual results and financial condition to differ significantly from those projections or expectations include, among other things, the following:
•reduction in or loss of business of one or more of our limited original equipment manufacturing (“OEM”) customers;
•loss of business to, and an inability to effectively compete with, competitors;
•pricing pressures and other factors that could result in margin erosion and loss of customers;
•failure to meet customers’ needs and demands;
•global, regional, and country-specific economic instability, shifting political environments, changing tax treatment, reactionary import/export regulatory regimes, and other risks associated with international manufacturing, operations, and sales;
•supply chain disruptions resulting in delayed product delivery, and increased costs as a result of reliance on a limited number of suppliers for certain key components;
•inability to maintain or defend our intellectual property rights, and high cost of protecting our intellectual property and defending against infringement claims;
•disruption of critical information systems or material breaches in the security of our systems;
•noncompliance with regulations applicable to marketing, manufacturing, labeling, and distributing our products and delays in obtaining regulatory clearances or approvals;
•limitations imposed by operating and financial restrictions of our debt financing agreements could harm our long-term interests, limit our ability to make payments on our debt obligations, and impact our ability to maintain sufficient liquidity and/or to refinance our debt obligations; and
•other factors cited in Part I, Item 1A, "Risk Factors" in our Annual Report and in Part II, Item 1A, "Risk Factors" of this Quarterly Report.
    Statements concerning supply chain and logistics challenges; cost increases and expense management; changes in U.S. and worldwide economic conditions, such as the impact of inflation, and fluctuations in foreign currency exchange rates; geopolitical tensions; industry or market segment outlook; market acceptance of or transition to new products or technologies such as advanced X-ray tube and digital flat panel detector products; growth drivers; future orders, revenues, backlog, earnings or other financial results; and any statements using the terms “believe,” “expect,” “anticipate,” “can,” “should,” “would,” “could,” “estimate,” “may,” “intend,” “potential,” and “possible” or similar statements are forward-looking statements that involve risks and uncertainties that could cause our actual results and the outcome and timing of certain events to differ materially from those projected or management’s current expectations.
    Any forward-looking statement made in this Quarterly Report (including in any exhibits or documents incorporated by reference) is based only on information currently available to Varex and its management and speaks only as of the date on which it is made. We have not assumed any obligation to, and you should not expect us to, update or revise those statements because of new information, future events or otherwise.
28
Overview
    Varex Imaging Corporation is a leading innovator, designer and manufacturer of X-ray imaging components including X-ray tubes, flat panel and photon counting detectors and accessories, linear accelerators, image software processing solutions, and stand-alone X-ray based systems in select application areas. Our components are used in medical diagnostic imaging, security inspection systems, and industrial quality inspection systems, as well as for analysis and measurement applications in industrial manufacturing applications. Global OEMs incorporate our X-ray imaging components into their systems to detect, diagnose, protect, irradiate, and inspect. Varex has approximately 2,300 full-time equivalent employees, located at engineering, manufacturing, and service center sites in North America, Europe, and Asia.
    Our products are sold in three geographic regions: the Americas, EMEA, and APAC. The Americas includes North America (primarily the United States) and Latin America. EMEA includes Europe, the Middle East, India, and Africa. APAC includes Asia (other than India) and Australia. Revenues by region are based on the known final destination of products sold.
    Our success depends, among other things, on our ability to anticipate and respond to changes in our markets, the direction of technological innovation, and the demand from our customers. We continually invest in research and development and employ approximately 350 individuals in product development related activities. Our focus on innovation and product performance along with strong and long-term customer relationships allows us to collaborate with our customers to bring industry-leading products to the X-ray imaging market. We continue to work to improve the life and quality of our imaging components and leverage our scale as one of the largest independent X-ray imaging component suppliers to provide cost-effective solutions for our customers.
Impact of General Economic Environment
    While there continues to be some improvement in the general economic environment, we remain cautious as many factors remain dynamic and unpredictable. The uncertain economic environment, supply chain and logistic challenges, and geopolitical tensions have contributed to, and may continue to contribute to, inflation, higher interest rates and capital costs, increased shipping costs, supply shortages, increased costs of labor and materials, exchange rate volatility, and other similar effects.
    During 2023, we experienced some supply chain, manufacturing, and logistics challenges. Currently, we anticipate such challenges to have less of an impact in fiscal year 2024. Shortages of certain materials have caused, and may continue to cause, delays in manufacturing products for our customers. In some cases, raw material shortages and delivery delays from our suppliers have caused operational and customer order fulfillment challenges. In addition, since late 2023 our Medical business has been negatively impacted by the China government initiated anti-corruption measures related to the healthcare industry. We expect these actions to continue into fiscal year 2024, which could impact revenues in our China business.
    For additional information on risks related to supply chain and logistics challenges, cost increases, changes in U.S. and worldwide economic conditions, geopolitical tensions, and other risks that could impact our results, see Item 1A “Risk Factors”.
Operating Segments and Products
    We have two reportable operating segments: Medical and Industrial. The segments align our products and services offerings with customer use in medical and industrial markets.
Medical
    In our Medical segment, we design, manufacture, sell and service X-ray imaging components, including X-ray tubes, flat panel and photon counting detectors and accessories, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and coolers. These components are used in a range of medical imaging applications including CT, mammography, oncology, cardiac, surgery, dental, fluoroscopy, and other diagnostic radiography uses.
    Our X-ray imaging components are primarily sold to OEM customers. These OEM customers then design-in our products to their X-ray imaging systems for a variety of medical modalities. A substantial majority of medical X-ray imaging OEMs globally are our customers, and many of these have been our customers for over 35 years. We believe one of the reasons for customer loyalty is that our hardware and software products are tightly integrated with our customers' systems. We work very closely with our customers to create custom built components for their systems based on technology platforms that we have developed. Because our products are often customized for our customers' specific equipment, it can be costly and complex for our customers to switch to another provider. Once our components are designed into our customers' equipment, our customers will typically continue to buy from us for any replacement components and for service and support for that equipment. Some of our products are also included in product registrations for our customers' equipment that require regulatory approval to change. In addition to sales to OEM customers, we sell our products to independent service companies and distributors as well as directly to end-users for replacement purposes.
29
    We are one of the largest independent global manufacturers of X-ray imaging components, and each year, we produce over 27,000 X-ray tubes and 20,000 X-ray detectors. We estimate that our world-wide installed base of products includes more than 160,000 X-ray tubes, 170,000 X-ray detectors, 600,000 connect and control components, and 16,500 software instances. Replacement and service of our existing installed base makes up a significant portion of our revenue. Many of our components need to be replaced regularly, depending upon usage and other factors. For example, CT X-ray tubes generally need to be replaced every 2 to 6 years, in comparison to a general radiography tube which can last up to 10 years, depending on utilization. In China, the replacement cycle for CT X-ray tubes currently can be as frequent as every 10 to 20 months due to high utilization of imaging equipment. Other products such as X-ray detectors have a useful life of as much as 7 years or more but can require more frequent service and repairs during their useful life. In addition, our detector customers often elect to upgrade products to newer technology before the end of a current product’s useful life. X-ray imaging software is a relatively small part of our business and includes maintenance revenue for software licenses.
    In China, the government is broadening the availability of healthcare services. As a result, the number of diagnostic X-ray imaging systems, including CT, has grown significantly. We are developing CT X-ray tubes and related subsystems for Chinese OEMs as they introduce new systems in China. Over the long-term, our objective is to become the partner of choice both for OEMs and in the replacement market as CT systems become more widely adopted throughout the Chinese market.
    In recent years our business in China has been impacted by the trade war with the United States in three principal ways: (1) importing raw materials from China to the United States has become more expensive, (2) importing raw materials and sub-assemblies from the United States to China has become more expensive, and (3) importing finished United States manufactured products into China has become more difficult and expensive. While the governments of both the United States and China have granted tariff exclusions that temporarily eliminate the additional duties payable for specific commodities, providing partial relief, these exclusions are temporary and/or must be solicited and approved on a shipment-by-shipment basis. There is no guarantee that such exclusions will be granted or extended by either government, and the U.S. tariff exclusions are set to expire on May 31, 2024 unless extended. In order to mitigate the impact of tariffs on materials imported from China, we have implemented changes to secure more non-China sources of materials used to manufacture our X-ray imaging products. To help mitigate the impact of tariffs on materials imported to China, and to be closer to our global customer base, we continue to expand manufacturing capabilities at our facilities in China, Germany, the Netherlands, and the Philippines. We have also implemented local sourcing strategies to offer local content. This local-for-local strategy has been well received by both our local customers as well as global OEMs, and acts as a natural hedge against trade wars and other potential supply chain disruptions. Our mitigation efforts could prove less effective than anticipated if tensions between China and Taiwan lead to worsening trade relations between China and the United States.
Industrial
    In our Industrial segment, we design, develop, manufacture, sell, and service X-ray imaging products for use in a number of markets, including security applications for cargo screening at ports and borders, baggage screening at airports, and nondestructive testing, irradiation, and inspection applications used in a number of other vertical markets. Our industrial products include Linatron® X-ray linear accelerators, X-ray tubes, flat panel and photon counting detectors, computed radiography scanners, high voltage connectors, and coolers. In addition, we license proprietary image-processing and detection software designed to work with other Varex products to provide packaged sub-assembly solutions to our industrial customers. Our Industrial business benefits from the research and development investment and manufacturing economies of scale on the Medical side of our business, as we continue to find new applications for our technology. Along with more favorable pricing dynamics, this allows us to generally achieve higher gross profit for industrial products relative to our Medical business. In addition, our Industrial business benefits from our long-term service agreements for our Linatron® products.
    The security market primarily consists of cargo security for the screening of trucks, trains, and cargo containers at ports and borders as well as airport security for checked baggage and palletized cargo. The end customers for border protection systems are typically government agencies, many of which are in oil-based economies and war zones where there can be significant variation in buying patterns.
    Non-destructive testing and inspection verticals utilize X-ray imaging to scan items for inspection of manufacturing defects and product integrity in a wide range of industries including aerospace, automotive, electronics, oil and gas, food packaging, metal castings, and additive manufacturing. In addition, new applications for X-ray sources are being developed, such as sterilization of food and its packaging. We provide X-ray sources, digital detectors, high voltage connectors, and image processing software to OEM customers, system integrators, and manufacturers in a variety of these verticals. We believe that the non-destructive testing market represents a significant growth opportunity for our business, and we are actively pursuing new potential applications for our products.
30
Critical Accounting Policies and Estimates
    The preparation of our unaudited condensed consolidated financial statements and related disclosures in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on historical experience and on various other factors that we believe are reasonable under the circumstances. Our critical accounting policies that are affected by accounting estimates require us to use judgments, often as a result of the need to make estimates and assumptions regarding matters that are inherently uncertain, and actual results could differ materially from these estimates.
    We periodically review our accounting policies, estimates, and assumptions and make adjustments when facts and circumstances dictate. Refer to our Annual Report on Form 10-K for the fiscal year ended September 29, 2023 filed with the SEC on November 16, 2023 and Note 1, Summary of Significant Accounting Policies, of the Notes to the Consolidated Financial Statements of this report for further details. Our critical accounting policies that are affected by accounting estimates include valuation of inventories, assessment of recoverability of goodwill and intangible assets, and income taxes. Except for the changes in certain policies upon adoption of the accounting standard described in Note 1, Summary of Significant Accounting Policies of the Notes to the Condensed Consolidated Financial Statements of this report, there have been no material changes to the Company’s significant accounting policies, compared to the accounting policies described in Note 1, Summary of Significant Accounting Policies, in the Company’s Annual Report on Form 10-K for fiscal year 2023.
Fiscal Year
    The fiscal years of the Company as reported are the 52 or 53-week periods ending on the Friday nearest September 30. Fiscal year 2024 is the 52-week period ending September 27, 2024. Fiscal year 2023 was the 52-week period that ended on September 29, 2023. The fiscal quarters ended December 29, 2023 and December 30, 2022 were both 13-week periods.
Discussion of Results of Operations for the Three Months Ended December 29, 2023 Compared to the Three Months Ended December 30, 2022
Revenues, net
Three Months Ended
(In millions)December 29, 2023December 30, 2022$ Change% Change
Medical$139.9 $160.1 $(20.2)(12.6)%
Industrial50.1 45.5 4.6 10.1 %
Total revenues$190.0 $205.6 $(15.6)(7.6)%
Medical as a percentage of total revenues73.6 %77.9 %
Industrial as a percentage of total revenues26.4 %22.1 %
    Medical revenues decreased $20.2 million, primarily due to decreased sales of fluoroscopic, dental, and CT, partially offset by increased sales in mammography.
    Industrial revenues increased $4.6 million, primarily due to increased sales of security inspection products, partially offset by decreased sales of digital detectors.
Gross Profit
Three Months Ended
(In millions)December 29, 2023December 30, 2022$ Change% Change
Medical$38.9 $46.3 $(7.4)(16.0)%
Industrial18.2 17.0 1.2 7.1 %
Total gross profit$57.1 $63.3 $(6.2)(9.8)%
Medical gross margin27.8 %28.9 %
Industrial gross margin36.3 %37.4 %
Total gross margin30.1 %30.8 %
    The decrease in Medical segment gross profit was primarily due an unfavorable shift in product sales mix, partially offset by decreased material costs.
31
    The Industrial segment gross profit increased primarily due to increased sales in security inspection products, partially offset by an unfavorable shift in product sales mix.
Operating Expenses
Three Months Ended
(In millions)December 29, 2023December 30, 2022$ Change% Change
Research and development$20.5 $20.0 $0.5 2.5 %
As a percentage of total revenues10.8 %9.7 %
Selling, general, and administrative$32.4 $30.3 $2.1 6.9 %
As a percentage of total revenues17.1 %14.7 %
Operating expenses$52.9 $50.3 $2.6 5.2 %
As a percentage of total revenues27.8 %24.5 %
Research and Development
    We are committed to investing in the business to support long-term growth and believe long-term research and development expenses of approximately 8% to 10% of annual revenues is the appropriate range that will allow us to innovate and bring new products to market for our global OEM customers. Research and development costs increased to 10.8% of revenues for the first quarter of fiscal year 2024, primarily due to decreased sales and increased research and development costs.
Selling, General, and Administrative
    Selling, general, and administrative expenses for the first quarter of fiscal year 2024 increased $2.1 million, primarily due to increased fixed cost commitments to a supplier and increased compensation costs.
Interest and Other Expense, Net
    The following table summarizes the Company’s interest and other expense, net:
Three Months Ended
(In millions)December 29, 2023December 30, 2022$ Change
Interest income$1.9 $0.5 $1.4 
Interest expense(7.3)(7.5)0.2 
Other income (expense), net0.6 (0.6)1.2 
Interest and other expense, net$(4.8)$(7.6)$2.8 
    Interest and other expense, net decreased in the first quarter of fiscal year 2024 compared to the first quarter of 2023. Interest expense decreased due to reduced fees on the ABL Facility and reduced outstanding other debt.
    Other income (expense), net increased due to a gain on business acquisition, partly offset with losses in certain investments in privately-held companies and equity investments and increased foreign exchange expense.
    Interest income increased primarily due to an increase in investments made into marketable debt securities.
Taxes on (Loss) income
    For the three months ended December 29, 2023 we recognized income tax benefit of $0.2 million on $0.6 million of pre-tax loss. For the three months ended December 30, 2022 we recognized income tax expense of $2.2 million on $5.4 million of pre-tax income. Our tax expense for the three months ended December 29, 2023 decreased, primarily due to decreased pre-tax income in certain jurisdictions and losses in certain foreign jurisdictions for which no benefit can be recorded.
32
Liquidity and Capital Resources
    We assess our liquidity in terms of our ability to generate cash to fund our operations, including working capital and investing activities. We believe that our operating cash flow, cash on our balance sheet, availability under our ABL Facility, and our ability to access the credit and capital markets are sufficient to meet our anticipated operating activities and cash commitments for at least the next 12 months and will be sufficient to allow us to continue to invest in our existing businesses, consummate strategic acquisitions, and manage our capital structure on a short-term and long-term basis. We are currently not aware of any trends or demands, commitments, events, or uncertainties that will result in or that are reasonably likely to result in a material change to our liquidity needs during or beyond the next 12 months, except our Convertible Notes that become due in June 2025 that we currently anticipate refinancing using some combination of future borrowings and cash. The maximum availability under our ABL Facility is $100.0 million; however, the borrowing base under the ABL Facility fluctuates from month to month depending on the amount of eligible accounts receivable, inventory, and real estate. As of December 29, 2023, the amount available under our ABL Facility was $71.9 million, and the ABL Facility remains undrawn. At December 29, 2023 we had total debt of $443.0 million, net of deferred issuance costs of $4.8 million.
Cash and Cash Equivalents, Certificates of Deposit, and Marketable Securities
    The following table summarizes our cash and cash equivalents, certificates of deposit, and marketable securities:
(In millions)December 29, 2023September 29, 2023$ Change
Cash and cash equivalents$141.3 $152.6 $(11.3)
Certificates of deposit not included in cash and cash equivalents
1.0 1.0 — 
Marketable securities not included in cash and cash equivalents
52.2 41.3 10.9 
Total
$194.5 $194.9 $(0.4)
33
Borrowings
    The following table summarizes the changes in our debt outstanding:
December 29, 2023September 29, 2023
(In millions, except for percentages)AmountAmount$ Change
Current maturities of long-term debt
Other debt$1.6 $1.5 $0.1 
Non-current maturities of long-term debt:
Convertible Senior Unsecured Notes$200.0 $200.0 $— 
Senior Secured Notes243.0 243.0 — 
Other debt3.2 3.5 (0.3)
Total non-current maturities of long-term debt:$446.2 $446.5 $(0.3)
Unamortized issuance costs
Unamortized issuance costs - Convertible Notes$(2.1)$(2.5)$0.4 
Unamortized issuance costs - Senior Secured Notes(2.7)(2.9)0.2 
Total(4.8)(5.4)0.6 
Total debt outstanding, net$443.0 $442.6 $0.4 
Cash Flows
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Net cash flow (used in) provided by:
Operating activities$10.3 $(3.7)
Investing activities(19.9)(3.7)
Financing activities(1.7)(0.4)
Net decrease in cash and cash equivalents and restricted cash$(11.3)$(7.8)
    Net cash provided by (used in) operating activities. Net cash provided by (used in) operating activities was $10.3 million and $(3.7) million for the three months ended December 29, 2023 and December 30, 2022, respectively. The increase in cash provided by operating activities was primarily due to increased collections from accounts receivable and a reduction in cash outflows for inventory and prepaid expenses, partially offset by a decrease in non-cash adjustments to income when compared to the three months ended December 30, 2022.
    Net cash used in investing activities. Net cash used in investing activities was $19.9 million and $3.7 million for the three months ended December 29, 2023 and December 30, 2022, respectively. The increase in cash used in investing activities was primarily due to increased purchases of marketable debt securities, along with increased purchases of property, plant, and equipment during the three months ended December 29, 2023, partially offset by the settlement of net investment hedges.
    Net cash used in financing activities. Net cash used in financing activities was $1.7 million and $0.4 million for the three months ended December 29, 2023 and December 30, 2022, respectively. The increase in cash used in financing activities was primarily due to cash payments related to the taxes for net share settlement of equity awards for the three months ended December 30, 2022.
Material Contractual Obligations
    In October 2013, we entered into an amended agreement with dpiX and other parties that, among other things, provides us with the right to 50% of dpiX’s total manufacturing capacity produced after January 1, 2014. The amended agreement requires us to pay for 50% of the fixed costs (as defined in the amended agreement), as determined at the beginning of each calendar year. In January 2024, the Company's fixed cost commitment was determined to be $12.4 million for calendar year 2024. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).
34
    In August 2015, pursuant to a Domination and Profit and Loss Transfer Agreement (the “DPLTA”), we committed to pay the noncontrolling shareholders of MeVis Medical an annual recurring net compensation of €0.95 per MeVis Medical share. The annual net payment will continue for the life of the DPLTA, which we anticipate will continue for as long as we remain as the controlling shareholder of MeVis Medical. As of December 29, 2023, noncontrolling shareholders together held approximately 0.5 million shares of MeVis Medical, representing 26.3% of the outstanding shares.
    In fiscal year 2022, the Company entered into several agreements with a third-party company, whose stock is publicly traded on a foreign exchange. Under these agreements, the Company will make certain milestone payments of up to $5.0 million upon achievement of specified milestones. During fiscal year 2022, the first of these milestones was achieved and the Company paid $1.0 million to the third-party company. During fiscal year 2023, two more milestones were achieved and the Company paid an additional $2.0 million to the third-party company. No additional milestones were achieved nor were any payments made during the first quarter of fiscal year 2024. Payments made under this agreement are recorded in research and development in the Condensed Consolidated Statements of Operations. As of December 29, 2023, there were two milestones remaining of $1.0 million each under these agreements.
    The Company enters into purchase agreements with its suppliers in the ordinary course of its business for the purchase of goods and services. Some of these purchase agreements are non-cancellable and thus contractually obligate the Company to future cash payments. As of December 29, 2023, our non-cancellable supplier purchase obligations totaled $8.2 million.
Contingencies
    From time to time, we are a party to or otherwise involved in legal proceedings, government inspections, investigations, customs and duty audits, and other claims and contingency matters, both inside and outside the United States, arising in the ordinary course of our business or otherwise. We accrue amounts for probable losses, to the extent they can be reasonably estimated, that we believe are adequate to address any liabilities related to legal proceedings as well as other loss contingencies that we believe will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. We did not have any material contingent liabilities as of December 29, 2023 and September 29, 2023. Legal expenses are expensed as incurred.
Days Sales Outstanding
    Trade accounts receivable days sales outstanding (“DSO”) was 67 days at December 29, 2023 and 65 days at September 29, 2023. Our accounts receivable and DSO are impacted by a number of factors, including the timing of product shipments, collections performance, payment terms, the mix of revenues from different regions and the effects of economic instability.
Recent Accounting Standards or Updates Not Yet Effective
    See Note 1, Summary of Significant Accounting Policies, of the accompanying Notes to the Condensed Consolidated Financial Statements for a description of recent accounting standards, including the expected dates of adoption and the estimated effects on our condensed consolidated financial statements.
Backlog
    Backlog is the accumulation of all orders for which revenues have not been recognized and are still considered valid. Backlog also includes a small portion of billed service contracts that are included in deferred revenue. Our estimated total backlog at December 29, 2023 was approximately $299 million.
    Orders may be revised or canceled, either according to their terms or as customers' needs change. Consequently, it is difficult to predict with certainty the amount of backlog that will result in revenues. We perform a quarterly review to verify that outstanding orders in the backlog remain valid. Aged orders that are not expected to be converted to revenues are deemed dormant and are reflected as a reduction in the backlog amounts in the period identified.
    In addition to orders for which revenues have not been recognized and are still considered valid, we have pricing agreements with many of our established customers that span multi-year periods. These pricing agreements include volume ranges under which orders are placed.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
    We are exposed to four primary types of market risks: foreign currency exchange rate risk, credit and counterparty risk, interest rate risk, and commodity price risk.
35
Foreign Currency Exchange Rate Risk
    A significant portion of our customers are outside the United States, while our financial statements are denominated, and our products are generally priced in U.S. Dollars. A strong U.S. Dollar may result in pricing pressure for our customers that are located outside the United States and that conduct their businesses in currencies other than the U.S. Dollar. Such pricing pressure has caused, and could continue to cause, some of our customers to ask for discounted prices, delay purchasing decisions, or consider moving to in-sourcing supply of components or migrating to lower cost alternatives. In addition, because our business is global and some payments may be made in local currency, fluctuations in foreign currency exchange rates can impact our revenues and expenses and/or the profitability in U.S. Dollars of products and services that we provide or purchase in foreign markets.
    We may enter into foreign currency forward and option contracts with financial institutions to protect against foreign exchange risks associated with certain existing assets and liabilities, net investments in foreign subsidiaries, and forecast purchases denominated in foreign currencies. We may hedge portions of forecasted foreign currency exposure, typically for one to three months. In addition, we hold cross-currency swaps between the Euro and U.S. Dollar as a net investment hedge of our acquisition of Direct Conversion. Depending on the spot rate between the Euro and U.S. Dollar at the time of settlement and whether we have sufficient Euros available, we may have to borrow incrementally in U.S. Dollars to settle this obligation. Additionally, we may choose not to hedge certain foreign exchange exposures for a variety of reasons including, but not limited to, accounting considerations, the prohibitive economic cost of hedging particular exposures, or due to natural offsets among the different exposures. See Note 5, Financial Derivatives and Hedging Activities, of the Notes to the Condensed Consolidated Financial Statements for further information.
Credit and Counterparty Risk
    We use a centralized approach to manage substantially all of our cash and to finance our operations. Our cash and cash equivalents and marketable securities may be exposed to a concentration of credit risk, and we may also be exposed to credit risk and interest rate risk to the extent that we enter into credit facilities.
    We perform ongoing credit evaluations of our customers and we maintain what we believe to be strong credit controls in evaluating and granting customer credit, including performing ongoing evaluations of our customers’ financial condition and creditworthiness and often using letters of credit or requiring certain customers to provide a down payment.
Interest Rate Risk
    Borrowings under our ABL Facility bear interest at floating interest rates. At December 29, 2023, we had no borrowings subject to floating interest rates. See Note 9, Borrowings, of the Notes to the Condensed Consolidated Financial Statements for further information.
    Our exposure to interest rate risk also relates to our interest-bearing assets, primarily our cash and cash equivalents and marketable securities. Fixed rate securities may have their market value adversely affected due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates fall. Due in part to these factors, our future investment income may fluctuate due to changes in interest rates or we may suffer losses in principal if we are forced to sell securities that decline in market value due to changes in interest rates.
Commodity Price Risk
    We are exposed to market risks related to volatility in the prices of raw materials used in our products. The prices of these raw materials fluctuate in response to changes in supply and demand fundamentals and our product margins and level of profitability tend to fluctuate with changes in these raw materials prices. We try to protect against such volatility through various business strategies. During the three months ended December 29, 2023, we did not have any commodity derivative instruments in place to manage our exposure to price changes.
36
Sensitivity Analysis
    The following table sets forth the potential loss in future earnings, fair value, or cash flows resulting from hypothetical changes in relevant market rates or prices as of December 29, 2023.
Market Risk CategoryHypothetical ChangeEstimated Annual Impact
(In millions)		Impact Category
Foreign Currency - Revenue10% decrease in foreign exchange rates$17.1 Earnings
Interest Rate - Marketable Securities100 basis point decrease in interest rate of underlying investments1.3 Earnings
Commodity Price10% increase in commodity prices$3.7 Earnings
Item 4. Controls and Procedures
Disclosure Controls and Procedures
    Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act") are designed to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), we conducted an evaluation of the effectiveness of our internal control over financial reporting as of the end of the period covered by this report. Based on this evaluation, our CEO and our CFO have concluded that our disclosure controls and procedures were effective as of December 29, 2023.
Changes in Internal Control Over Financial Reporting
    There were no changes in our internal control over financial reporting during the quarter ended December 29, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) under the Exchange Act).
37
PART II
OTHER INFORMATION
Item 1. Legal Proceedings
    We are subject to various claims, complaints and legal actions in the normal course of business from time to time. The resolution of such claims, complaints, and legal actions is subject to significant uncertainty and may be expensive, time consuming and disruptive to our operations. At the present time, we do not believe we have any current or pending litigation for which the outcome could have a material adverse effect on our operations or financial position.
Item 1A. Risk Factors
Investing in Varex Imaging Corporation common stock involves risks and the following risk factors and other information included in this Quarterly Report on Form 10-Q (this "Quarterly Report") under Part I, Item 2 "Management’s Discussion and Analysis of Financial Condition and Results of Operations" and Part I, Item 3 "Quantitative and Qualitative Disclosures about Market Risk" should be carefully considered. Although the risk factors described below are the ones management deems significant, additional risks and uncertainties not presently known to us or that are presently known to us that we presently deem not material may also adversely affect our business operations.
Risks Relating to Our Business
We sell our products and services to a limited number of OEM customers, many of which are also our competitors, and a reduction in or loss of business of one or more of these customers may materially reduce our sales.
    We had one customer during the three months ended December 29, 2023 that accounted for 15% of our revenue. Our ten largest customers as a group accounted for approximately 52% and 55% of our revenue for the three months ended December 29, 2023 and December 30, 2022, respectively. Because we often take significant time to replace lost business, in the past our operating results have been, and in the future it is likely that our operating results would be, materially and adversely affected if one or more of our major OEM customers were to cancel, delay, or reduce orders in the future.
    Furthermore, we generate significant accounts receivables from the sale of our products and the provision of services directly to our major customers. One customer accounted for 8.2% of our accounts receivables as of December 29, 2023. If one or more of these customers were to cancel a product order or service contract, become insolvent, or otherwise be unable or fail to pay for our products and/or services in a timely manner, our operating results and financial condition could be materially and adversely affected.
We may not be able to accurately predict the demand or delivery schedules for our products.
    End-user product demand, economic uncertainties, the impact of pandemic diseases, natural disasters, armed conflict, geopolitical tensions, government actions (for example, the Chinese government initiated anti-corruption investigation related to its healthcare industry), and other matters beyond our control, make it difficult for our customers to accurately forecast and plan future business activities, which makes it difficult for us to accurately predict demand for our products. Because the manufacture of our products requires some lead-time, changes in customer purchasing forecasts have previously resulted in excess inventory and slowdowns in sales, which are likely to occur again in the future. Changes to customer forecasts can occur on short notice, as our customers face inherent competitive issues, new product introduction delays, and market and regulatory risks. Our agreements for imaging components contain purchasing estimates that are typically based on our customers’ forward-looking forecasts rather than firm commitments, and actual purchasing volumes under the agreements may vary significantly from these estimates. The variation from forecasted purchasing volume may be due, in part, to the increasing life of X-ray tubes, which can result in reduced demand for replacement X-ray tubes in ways we may not be able to accurately forecast. Reductions in purchasing patterns have in the past, and may in the future, materially and adversely affect our operating results.
We compete in highly competitive markets, and we are subject to pricing pressures and other factors that could result in margin erosion and loss of customers.
    We compete in markets characterized by rapidly-evolving technology, intense competition and pricing pressure. We often compete with companies that have greater financial, marketing and other resources than us. Some of the major diagnostic imaging systems companies, which are the primary OEM customers for our X-ray imaging components, also manufacture X-ray imaging components, including X-ray tubes and flat panel detectors, for use in their own imaging systems products. We have experienced, and may in the future experience, decreased sales of our products to these customers if they manufacture a greater percentage of their components in-house or purchase components from external sources other than us, which has had and may in the future have an
38
adverse effect on our business and results of operations. We have in the past made price and other concessions to maintain existing customers and attract new customers, and may have to make additional price concessions in the future.
    In addition, we compete against other stand-alone, independent X-ray tube manufacturers for both the OEM business of major diagnostic imaging equipment manufacturers and the independent servicing business for X-ray tubes. The market for flat panel detectors is also very competitive, and we face intense competition from over a dozen smaller competitors. In our Industrial segment, we also compete with other OEM suppliers primarily outside of the United States. Some of our competitors outside of the United States may have resources and support from their governments that we do not, such as preferences for local manufacturers, and may not be subject to the same trade compliance regulations as us.
    Our competitors are not all subject to the same standards, regulatory and/or other legal requirements to which we are subject and, therefore, they could have a competitive advantage in developing, manufacturing, and marketing products and services. Any inability to develop, gain regulatory approval for, and supply commercial quantities of competitive products to the market as quickly and effectively as our competitors could limit market acceptance of our products and negatively and materially affect our pricing, sales, revenues, market share, and gross margins and our ability to maintain or increase our operating margins.
Our success depends on meeting our customers' needs and demands.
    To be successful, we must anticipate our customers’ needs and demands, as well as potential shifts in market preferences. If we are unable to anticipate these needs and demands, or the mix of products requested by our customers changes from what we expect, our revenue, margins, and financial results could be adversely affected. When the U.S. Dollar is strong compared to the operating currencies of our international customers, our ability to meet such customers’ pricing expectations is particularly challenging and may result in erosion of revenues, product margin, and/or market share or other concessions on business terms.
    In addition, certain costs, including installation and warranty costs, associated with new products may be proportionately greater than the costs associated with existing products and may therefore disproportionately, materially, and adversely affect our gross and operating margins. We may also experience lower margins due to increased commodities prices, and inadequate transfer pricing favoring sales to third parties over internal sales. If we are unable to lower these costs over time, our operating results could be materially and adversely affected. Some of the electronic components and integrated circuits used in our flat panel detectors are susceptible to discontinuance and obsolescence risks, which may force us to incorporate newer generations of these components, resulting in unplanned additional R&D expenses, delays in the launch of new products, supply disruptions, or inventory write-downs. Further, using aging production equipment might hamper our capacity to innovate to meet customers’ needs and demands and stay competitive. Failure to develop and adopt artificial intelligence ("AI") technology could also hinder competitiveness and growth potential in a rapidly evolving market. We may also experience challenges in developing and implementing effective market strategies, leading to missed opportunities and customer dissatisfaction.
Our success depends on the successful development, introduction, and commercialization of new generations of products and enhancements to or simplifications of existing product lines.
    We operate in a market characterized by rapid change and technological innovation. Our customers use our products in their medical diagnostic, security, and industrial imaging systems, and we must continually introduce new products at competitive prices while also improving existing products with higher quality, lower costs, and increased features. We and our joint ventures have in the past spent, and in the future may need to spend, more time and money than we expect to develop, market, and introduce new products, product enhancements, and technologies. Even if we succeed in introducing new products, enhancements, or technologies as soon as expected, if at all, potential customers may not accept or purchase these new products, enhancements, or technologies, and we may not be able to recover all or a meaningful part of our investment. Once introduced, new products may materially and adversely impact sales of our existing products or make them less desirable or even obsolete, which could materially and adversely impact our revenues and operating results.
    Furthermore, we may not be able to successfully develop, manufacture, or introduce new products or enhancements to existing products, the roll-out of which involves compliance with complex quality assurance processes, including the Quality System Regulation (“QSR”) of the U.S. Food and Drug Administration (“FDA”). Failure to complete these processes timely and efficiently could result in delays that could affect our ability to attract and retain customers or cause customers to delay or cancel orders, which would materially and adversely affect our revenues and operating results.
39
More than half of our revenue is generated from customers located outside the United States, and is subject to global, regional, and country-specific economic instability, shifting political environments, changing tax treatment, and other risks associated with international manufacturing, operations, and sales.
    Revenues generated from customers located outside the United States accounted for approximately 68% and 68% of our total revenues for the three months ended December 29, 2023 and December 30, 2022, respectively. We intend to continue to expand our presence in international markets and expect to expend significant resources in doing so. Our future results could be impacted by a variety of factors, including:
•currency fluctuations, and in particular the strength of the U.S. Dollar (which is our functional and reporting currency);
•political and economic instability, including the possibility of civil unrest, terrorism, mass violence or armed conflict, which may among other things, impact our operations and business access;
•difficulties in staffing and managing employee relations in foreign operations, including in foreign joint ventures, particularly in attracting and retaining personnel qualified to design, test, sell and support our products;
•difficulties in coordinating our operations globally and in maintaining uniform standards, controls, procedures, and policies across our operations;
•the longer payment cycles associated with many customers located outside the United States;
•difficulties in interpreting or enforcing agreements and collecting receivables through many foreign countries’ legal systems;
•imposition of burdensome governmental regulations, including changing laws and regulations with respect to collection and maintenance of personally identifiable data;
•the imposition by governments of additional taxes, tariffs, global economic sanctions programs, or other restrictions on foreign trade; and
•compliance with export laws and requirements.
    Our international locations expose us to higher security risks compared to our United States locations, which could result in both harm to our employees and contractors or substantial costs. Some of our services are performed in or adjacent to high-risk locations where the country or location and surrounding area is suffering from political, social, or economic turmoil, war or civil unrest, or has a high level of criminal or terrorist activity. In those locations where we have employees or operations, we may incur substantial costs to maintain the safety of our personnel, and we may suffer the loss of employees and contractors, which could harm our business reputation and operating results.
We may be unable to complete future acquisitions or joint ventures or realize expected benefits from acquisitions of or investments in new businesses and joint ventures, products, or technologies, which could harm our business.
    Our ability to identify and take advantage of attractive acquisitions or other business development opportunities (including through joint ventures) is an important component in implementing our overall business strategy. Such transactions involve a number of risks, including the following:
•we may not be able to identify suitable candidates or successfully complete or finance identified acquisitions,
•we may incur substantial costs, including advisory fees and diversion of management attention, in evaluating a potential transaction;
•we may be unable to achieve the anticipated benefits from the transaction, including a return on our investment;
•we may have difficulty integrating organizations, products, technologies, or employees of an acquired business into our operations and may have difficulty retaining the key personnel of the acquired business;
•acquisitions, investments, and joint ventures could result in increased risks, including from potential litigation,
•we may find that we need to restructure or divest acquired businesses or assets of the acquired business; and
•if we fail to achieve the anticipated growth from an acquisition or joint venture, or if we decide to sell assets or a business, we may be required to dispose of a business at a lower price or on less advantageous terms, or to recognize an impairment loss on the write-down of our assets and goodwill.
    We participate in joint ventures and other investments in privately held and publicly traded companies. For example, we hold a 40% ownership interest in dpiX LLC, our major supplier of our amorphous silicon-based thin film transistor arrays for flat panels used in our digital image detectors, and a 50% interest in VEC Imaging GmbH & Co. KG, ("VEC") a joint venture formed to develop technology for use in X-ray imaging components, and a minority interest in another X-ray imaging components technology company. These and other investments are subject to risk of loss of investment capital as well as losses associated with contributed or jointly developed intellectual property, or intellectual property developed at or about the same time as these investments. These types of investments are inherently risky, in some instances because the markets for the technologies or products these companies have under development may never materialize, may develop slower than expected, or may underperform relative to our expectations. If these companies do not succeed, we could lose some or all of our investment in these companies. In addition, we may incur significant costs and management resources to enforce our rights, protect our intellectual property and other assets, address disputes or legal claims that have arisen, are ongoing, or may arise in the future, and/or unwind, dispose of or terminate our arrangements with respect to these
40
investments. There is no guarantee that the time and money invested by us in these projects, developed intellectual property, or product or product enhancements, will yield the expected returns on the anticipated timeline or at all.
Legal proceedings may materially and adversely affect our business, results of operations, or cash flows.
    From time to time, we are a party to or otherwise involved in legal proceedings, claims, government inspections, audits or investigations, and other legal matters, both inside and outside the United States, arising in the ordinary course of our business or otherwise. Such proceedings are often lengthy, subject to significant uncertainty and may be expensive, time consuming, and disruptive to our operations. For these and other reasons, we may choose to settle legal proceedings and claims, regardless of their actual merit. If a legal proceeding were ultimately resolved against us, we may be required to pay damages or fines, some of which may be in excess of our insurance coverage, or may require us to change our business practices, which could materially and adversely impact our business, results of operations, or cash flows.     
    Our subsidiary Varex Imaging Deutschland AG holds a 50% interest in VEC. In August 2023, the partners to the VEC joint venture filed judicial proceedings in Germany against one another disputing the validity of shareholder resolutions passed in January 2023. Each party is seeking to have the other party’s managing director(s) removed and to exclude the other party from the joint venture. If either party is successful, the prevailing party would be required to purchase the non-prevailing party’s interest in the joint venture for an amount equal to 75% of the fair market value thereof, which amount is in dispute.
Product defects or misuse may result in material product or other liability or professional errors and omissions claims, litigation, investigation by regulatory authorities, or product recalls.
    Our business exposes us to potential product and other liability claims that are inherent in the manufacture, sale, installation, servicing, and support of components that are used in medical devices and other devices that deliver radiation. Because our products, through incorporation into OEMs’ systems, are involved in the intentional delivery of radiation to the human body and other situations where people may come into contact with radiation, the possibility for significant personal injury or loss of life exists. Furthermore, if our x-ray inspection systems fail to detect the presence of bombs, explosives, weapons, contraband, or other threats to personal safety, this may lead to personal injury, loss of life, and extensive property damage. We may also be subject to warranty and damage claims for property damage, personal injury, or economic loss related to or resulting from any errors or defects in our products or the installation, servicing, or support of our products. Any accident or mistreatment could subject us to legal costs, litigation, adverse publicity, and damage to our reputation, whether or not our products or services were a factor. We are currently a party to certain products liability litigation which, if adversely determined, could have an adverse material impact on our financial results. If a product we design or manufacture were defective, we may be required to correct or recall the product and notify regulatory authorities.
    We may choose to settle product liability claims against us regardless of their actual merit. A product liability action determined against us could result in adverse publicity or significant damages, including the possibility of punitive damages, and our combined financial position, results of operations, or cash flows could be materially and adversely affected.
    We maintain limited product liability insurance coverage. Our product liability insurance policies are expensive and have high deductible amounts and self-insured retentions. Our insurance coverage may prove to be inadequate, and future policies may not be available on acceptable terms or in sufficient amounts, if at all. If a material claim is not insured or is in excess of our insurance coverage, we could have to pay substantial damages, which could have a material and adverse effect on our financial position and/or results of operations.
Risks Relating to the Manufacture of our Products
Supply chain disruptions, including the loss of a supplier, and any inability to obtain raw materials or supplies of important components due to inflation have impacted our ability to manufacture products, have caused delays in our ability to deliver products, and have increased our costs and may continue to do so.
    Inflation and supply chain disruptions have had, are currently having, and could continue to have, an impact on our ability to manufacture certain products. Inflation has the potential to increase our overall cost structure, and sustained inflation has resulted in, and may continue to result in, higher interest rates and capital costs, increased shipping costs, supply shortages, increased costs of labor, weakening exchange rates, and other similar effects.
41
    Material shortages and delays due to inflation and other market constraints have caused, and could in the future cause, us to temporarily stop production of certain products or miss opportunities to pursue additional sales of some products. We require certain raw materials, such as copper, nickel, silver, gold, lead, tungsten, iridium, rhenium, molybdenum, rhodium, niobium, zirconium, beryllium, and various high grades of steel alloy for X-ray tubes and industrial products. Worldwide demand, availability, and pricing of these raw materials have been volatile. If we are unable to obtain the materials necessary to make certain products without unreasonable delay, our customers may seek alternative suppliers or decide to in-source certain products or if we must pay more for certain materials, it could reduce our profit margin or otherwise have a material adverse effect on our business and financial results. Further, our competitors with greater financial resources may be better able to restructure their manufacturing and supply chains in response to geopolitical and economic trends and thereby have a competitive advantage over us.
    We obtain some of the components included in our products from a limited group of suppliers or from sole-source suppliers, such as transistor arrays, cesium iodide coatings and specialized integrated circuits for flat panel detectors, X-ray tube targets, housings, glass frames, high-voltage cable, bearings, and various other components. If current suppliers cease producing these or other components, fail to provide products on our delivery timelines, or become insufficiently solvent to continue operations, there can be no assurance that the components will be available from other suppliers on reasonable terms or at all, and this could materially and adversely affect our business and financial results.
    Furthermore, we may be required to obtain and qualify one or more replacement suppliers or to manufacture the components internally. Such an event (1) may then also require us to redesign or modify our products to incorporate new parts and/or further require us to obtain clearance, qualification, or certification of these products, including by the FDA, or obtain other applicable regulatory approvals in other countries, (2) could significantly increase costs for the affected products, (3) cause material delays in delivery of affected and other related products, or (4) could prevent us from meeting our delivery obligations to our customers.
If we are not able to match our manufacturing capacity with demand for our products, our financial results may suffer.
    Many of our products have a long production cycle, and we must anticipate demand for our products to ensure adequate manufacturing and testing capacity. If we are unable to anticipate demand, and our manufacturing or testing capacity does not keep pace with product demand, we will be unable to fulfill orders in a timely manner, which may negatively impact our financial results and overall business. Conversely, if demand for our products decreases, the fixed costs associated with excess manufacturing capacity may harm our financial results, including by decreasing gross margins and increasing research and development costs as a percentage of revenue.
Delivery schedules for our security, industrial, and inspection products tend to be unpredictable.
    The demand for our security and inspection products is heavily influenced by United States and foreign governmental policies on national and homeland security, border protection, and customs activities, which depend upon government budgets and appropriations that are subject to economic conditions, as well as political changes and oil prices. As economic growth remains sluggish in various jurisdictions and appears to be deteriorating in others, and as concerns about levels of government employment and government debt continue, this could cause volatility in our revenues and earnings.
Our operations are vulnerable to interruption or loss due to natural or other disasters, the effects of climate change, power loss, strikes, and other events beyond our control.
    We conduct some of our activities, including manufacturing, research and development, administration, and data processing at facilities located in areas that have in the past experienced or may in the future experience natural disasters. A major disaster (such as a major fire, hurricane, earthquake, flood, tsunami, volcanic eruption, or terrorist attack) or a climate change-related event affecting our facilities, or those of our suppliers, could significantly disrupt our operations and delay or prevent product manufacture and shipment during the time required to repair, rebuild, or replace our or our suppliers’ damaged manufacturing facilities. These delays could be lengthy and costly. If any of our customers’ facilities are adversely affected by such a disaster or event, shipments of our products could be delayed. Additionally, customers may delay purchases of our products until our or their operations return to normal. Even if our suppliers or customers are able to quickly respond to such a disaster or event, the ongoing effects could create some uncertainty in the operations of our business. In addition, concerns about terrorism, the effects of a terrorist attack, political turmoil, or an outbreak of epidemic diseases have in the past had, and could in the future have, a negative effect on our business operations, those of our suppliers and customers, and the ability to travel, resulting in adverse consequences on our revenues and financial performance.
42
Risks Relating to our Intellectual Property and Information Systems
Our competitive position would be harmed if we are not able to maintain or defend our intellectual property rights, and protecting our intellectual property and defending against infringement claims can be costly.
    We file applications as appropriate for patents covering new products and manufacturing processes. We cannot be sure, however, that patents will be issued from any of our pending or future patent applications or that our current patents, the claims allowed under our current patents, or patents for technologies licensed to us will be sufficiently broad to protect our technology position against competitors. We also jointly develop intellectual property with third parties and seek to protect our rights to such intellectual property through licenses and other contractual arrangements.
    We also rely on a combination of copyright, trade secret, and other laws, and contractual restrictions on disclosure, copying and transferring title (including confidentiality agreements with vendors, strategic partners, co-developers, employees, consultants, and other third parties), to protect our proprietary, and other confidential rights. Our trade secrets may become known to or be independently developed by others, including as a result of misappropriation by unauthorized access to our technology systems, and our business and financial results could be materially and adversely impacted. We have trademarks, both registered and unregistered, that are maintained and enforced to provide customer recognition for our products in the marketplace, but unauthorized parties may still use them. We also license certain patented or proprietary technologies from others. In some cases, products with substantial revenues may depend on these license rights. If we were to lose the rights to license these technologies, or our costs to license these technologies were to materially increase, our business would suffer.
    There is a substantial amount of litigation over patent and other intellectual property rights in the industries in which we compete. Our competitors, like companies in many high technology businesses, continually review other companies’ activities for possible conflicts with their own intellectual property rights. In addition, non-practicing entities may review our activities for conflicts with their patent rights. From time to time, we have received notices from parties asserting infringement, and we have been subject to lawsuits alleging infringement of patent or other intellectual property rights. In addition, from time to time we have entered, and in the future we may enter, into agreements that require us to indemnify our customers for intellectual property infringement, which agreements could subject us to liability. One of our subsidiary's customers has been named as a defendant in a lawsuit alleging that the customer’s system (which incorporates our subsidiary’s products) infringes upon the plaintiff’s patent. Under the contract with the customer, our subsidiary has an obligation to indemnify the customer for damages resulting from that lawsuit, which if determined adversely could have a negative impact of our results of operations. Legal disputes relating to intellectual property have occurred, are occurring, and may occur in the future. Any dispute regarding patents or other intellectual property, including with respect to breaches of licensing agreements or other contractual arrangements, could be costly and time consuming and could divert our management and key personnel from our business operations. We may not prevail in a dispute. We do not maintain insurance for intellectual property infringement, so costs of defense, whether or not we are successful in defending an infringement claim, will be borne by us and could be significant. If we are unsuccessful in defending or appealing an infringement claim or claims alleging other contractual breaches, we may be subject to significant damages, and our combined financial position, results of operations, or cash flows could be materially and adversely affected. We may also be subject to injunctions against development and sale of our products, the effect of which could be to materially reduce our revenues. Additionally, as we expand our manufacturing capabilities outside of the United States, more of our intellectual property may be held in jurisdictions that lack robust intellectual property protections, which may make it harder for us to adequately protect our intellectual property.
Disruption of critical information systems or material breaches in the security of our systems may materially and adversely affect our business and customer relations.
    Information technology (including technology from third-party providers) helps us operate efficiently, interface with and support our customers, maintain financial accuracy and efficiency, and produce our financial statements. In the ordinary course of our business, we collect, process, and store sensitive data, including intellectual property, proprietary business information, and information of customers, suppliers, business partners, and third parties accessing our website, patient data, and personally identifiable information of customers and employees, in our data centers and on our networks, as well as in third-party off-site data centers. Despite security measures, there is an increasing threat of information security attacks, including from computer viruses or other malicious codes, unauthorized access attempts, and cyber-attacks that pose risks to companies, including us. Because the techniques used to obtain unauthorized access, or to sabotage systems, change frequently, have become increasingly sophisticated, and generally are not recognized until launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures, which could result in data leaks or otherwise compromise our confidential or proprietary information and materially disrupt our operations. Such security breaches could expose us to a risk of loss of information and intellectual property, litigation, and possible liability to employees, customers, shareholders, and/or regulatory authorities. If our data management systems do not effectively collect, secure, store, process, and report relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies, or human error, our ability to effectively plan, forecast, and execute our business
43
plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our financial condition, results of operations, cash flows, and the timeliness with which we report our operating results internally and externally.
    We use certain cloud-based software. A security breach, whether of our products, of our customers’ network security and systems, or of third-party hosting services could disrupt access to our customers’ stored information and could lead to the loss of, damage to, or public disclosure of our customers’ stored information, including patient health information. Such an event could have serious negative consequences, including possible patient injury, regulatory action, fines, penalties and damages, reduced demand for our solutions, an unwillingness of our customers to use our solutions, harm to our reputation and brand, and time-consuming and expensive litigation, any of which could have a material and adverse effect on our financial results.
Risks Relating to Our Legal and Regulatory Environment
Changes in import/export regulatory regimes, tariffs, and national policies could continue to negatively impact our business.
    As a component manufacturer, our products are integrated into the systems and products of our OEM customers. If the United States, China or other countries levy tariffs, import restrictions, duties or other additional taxes or restrictions on our customer’s products, the demand for such products, and our components included in such products, could decrease, which could have a material adverse effect on our business. Uncertainty over tariffs and trade wars could also cause our customers to delay or cancel orders for our products.
    In the past, the United States has imposed tariffs on items imported from China and other countries that are incorporated into our products. Tariffs on these items have increased our costs and prices and lowered gross margins on some of our products, thereby having a direct adverse impact on our business and results of operations. China has also imposed retaliatory tariffs that impact a number of our products, including United States origin X-ray tubes, heat exchange units, and certain flat panel detectors. These tariffs have increased our customers’ costs for products imported into China, which has caused us to make price concessions on some products and has caused some customers to stop purchasing our products.
    Tariffs could limit our ability to compete for increased market share in China, which could cause our long-term prospects in China to suffer. The imposition of additional tariffs by the United States could result in the adoption of additional tariffs by China and other countries, as well as further retaliatory actions by any affected country, which could negatively impact the global market for imaging equipment and could have a significant adverse effect on our business.
    Both the governments of the United States and China have granted tariff exclusions that temporarily eliminate duties payable for specific commodities, providing partial relief from such tariffs, but they must be solicited and approved on a shipment-by-shipment basis. There is no guarantee that such exclusions will be granted or extended by either government, and the United States tariff exclusions are set to expire on May 31, 2024, unless extended.
    In addition to tariffs, China’s stated policy of reducing its dependence on foreign manufacturers and technology companies may result in reduced demand for our products in China, which could have a material adverse impact on our business, results of operations and financial position. There are risks that the Chinese government may, among other things, require the use of local suppliers, compel companies that do business in China to partner with local companies to conduct business, or provide incentives to government-backed local customers to buy from local suppliers rather than companies like ours, all of which could adversely impact our business, results of operations and financial position.
    The Chinese government recently initiated investigations into corruption in its healthcare industry. This has had a broad-based impact on the healthcare industry in China and slowed sales of healthcare products there. As a result, our sales in China have also slowed. We expect the investigations to continue into fiscal year 2024, and this could continue to adversely impact revenues in our China business.
    Increasing tensions between China and Taiwan may cause the United States and/or China to impose higher tariffs, commence trade wars, move more quickly to reduce their dependence on each other’s goods, or enact boycotts against each other’s goods, which could cause significant disruptions in the markets and industries we serve, and in our supply chain, decrease demand from customers for the ultimate products using our solutions, and materially harm our business, financial condition and results of operations.
    In response to Russia's ongoing aggression against Ukraine, as substantially enabled by Belarus, the United States Department of Commerce strengthened its existing sanctions under the Export Administration Regulations against Russia and Belarus. The enhanced sanctions would require Bureau of Industry and Security export licenses in order to export our products, including for medical, health and safety, or humanitarian purposes, to Russia and Belarus. Applications for the export of products to Russia or Belarus will be reviewed under a policy of denial and reviewed on a case-by-case basis. If licenses for the export of our product are denied, it could adversely affect our business and results of operations.
44
A change in the percentage of our total earnings from international sales or additional changes in tax laws could increase our effective tax rate.
    Earnings from our international subsidiaries are generally taxed at rates that differ from United States rates. A change in the percentage of our total earnings from our international subsidiaries, a change in the mix of particular tax jurisdictions between our international subsidiaries, or a change in currency exchange rates could cause our effective tax rate to increase. Furthermore, while United States tax reform imposed a current tax on cumulative undistributed earnings, these earnings could also become subject to incremental foreign withholding or United States state taxes should they actually be remitted to the United States, in which case our financial results could be materially and adversely affected.
    Statutory changes included in proposed United States legislation, if passed, including interpretive guidance, could materially impact our income tax expense, effective tax rate, or the value of deferred tax assets and liabilities. Changes in the valuation of our deferred tax assets or liabilities, changes in tax laws or rates, changes in the interpretation of tax laws in other jurisdictions, or other changes beyond our control could materially and adversely affect our financial position and results of operations.
    We have entities in certain jurisdictions with cumulative net operating losses for which no income tax benefit can be recorded due to full valuation allowance positions. There could be additional future losses in these and other jurisdictions that would negatively impact our effective tax rate.
Compliance with foreign laws and regulations applicable to the marketing, manufacturing, and distribution of our products may be costly, and failure to comply may result in unfavorable legal proceedings, in significant penalties and other harm to our business.
    Outside the United States, some of our products are regulated as medical devices by foreign governmental agencies similar to the FDA. For us to market our products internationally, we must obtain clearances or approvals for products and product modifications, which can be time consuming, expensive, uncertain, and which can delay our ability to market products. Delays in the receipt of or failure to receive regulatory approvals, the inclusion of significant limitations on the indicated uses of a product, the loss of previously obtained approvals or failure to comply with existing or future regulatory requirements could restrict or prevent us from doing business in a country or subject us to a variety of enforcement actions and civil or criminal penalties, which would materially and adversely affect our business. In addition, compliance with changing regulatory schemes may add additional complexity, cost, and delays in marketing, or selling our products.
    Within the European Union ("EU") and the European Economic Area ("EEA"), we must obtain, and in turn affix, a CE mark certification, that indicates that a product meets the essential requirements of the EU’s Medical Device Directive (“MDD”) and the EU Medical Device Regulations. By affixing the CE mark to our product, we are certifying that our products comply with the laws and regulations required by the EU/EEA countries, thereby allowing the free movement of our products within these countries and others that accept CE mark standards. If we cannot support our performance claims and demonstrate compliance with the applicable European laws and the MDD, we would lose our right to affix the CE mark to our products, which would prevent us from selling our products within the EU/EEA/Switzerland territory and in other countries that recognize the CE mark.
    We are subject to international laws and regulations of general applicability relating to matters such as environmental protection, safe working conditions, and manufacturing practices, as well as others. These are often comparable to, or more stringent than, equivalent regulations in the United States. Sales overseas are also affected by regulation of matters such as product standards, packaging, labeling, environmental and product recycling requirements, import and export restrictions, tariffs, duties, and taxes.
    In addition, we are required to timely file various reports with international regulatory authorities similar to the reports we are required to timely file with United States regulatory authorities, including reports required by international adverse event reporting regulations. If these reports are not timely filed, regulators may impose sanctions, including temporarily suspending our market authorizations or CE mark, and sales of our products may suffer.
    As we enter new businesses or pursue new business opportunities internationally, or as regulatory schemes change, we may become subject to additional laws, rules, and regulations, and compliance can be costly. The failure by us or our agents to comply with these laws, rules, and regulations could delay the introduction of new products, cause reputational harm, or result in investigations, fines, injunctions, civil penalties, criminal prosecution, or an inability to sell our products in or to import our products into certain countries, which could materially and adversely affect our business.
Compliance with United States laws and regulations applicable to the marketing, manufacturing, and distribution of our products may be costly, and failure or delays in obtaining regulatory clearances or approvals, or failure to comply with applicable laws and regulations could harm our business.
    If we or any of our suppliers, distributors, agents, or customers fail to comply with FDA, Federal Trade Commission, or other applicable United States regulatory requirements or are perceived to have failed to comply with regulations, we may face:
45
•adverse publicity affecting both us and our customers;
•increased pressures from competitors;
•investigations by governmental authorities;
•fines, injunctions, civil penalties, and criminal prosecution;
•partial suspension or total shutdown of production facilities or the imposition of operating restrictions;
•increased difficulty in obtaining required clearances or approvals or losses of clearances or approvals already granted;
•seizures or recalls of our products or those of our customers;
•delays in purchasing decisions by customers or cancellation of existing orders;
•the inability to sell our products; and
•difficulty in obtaining product liability or operating insurance at a reasonable cost, or at all.
    Generally, our manufacturing operations for medical devices, and those of our third-party manufacturers, are required to comply with the QSR of the FDA, as well as other federal and state regulations for medical devices and radiation-emitting products. Failure to respond in a timely manner to a warning letter or any other notice of noncompliance with applicable regulations and/or procedures and to promptly come into compliance could result in the FDA bringing an enforcement action, which could include the total shutdown of our production facilities, denial of importation rights to the United States for products manufactured in overseas locations, adverse publicity, and criminal and civil fines. The expense and costs of any corrective actions that we may take, which may include product recalls, correction and removal of products from customer sites, or changes to our product manufacturing and quality systems, could materially and adversely impact our financial results and may also divert management resources, attention, and time. Additionally, if a warning letter were issued, customers could delay purchasing decisions or cancel orders, and we could face increased pressure from our competitors, who could use the warning letter against us in competitive sales situations, either of which could materially and adversely affect our reputation, business, and stock price.
    Our OEM customers are responsible for obtaining 510(k) pre-market notification clearance on their systems that integrate our products. A substantial majority of our products are “Class I” devices that do not require 510(k) clearance, but we do produce software that is classified as a Class II device subject to 510(k) clearance. Unless an exception applies, we may be required by FDA regulations to obtain a 510(k) pre-market notification clearance in connection with the manufacture of a new medical device or a new indication for use of, or other significant change in, an existing currently marketed medical device before we can market or sell those products in the United States or in connection with modifications or enhancements to a product that could significantly affect its safety or effectiveness, or that would constitute a major change in the intended use of the device, technology, materials, labeling, packaging, or manufacturing process. We cannot ensure that the FDA will agree with our decisions not to seek additional approvals or clearances for particular modifications to our products or that we will be successful in obtaining new 510(k) clearances for modifications. Obtaining clearances or approvals is time consuming, expensive, and uncertain. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses of the product, which may limit the market for the product. If we are unable to obtain required FDA clearance or approval for a product or are unduly delayed in doing so, or the uses of that product were limited, our business could suffer.
    We are required to timely file various reports with the FDA, including reports required by the medical device reporting regulations (“MDRs”), that require we report to regulatory authorities if our devices may have caused or contributed to a death or serious injury, or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. If we initiate a correction or removal of a device to reduce a risk to health posed by the device, we would be required to submit a publicly-available correction and removal report to the FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by the FDA as a device recall, which could lead to increased scrutiny by the FDA, other international regulatory agencies, and our customers regarding the quality and safety of our devices. If these MDRs or correction and removal reports are not filed on a timely basis, regulators may impose sanctions, sales of our products may suffer, and we may be subject to product liability or regulatory enforcement actions, all of which could harm our business.
    Government regulation may also cause significant delays or prevent the marketing and full commercialization of future products or services that we may develop and/or may impose costly requirements on our business. As we enter new businesses or pursue new business opportunities, we will become subject to additional laws, rules, and regulations, including FDA and foreign rules and regulations and compliance can be costly. Failure to comply with these laws, rules and regulations could delay the introduction of new products and could materially and adversely affect our business.
    We are also subject to federal and state laws and regulations of general applicability relating to matters such as environmental protection, safe working conditions, manufacturing practices, and other matters. Insurance coverage is not commercially available for violations of law, including the fines, penalties, or investigatory costs that we may incur as the consequence of regulatory violations. Consequently, we do not have insurance that would cover this type of liability.
46
We sell certain X-ray tube products as replacements which are subject to medical device certification and product registration laws and regulations, which vary by country and are subject to change, and we may be unable to receive registration approval or renewal of existing registrations.
    We market and distribute certain X-ray tubes through distributors and third-party/multi-vendor service organizations that are used as equivalent replacements for specific OEM tubes. We are subject to medical device certification and product registration laws, which vary by country and are subject to periodic reviews and changes by regulatory authorities in those countries. Certain of these local laws and regulations have the effect of serving as a barrier to trade and can be difficult to navigate predictably. In addition, certain countries where we sell our products require products to undergo re-registration if the product is altered in any significant way. These registration processes can be costly and time consuming, and customers may decide to purchase products from our competitors that do not have to be involved in a re-registration process. In addition, our inability to receive or renew product registrations may prevent us from marketing and/or distributing those particular products for replacement applications in the specific country.
Existing and future healthcare reforms and changes to reimbursement rates, may indirectly have a material adverse effect on our business and results of operations.
    Sales of our products to OEMs in the medical sector indirectly depend on whether adequate reimbursement is available for our customers’ products from a variety of sources, such as government healthcare insurance programs, including U.S. Medicare and Medicaid programs, foreign government programs, private insurance plans, health maintenance organizations, and preferred provider organizations. Without adequate reimbursement, the demand for our customers’ products, and therefore indirectly our products, may be limited, which could harm our business, results of operations, financial condition, and prospects.
    Healthcare reform proposals and medical cost containment measures in the United States and in many foreign countries could limit the use of both ours and our customers’ products, reduce reimbursement available for such use, further tax the sale or use of our products, and further increase the administrative and financial burden of compliance. Any changes that lower reimbursements for us or our customers’ products and/or procedures using these products, including, for example, existing reimbursement incentives to convert from analog to digital X-ray systems, or changes that reduce medical procedure volumes or increase cost containment pressures on us or others in the healthcare sector could materially and adversely affect our business and results of operations.
We are subject to federal, state, and foreign laws governing our business practices which, if violated, could result in substantial penalties. Additionally, challenges to or investigations into our practices could cause adverse publicity and be costly to respond to and thus could harm our business.
    Anti-corruption laws and regulations. We are subject to the U.S. Foreign Corrupt Practices Act and anti-corruption laws, and similar laws in foreign countries, such as the U.K. Bribery Act. Any violation of these laws by us or our agents or distributors could create substantial liability for us, subject our officers and directors to personal liability, and cause a loss of reputation in the market. We operate in many countries, including India and China, where the public sector is perceived as being corrupt. Our strategic business plans include expanding our business in regions and countries that are rated as higher risk for corruption activity by Transparency International e.V., an international non-profit that publishes an annual corruption perception index, which could subject us and our officers and directors to increased scrutiny and increased liability from our business operations. Becoming familiar with and implementing the infrastructure necessary to comply with laws, rules, and regulations applicable to new business activities and mitigating and protecting against corruption risks could be costly. Failure by us or our agents or distributors to comply with these laws, rules, and regulations could delay our expansion into high-growth markets and materially and adversely affect our business.
    Competition and trade compliance laws. We are subject to various competition and trade compliance laws in the jurisdictions where we operate throughout the world. Regulatory authorities in those jurisdictions may have the power to subject us to sanctions and impose changes or conditions in the way we conduct our business. An increasing number of jurisdictions provide private rights of action for competitors or consumers to assert claims of anti-competitive conduct and seek damages. Increased government scrutiny of our actions or enforcement or private rights of action could materially and adversely affect our business or damage our reputation. We may be required to conduct internal investigations or face audits or investigations by one or more domestic or foreign government agencies, which could be costly and time consuming and could divert our management and key personnel from our business operations. An adverse outcome under any such investigation or audit could subject us to fines and criminal or other penalties, which could materially and adversely affect our business and financial results. Furthermore, competition laws may prohibit or increase the cost of future acquisitions that we may desire to undertake.
47
    Laws and ethical rules governing interactions with healthcare providers. We may occasionally sell our products to healthcare providers through distributors or otherwise engage healthcare providers to provide services. The U.S. Medicare and Medicaid “anti-kickback” laws, and similar state laws, prohibit payments or other remuneration that is intended to induce hospitals, physicians, or others either to refer patients or to purchase, lease, or order, or to arrange for or recommend the purchase, lease, or order of healthcare products or services for which payment may be made under federal and state healthcare programs, such as Medicare and Medicaid. These laws affect our sales, marketing, and other promotional activities by limiting the kinds of financial arrangements we may have with hospitals, physicians, or other potential purchasers of our products. They particularly impact how we structure our sales offerings, including discount practices, customer support, education and training programs, physician consulting, research grants, and other fee-for-service arrangements. These laws are broadly written, and it is often difficult to determine precisely how these laws will be applied to specific circumstances.
    Federal and state “false claims” laws generally prohibit knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government payors that are false or fraudulent, or for items or services that were not provided as claimed. Although we do not submit claims directly to payors, manufacturers can be, and have been, held liable under these laws if they are deemed to “cause” the submission of false or fraudulent claims by providing inaccurate billing or coding information to customers or through certain other activities, including promoting products for uses not approved or cleared by the FDA, which is called off-label promotion. Violating “anti-kickback” and “false claims” laws can result in civil and criminal penalties, which can be substantial, as well as potential mandatory or discretionary exclusion from healthcare programs for noncompliance. Even an unsuccessful challenge or investigation into our practices could cause adverse publicity and be costly to defend and thus could harm our business and results of operations. Additionally, several recently-enacted state and federal laws, including laws in Massachusetts and Vermont, and the federal Physician Payment Sunshine Act, now require, among other things, extensive tracking and maintenance of databases regarding the disclosure of equity ownership and payments to physicians, healthcare providers, and hospitals. These laws may require us to implement the necessary and costly infrastructure to track and report certain payments to healthcare providers. Failure to comply with these tracking and reporting laws could subject us to significant civil monetary penalties.
    Other Laws. We are subject to other laws in foreign countries where we conduct business. For example, within the EU, the control of unlawful marketing activities is a matter of national law in each of the member states. The member states of the EU closely monitor perceived unlawful marketing activities. We could face civil, criminal, and administrative sanctions if any member state determines that we have breached such state’s national laws. Industry associations also closely monitor the activities of member companies. If these organizations or authorities name us as having breached our obligations under their regulations, rules, or standards, our reputation would suffer, and our business and financial condition could be materially and adversely affected.
Certain of our products are subject to regulations relating to use of radioactive material, compliance with which may be costly, and a failure to comply with these regulations may materially and adversely affect our business.
    As a manufacturer and seller of medical devices and devices emitting radiation or utilizing radioactive by-product material, we and some of our suppliers and distributors are subject to extensive regulation by United States governmental authorities, such as the FDA, the Nuclear Regulatory Commission (“NRC”), and state and local regulatory agencies, which is intended to ensure the devices are safe and effective and comply with laws governing products which emit, produce, or control radiation. These regulations govern, among other things, the design, development, testing, manufacturing, packaging, labeling, distribution, import/export, sale, marketing, and disposal of our products. We are also subject to international laws and regulations that apply to manufacturers of radiation-emitting devices and products utilizing radioactive materials. These are often comparable to, if not more stringent than, the equivalent regulations in the United States.
    Our industrial and medical devices utilizing radioactive material are subject to NRC clearance and approval requirements, and the manufacture and sale of these products are subject to extensive federal and state regulation that varies from state to state and among regions. Our manufacture, distribution, installation, service, and removal of industrial devices utilizing radioactive material or emitting radiation also requires us to obtain a number of licenses and certifications for these devices and materials. Service of these products must also be performed in accordance with specific radioactive materials licenses. Obtaining licenses and certifications may be time consuming, expensive, and uncertain.
    The handling and disposal of radioactive materials resulting from the manufacture, use, or disposal of our products may impose significant costs and requirements. Disposal sites for the lawful disposal of materials generated by the manufacture, use, or decommissioning of our products may no longer accept these substances in the future or may accept them on unfavorable terms.
48
Environmental laws impose compliance costs on our business and may also result in liability.
    Environmental laws regulate many aspects of our operations, including our handling, storage, transport, and disposal of hazardous substances, such as the chemicals and materials that we use in the course of our manufacturing operations. They can also impose cleanup liabilities, including with respect to discontinued operations. Like other businesses, we may mishandle or inadequately manage hazardous substances used in our manufacturing operations and can never completely eliminate the risk of contamination or injury from certain materials that we use in our business and, therefore, we cannot completely eliminate the prospect of resulting claims and damage payments. We may also be assessed fines and/or other penalties for failure to comply with environmental laws and regulations. Insurance has provided coverage for portions of cleanup costs resulting from historical occurrences, but we do not expect to maintain insurance coverage for costs or claims that might result from any future contamination.
    Pursuant to the Separation and Distribution Agreement we entered into with Varian Medical Systems, Inc. ("Varian") when we spun off from Varian, we are obligated to indemnify Varian for 20% of the cleanup liabilities related to prior corporate restructuring activities undertaken while we were a division of Varian. This includes facilities sold as part of Varian’s electron devices business in 1995 and thin film systems business in 1997. The U.S. Environmental Protection Agency (“EPA”) or third parties have named Varian as a potentially responsible party under the amended Comprehensive Environmental Response Compensation and Liability Act of 1980 (“CERCLA”), at sites to which Varian or the facilities of the businesses sold in 1995 and 1997 were alleged to have shipped waste for recycling or disposal (the “CERCLA sites”). We anticipate that we will be obligated to reimburse Varian for 20% of the liabilities of Varian related to these CERCLA sites (after adjusting for any insurance proceeds or tax benefits received by Varian). We assess this indemnification obligation quarterly with Varian and make accruals accordingly. These accruals have historically been small, but can sometimes fluctuate significantly from period to period. For example, during the second quarter of fiscal year 2023, Varian informed us of an adjustment to their estimate of their liability, which resulted in an increase in our liability of approximately $2.9 million, net of expected insurance proceeds.
    Future changes in environmental laws could also increase our costs of doing business, perhaps significantly. Several countries, including some in the EU, now require medical equipment manufacturers to bear certain disposal costs of products at the end of the product’s useful life, thereby increasing its costs. The EU has also adopted directives that may lead to restrictions on the use of certain hazardous substances or other regulated substances in some of our products sold there. These directives, along with another that requires substance information to be provided upon request, could increase our operating costs in order to maintain our access to certain markets. All of these costs, and any future violations or liabilities under environmental laws or regulations, could have a material adverse effect on our business.
Environmental, Social, Governance Risks
Our business is subject to evolving Environmental, Social, and Governance (“ESG”) requirements and stakeholder expectations that could expose us to numerous risks.
    Regulators, customers, investors, and other stakeholders are increasingly focusing on ESG issues and related disclosures. Changing ESG requirements and stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses and increased management time and attention spent complying with or meeting such regulations and expectations. We may also communicate certain ESG initiatives and goals in our SEC filings or in other public disclosures. If our ESG-related data, processes, and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to our ESG goals on a timely basis, or at all, our reputation, business, financial performance, and growth could be adversely affected.
    In addition, our customers have adopted, and may continue to adopt, procurement policies that require us to comply with social and environmental provisions. An increasing number of investors have adopted, and may continue to adopt, ESG policies for their portfolio companies, and various voluntary sustainability initiatives and organizations have promulgated different social and environmental and sustainability guidelines. These practices, policies, provisions, and initiatives are under active development, subject to change, can be unpredictable and conflicting, and may prove difficult and expensive for us to comply with and could negatively affect our reputation, business, or financial condition.
49
If we are unable to retain, attract, expand, integrate, and train our management team and other key personnel, we may not be able to maintain or expand our business.
    Our future success depends on our ability to retain, attract, expand, integrate, and train our management team and other key personnel, such as qualified engineering, service, sales, marketing, manufacturing, and other staff. We compete for key personnel with other medical equipment and software manufacturers and technology companies, as well as universities and research institutions. We have observed an overall tightening and increasingly competitive labor market over the past years, which has resulted in increased wages offered by other employers and voluntary attrition of employees in the industry, making it more difficult to recruit, hire, and retain talent. Because competition is intense, particularly in Utah, where unemployment rates are relatively low, compensation-related costs have increased and could continue to increase, significantly. Additionally, our United States-based employees, including our senior management team, work for us on an at-will basis, and there is no assurance that any such employees will remain with us. Replacing key employees may take an extended period of time, and to the extent we hire employees from competitors, we also may be subject to allegations that they have been improperly solicited or divulged proprietary or other confidential information. Freezing new positions or terminating existing ones could hinder our ability to execute our strategic plan and achieve growth targets, resulting in long-term sacrifices for short-term gains. Further, potential employee turnover resulting from work from home policy changes, limited growth opportunities and competitive market conditions could lead to knowledge loss and decreased productivity. If we are unable to retain or hire and train qualified personnel, we may not be able to maintain or expand our business. Similarly, if we fail to adequately invest in leadership training and career development resources this could limit employee growth, lead to shortages of skilled personnel, hinder effective management and decision making, and hamper overall organizational success.
Risks Relating to Our Indebtedness
The ABL Facility and the indenture governing our Senior Secured Notes impose significant operating and financial restrictions that may limit our current and future operating flexibility, particularly our ability to respond to changes in the economy or our industry or to take certain actions, which could harm our long-term interests and may limit our ability to make payments on the notes. Because our Convertible Notes mature in June 2025, failure to maintain sufficient liquidity and/or to refinance our Convertible Notes could result in a material adverse effect on our results of operations and financial position.
    As of December 29, 2023, our total combined indebtedness was approximately $447.8 million of principal, including our 4.00% Convertible Senior Unsecured Notes due 2025 (the "Convertible Notes") and our 7.875% Senior Secured Notes due 2027 (the “Senior Secured Notes”). For more information regarding our borrowings, see Note 9, Borrowings of the Notes to the Condensed Consolidated Financial Statements of this report.
    Our $100.0 million ABL Facility and the indenture governing our Senior Secured Notes impose significant operational and financial restrictions on us that include, but are not limited to our ability to:
•incur, assume, or permit to exist additional indebtedness (including guarantees thereof);
•pay dividends or certain other distributions on our capital stock or repurchase our capital stock or prepay subordinated indebtedness;
•prepay, redeem, or repurchase certain debt;
•issue certain preferred stock or similar equity securities;
•incur liens on assets;
•make certain loans, investments, or other restricted payments;
•allow to exist certain restrictions on the ability of our restricted subsidiaries to pay dividends or make other payments to us;
•engage in transactions with affiliates;
•alter the business that we conduct; and
•sell certain assets or merge or consolidate with or into other companies.
    As a result of these restrictions, we may be:
•limited in how we conduct our business;
•unable to raise additional debt or equity financing to operate during general economic or business downturns;
•limited in our ability to borrow additional funds as needed or increasing the cost of such borrowing;
•challenged in satisfying our obligations, including our debt obligations;
•vulnerable to adverse economic and general industry conditions, including interest rate fluctuations, because a portion of our borrowings are and will continue to be at variable rates of interest;
•required to dedicate a substantial portion of our cash flow from operations to payments on our debt, which would reduce the availability of our cash flow from operations to fund working capital, capital expenditures, or other general corporate purposes;
•at a disadvantage compared to competitors that may have proportionately less debt; or
•unable to compete effectively or to take advantage of new business opportunities.
50
    A breach of the covenants under the indenture governing our Senior Secured Notes or the ABL Facility could result in an event of default under the applicable indebtedness. Such a default, if not cured or waived, may allow the creditors to accelerate the related debt, may result in the acceleration of any other debt that is subject to an applicable cross-acceleration or cross-default provision, and would permit the lenders under the ABL Facility to terminate all commitments to extend further credit under the ABL Facility. Furthermore, if we were unable to repay the amounts due and payable under the ABL Facility, those lenders could proceed against the collateral securing such indebtedness. In the event our lenders or holders of the notes accelerate the repayment of our borrowings, we and our subsidiaries may not have sufficient assets to repay that indebtedness.
    If our cash requirements in the future are greater than expected or our cash flow from operations is less than expected, our cash flow from operations may not be sufficient to repay all of the outstanding debt as it becomes due, and we may not be able to borrow money, sell assets, or otherwise raise funds on acceptable terms, or at all, to refinance our debt. Our Convertible Notes mature in June 2025, and the conversion price is currently above the trading price of our common stock. If the holders of the Convertible Notes have not converted their notes into our common stock, we currently anticipate we will need to refinance the Convertible Notes through a combination of borrowings under our ABL Facility, the entry into an expanded credit facility or the issuance of additional debt or equity securities, and cash. Any future refinancing of our indebtedness could be at higher interest rates and may require us to comply with more onerous covenants which could further restrict our business operations. Additionally, the indenture relating to our secured notes limit the use of the proceeds from any disposition of our assets. As a result, the indenture may prevent us from using the proceeds from such dispositions to satisfy our debt service obligations.
Our ability to continue to have the necessary liquidity to operate our business may be adversely impacted by a number of factors, and a deterioration of our results of operations and cash flow resulting from decreases in consumer spending, could, among other things, impact our ability to comply with the fixed charge coverage ratio contained in our ABL Facility.
    Our historical sources of liquidity to fund ongoing cash requirements include cash flows from operations, cash and cash equivalents, borrowings through our previous credit facility, and debt offerings. The sufficiency and availability of credit may be adversely affected by a variety of factors, including, without limitation, the tightening of the credit markets, including lending by financial institutions who are sources of credit for our borrowing and liquidity; an increase in the cost of capital; the reduced availability of credit; our ability to execute our strategy; the level of our cash flows, which will be impacted by customer demand for our products; compliance with a fixed charge coverage ratio that is included in our ABL Facility; and interest rate fluctuations. We cannot predict the future level of interest rates or the effect of any increase in interest rates on the availability or aggregate cost of our borrowings. We cannot be certain that any additional required financing, whether debt or equity, will be available in amounts needed or on terms acceptable to us, if at all.
    The ABL Facility contains a minimum Fixed Charge Coverage Ratio of 1.00 to 1.00 that is tested when excess availability under the ABL is less than the greater of (i) 10.0% of the Loan Cap (the lesser of (a) the aggregate commitments under the ABL Facility and (b) the aggregate borrowing base) and (ii) $7.5 million. Adverse developments in the economy in the past have led and in the future could lead to reduced spending by our customers and end-users which could adversely impact our net sales and cash flow, which could affect our ability to comply with the fixed charge coverage ratio.
We entered into certain hedging positions that may affect the value of the Convertible Notes and the volatility and value of our common stock.
    In connection with the issuance of the Convertible Notes, we entered into certain convertible note hedge transactions. These hedge transactions are expected generally to reduce potential dilution of our common stock on any conversion of the Convertible Notes or offset any cash payments we are required to make in excess of the principal amount of such converted Convertible Notes, as the case may be, with such reduction or offset subject to a cap. The counterparties to these hedging positions or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to our common stock or purchasing or selling our common stock in secondary market transactions prior to the maturity of the Convertible Notes (and are likely to do so during any observation period related to a conversion of Convertible Notes or following any repurchase of Convertible Notes by us on any fundamental change repurchase date or otherwise) which could cause or avoid an increase or a decrease in the market price of our common stock or the Convertible Notes and could adversely affect the value of our common stock.
51
Risks Relating to Our Common Stock
The conditional conversion feature of the Convertible Notes, if triggered, may adversely affect our financial condition and operating results.
    In the event the conditions for optional conversion of the Convertible Notes by holders are met before the close of business on the business day immediately preceding June 1, 2025, holders of the Convertible Notes will be entitled to convert the Convertible Notes at any time during specified periods at their option. If we elect to satisfy our conversion obligation by settling all or a portion of our conversion obligation in cash, it could adversely affect our liquidity. In addition, even if holders do not elect to convert their Convertible Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Convertible Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital and may seriously harm our business. If we elect to settle our conversion obligation in shares of common stock or a combination of cash and shares of common stock, any sales of our common stock issuable on such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Convertible Notes may encourage short selling by market participants because the conversion of the Convertible Notes could be used to satisfy short positions, or anticipated conversion of the Convertible Notes into shares of our common stock, any of which could depress the market price of our common stock.
Risks Relating to Our Spin-Off
Liabilities related to our operations when we were part of Varian, or liabilities associated with the spin-off from Varian, could materially and adversely affect our business, financial condition, results of operations, and cash flows.
    We entered into a Separation and Distribution Agreement when we spun off from Varian. This agreement provides for, among other things, indemnification obligations designed to make Varex financially responsible for information contained in our registration statement that describes Varex, our separation from Varian, the transactions contemplated by the Separation and Distribution Agreement, and liabilities that were allocable to Varex before the spin-off. We may be subject to substantial liabilities if we were required to indemnify Varian or if Varian were required, but unable, to indemnify us. Either of these could negatively affect our business, financial position, results of operations, and/or cash flows.
General Risks
Failure to maintain effective internal controls and procedures could negatively impact us.
    In the past, we have not always been successful in maintaining effective internal controls and procedures. Internal control over financial reporting is complex and may be revised over time to adapt to changes in our business or changes in applicable accounting rules. We cannot assure that our internal control over financial reporting will be effective in the future or that material weaknesses will not be discovered with respect to a prior period for which we had previously believed that internal controls were effective. If our internal controls and procedures are not effective, our financial statements may not accurately reflect the results of our business and operations. In addition, there could also be a negative reaction in the financial markets due to a loss of investor confidence in us and the reliability of our financial statements, which could affect our stock price.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
52
Item 5. Other Information
    During the fiscal quarter ended December 29, 2023, none of our directors or officers informed us of the adoption or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, except as follows:
    On December 15, 2023, Kimberley Honeysett, our Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale of up to 21,821 shares of our common stock that have vested or may vest to Ms. Honeysett pursuant to previously awarded stock options and restricted stock unit awards. The arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c). The first date that shares are permitted to be sold under the trading arrangement is March 15, 2024, and subsequent sales may occur until the arrangement’s expiration date, which is February 14, 2025, or earlier if all transactions under the trading arrangement are completed or the trading arrangement is otherwise earlier terminated.
53
Item 6. Exhibits
(a) Exhibits required to be filed by Item 601 of Regulation S-K:
Exhibit
No.		Description
3.1
3.2
31.1*
31.2*
32.1**
32.2**
101.INS*Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*Cover Page Interactive Data File - (formatted as Inline XBRL and contained in Exhibit 101)
*Filed herewith.
**Furnished herewith.
54
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
VAREX IMAGING CORPORATION
Date:February 6, 2024By:/s/ SHUBHAM MAHESHWARI
Shubham Maheshwari
Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)
55
 EX-31.1 2 varexq124exhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Sunny S. Sanyal, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Varex Imaging Corporation (the “registrant”);
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;    
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:    
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:February 6, 2024By:/s/ Sunny S. Sanyal
Sunny S. Sanyal
President, Chief Executive Officer


 EX-31.2 3 varexq124exhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002

I, Shubham Maheshwari, certify that:

1.    I have reviewed this Quarterly Report on Form 10-Q of Varex Imaging Corporation (the “registrant”);
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;    
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:    
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated:February 6, 2024By:/s/ Shubham Maheshwari
Shubham Maheshwari
Chief Financial Officer


 EX-32.1 4 varexq124exhibit321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report of Varex Imaging Corporation (the “Company”) on Form 10-Q for the quarter ended December 29, 2023 (the “Report”), I, Sunny S. Sanyal, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that, to my knowledge:

1.the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:February 6, 2024By:/s/ Sunny S. Sanyal
Sunny S. Sanyal
President, Chief Executive Officer







 EX-32.2 5 varexq124exhibit322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Quarterly Report of Varex Imaging Corporation (the “Company”) on Form 10-Q for the quarter ended December 29, 2023 (the “Report”), I, Shubham Maheshwari, Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002 that, to my knowledge:

1.the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:February 6, 2024By:/s/ Shubham Maheshwari
Shubham Maheshwari
Chief Financial Officer


 EX-101.SCH 6 var-20231229.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - REVENUE RECOGNITION link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - INVENTORIES link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - BORROWINGS link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - BUSINESS COMBINATIONS link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - NONCONTROLLING INTERESTS link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - NET (LOSS) INCOME PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - EMPLOYEE STOCK PLANS link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - TAXES ON (LOSS) INCOME link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - SEGMENT INFORMATION link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - REVENUE RECOGNITION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - FAIR VALUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - INVENTORIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - BORROWINGS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - BUSINESS COMBINATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - NONCONTROLLING INTERESTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - NET (LOSS) INCOME PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - EMPLOYEE STOCK PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - SEGMENT INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Supplier Finance Programs (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Environmental Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - REVENUE RECOGNITION - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - REVENUE RECOGNITION - Schedule of Right of Return Assets and Refund Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Income Recognized From Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Balance Sheet Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - FAIR VALUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - FAIR VALUE - Schedule of Fair Value Inputs (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - FAIR VALUE - Schedule of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - FAIR VALUE - Schedule of Contractual Maturities of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - FAIR VALUE - Schedule of Balance Sheet Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - INVENTORIES - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - BORROWINGS - Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - BORROWINGS - Schedule of Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - BORROWINGS - Convertible Senior Unsecured Notes Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - BORROWINGS - Call Spread Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - BORROWINGS - Senior Secured Notes Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - BORROWINGS - Asset-Based Loan Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - BUSINESS COMBINATIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - BUSINESS COMBINATIONS - Schedule of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - NONCONTROLLING INTERESTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954519 - Disclosure - NONCONTROLLING INTERESTS - Schedule of Noncontrolling Interest (Details) link:presentationLink link:calculationLink link:definitionLink 9954520 - Disclosure - NET (LOSS) INCOME PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net Income Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954521 - Disclosure - EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954522 - Disclosure - EMPLOYEE STOCK PLANS - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954523 - Disclosure - EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9954524 - Disclosure - TAXES ON (LOSS) INCOME (Details) link:presentationLink link:calculationLink link:definitionLink 9954525 - Disclosure - SEGMENT INFORMATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954526 - Disclosure - SEGMENT INFORMATION - Income Statement Information (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 var-20231229_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 var-20231229_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 var-20231229_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT VEC Imaging GmbH & Co. KG VEC Imaging GmbH & Co. KG [Member] VEC Imaging GmbH & Co. KG [Member] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Less: Net income attributable to noncontrolling interests Less: Comprehensive income attributable to noncontrolling interests Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Accrued liabilities and other current liabilities Accrued Liabilities, Current Other long-term liabilities Other Noncurrent Liabilities [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction Related Party Transaction [Line Items] Purchases Purchases [Member] Purchases Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Raw materials and parts Inventory, Raw Materials and Supplies, Net of Reserves Settlement of net investment hedge Proceeds from Hedge, Investing Activities All Award Types Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Restricted stock units, nonvested, beginning balance (in shares) Restricted stock units, nonvested, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number BORROWINGS Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Purchase price Cash Payments to Acquire Businesses, Gross Revolving Credit Facility Revolving Credit Facility [Member] Cross currency swap contracts Cross Currency Interest Rate Contract [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Segment Reporting [Abstract] Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Options, exercisable, weighted average remaining contractual term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Restatement Determination Date: Restatement Determination Date [Axis] Cumulative percentage of voting interests acquired (as a percent) Business Acquisition, Cumulative Percentage Of Voting Interests Acquired Business Acquisition, Cumulative Percentage Of Voting Interests Acquired Investment, Name [Axis] Investment, Name [Axis] Interest and other expense, net Interest and other expense, net Nonoperating Income (Expense) Insider Trading Policies and Procedures [Line Items] Options, exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Recognized amounts of identifiable assets acquired and liabilities assumed Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Disaggregation of Revenue Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Industrial Industrial Segment [Member] Industrial [Member] Price Range Exercise Price Range [Roll Forward] Exercise Price Range [Rollforward] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Geographical [Axis] Geographical [Axis] Inventory write-down Inventory Write-down Product Warranty Liability [Table] Product Warranty Liability [Table] TAXES ON (LOSS) INCOME Income Tax Disclosure [Text Block] Deferred revenues Increase (Decrease) in Contract with Customer, Liability Ownership [Axis] Ownership [Axis] Concentration Risk Concentration Risk [Line Items] Leases Lessee, Leases [Policy Text Block] Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Unamortized issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net [Abstract] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Annual recurring compensation (in euros per share) Business Acquisition, Annual Recurring Compensation Business Acquisition, Annual Recurring Compensation Business Acquisition Business Acquisition [Line Items] Due after one year through five years Marketable Securities, Maturity, Allocated and Single Maturity Date, After Year One Through Five Marketable Securities, Maturity, Allocated and Single Maturity Date, After Year One Through Five Weighted Average Grant-Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Canceled, expired or forfeited (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Remeasurement gain Remeasurement gain recorded on previous equity interest Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Diluted (in USD per share) Diluted net (loss) income per share attributable to Varex (in USD per share) Earnings Per Share, Diluted Derivative liabilities fair value, gross Derivative Liability, Subject to Master Netting Arrangement, before Offset Customer contracts and supplier relationship Customer Contracts and Supplier Relationships [Member] Customer Contracts and Supplier Relationships [Member] PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Accounts receivable, net of allowance for credit losses of $0.6 million and $0.6 million at December 29, 2023 and September 29, 2023, respectively Accounts Receivable, after Allowance for Credit Loss, Current Goodwill Goodwill [Roll Forward] Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible Enumeration] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Trading Symbol Trading Symbol Government agencies US Government Agencies Debt Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Fair Value, Investments, Entities that Calculate Net Asset Value Per Share Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items] U.S. Treasury bills Investments, Fair Value Disclosure Long-term debt, fair value Long-Term Debt, Fair Value Net (loss) income attributable to Varex Net (loss) income attributable to Varex - basic Net Income (Loss) Indian Rupee India, Rupees Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name LEASES Lessee, Operating Leases [Text Block] Commercial paper Commercial Paper Receivable Commercial Paper Receivable Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Corporate notes/bonds Corporate Bond Securities [Member] All Currencies [Domain] All Currencies [Domain] Property, plant, and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Liabilities and stockholders' equity Liabilities and Equity [Abstract] Finite-Lived Intangible Assets Finite-Lived Intangible Assets [Line Items] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Fixed Cost Commitments Fixed Cost Commitments [Member] Fixed Cost Commitments [Member] Amount of Loss Recognized in OCI on Derivative Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Schedule of Income Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of revenues Cost of Goods and Services Sold Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Related party transaction, amounts of transaction Related Party Transaction, Amounts of Transaction Executive Category: Executive Category [Axis] dpiX Holding dpiX Holding [Member] dpiX Holding [Member] Total non-current maturities of long-term debt: Long-term debt excluding current maturities, gross Long-term Debt Excluding Current Maturities, Gross Long-term Debt Excluding Current Maturities, Gross Foreign Exchange Contract Foreign Exchange Contract [Member] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Product Warranty Liability Product Warranty Liability [Line Items] Level 1 Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Right of Return Assets Contract with Customer, Right to Recover Product [Abstract] Goodwill Balance at September 29, 2023 Balance at December 29, 2023 Goodwill Equity Components [Axis] Equity Components [Axis] Warrant exercise price (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued liabilities and other current and long-term liabilities Increase (Decrease) in Accrued Liabilities Hedging Relationship [Domain] Hedging Relationship [Domain] Investment Type [Axis] Investment Type [Axis] Release of refund liability included in beginning of year refund liability Contract With Customer, Refund Liability, Amount Released Contract With Customer, Refund Liability, Amount Released Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Smaller Reporting Company Entity Small Business Investments [Domain] Investments [Domain] Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Scenario, Forecast Forecast [Member] Foreign currency translation adjustments OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax Selling, general, and administrative Selling, General and Administrative Expenses [Member] Notional Value Derivative, Notional Amount Amounts due for supplier finance program Supplier Finance Program, Obligation Accounts receivable Accounts Receivable [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Warrants Warrant [Member] Operating lease liabilities Operating lease liabilities (non-current) Operating Lease, Liability, Noncurrent Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Equity Method Investee Equity Method Investee [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Deferred tax liabilities of undistributed foreign earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Schedule of Marketable Securities Marketable Securities [Table Text Block] Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Income Statement Location [Axis] Income Statement Location [Axis] Total Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Loss Contingencies Commitments and Contingencies, Policy [Policy Text Block] Shares withheld on vesting of restricted stock Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Related party transaction expected fixed cost Related Party Transaction Expected Fixed Cost Related Party Transaction Expected Fixed Cost Schedule of Business Acquisitions Schedule of Business Acquisitions, by Acquisition [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Schedule of Lease Cost and Supplemental Cash Flow Information Lease, Cost [Table Text Block] Inventories Increase (Decrease) in Inventories Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Award Type Award Type [Axis] Anti-dilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Restricted stock units, grants in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Percentage of additional outstanding shares purchased (as a percent) Percentage Of Additional Outstanding Shares Purchased Percentage Of Additional Outstanding Shares Purchased Document Quarterly Report Document Quarterly Report Supplemental non-cash activities: Noncash Investing and Financing Items [Abstract] Interest expense Total interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Percent increase of strike price over sale price Class Of Warrant Or Right, Percent Increase Of Strike Price Over Sale Price Class Of Warrant Or Right, Percent Increase Of Strike Price Over Sale Price Hedging Designation [Axis] Hedging Designation [Axis] Goodwill [Line Items] Goodwill [Line Items] Options, outstanding, weighted average remaining contractual term, (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Noncash operating right-of-use assets obtained in exchange for new lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Trading Arrangement: Trading Arrangement [Axis] Schedule of Noncontrolling Interest Noncontrolling Interest [Table Text Block] Noncontrolling Interest RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Schedule of Interest Expense Interest Income and Interest Expense Disclosure [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount LEASES Lessee, Finance Leases [Text Block] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Dpi X LLC Dpi X LLC [Member] Dpi X LLC Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Supplier Finance Programs Supplier Finance Program [Policy Text Block] Supplier Finance Program Amortization of deferred loan costs Amortization of Deferred Loan Origination Fees, Net Current operating lease liabilities Operating lease liabilities (current) Operating Lease, Liability, Current Proceeds from maturities of marketable debt securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Amortization of intangible assets Amortization of Intangible Assets Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued Preferred Stock, Value, Outstanding Entity Shell Company Entity Shell Company Noncontrolling interest in MeVis Breastcare Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Net Carrying Amount Finite-Lived Intangible Assets, Net Recently Adopted Accounting Pronouncements and Recent Accounting Standards or Updates Not Yet Effective New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents and restricted cash at beginning of period Cash and cash equivalents and restricted cash at end of period Total as presented in the Condensed Consolidated Statements of Cash Flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Stockholders' Equity Attributable to Noncontrolling Interest Equity, Attributable to Noncontrolling Interest [Roll Forward] Subsequent Events Subsequent Events, Policy [Policy Text Block] Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Total operating lease costs Operating Lease, Cost Common stock, shares, issued (in shares) Common Stock, Shares, Issued Total right-of-use assets obtained in exchange for new lease liabilities Right-Of-Use Asset Obtained In Exchange For Operating Lease Liability And Finance Lease Liability Right-Of-Use Asset Obtained In Exchange For Operating Lease Liability And Finance Lease Liability Total cash paid for amounts included in the measurement of lease liabilities Cash Paid For Operating And Finance Leases Cash Paid For Operating And Finance Leases Restricted stock units, vested in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Fair value of total consideration transferred Business Combination, Consideration Transferred Gross profit Gross profit Gross Profit Used capacity, commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Deferred revenues Contract with Customer, Liability, Current Security Exchange Name Security Exchange Name Total debt outstanding, net Long-Term Debt Total assets measured at fair value Assets, Fair Value Disclosure Current maturities of long-term debt Long-Term Debt, Current Maturities [Abstract] Selling, general, and administrative Selling, General and Administrative Expense Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Government agencies US Government Agencies Securities, at Carrying Value Employee Stock Option Employee Stock Option [Member] FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES Derivative Instruments and Hedging Activities Disclosure [Text Block] Equity Method Investments and Marketable Securities Investment, Policy [Policy Text Block] NONCONTROLLING INTERESTS Noncontrolling Interest Disclosure [Text Block] Other, net Proceeds from (Payments for) Other Financing Activities Maximum Maximum [Member] Comprehensive (loss) income attributable to Varex Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Tabular List, Table Tabular List [Table Text Block] Gain on purchase of business Gain on Purchase Of Business Including Remeasurment Gain (Loss) Gain on Purchase Of Business Including Remeasurment Gain (Loss) Business acquisitions Stock Issued During Period, Value, Acquisitions EMEA EMEA [Member] Entity Address, Address Line One Entity Address, Address Line One Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] EMPLOYEE STOCK PLANS Share-Based Payment Arrangement [Text Block] Majority voting rights (as a percent) Subsidiary, Ownership Percentage, Parent Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other, net Other Noncash Income (Expense) Business Combination, Consideration Transferred [Abstract] Business Combination, Consideration Transferred [Abstract] Purchase of marketable debt securities Payments to Acquire Debt Securities, Available-for-Sale Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Medical Medical Segment [Member] Medical [Member] Derivative [Table] Derivative [Table] Customer concentration risk Customer Concentration Risk [Member] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Accrued liabilities and other current liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities And Other Current Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities And Other Current Liabilities Title of 12(b) Security Title of 12(b) Security Other long-term liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Related Party [Domain] Related Party, Type [Domain] BUSINESS COMBINATIONS Business Combination Disclosure [Text Block] Derivative liabilities Derivative Liability Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Noncontrolling interest, ownership percentage by noncontrolling owners (as a percent) Subsidiary, Ownership Percentage, Noncontrolling Owner Restricted stock units, nonvested, beginning of period (in USD per share) Restricted stock units, nonvested, end of period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Environmental Obligations Environmental Costs, Policy [Policy Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Net (loss) income per share - diluted Earnings Per Share, Diluted [Abstract] Non-current maturities of long-term debt: Maturities of Long-Term Debt [Abstract] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Foreign currency translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Equity method investments Equity Method Investments Inventories Total inventories Inventory, Net Purchase of marketable equity securities Payments to Acquire Marketable Securities Statistical Measurement [Axis] Statistical Measurement [Axis] Senior Secured Notes Senior Secured Notes [Member] Senior Secured Notes Balance Sheet Location [Domain] Balance Sheet Location [Domain] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Entity Interactive Data Current Entity Interactive Data Current Total Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Debt redeemed Debt Redeemed, Face Amount Debt Redeemed, Face Amount Total Shareholder Return Amount Total Shareholder Return Amount Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Total Varex Equity Parent [Member] Segments [Domain] Segments [Domain] Deferred compensation plan Deferred Compensation Plan Assets Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Common stock issued upon vesting of restricted shares (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Other debt Other Debt Obligations [Member] Face amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Short Short [Member] Counterparty Name [Axis] Counterparty Name [Axis] Asset-Based Loan Asset-Based Loan Revolving Credit Facility [Member] Asset-Based Loan Revolving Credit Facility Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Operating cash flows from operating leases Operating Lease, Payments Common stock, shares, outstanding (in shares) Common stock, shares, outstanding, beginning balance (in shares) Common stock, shares, outstanding, ending balance (in shares) Common Stock, Shares, Outstanding Conversion price (in USD per share) Debt Instrument, Convertible, Conversion Price Conversion ratio Debt Instrument, Convertible, Conversion Ratio Net (loss) income per share - basic Earnings Per Share, Basic [Abstract] PEO PEO [Member] Concentration of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Other Stockholders' Equity, Other Derivative assets fair value, gross Derivative Asset, Subject to Master Netting Arrangement, before Offset Common stock, par value per share (in USD per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities U.S. Treasury bills US Treasury Bill Securities [Member] Marketable equity securities Equity Securities, FV-NI, Current Customer [Domain] Customer [Domain] Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Schedule of Inventory, Current Schedule of Inventory, Current [Table Text Block] Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Debt Instrument [Axis] Debt Instrument [Axis] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Schedule of Net Investment Hedges Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block] Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Repayments of borrowing under credit agreements Repayments of Long-Term Lines of Credit Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Related Party Transaction [Domain] Related Party Transaction [Domain] Net (loss) income per common share attributable to Varex Earnings Per Share [Abstract] Percentage of manufacturing capacity Percentage Of Manufacturing Capacity The percentage of manufacturing capacity that the entity has the guaranteed right to purchase up to. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Investments in privately-held companies Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures Financing cash flows from finance leases Finance Lease, Principal Payments Restricted cash Restricted Cash Schedule of Customers with a Significant Portion of Revenue Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Supplemental cash flow information: Supplemental Cash Flow Information [Abstract] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Other income (expense), net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Contractual interest coupon and other Interest Expense, Debt, Contractual Interest Coupon Interest Expense, Debt, Contractual Interest Coupon Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] PEO Name PEO Name Concentration risk (as a percent) Concentration Risk, Percentage MeVis Breastcare MeVis Breastcare [Member] MeVis Breastcare APAC Asia Pacific [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Restricted stock units, grants in period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of Goodwill Schedule of Goodwill [Table Text Block] Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Options, exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Contractual Interest Rate (as a percent) Contractual interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Euro Euro Member Countries, Euro Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Percentage of fixed costs Percentage Of Fixed Costs The percentage of fixed costs as defined in the agreement and determined at the beginning of each calendar year that the entity is required to pay. Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total Varex stockholders' equity Equity, Attributable to Parent Total of consideration paid and fair value of previous equity interest Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination Commercial paper Commercial Paper [Member] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Canon Medical Systems Corporation Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member] Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member] Share-based awards and other Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Supplemental Balance Sheet Information Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Contract with customer, liability, revenue recognized Contract with Customer, Liability, Revenue Recognized Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Concentration Risk Type [Axis] Concentration Risk Type [Axis] (Loss) income before taxes (Loss) income before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Canceled, expired or forfeited (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Net Investment Hedging Net Investment Hedging [Member] Emerging Growth Company Entity Emerging Growth Company Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table] Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table] Unamortized issuance costs Debt Issuance Costs, Net Total finance lease costs Lease, Cost, Finance Lease Costs Lease, Cost, Finance Lease Costs Fair Value Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Schedule of Product Warranty Liability Schedule of Product Warranty Liability [Table Text Block] Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Product Warranty Standard Product Warranty, Policy [Policy Text Block] Loss on settlement of cash flow hedge Gain (Loss) On Settlement Of Hedge, Investing Activities Gain (Loss) On Settlement Of Hedge, Investing Activities Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Balance at beginning of period Balance at end of period Contract with Customer, Right to Recover Product Due within one year Marketable Securities, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Amortized Cost Marketable Securities, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Amortized Cost Document Fiscal Period Focus Document Fiscal Period Focus Product warranty expenditures Standard Product Warranty Accrual, Decrease for Payments Available borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Options outstanding beginning balance (in USD per share) Options outstanding ending balance (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Percentage of liabilities obligated to reimburse Percentage of Liabilities Obligated To Reimburse Percentage of Liabilities Obligated To Reimburse Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Position [Domain] Position [Domain] Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code NET (LOSS) INCOME PER SHARE Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Ownership interest (as a percent) Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Total stockholders' equity Stockholders' equity, outstanding, beginning balance Stockholders' equity, outstanding, ending balance Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Schedule of Share-based Compensation, Stock Options, Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Deferred taxes Deferred Income Tax Expense (Benefit), Cash Impact Deferred Income Tax Expense (Benefit), Cash Impact Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items] Additions to refund liabilities Contract With Customer, Refund Liability, Additions Contract With Customer, Refund Liability, Additions Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table] Total liabilities measured at fair value Liabilities, Fair Value Disclosure Taxes related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Fiscal Year Fiscal Period, Policy [Policy Text Block] Liabilities Liabilities: Liabilities [Abstract] Prepaid expenses and other current assets Other Current Assets [Member] Net (loss) income Net (loss) income Net (loss) income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income taxes paid, net of (refunds) Income Taxes Paid, Net Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Accrued product warranty, at beginning of period Accrued product warranty, at end of period Standard Product Warranty Accrual Other, net Payments for (Proceeds from) Other Investing Activities Percentage of voting interests acquired (as a percent) Business Acquisition, Percentage of Voting Interests Acquired Acquired existing technology Developed Technology Rights [Member] Due after one year through five years Marketable Securities, Maturity, Allocated and Single Maturity Date, Rolling After One Through Five Years, Amortized Cost Marketable Securities, Maturity, Allocated and Single Maturity Date, Rolling After One Through Five Years, Amortized Cost Retained Earnings Retained Earnings [Member] Current maturities of long-term debt Long-Term Debt, Current Maturities New accruals charged to cost of revenues Standard Product Warranty Accrual, Increase for Warranties Issued Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and stockholders' equity Liabilities and Equity Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Operating lease assets Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Basic (in USD per share) Basic net (loss) income per share attributable to Varex (in USD per share) Earnings Per Share, Basic Right of return assets from shipments of products subject to return during the period Contract With Customer, Right To Recover Product, Right Of Return Asset From Shipments Contract With Customer, Right To Recover Product, Right Of Return Asset From Shipments Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Outstanding at period beginning (in USD per share) Outstanding at period ending (in USD per share) Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price Currency [Axis] Currency [Axis] Net (loss) income attributable to Varex - diluted Net Income (Loss) Available to Common Stockholders, Diluted Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Schedule of Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Fair value of previous equity interest at acquisition date Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Consolidation Consolidation, Policy [Policy Text Block] Total marketable debt securities Marketable Securities, Amortized Cost Marketable Securities, Amortized Cost Chinese Renminbi China, Yuan Renminbi Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Interest Expense Interest Expense [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Income from equity method investments Income (Loss) from Equity Method Investments, Net of Dividends or Distributions Business Combinations [Abstract] Business Combinations [Abstract] Termination Date Trading Arrangement Termination Date Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Americas Americas [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Exercisable (in USD per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price Warranty term Warranty Term Warranty Term Noncontrolling Interest Noncontrolling Interest [Line Items] Derivative Instrument [Axis] Derivative Instrument [Axis] Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Noncontrolling Interest, Other Changes Noncontrolling Interest, Other Changes All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative Derivative [Line Items] Common stock, $.01 par value: 150,000,000 shares authorized Shares issued and outstanding: 40,618,590 and 40,529,573 at December 29, 2023 and September 29, 2023, respectively Common Stock, Value, Outstanding Award Timing Disclosures [Line Items] Cash and Cash Equivalents, Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Compensation Amount Outstanding Recovery Compensation Amount Due within one year Marketable Securities, Maturity, Allocated And Single Maturity Date, Year One Marketable Securities, Maturity, Allocated And Single Maturity Date, Year One Additional paid-in capital Additional Paid in Capital Convertible notes Convertible Debt Securities [Member] Derivative assets Derivative Asset Restricted stock units, canceled or expired (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Number of equity instruments for convertible debt (in shares) Debt Instrument, Convertible, Number of Equity Instruments Australian Dollar Australia, Dollars Refund Liabilities Change in Contract with Customer, Liability [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Convertible Debt Convertible Debt [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Restricted stock units, canceled or expired in period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Insider Trading Arrangements [Line Items] Accounts receivable, allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Balance at beginning of period Balance at end of period Contract with Customer, Refund Liability Share price (in USD per share) Share Price Related Party [Axis] Related Party, Type [Axis] Options, outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Remeasurement of previous equity interest Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net [Abstract] Movement in Standard Product Warranty Accrual Movement in Standard Product Warranty Accrual [Roll Forward] Patents, licenses and other Intellectual Property [Member] Entity Registrant Name Entity Registrant Name Award Timing Method Award Timing Method [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Dilutive effect of share-based awards and other (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Accrual for environmental losses Accrual for Environmental Loss Contingencies Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of revenues Cost of Sales [Member] Noncontrolling interests Noncontrolling interests, at beginning of period Noncontrolling interests, at end of period Equity, Attributable to Noncontrolling Interest Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Revenue from contract with customer Revenue from Contract with Customer Benchmark [Member] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options, exercisable, weighted average exercise price (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Medical Medical [Member] Medical [Member] Finance lease liabilities (non-current) Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Gain on purchase of business Bargain purchase gain Business Combination, Bargain Purchase, Gain Recognized, Amount Segment Reporting Information Segment Reporting Information [Line Items] Total share-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Income tax (benefit) expense Income tax (benefit) expense Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Accounts receivable, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Designated as Hedging Instrument Derivatives Designated as Net Investment Hedges Designated as Hedging Instrument [Member] Equity method investment, amount written off Equity Method Investment, Other than Temporary Impairment Finance lease right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization FAIR VALUE Fair Value Disclosures [Text Block] Kimberley Honeysett [Member] Kimberley Honeysett Number of reportable operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Joint Venture In Saudi Arabia Joint Venture In Saudi Arabia [Member] Joint Venture In Saudi Arabia [Member] Schedule of Disaggregation of Revenue by Geographic Location Disaggregation of Revenue [Table Text Block] Industrial Industrial [Member] Industrial [Member] INVENTORIES Inventory Disclosure [Text Block] Carrying value of previous equity interest before acquisition Business Combination, Step Acquisition, Equity Interest in Acquiree, Prior To Acquisition Business Combination, Step Acquisition, Equity Interest in Acquiree, Prior To Acquisition Revenues, net Revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Convertible Notes Convertible Notes [Member] Convertible Notes Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Temporary equity, shares outstanding (in shares) Temporary Equity, Shares Outstanding Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Acquisitions of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Shares withheld on vesting of restricted stock (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Total comprehensive (loss) income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Credit Facility [Domain] Credit Facility [Domain] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt, net Long-Term Debt, Excluding Current Maturities Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration] Number of Instruments Derivative, Number of Instruments Held Schedule of Gains and (Losses) on Marketable Securities Gain (Loss) on Securities [Table Text Block] Diluted (in shares) Diluted weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Intangible assets, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Schedule of Right of Return Assets and Refund Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Noncash finance right-of-use assets obtained in exchange for new lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Money market funds Money Market Funds, at Carrying Value Operating expenses: Operating Expenses [Abstract] REVENUE RECOGNITION Revenue from Contract with Customer [Text Block] Purchases of property, plant, and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Purchases of property, plant, and equipment financed through accounts payable Fair Value of Assets Acquired Additional Paid-in Capital Additional Paid-in Capital [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Income (loss) from equity investments Income (Loss) from Equity Method Investments Cover page. Cover [Abstract] Position [Axis] Position [Axis] Borrowings under credit agreements Proceeds from Convertible Debt Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of debt issuance costs Amortization of Debt Issuance Costs United States UNITED STATES Fair Value, Recurring Fair Value, Recurring [Member] Other long-term liabilities Other Liabilities, Noncurrent Restricted stock units, vested in period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Canceled, expired or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Business Combination, Bargain Purchase, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration] Business Combination, Bargain Purchase, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration] Effective Interest Rate (as a percent) Long-Term Debt, Weighted Average Interest Rate, over Time Total operating expenses Operating Expenses SEGMENT INFORMATION Segment Reporting Disclosure [Text Block] Net decrease in cash and cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] MeVis Medical Solutions AG (MeVis) MeVis Medical Solutions AG (MeVis) [Member] MeVis Medical Solutions AG (MeVis) [Member] Secured Debt Secured Debt [Member] Non-PEO NEO Non-PEO NEO [Member] Total marketable debt securities Total marketable debt securities Marketable Securities Equity Component [Domain] Equity Component [Domain] Finance lease liabilities (current) Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Work-in-process Inventory, Work in Process, Net of Reserves Amortized Costs Debt Securities, Available-for-Sale, Amortized Cost, Rolling Maturity [Abstract] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument Debt Instrument [Line Items] Scenario [Axis] Scenario [Axis] Basic (in shares) Basic weighted average shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Business acquisitions Noncontrolling Interest, Increase from Business Combination Marketable securities credit loss Marketable Security, Unrealized Gain (Loss) Operating income Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Corporate notes/bonds Corporate Bonds Corporate Bonds Cash and cash equivalents Cash and Cash Equivalents [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Granted (in USD per share) SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsGrantsinPeriodPrice SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsGrantsinPeriodPrice Concentration Risk [Table] Concentration Risk [Table] Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax [Abstract] Scenario [Domain] Scenario [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Schedule of Derivative Instruments Schedule of Derivative Instruments [Table Text Block] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Schedule of Debt Schedule of Debt [Table Text Block] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Costs recovered from product returns during the period Contract With Customer, Right To Recover, Product Costs Recovered Contract With Customer, Right To Recover, Product Costs Recovered Stockholders' equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Noncontrolling Interests Noncontrolling Interest [Member] Accounting Standards Update 2020-06 [Member] EX-101.PRE 10 var-20231229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 var-20231229_g1.jpg begin 644 var-20231229_g1.jpg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�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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - shares
 3 Months Ended
Dec. 29, 2023
Jan. 30, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Dec. 29, 2023  
Document Transition Report false  
Entity File Number 001-37860  
Entity Registrant Name VAREX IMAGING CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 81-3434516  
Entity Address, Address Line One 1678 S. Pioneer Road  
Entity Address, City or Town Salt Lake City  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84104  
City Area Code 801  
Local Phone Number 972-5000  
Title of 12(b) Security Common Stock  
Trading Symbol VREX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Smaller Reporting Company false  
Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   40,600,000
Amendment Flag false  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001681622  
Current Fiscal Year End Date --09-27  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Income Statement [Abstract]    
Revenues, net $ 190.0 $ 205.6
Cost of revenues 132.9 142.3
Gross profit 57.1 63.3
Operating expenses:    
Research and development 20.5 20.0
Selling, general, and administrative 32.4 30.3
Total operating expenses 52.9 50.3
Operating income 4.2 13.0
Interest income 1.9 0.5
Interest expense (7.3) (7.5)
Other income (expense), net 0.6 (0.6)
Interest and other expense, net (4.8) (7.6)
(Loss) income before taxes (0.6) 5.4
Income tax (benefit) expense (0.2) 2.2
Net (loss) income (0.4) 3.2
Less: Net income attributable to noncontrolling interests 0.1 0.1
Net (loss) income attributable to Varex $ (0.5) $ 3.1
Net (loss) income per common share attributable to Varex    
Basic (in USD per share) $ (0.01) $ 0.08
Diluted (in USD per share) $ (0.01) $ 0.08
Weighted average common shares outstanding    
Basic (in shares) 40.6 40.1
Diluted (in shares) 40.6 40.6
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Statement of Comprehensive Income [Abstract]    
Net (loss) income $ (0.4) $ 3.2
Other comprehensive loss    
Foreign currency translation adjustments (1.0) 0.0
Total comprehensive (loss) income (1.4) 3.2
Less: Comprehensive income attributable to noncontrolling interests 0.1 0.1
Comprehensive (loss) income attributable to Varex $ (1.5) $ 3.1
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Current assets:    
Cash and cash equivalents $ 141.3 $ 152.6
Accounts receivable, net of allowance for credit losses of $0.6 million and $0.6 million at December 29, 2023 and September 29, 2023, respectively 139.6 163.6
Inventories 289.7 277.5
Prepaid expenses and other current assets 75.1 64.6
Total current assets 645.7 658.3
Property, plant, and equipment, net 148.3 143.6
Goodwill 290.4 288.5
Intangible assets, net 22.1 22.4
Investments in privately-held companies 28.3 29.0
Deferred tax assets 42.0 41.3
Operating lease assets 28.4 29.0
Other assets 37.1 37.5
Total assets 1,242.3 1,249.6
Current liabilities:    
Accounts payable 73.7 64.7
Accrued liabilities and other current liabilities 61.6 82.6
Current operating lease liabilities 3.8 3.8
Current maturities of long-term debt 1.6 1.5
Deferred revenues 9.4 10.2
Total current liabilities 150.1 162.8
Long-term debt, net 441.4 441.1
Operating lease liabilities 22.9 23.1
Other long-term liabilities 44.9 41.6
Total liabilities 659.3 668.6
Stockholders' equity:    
Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued 0.0 0.0
Common stock, $.01 par value: 150,000,000 shares authorized Shares issued and outstanding: 40,618,590 and 40,529,573 at December 29, 2023 and September 29, 2023, respectively 0.4 0.4
Additional paid-in capital 453.2 450.4
Accumulated other comprehensive loss (2.2) (1.2)
Retained earnings 117.5 118.1
Total Varex stockholders' equity 568.9 567.7
Noncontrolling interests 14.1 13.3
Total stockholders' equity 583.0 581.0
Total liabilities and stockholders' equity $ 1,242.3 $ 1,249.6
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Statement of Financial Position [Abstract]    
Accounts receivable, allowance for doubtful accounts $ 0.6 $ 0.6
Preferred stock, par value (in USD per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 20,000,000 20,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value per share (in USD per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 150,000,000 150,000,000
Common stock, shares, issued (in shares) 40,618,590 40,529,573
Common stock, shares, outstanding (in shares) 40,618,590 40,529,573
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Millions
Total
Cumulative Effect, Period of Adoption, Adjustment
Total Varex Equity
Total Varex Equity
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Other Comprehensive (Loss) Income
Retained Earnings
Retained Earnings
Cumulative Effect, Period of Adoption, Adjustment
Noncontrolling Interests
Stockholders' equity, outstanding, beginning balance at Sep. 30, 2022 $ 546.7 $ (28.1) $ 533.4 $ (28.1) $ 0.4 $ 469.1 $ (34.6) $ 0.1 $ 63.8 $ 6.5 $ 13.3
Common stock, shares, outstanding, beginning balance (in shares) at Sep. 30, 2022         40,100,000            
Increase (Decrease) in Stockholders' Equity                      
Net (loss) income 3.2   3.1           3.1   0.1
Share-based compensation 3.3   3.3     3.3          
Other (0.1)         0.1     (0.1)   (0.1)
Stockholders' equity, outstanding, ending balance at Dec. 30, 2022 525.0   511.7   $ 0.4 437.9   0.1 73.3   13.3
Common stock, shares, outstanding, ending balance (in shares) at Dec. 30, 2022         40,100,000            
Stockholders' equity, outstanding, beginning balance at Sep. 29, 2023 $ 581.0   567.7   $ 0.4 450.4   (1.2) 118.1   13.3
Common stock, shares, outstanding, beginning balance (in shares) at Sep. 29, 2023 40,529,573       40,500,000            
Increase (Decrease) in Stockholders' Equity                      
Net (loss) income $ (0.4)   (0.5)           (0.5)   0.1
Common stock issued upon vesting of restricted shares (in shares)         200,000            
Shares withheld on vesting of restricted stock (1.0)   (1.0)     (1.0)          
Shares withheld on vesting of restricted stock (in shares)         (100,000)            
Share-based compensation 3.7   3.7     3.7          
Foreign currency translation adjustments (1.0)   (1.0)         (1.0)      
Business acquisitions 0.7                   0.7
Other 0.0         0.1     (0.1)    
Stockholders' equity, outstanding, ending balance at Dec. 29, 2023 $ 583.0   $ 568.9   $ 0.4 $ 453.2   $ (2.2) $ 117.5   $ 14.1
Common stock, shares, outstanding, ending balance (in shares) at Dec. 29, 2023 40,618,590       40,600,000            
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Cash flows from operating activities:    
Net (loss) income $ (0.4) $ 3.2
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:    
Share-based compensation expense 3.7 3.3
Depreciation 5.1 4.6
Amortization of intangible assets 3.6 3.4
Deferred taxes (0.8) (0.2)
Income from equity method investments (0.4) (1.3)
Amortization of deferred loan costs 0.7 0.6
Gain on purchase of business (2.1) 0.0
Inventory write-down 0.9 2.0
Other, net (0.5) 0.0
Changes in assets and liabilities:    
Accounts receivable 25.3 15.6
Inventories (13.2) (18.8)
Prepaid expenses and other assets 2.2 (0.4)
Accounts payable 9.0 8.0
Accrued liabilities and other current and long-term liabilities (22.0) (25.4)
Deferred revenues (0.8) 1.7
Net cash provided by (used in) operating activities 10.3 (3.7)
Cash flows from investing activities:    
Purchases of property, plant, and equipment (10.4) (5.5)
Loss on settlement of cash flow hedge 0.0 (0.3)
Proceeds from maturities of marketable debt securities 14.2 4.0
Purchase of marketable debt securities (24.5) (6.3)
Purchase of marketable equity securities 0.0 (2.7)
Settlement of net investment hedge 0.0 7.0
Acquisitions of businesses, net of cash acquired 0.9 0.0
Other, net (0.1) 0.1
Net cash used in investing activities (19.9) (3.7)
Cash flows from financing activities:    
Taxes related to net share settlement of equity awards (1.0) 0.0
Repayments of borrowing under credit agreements (0.4) (0.5)
Other, net (0.3) 0.1
Net cash used in financing activities (1.7) (0.4)
Net decrease in cash and cash equivalents and restricted cash (11.3) (7.8)
Cash and cash equivalents and restricted cash at beginning of period 154.0 90.6
Cash and cash equivalents and restricted cash at end of period 142.7 82.8
Supplemental cash flow information:    
Cash paid for interest 13.7 13.7
Income taxes paid, net of (refunds) 2.7 4.5
Supplemental non-cash activities:    
Purchases of property, plant, and equipment financed through accounts payable $ 2.5 $ 2.0
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Dec. 29, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Description of Business
    Varex Imaging Corporation (the “Company” or “Varex”) designs, manufactures, sells, and services a broad range of medical products, which include X-ray imaging components including X-ray tubes, flat panel and photon counting detectors and accessories, ionization chambers, high voltage connectors, image processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. The Company sells its products to imaging system original equipment manufacturer (“OEM”) customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary equipment, as well as to independent service companies and distributors, and directly to end-users for replacement purposes.
    The Company also designs, manufactures, sells and services industrial products, which include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, coolers, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex’s products into their inspection or irradiation systems and processes. The Company conducts an active research and development program to focus on new technology and applications in both the medical and industrial X-ray imaging markets.
Basis of Presentation
    The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements include all adjustments necessary for a fair presentation of the results for the interim periods. The Company has consolidated all of its majority owned subsidiaries and entities over which it has control. All intercompany balances and transactions have been eliminated as part of the consolidation.
    These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended September 29, 2023 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on November 16, 2023. The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures. Except for the change in certain policies upon adoption of the accounting standards described below, there have been no material changes to the Company's significant accounting policies, compared to the accounting policies described in Note 1, Summary of Significant Accounting Policies, in the Company’s Annual Report on Form 10-K for fiscal year 2023.
Segment Reporting
    The Company has two reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its Chief Executive Officer, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance. See Note 15, Segment Information, for further information on the Company’s segments.
Fiscal Year
    The fiscal years of the Company as reported are the 52 or 53-week periods ending on the Friday nearest September 30. Fiscal year 2024 is the 52-week period ending September 27, 2024. Fiscal year 2023 was the 52-week period that ended on September 29, 2023. The fiscal quarters ended December 29, 2023 and December 30, 2022 were both 13-week periods.
Use of Estimates
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, valuation of goodwill and intangible assets, receivables, warranties, refund liabilities, long-lived asset valuations, impairment of investments, valuation of financial instruments, and taxes on income. Actual results could differ from these estimates.
Cash and Cash Equivalents
    The Company considers unrestricted currency on hand, demand deposits, time deposits, and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents.
Restricted Cash
    Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the Company's Condensed Consolidated Balance Sheets. Cash and cash equivalents and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows consisted of the following:
Three Months EndedThree Months Ended
December 29, 2023December 30, 2022
(In millions)Beginning of PeriodEnd of PeriodBeginning of PeriodEnd of Period
Cash and cash equivalents$152.6 $141.3 $89.4 $81.5 
Restricted cash1.4 1.4 1.2 1.3 
Total as presented in the Condensed Consolidated Statements of Cash Flows$154.0 $142.7 $90.6 $82.8 
Concentration of Risk
    Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities, certificates of deposit, and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. To date, the Company has not realized any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases, and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for credit losses based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. When these suppliers are unable to meet the Company's supply needs, the Company's production is negatively impacted.
    Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. In certain circumstances, a customer may be required to prepay all or a portion of the contract price prior to transfer of control. During the periods presented, one of the Company's customers accounted for a significant portion of revenues, as set forth below:
Three Months Ended
December 29, 2023December 30, 2022
Canon Medical Systems Corporation14.7 %20.1 %
    Canon Medical Systems Corporation accounted for 8.2% and 13.8% of the Company’s accounts receivable as of December 29, 2023 and September 29, 2023, respectively.
Equity Method Investments
    The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in, but not control, these investments. The Company records impairment losses on its equity method investments if an impairment exists and is deemed to be other-than-temporary, which is based on various factors, including but not limited to, the length of time the fair value of the investment is below the carrying value, the absence of an ability to recover the carrying amount of the investment, and the inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. There were no impairments recorded during the three months ended December 29, 2023 and December 30, 2022.
Marketable Securities
    The Company's marketable securities consist primarily of financial instruments such as United States treasury securities, United States agency obligations, corporate bonds, commercial paper, money market funds, and equity securities.
Marketable Debt Securities
    The Company's marketable debt securities are classified as available-for-sale. Classification of marketable debt securities is determined at the time of purchase, and the Company reevaluates such classification as of each balance sheet date. Marketable debt securities are recorded at estimated fair value and included in cash and cash equivalents, prepaid expenses and other current assets, and other assets within the Condensed Consolidated Balance Sheets. Any unrealized gains or losses are included in accumulated other comprehensive loss within the Condensed Consolidated Balance Sheets. When the fair value of a marketable debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in the Condensed Consolidated Statements of Operations. When the fair value of a marketable debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss, and are recognized in the Condensed Consolidated Statements of Operations only if the Company sells or intends to sell the security before recovery of its cost basis. There were no impairments related to marketable debt securities recorded during the three months ended December 29, 2023 and December 30, 2022.
Marketable Equity Securities
    Marketable equity securities are stated at fair value as determined by the most recently traded price of each security at the balance sheet date and included in other assets within the Condensed Consolidated Balance Sheets. All unrealized gains and losses on marketable equity securities are recorded as part of other income (expense), net in the Company's Condensed Consolidated Statements of Operations. See Note 6, Fair Value, for further details.
Loss Contingencies
    From time to time, the Company is involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, and other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. When a loss contingency is probable but not reasonably estimable the nature of the contingency and the fact that an estimate cannot be made is disclosed.
Supplier Finance Programs
    The Company participates in voluntary supply chain finance programs with a financial intermediary which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. As part of participating in these arrangements, the Company generally receives more favorable payment terms from its suppliers. The Company does not receive fees, payments, extended payment terms, or other direct economic benefits from the intermediary. The total amounts due to the financial intermediary to settle supplier invoices under supply chain finance programs as of December 29, 2023 and September 29, 2023 were $2.3 million and $4.2 million, respectively. These amounts are included within accounts payable in the Condensed Consolidated Balance Sheets.
Environmental Obligations
    The Company's operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport, and disposal of hazardous substances. Certain of those laws impose cleanup liabilities under certain circumstances. In connection with those laws and certain of our past and present operations and facilities, the Company is obligated to indemnify Varian Medical Systems, Inc. ("Varian") for the cleanup liabilities related to prior corporate restructuring activities. The Company anticipates that it will be obligated to reimburse Varian for 20% of the liabilities of Varian related to these sites (after adjusting for any insurance proceeds or tax benefits received by Varian). As of December 29, 2023, our estimated environmental liability for these sites was $2.6 million, net of expected insurance proceeds. As of September 29, 2023, our estimated liability for these sites was $2.8 million, net of expected insurance proceeds.
Product Warranty
    The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.
    The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience of product failures, adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.
    The following table reflects the changes in the Company’s accrued product warranty:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Accrued product warranty, at beginning of period$7.7 $7.9 
New accruals charged to cost of revenues3.7 2.8 
Product warranty expenditures(3.4)(3.0)
Accrued product warranty, at end of period$8.0 $7.7 
Leases
    The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represent the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate. The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its Condensed Consolidated Balance Sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its Condensed Consolidated Balance Sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option.
Revenue Recognition
    The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts.
    The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray imaging components including X-ray tubes, digital detectors and image-processing tools, and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X-ray imaging and sells its Linatron® X-ray linear accelerators together with its image processing software and image detection products to OEM customers that incorporate them into their inspection or irradiation systems and processes. Service contracts are often sold with certain security and inspection products and computer-aided detection products.
    The Company determines revenue recognition through the following steps:
•Identification of the contract, or contracts, with a customer
•Identification of the performance obligations in the contract
•Determination of the transaction price
•Allocation of the transaction price to the performance obligations in the contract
•Recognition of revenue when, or as, a performance obligation is satisfied
Contracts and Performance Obligations
    The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.
Transaction Price and Allocation to Performance Obligations
    Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current, and forecasted) that is reasonably available.
    The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. For sales with a right of return, revenue is reduced and a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding refund liability and right of return asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.
    If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation could be sold separately.
Recognition of Revenue
    Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.
    Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
    Service revenue is generally recognized over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract, and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.
Disaggregation of Revenue
    Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note 15, Segment Information, included in this report, for the disaggregation of the Company’s revenue based on reportable operating segments and Note 2, Revenue Recognition, for the disaggregation of revenue by geographic region.
Contract Balances
    Contract liabilities are included within the deferred revenues, and other long-term liabilities balances in the Condensed Consolidated Balance Sheets. The Company does not have any material contract assets.
    Deferred revenue represents the Company's obligation to transfer goods or services to its customers for which it has already received consideration (or the amount is due) from the customer. The Company's deferred revenue balance primarily relates to contract advances and billings for warranty contracts.
    Deferred revenue that is estimated to be recognized during the following twelve-month period is recorded as deferred revenues and the remaining portion is recorded as other long-term liabilities in the Condensed Consolidated Balance Sheets.
Costs to Obtain or Fulfill a Customer Contract
    The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.
Recently Adopted Accounting Pronouncements
    In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The Company adopted this ASU on October 1, 2022, using the modified retrospective method. For further details, refer to Note 1, Summary of Significant Accounting Policies, of the Notes to the Condensed Consolidated Financial Statements of our Annual Report on Form 10-K for the fiscal year ended September 29, 2023 filed with the SEC on November 16, 2023.
    In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs, which requires entities to provide qualitative and quantitative disclosures about their supplier finance programs, including a rollforward of related obligations. The adoption of ASU 2022-04 did not affect the Company’s financial condition, results of operations, or cash flows as the guidance only requires additional disclosures. We adopted this ASU effective September 30, 2023 on a retrospective basis, except for the amendment on rollforward information, which has been adopted on a prospective basis.
Recent Accounting Standards or Updates Not Yet Effective
    There are no new accounting standards not yet adopted or effective that are expected to have a material impact on the Company's Condensed Consolidated Financial Statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE RECOGNITION
 3 Months Ended
Dec. 29, 2023
Revenue from Contract with Customer [Abstract]  
REVENUE RECOGNITION REVENUE RECOGNITION
Disaggregation of Revenue
    Revenue is disaggregated from contracts by geographic region and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors.
    The following table disaggregates the Company’s revenue by geographic region:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Americas$62.4 $66.6 
EMEA66.0 65.3 
APAC61.6 73.7 
$190.0 $205.6 
    Revenue in the United States was $60.6 million and $65.4 million for the three months ended December 29, 2023 and December 30, 2022, respectively.
    Our products are sold in three geographic regions: the Americas, EMEA, and APAC. The Americas includes North America (primarily the United States) and Latin America. EMEA includes Europe, the Middle East, India, and Africa. APAC includes Asia (other than India) and Australia. Revenues by region are based on the known final destination of products sold.
    Refer to Note 15, Segment Information, for the disaggregation of the Company’s revenue based on reportable operating segments.
Right of Return Assets and Refund Liabilities
    Right of return assets are included within the prepaid expenses and other current assets, and other assets balances in the Condensed Consolidated Balance Sheets. Refund liabilities are included within the accrued liabilities and other current liabilities and other long-term liabilities balances in the Condensed Consolidated Balance Sheets. The following table summarizes the changes in the right of return assets and refund liabilities for the three months ended December 29, 2023 and December 30, 2022:
Right of Return Assets
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Balance at beginning of period$26.0 $25.4 
Costs recovered from product returns during the period(1.9)(1.5)
Right of return assets from shipments of products subject to return during the period1.4 1.5 
Balance at end of period$25.5 $25.4 
Refund Liabilities
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Balance at beginning of period$28.9 $28.2 
Release of refund liability included in beginning of year refund liability(2.1)(1.6)
Additions to refund liabilities1.5 1.7 
Balance at end of period$28.3 $28.3 
Contract Balances
    During the three months ended December 29, 2023, the Company recognized revenue of $6.8 million related to deferred revenues which existed at September 29, 2023. During the three months ended December 30, 2022, the Company recognized revenue of $4.2 million related to deferred revenues that existed at September 30, 2022.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES
 3 Months Ended
Dec. 29, 2023
Leases [Abstract]  
LEASES LEASES
    The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles, and equipment. The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
(In millions)Balance Sheet LocationDecember 29, 2023September 29, 2023
Assets
Operating lease right-of-use assetsOperating lease assets$28.4 $29.0 
Finance lease right-of-use assetsProperty, plant, and equipment, net1.0 0.3 
Liabilities
Operating lease liabilities (current) Current operating lease liabilities3.8 3.8 
Finance lease liabilities (current) Accrued liabilities and other current liabilities0.2 0.1 
Operating lease liabilities (non-current)Operating lease liabilities22.9 23.1 
Finance lease liabilities (non-current)Other long-term liabilities$0.6 $0.2 
    The following table provides information related to the Company’s operating and finance leases:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Total operating lease costs(1)
$1.5 $1.5 
Total finance lease costs$0.1 $0.1 
Operating cash flows from operating leases$1.4 $1.6 
Financing cash flows from finance leases0.3 0.1 
Total cash paid for amounts included in the measurement of lease liabilities$1.7 $1.7 
Noncash operating right-of-use assets obtained in exchange for new lease liabilities$1.5 $— 
Noncash finance right-of-use assets obtained in exchange for new lease liabilities0.7 — 
Total right-of-use assets obtained in exchange for new lease liabilities$2.2 $— 
(1) Includes variable and short-term lease expense, which were immaterial for the three months ended December 29, 2023 and December 30, 2022.
LEASES LEASES
    The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles, and equipment. The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
(In millions)Balance Sheet LocationDecember 29, 2023September 29, 2023
Assets
Operating lease right-of-use assetsOperating lease assets$28.4 $29.0 
Finance lease right-of-use assetsProperty, plant, and equipment, net1.0 0.3 
Liabilities
Operating lease liabilities (current) Current operating lease liabilities3.8 3.8 
Finance lease liabilities (current) Accrued liabilities and other current liabilities0.2 0.1 
Operating lease liabilities (non-current)Operating lease liabilities22.9 23.1 
Finance lease liabilities (non-current)Other long-term liabilities$0.6 $0.2 
    The following table provides information related to the Company’s operating and finance leases:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Total operating lease costs(1)
$1.5 $1.5 
Total finance lease costs$0.1 $0.1 
Operating cash flows from operating leases$1.4 $1.6 
Financing cash flows from finance leases0.3 0.1 
Total cash paid for amounts included in the measurement of lease liabilities$1.7 $1.7 
Noncash operating right-of-use assets obtained in exchange for new lease liabilities$1.5 $— 
Noncash finance right-of-use assets obtained in exchange for new lease liabilities0.7 — 
Total right-of-use assets obtained in exchange for new lease liabilities$2.2 $— 
(1) Includes variable and short-term lease expense, which were immaterial for the three months ended December 29, 2023 and December 30, 2022.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
RELATED-PARTY TRANSACTIONS
 3 Months Ended
Dec. 29, 2023
Related Party Transactions [Abstract]  
RELATED-PARTY TRANSACTIONS RELATED-PARTY TRANSACTIONS
Investments in Privately-Held Companies
    The Company has a 40% ownership interest in dpiX Holding LLC (“dpiX Holding”), a holding company that has a 100% ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon-based thin film transistor arrays for flat panels used in the Company's digital image detectors. In accordance with the dpiX Holding operating agreement, net profits or losses are allocated to the members in accordance with their ownership interests.
    The investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are also eliminated. During the three months ended December 29, 2023 and December 30, 2022, the Company recorded income on the equity investment in dpiX Holding of $0.5 million and $2.0 million, respectively. The income and loss on the equity investment in dpiX Holding are included in other income (expense), net in the Condensed Consolidated Statements of Operations. The carrying value of the equity investment in dpiX Holding was $26.3 million and $25.8 million at December 29, 2023 and September 29, 2023, respectively.
    During the three months ended December 29, 2023 and December 30, 2022, the Company purchased glass transistor arrays from dpiX totaling $5.0 million and $5.0 million, respectively. These purchases of glass transistor arrays are included as a component of inventories on the Condensed Consolidated Balance Sheets or cost of revenues in the Condensed Consolidated Statements of Operations.
    As of December 29, 2023 and September 29, 2023, the Company had accounts payable to dpiX totaling $2.8 million and $2.7 million, respectively.
     In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides it with the right to 50% of dpiX’s total manufacturing capacity. In addition, the Company is required to pay for 50% of dpiX's fixed costs, as determined at the beginning of each calendar year. In January 2024, the Company's fixed cost commitment was determined and approved by the dpiX board of directors to be $12.4 million for calendar year 2024. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).
    The Company has determined that dpiX Holding is a variable interest entity because the at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to unilaterally direct the activities of dpiX Holding, and therefore, is not the primary beneficiary of dpiX Holding. The Company’s exposure to loss as a result of its involvement with dpiX Holding is limited to the carrying value of the Company’s investment of $26.3 million and fixed cost commitments.
    In November 2018, the Company (through one of its wholly-owned subsidiaries) and CETTEEN GmbH (“CETTEEN”), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging GmbH & Co. KG (“VEC”), a joint venture formed to develop technology for use in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method of accounting. The Company has determined that VEC is a variable interest entity.
    During the three months ended December 29, 2023 and December 30, 2022, the Company recorded a loss on the equity investment in VEC of $0.1 million and $0.3 million, respectively. The Company's investment in VEC was $2.0 million and $2.1 million at December 29, 2023 and September 29, 2023, respectively. As of December 29, 2023 and September 29, 2023, the Company had loans and other receivables outstanding from VEC of $0.7 million, and $0.7 million, respectively, which are recorded in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES
 3 Months Ended
Dec. 29, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES
    As part of the Company’s overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates.
    The Company records all derivatives on the Condensed Consolidated Balance Sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective, in which case the Company would test for effectiveness on a more frequent basis. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period income. The Company does not offset fair value amounts recognized for derivative instruments in its Condensed Consolidated Balance Sheets for presentation purposes.
    Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions that meet certain minimum credit ratings to help mitigate counterparty credit risk.
Derivatives Designated as Hedging Instruments - Net Investment Hedges
    The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in wholly-owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive loss along with the foreign currency translation adjustments on those investments.
    As of December 29, 2023, the Company had the following outstanding derivatives designated as net investment hedging instruments:
(In millions, except number of instruments)Number of InstrumentsNotional Value
Cross currency swap contracts2$58.7 
    The following table summarizes the amount of pre-tax income recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:
Amount of Loss Recognized in OCI on Derivative
Three Months Ended		Location of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
Three Months Ended
(In millions)December 29, 2023December 30, 2022December 29, 2023December 30, 2022
Cross currency swap contracts$(2.7)$(4.0)Interest expense$0.3 $0.2 
    These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying Condensed Consolidated Balance Sheets where the instruments are recorded:
(In millions)Derivative Assets and Liabilities
Derivatives Designated as Net Investment HedgesBalance Sheet LocationDecember 29, 2023September 29, 2023
Cross currency swap contractsPrepaid expenses and other current assets$0.8 $0.7 
Cross currency swap contractsOther long-term liabilities$7.7 $4.9 
Balance Sheet Hedges
    The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency-denominated monetary assets and liabilities, primarily cash, lease contracts, third-party accounts receivable and payable, and intercompany accounts receivable and payable. These forward contracts are generally entered into at the end of one fiscal period and expire by the end of the next fiscal period. These forward contracts are not designated for hedge accounting treatment; therefore, the change in fair value of these derivatives is recorded as a component of other income (expense), net in the Condensed Consolidated Statements of Operations and offsets the change in fair value of the foreign currency-denominated assets and liabilities, which are also recorded as a component of other income (expense), net. The Company has not and does not intend to use derivative financial instruments for speculative or trading purposes.
    The following table shows the notional amounts of outstanding foreign currency contracts as of December 29, 2023:
Notional Value of Derivatives not Designated as Hedging Instruments:
(In millions of equivalent USD)Sell contracts
Australian Dollar$3.8 
Chinese Renminbi10.2 
Euro13.3 
Indian Rupee5.0 
$32.3 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE
 3 Months Ended
Dec. 29, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE FAIR VALUE
Assets and Liabilities Measured at Fair Value on a Recurring Basis
    The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable, net and accounts payable, approximate their fair values due to their short maturities. As of December 29, 2023, the fair values of the Company’s Convertible Notes and Senior Secured Notes, as defined in Note 9, Borrowings and measured using Level 1 inputs, were $234.0 million and $244.4 million, respectively. As of September 29, 2023, the fair values of the Company’s Convertible Notes and Senior Secured Notes, measured using Level 1 inputs, were $228.4 million and $243.6 million, respectively. The Company has elected to use the income approach to value its derivative instruments using standard valuation techniques and Level 2 inputs, such as currency spot rates, forward points and credit default swap spreads.
    In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
Fair Value at December 29, 2023
(In millions)
Quoted Prices in Active Markets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Total
Assets:
Money market funds$— $20.5 $— $20.5 
Commercial paper— 8.3 — 8.3 
Corporate notes/bonds— 10.3 — 10.3 
Government agencies— 20.1 — 20.1 
U.S. Treasury bills— 21.8 — 21.8 
Derivative assets
— 0.8 — 0.8 
Deferred compensation plan(1)
6.9 — — 6.9 
Marketable equity securities3.6 — — 3.6 
Total assets measured at fair value$10.5 $81.8 $— $92.3 
Liabilities:
Derivative liabilities
$— $7.7 $— $7.7 
Total liabilities measured at fair value$— $7.7 $— $7.7 
(1) The assets held under the Company’s deferred compensation plan are classified in Level 1, as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.
Fair Value at September 29, 2023
(In millions)
Quoted Prices in Active Markets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Total
Assets:
Money market funds$— $45.4 $— $45.4 
Commercial paper— 6.0 — 6.0 
Corporate notes/bonds— 8.3 — 8.3 
Government agencies— 6.6 — 6.6 
U.S. Treasury bills— 28.6 — 28.6 
Derivative assets— 0.7 — 0.7 
Deferred compensation plan(1)
6.3 — — 6.3 
Marketable equity securities4.1 — — 4.1 
Total assets measured at fair value$10.4 $95.6 $— $106.0 
Liabilities:
Derivative liabilities$— $4.9 $— $4.9 
Total liabilities measured at fair value$— $4.9 $— $4.9 
(1) The assets held under the Company’s deferred compensation plan are classified in Level 1 as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.
Marketable Debt Securities
    The following is a summary of marketable debt securities, which are included within the cash and cash equivalents, prepaid expenses and other current assets, and other assets balances on the Condensed Consolidated Balance Sheets.
December 29, 2023
(In millions)Amortized CostsFair Value
Commercial paper$8.3 $8.3 
Corporate notes/bonds10.3 10.3 
U.S. Treasury bills21.8 21.8 
Government agencies20.120.1
Total marketable debt securities$60.5 $60.5 
September 29, 2023
(In millions)Amortized CostsFair Value
Commercial paper$6.0 $6.0 
Corporate notes/bonds8.3 8.3 
U.S. Treasury bills28.6 28.6 
Government agencies6.66.6
Total marketable debt securities$49.5 $49.5 
    The contractual maturities of marketable debt securities as of December 29, 2023, are shown in the table below. Actual maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations.
December 29, 2023
(In millions)Amortized CostsFair Value
Contractual maturities:
Due within one year$60.5 $60.5 
Due after one year through five years— — 
Total marketable debt securities$60.5 $60.5 
    During the three months ended December 29, 2023, there were no gross realized gains or losses from the sale of certain marketable debt securities that were reclassified out of accumulated other comprehensive loss.
    The following tables summarize the balance sheet locations for marketable debt securities:
December 29, 2023
(In millions)Commercial paperCorporate notes/bondsGovernment agenciesTreasury billsTotal
Cash and cash equivalents$8.3 $— $— $— $8.3 
Prepaid expenses and other current assets— 10.3 20.1 21.8 52.2 
Total marketable debt securities$8.3 $10.3 $20.1 $21.8 $60.5 
September 29, 2023
(In millions)Commercial paperCorporate notes/bondsGovernment agenciesTreasury billsTotal
Cash and cash equivalents$6.0 $— $— $2.2 $8.2 
Prepaid expenses and other current assets— 8.3 6.6 26.4 41.3 
Total marketable debt securities$6.0 $8.3 $6.6 $28.6 $49.5 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORIES
 3 Months Ended
Dec. 29, 2023
Inventory Disclosure [Abstract]  
INVENTORIES INVENTORIES
    The following table summarizes the Company’s inventories:
(In millions)December 29, 2023September 29, 2023
Raw materials and parts$223.5 $217.5 
Work-in-process19.5 20.0 
Finished goods46.7 40.0 
Total inventories$289.7 $277.5 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS
 3 Months Ended
Dec. 29, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETS
    The following table reflects goodwill by reportable operating segment:
(In millions)MedicalIndustrialTotal
Balance at September 29, 2023$171.5 $117.0 $288.5 
Foreign currency translation adjustments1.1 0.8 1.9 
Balance at December 29, 2023$172.6 $117.8 $290.4 
    The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the Condensed Consolidated Balance Sheets:
December 29, 2023September 29, 2023
(In millions)
Gross Carrying Amount
Accumulated Amortization
Net Carrying AmountGross Carrying Amount
Accumulated Amortization
Net Carrying Amount
Acquired existing technology
$73.5 $(59.9)$13.6 $72.3 $(57.8)$14.5 
Patents, licenses and other
12.6 (12.4)0.2 12.5 (12.2)0.3 
Customer contracts and supplier relationship
52.7 (44.4)8.3 50.3 (42.7)7.6 
Total intangible assets
$138.8 $(116.7)$22.1 $135.1 $(112.7)$22.4 
    Amortization expense for intangible assets was $3.6 million and $3.4 million for the three months ended December 29, 2023 and December 30, 2022, respectively. In connection with the business combination discussed in Note 10. Business Combinations, the Company recorded additional intangible assets of $2.6 million, of which $2.1 million related to customer contracts and supplier relationships and $0.5 million related to acquired existing technology.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.0.1
BORROWINGS
 3 Months Ended
Dec. 29, 2023
Debt Disclosure [Abstract]  
BORROWINGS BORROWINGS
    The following table summarizes the Company’s short-term and long-term debt:
December 29, 2023September 29, 2023
(In millions, except for percentages)AmountAmountContractual Interest RateEffective Interest Rate
Current maturities of long-term debt
Other debt$1.6 $1.5 
Total current maturities of long-term debt$1.6 $1.5 
Non-current maturities of long-term debt:
Convertible Senior Unsecured Notes$200.0 $200.0 4.0%4.8%
Senior Secured Notes243.0 243.0 7.9%8.2%
Other debt3.2 3.5 
Total non-current maturities of long-term debt:$446.2 $446.5 
Unamortized issuance costs
Unamortized issuance costs - Convertible Notes$(2.1)$(2.5)
Unamortized issuance costs - Senior Secured Notes(2.7)(2.9)
Total(4.8)(5.4)
Total debt outstanding, net$443.0 $442.6 
    The following table summarizes the Company’s interest expense:
Three Months Ended
December 29, 2023December 30, 2022
Contractual interest coupon and other$6.6 $6.9 
Amortization of debt issuance costs0.7 0.6 
Total interest expense$7.3 $7.5 
Convertible Senior Unsecured Notes
    On June 9, 2020, Varex issued $200.0 million in aggregate principal amount of 4.00% Convertible Senior Unsecured Notes due 2025 (“Convertible Notes”). The net proceeds from the issuance of the Convertible Notes, after deducting transaction fees and offering expense payable by the Company, were approximately $193.1 million. The Convertible Notes bear interest at the annual rate of 4.00%, payable semiannually on June 1 and December 1 of each year, beginning on December 1, 2020, and will mature on June 1, 2025, unless earlier converted or repurchased by Varex.
    The Convertible Notes are convertible into cash, shares of Varex common stock or a combination thereof, at Varex’s election, at an initial conversion rate of 48.048 shares of common stock per $1,000 principal amount of Convertible Notes, which is equivalent to an initial conversion price of approximately $20.81 per share, subject to adjustment pursuant to the terms of the indenture governing the Convertible Notes. The Convertible Notes may be converted at any time after, and including, December 15, 2024, until the close of business on the second scheduled trading day immediately before the maturity date. The maximum number of shares issuable upon conversion of the Convertible Notes is 9.6 million.
Call Spread
    On June 4, 2020 and June 5, 2020, in connection with the offering of the Convertible Notes, Varex entered into privately negotiated convertible note hedge transactions (collectively, the “Hedge Transactions”). The Hedge Transactions cover, subject to customary anti-dilution adjustments, the number of shares of Varex common stock that initially underlie the Convertible Notes. The Hedge Transactions are expected generally to reduce the potential dilution and/or offset any cash payments Varex is required to make in excess of the principal amount due upon conversion of the Convertible Notes in the event that the market price of Varex common stock is greater than the strike price of the Hedge Transactions, which was initially $20.81 per share (subject to adjustment under the terms of the Hedge Transactions). The strike price of $20.81 corresponds to the initial conversion price of the Convertible Notes. The number of shares underlying the Hedge Transactions is 9.6 million.
    On June 4, 2020 and June 5, 2020, Varex also entered into privately negotiated warrant transactions (collectively, the “Warrant Transactions” and, together with the Hedge Transactions, the “Call Spread Transactions”), whereby the Company sold warrants at a higher strike price relating to the same number of shares of Varex common stock that initially underlie the Convertible Notes, subject to customary anti-dilution adjustments. The initial strike price of the warrants is $24.975 per share (subject to adjustment under the terms of the Warrant Transactions), which was 50% above the last reported sale price of Varex common stock on June 4, 2020. The Warrant Transactions could have a dilutive effect to the Company's stockholders to the extent that the market price per share of Varex common stock, as measured under the terms of the Warrant Transactions, exceeds the applicable strike price of the warrants. The number of shares underlying the Warrant Transactions is 9.6 million. The number of warrants outstanding as of December 29, 2023 was 9.6 million.
Senior Secured Notes
    Varex issued $300.0 million aggregate principal amount of 7.875% Senior Secured Notes due 2027 (the "Senior Secured Notes") pursuant to an indenture dated September 30, 2020. Interest payments are paid semiannually on April 15 and October 15 of each year, beginning on April 15, 2021. The Senior Secured Notes will mature on October 15, 2027, unless earlier redeemed or repurchased by Varex. On July 15, 2021, we redeemed $30.0 million, and on March 18, 2022, we redeemed $27.0 million of the Senior Secured Notes. As of December 29, 2023, the aggregate principal amount of the outstanding Senior Secured Notes was $243.0 million.
    The Senior Secured Notes are secured by a first priority lien on substantially all of the assets of Varex and the assets and capital stock of its subsidiary guarantors (subject to exceptions), except for assets for which a first priority security interest is pledged for the ABL Facility (defined below), in which the Senior Secured Notes have a second lien security interest. The Senior Secured Notes include negative covenants, subject to certain exceptions, restricting or limiting Varex's ability and the ability of its restricted subsidiaries to, among other things, incur liens on collateral; sell certain assets; incur additional indebtedness; pay dividends; issue preferred shares; consolidate, merge, or sell all or substantially all of its assets; and enter into certain transactions with their affiliates.
Asset-Based Loan
    On September 30, 2020, the Company entered into a revolving credit agreement consisting of a $100.0 million asset-based loan revolving credit facility (the “Asset-Based Loan” or "ABL Facility"). Borrowings under the Asset-Based Loan bear interest at floating rates based on the Secured Overnight Financing Rate ("SOFR"), or a comparable rate, or a base rate, and an applicable margin based on Average Daily Excess Availability (as defined in the Asset-Based Loan Agreement). In addition, the Company is required to pay a quarterly commitment fee of 0.25% annualized, based on the aggregate unused commitments under the Asset-Based Loan.
    The ABL Facility matures on the earlier of September 30, 2025 or 91 days prior to the maturity of the Convertible Notes, at which time all outstanding amounts under the ABL Facility will be due and payable. The maximum availability under the ABL Facility is $100.0 million; however, the borrowing base under the ABL Facility fluctuates from month-to-month depending on the amount of eligible accounts receivable, inventory, and real estate. As of December 29, 2023, the amount available under the ABL Facility was $71.9 million and the ABL Facility remains undrawn.
    The ABL Facility includes various restrictive covenants that limit our ability to engage in certain transactions, including the incurrence of debt, payment of dividends and other restrictive payments, existence of restrictions affecting subsidiaries, sales of stock and assets, certain affiliate transactions, modifications of debt documents and organizational documents, changes to line of business and fiscal year, incurrence of liens, making fundamental changes, prepayments of junior indebtedness, and certain other transactions.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS
 3 Months Ended
Dec. 29, 2023
Business Combinations [Abstract]  
BUSINESS COMBINATIONS BUSINESS COMBINATIONS
    As of September 29, 2023, the Company, through two of its consolidated subsidiaries, Varex Imaging Deutschland AG and MeVis Medical Solutions AG ("MeVis Medical"), held a combined ownership interest in MeVis BreastCare GmbH and MeVis BreastCare Gmbh & Co KG (referred to in combination as "MeVis Breastcare") of 37.6%. Because the Company had the ability to exercise significant influence in, but not control, over MeVis Breastcare, it was historically accounted for as an equity method investment.
    In October 2023, the Company increased its ownership in MeVis Breastcare to 87.1% for a purchase price of $0.9 million, resulting in the Company now holding a controlling interest in MeVis Breastcare. The purchase of this additional ownership interest was accounted for as a business combination achieved in stages, or step acquisition. As a result, the previously held equity interest was remeasured to its acquisition-date fair value, with a gain of $0.9 million recognized in other income (expense), net in the Condensed Consolidated Statements of Operations. The assets and liabilities of MeVis Breastcare were then recorded on the Company's balance sheet at their fair values in accordance with ASC 805, and a gain on bargain purchase of $1.2 million was recorded in other income (expense), net in the Condensed Consolidated Statements of Operations. Because the purchase price did not give consideration to the other assets of the business, the fair value of the ownership interest acquired exceeded the price paid to the third party partial owner and this resulted in a gain on bargain purchase.
    The following table summarizes the consideration paid for MeVis Breastcare and the amounts of the assets acquired and liabilities assumed recognized at their estimated acquisition date fair values, as well as the estimated fair value at the acquisition date of the noncontrolling interest in MeVis Breastcare.
USD
(in millions)
Consideration paid
Cash$0.9 
Fair value of total consideration transferred0.9 
Remeasurement of previous equity interest
Carrying value of previous equity interest before acquisition1.1 
Fair value of previous equity interest at acquisition date2.0 
Remeasurement gain recorded on previous equity interest0.9 
Total of consideration paid and fair value of previous equity interest$2.9 
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash and cash equivalents$1.8 
Accounts receivable, net 1.2 
Intangible assets, net2.6 
Accounts payable(0.1)
Accrued liabilities and other current liabilities(0.6)
Other long-term liabilities(0.1)
Total identifiable net assets4.8 
Noncontrolling interest in MeVis Breastcare(0.7)
Bargain purchase gain(1.2)
Total$2.9 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.0.1
NONCONTROLLING INTERESTS
 3 Months Ended
Dec. 29, 2023
Noncontrolling Interest [Abstract]  
NONCONTROLLING INTERESTS NONCONTROLLING INTERESTS
    In September 2018, the Company entered into a partnership in Saudi Arabia. The Company has majority voting rights with an approximate 75% interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in its Condensed Consolidated Financial Statements and recorded the noncontrolling interests. The noncontrolling interest related to the partner’s 25% interest is included in noncontrolling interests in the equity section of the Company’s Condensed Consolidated Balance Sheets. Income representing the noncontrolling partner's share of income from operations is included in the Company's Condensed Consolidated Statements of Operations.
    In April 2015, the Company acquired 73.5% of the then outstanding shares of MeVis Medical, a publicly traded company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a Domination and Profit and Loss Transfer Agreement (the “DPLTA”) with MeVis Medical. In fiscal years 2017 and 2018, the Company purchased an additional 0.2% of outstanding shares such that the Company now owns 73.7% of the outstanding shares of common stock of MeVis Medical. Under the DPLTA, MeVis Medical subordinates its management to the Company and undertakes to transfer all its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis Medical, an annual recurring net compensation of €0.95 per MeVis Medical share. At December 29, 2023, noncontrolling shareholders together held approximately 0.5 million shares of MeVis Medical, representing 26.3% of the outstanding shares.
    During the first quarter of fiscal year 2024, the Company acquired a controlling interest in MeVis Breastcare, in which the Company now holds an 87.1% ownership interest. In association with this acquisition, the Company recorded an associated noncontrolling interest of $0.7 million.
    Changes in noncontrolling interests were as follows:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Noncontrolling interests, at beginning of period$13.3 $13.3 
Net income attributable to noncontrolling interests0.1 0.1 
Business acquisitions0.7 — 
Other— (0.1)
Noncontrolling interests, at end of period$14.1 $13.3 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.0.1
NET (LOSS) INCOME PER SHARE
 3 Months Ended
Dec. 29, 2023
Earnings Per Share [Abstract]  
NET (LOSS) INCOME PER SHARE NET (LOSS) INCOME PER SHARE
    Basic net (loss) income per common share is computed by dividing the net (loss) income for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted net (loss) income per common share reflects the effects of potentially dilutive securities, which is computed by dividing the sum of net (loss) income and any adjustments to net income by the sum of the weighted average number of common shares outstanding and dilutive common shares.
    A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:
Three Months Ended
(In millions, except per share amounts)
December 29, 2023December 30, 2022
Net (loss) income per share - basic
Net (loss) income attributable to Varex$(0.5)$3.1 
Basic weighted average shares outstanding
40.6 40.1 
Basic net (loss) income per share attributable to Varex$(0.01)$0.08 
Net (loss) income per share - diluted
Net (loss) income attributable to Varex$(0.5)$3.1 
Basic weighted average shares outstanding40.6 40.1 
Dilutive effect of share-based awards and other— 0.5 
Diluted weighted average shares outstanding
40.6 40.6 
Diluted net (loss) income per share attributable to Varex$(0.01)$0.08 
Anti-dilutive share summary
Share-based awards and other
3.6 3.0 
Convertible notes9.6 9.6 
Warrants9.6 1.9 
Total anti-dilutive shares22.8 14.5 
    Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying stock options, unvested stock awards, purchase rights granted under the employee stock purchase plan, warrants, and Convertible Notes using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net (loss) income per share attributable to Varex when their effect is dilutive. In connection with the offering of the Convertible Notes, the Company entered into convertible note hedges and warrants (see Note 9, Borrowings). However, the Company's convertible note hedges are not included when calculating potentially dilutive shares since their effect is always anti-dilutive.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE STOCK PLANS
 3 Months Ended
Dec. 29, 2023
Share-Based Payment Arrangement [Abstract]  
EMPLOYEE STOCK PLANS EMPLOYEE STOCK PLANS
Share-Based Compensation Expense
    Share-based compensation expense recognized in the Condensed Consolidated Statements of Operations is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company’s direct employees.
    The table below summarizes the effect of recording share-based compensation expense and the option value of the employee stock purchase plan shares:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Cost of revenues$0.5 $0.4 
Research and development0.9 0.8 
Selling, general, and administrative
2.3 2.1 
Total share-based compensation expense$3.7 $3.3 
Stock Option Activity
    The following table summarizes the activity for stock options under Varex’s employee incentive plans for the Company's employees:
(In thousands, except per share amounts and the remaining term)OptionsPrice Range
Weighted Average Exercise Price
Weighted Average Remaining Term (in years)
Aggregate Intrinsic Value(1)
Outstanding at September 29, 20232,862 
$13.61 - $37.60
$28.08 4.8$871.4 
Granted— 
$0.00 - $0.00
— 
Canceled, expired or forfeited— 
$0.00 - $0.00
— 
Outstanding at December 29, 20232,862 
$13.61 - $37.60
$28.08 4.6$1,159.0 
Exercisable at December 29, 20232,249 
$13.61 - $37.60
$29.01 3.6$937.8 
(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $20.50 as of December 29, 2023, the last trading date of the Company's first quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their in-the-money options and sold the shares received upon exercise as of that date.
Restricted Stock Units, Performance Stock Units, Restricted Stock Awards, and Deferred Stock Units
    In the first quarter of fiscal year 2024, the Company issued performance stock units ("PSUs"). PSUs are awarded to certain officers and key employees in connection with our long-term incentive program. Each PSU represents the right to receive one share of our common stock, provided that the applicable performance and vesting conditions are satisfied. The fair value of certain PSUs are linked to the achievement of performance goals based on Adjusted EBITDA margin. Share-based compensation expense for these PSUs are recognized over the performance period based on the probability of achieving the performance targets. Certain PSUs include a performance objective based on our relative total shareholder return over the performance period compared to a predetermined peer group. The fair value of these awards is determined using a Monte Carlo simulation as of the date of the grant and share-based compensation expense will not be adjusted should the target awards vary from actual awards.
    The following table summarizes the activity for restricted stock units, performance stock units, restricted stock awards, and deferred stock units under the 2020 Omnibus Stock Plan:
(In thousands, except per share amounts)Number of SharesWeighted Average Grant-Date Fair Value
Outstanding at September 29, 20231,277 $22.30 
Granted785 20.17 
Vested(142)28.04 
Canceled or expired(16)21.91 
Outstanding at December 29, 20231,904 $21.00 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.0.1
TAXES ON (LOSS) INCOME
 3 Months Ended
Dec. 29, 2023
Income Tax Disclosure [Abstract]  
TAXES ON (LOSS) INCOME TAXES ON (LOSS) INCOME
    For the three months ended December 29, 2023, the Company recognized income tax benefit of $0.2 million on $0.6 million of pre-tax loss. For the three months ended December 30, 2022, the Company recognized income tax expense of $2.2 million on $5.4 million of pre-tax income. The Company is unable to recognize a tax benefit for pre-tax book losses in certain foreign jurisdictions but has recognized tax expense for profitable foreign jurisdictions.
    The Company's tax expense for the three months ended December 29, 2023 decreased, primarily due to decreased pre-tax income in certain jurisdictions and losses in certain foreign jurisdictions for which no benefit can be recorded.
    The Company is maintaining its reinvestment assertion with respect to foreign earnings for the three months ended December 29, 2023, which is that all earnings prior to fiscal year 2018 are permanently reinvested for all countries, and that all earnings for Varex Imaging Sweden and Oy Varex Imaging Finland are also indefinitely reinvested in those countries, but post fiscal year 2017 earnings in all other countries are not permanently reinvested. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable United States tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately $0.1 million. This estimated liability is for United States state income taxes and foreign withholding taxes that would apply if the foreign earnings were repatriated in the form of a dividend.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION
 3 Months Ended
Dec. 29, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
    The Company has two reportable operating segments: Medical and Industrial, which aligns with how the CODM reviews the Company’s performance. The segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s CEO evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross profit. The operating and reportable segment structure provides alignment between business strategies and operating results.
Description of Segments
    The Medical segment designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. These components are used in a range of medical imaging applications including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses.
    The Industrial segment designs, develops, manufactures, sells and services X-ray imaging products for use in a number of markets, including security applications for cargo screening at ports and borders, baggage screening at airports, and nondestructive testing, irradiation, and inspection applications used in a number of other vertical markets. The Company's industrial products include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, and coolers. In addition, the Company licenses proprietary image-processing and detection software designed to work with other Varex products to provide packaged sub-assembly solutions to industrial customers.
    Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.
    Information related to the Company’s segments is as follows:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Revenues, net
Medical$139.9 $160.1 
Industrial50.1 45.5 
Total revenues190.0 205.6 
Gross profit
Medical38.9 46.3 
Industrial18.2 17.0 
Total gross profit57.1 63.3 
Total operating expenses52.9 50.3 
Interest and other expense, net(4.8)(7.6)
(Loss) income before taxes(0.6)5.4 
Income tax (benefit) expense(0.2)2.2 
Net (loss) income(0.4)3.2 
Less: Net income attributable to noncontrolling interests0.1 0.1 
Net (loss) income attributable to Varex$(0.5)$3.1 
    The Company does not disclose total assets by segment as this information is not provided to the CODM.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.0.1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Pay vs Performance Disclosure    
Net (loss) income attributable to Varex - basic $ (0.5) $ 3.1
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 29, 2023
shares
Trading Arrangements, by Individual  
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Kimberley Honeysett [Member]  
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement On December 15, 2023, Kimberley Honeysett, our Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale of up to 21,821 shares of our common stock that have vested or may vest to Ms. Honeysett pursuant to previously awarded stock options and restricted stock unit awards. The arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c). The first date that shares are permitted to be sold under the trading arrangement is March 15, 2024, and subsequent sales may occur until the arrangement’s expiration date, which is February 14, 2025, or earlier if all transactions under the trading arrangement are completed or the trading arrangement is otherwise earlier terminated.
Name Kimberley Honeysett
Title Chief Legal Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date December 15, 2023
Arrangement Duration 336 days
Aggregate Available 21,821
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Dec. 29, 2023
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
    The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements include all adjustments necessary for a fair presentation of the results for the interim periods. The Company has consolidated all of its majority owned subsidiaries and entities over which it has control. All intercompany balances and transactions have been eliminated as part of the consolidation.
Consolidation These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended September 29, 2023 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on November 16, 2023.
Subsequent Events The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures.
Segment Reporting
Segment Reporting
    The Company has two reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its Chief Executive Officer, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance.
Fiscal Year
Fiscal Year
    The fiscal years of the Company as reported are the 52 or 53-week periods ending on the Friday nearest September 30. Fiscal year 2024 is the 52-week period ending September 27, 2024. Fiscal year 2023 was the 52-week period that ended on September 29, 2023. The fiscal quarters ended December 29, 2023 and December 30, 2022 were both 13-week periods.
Use of Estimates
Use of Estimates
    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, valuation of goodwill and intangible assets, receivables, warranties, refund liabilities, long-lived asset valuations, impairment of investments, valuation of financial instruments, and taxes on income. Actual results could differ from these estimates.
Cash and Cash Equivalents, Restricted Cash
Cash and Cash Equivalents
    The Company considers unrestricted currency on hand, demand deposits, time deposits, and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents.
Restricted Cash
    Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the Company's Condensed Consolidated Balance Sheets.
Concentration of Risk
Concentration of Risk
    Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities, certificates of deposit, and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. To date, the Company has not realized any losses on its deposits of cash and cash equivalents.
Equity Method Investments and Marketable Securities
Equity Method Investments
    The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in, but not control, these investments. The Company records impairment losses on its equity method investments if an impairment exists and is deemed to be other-than-temporary, which is based on various factors, including but not limited to, the length of time the fair value of the investment is below the carrying value, the absence of an ability to recover the carrying amount of the investment, and the inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.
Marketable Securities
    The Company's marketable securities consist primarily of financial instruments such as United States treasury securities, United States agency obligations, corporate bonds, commercial paper, money market funds, and equity securities.
Marketable Debt Securities
    The Company's marketable debt securities are classified as available-for-sale. Classification of marketable debt securities is determined at the time of purchase, and the Company reevaluates such classification as of each balance sheet date. Marketable debt securities are recorded at estimated fair value and included in cash and cash equivalents, prepaid expenses and other current assets, and other assets within the Condensed Consolidated Balance Sheets. Any unrealized gains or losses are included in accumulated other comprehensive loss within the Condensed Consolidated Balance Sheets. When the fair value of a marketable debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in the Condensed Consolidated Statements of Operations. When the fair value of a marketable debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss, and are recognized in the Condensed Consolidated Statements of Operations only if the Company sells or intends to sell the security before recovery of its cost basis. There were no impairments related to marketable debt securities recorded during the three months ended December 29, 2023 and December 30, 2022.
Marketable Equity Securities
    Marketable equity securities are stated at fair value as determined by the most recently traded price of each security at the balance sheet date and included in other assets within the Condensed Consolidated Balance Sheets. All unrealized gains and losses on marketable equity securities are recorded as part of other income (expense), net in the Company's Condensed Consolidated Statements of Operations. See Note 6, Fair Value, for further details.
Loss Contingencies
Loss Contingencies
    From time to time, the Company is involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, and other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. When a loss contingency is probable but not reasonably estimable the nature of the contingency and the fact that an estimate cannot be made is disclosed.
Supplier Finance Programs
Supplier Finance Programs
    The Company participates in voluntary supply chain finance programs with a financial intermediary which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. As part of participating in these arrangements, the Company generally receives more favorable payment terms from its suppliers. The Company does not receive fees, payments, extended payment terms, or other direct economic benefits from the intermediary.
Environmental Obligations
Environmental Obligations
    The Company's operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport, and disposal of hazardous substances. Certain of those laws impose cleanup liabilities under certain circumstances. In connection with those laws and certain of our past and present operations and facilities, the Company is obligated to indemnify Varian Medical Systems, Inc. ("Varian") for the cleanup liabilities related to prior corporate restructuring activities. The Company anticipates that it will be obligated to reimburse Varian for 20% of the liabilities of Varian related to these sites (after adjusting for any insurance proceeds or tax benefits received by Varian). As of December 29, 2023, our estimated environmental liability for these sites was $2.6 million, net of expected insurance proceeds. As of September 29, 2023, our estimated liability for these sites was $2.8 million, net of expected insurance proceeds.
Product Warranty
Product Warranty
    The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.
    The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience of product failures, adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.
Leases
Leases
    The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represent the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate. The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its Condensed Consolidated Balance Sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its Condensed Consolidated Balance Sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option.
Revenue Recognition
Revenue Recognition
    The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts.
    The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray imaging components including X-ray tubes, digital detectors and image-processing tools, and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X-ray imaging and sells its Linatron® X-ray linear accelerators together with its image processing software and image detection products to OEM customers that incorporate them into their inspection or irradiation systems and processes. Service contracts are often sold with certain security and inspection products and computer-aided detection products.
    The Company determines revenue recognition through the following steps:
•Identification of the contract, or contracts, with a customer
•Identification of the performance obligations in the contract
•Determination of the transaction price
•Allocation of the transaction price to the performance obligations in the contract
•Recognition of revenue when, or as, a performance obligation is satisfied
Contracts and Performance Obligations
    The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.
Transaction Price and Allocation to Performance Obligations
    Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current, and forecasted) that is reasonably available.
    The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. For sales with a right of return, revenue is reduced and a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding refund liability and right of return asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.
    If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation could be sold separately.
Recognition of Revenue
    Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.
    Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.
    Service revenue is generally recognized over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract, and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.
Disaggregation of Revenue
    Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note 15, Segment Information, included in this report, for the disaggregation of the Company’s revenue based on reportable operating segments and Note 2, Revenue Recognition, for the disaggregation of revenue by geographic region.
Contract Balances
    Contract liabilities are included within the deferred revenues, and other long-term liabilities balances in the Condensed Consolidated Balance Sheets. The Company does not have any material contract assets.
    Deferred revenue represents the Company's obligation to transfer goods or services to its customers for which it has already received consideration (or the amount is due) from the customer. The Company's deferred revenue balance primarily relates to contract advances and billings for warranty contracts.
    Deferred revenue that is estimated to be recognized during the following twelve-month period is recorded as deferred revenues and the remaining portion is recorded as other long-term liabilities in the Condensed Consolidated Balance Sheets.
Costs to Obtain or Fulfill a Customer Contract
    The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.
Recently Adopted Accounting Pronouncements and Recent Accounting Standards or Updates Not Yet Effective
Recently Adopted Accounting Pronouncements
    In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The Company adopted this ASU on October 1, 2022, using the modified retrospective method. For further details, refer to Note 1, Summary of Significant Accounting Policies, of the Notes to the Condensed Consolidated Financial Statements of our Annual Report on Form 10-K for the fiscal year ended September 29, 2023 filed with the SEC on November 16, 2023.
    In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs, which requires entities to provide qualitative and quantitative disclosures about their supplier finance programs, including a rollforward of related obligations. The adoption of ASU 2022-04 did not affect the Company’s financial condition, results of operations, or cash flows as the guidance only requires additional disclosures. We adopted this ASU effective September 30, 2023 on a retrospective basis, except for the amendment on rollforward information, which has been adopted on a prospective basis.
Recent Accounting Standards or Updates Not Yet Effective
    There are no new accounting standards not yet adopted or effective that are expected to have a material impact on the Company's Condensed Consolidated Financial Statements.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 3 Months Ended
Dec. 29, 2023
Accounting Policies [Abstract]  
Schedule of Cash and Cash Equivalents Cash and cash equivalents and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows consisted of the following:
Three Months EndedThree Months Ended
December 29, 2023December 30, 2022
(In millions)Beginning of PeriodEnd of PeriodBeginning of PeriodEnd of Period
Cash and cash equivalents$152.6 $141.3 $89.4 $81.5 
Restricted cash1.4 1.4 1.2 1.3 
Total as presented in the Condensed Consolidated Statements of Cash Flows$154.0 $142.7 $90.6 $82.8 
Schedule of Restrictions on Cash and Cash Equivalents Cash and cash equivalents and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows consisted of the following:
Three Months EndedThree Months Ended
December 29, 2023December 30, 2022
(In millions)Beginning of PeriodEnd of PeriodBeginning of PeriodEnd of Period
Cash and cash equivalents$152.6 $141.3 $89.4 $81.5 
Restricted cash1.4 1.4 1.2 1.3 
Total as presented in the Condensed Consolidated Statements of Cash Flows$154.0 $142.7 $90.6 $82.8 
Schedule of Customers with a Significant Portion of Revenue During the periods presented, one of the Company's customers accounted for a significant portion of revenues, as set forth below:
Three Months Ended
December 29, 2023December 30, 2022
Canon Medical Systems Corporation14.7 %20.1 %
Schedule of Product Warranty Liability The following table reflects the changes in the Company’s accrued product warranty:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Accrued product warranty, at beginning of period$7.7 $7.9 
New accruals charged to cost of revenues3.7 2.8 
Product warranty expenditures(3.4)(3.0)
Accrued product warranty, at end of period$8.0 $7.7 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE RECOGNITION (Tables)
 3 Months Ended
Dec. 29, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue by Geographic Location The following table disaggregates the Company’s revenue by geographic region:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Americas$62.4 $66.6 
EMEA66.0 65.3 
APAC61.6 73.7 
$190.0 $205.6 
Schedule of Right of Return Assets and Refund Liabilities The following table summarizes the changes in the right of return assets and refund liabilities for the three months ended December 29, 2023 and December 30, 2022:
Right of Return Assets
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Balance at beginning of period$26.0 $25.4 
Costs recovered from product returns during the period(1.9)(1.5)
Right of return assets from shipments of products subject to return during the period1.4 1.5 
Balance at end of period$25.5 $25.4 
Refund Liabilities
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Balance at beginning of period$28.9 $28.2 
Release of refund liability included in beginning of year refund liability(2.1)(1.6)
Additions to refund liabilities1.5 1.7 
Balance at end of period$28.3 $28.3 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES (Tables)
 3 Months Ended
Dec. 29, 2023
Leases [Abstract]  
Schedule of Supplemental Balance Sheet Information The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
(In millions)Balance Sheet LocationDecember 29, 2023September 29, 2023
Assets
Operating lease right-of-use assetsOperating lease assets$28.4 $29.0 
Finance lease right-of-use assetsProperty, plant, and equipment, net1.0 0.3 
Liabilities
Operating lease liabilities (current) Current operating lease liabilities3.8 3.8 
Finance lease liabilities (current) Accrued liabilities and other current liabilities0.2 0.1 
Operating lease liabilities (non-current)Operating lease liabilities22.9 23.1 
Finance lease liabilities (non-current)Other long-term liabilities$0.6 $0.2 
Schedule of Lease Cost and Supplemental Cash Flow Information The following table provides information related to the Company’s operating and finance leases:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Total operating lease costs(1)
$1.5 $1.5 
Total finance lease costs$0.1 $0.1 
Operating cash flows from operating leases$1.4 $1.6 
Financing cash flows from finance leases0.3 0.1 
Total cash paid for amounts included in the measurement of lease liabilities$1.7 $1.7 
Noncash operating right-of-use assets obtained in exchange for new lease liabilities$1.5 $— 
Noncash finance right-of-use assets obtained in exchange for new lease liabilities0.7 — 
Total right-of-use assets obtained in exchange for new lease liabilities$2.2 $— 
(1) Includes variable and short-term lease expense, which were immaterial for the three months ended December 29, 2023 and December 30, 2022.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables)
 3 Months Ended
Dec. 29, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Instruments As of December 29, 2023, the Company had the following outstanding derivatives designated as net investment hedging instruments:
(In millions, except number of instruments)Number of InstrumentsNotional Value
Cross currency swap contracts2$58.7 
The following table shows the notional amounts of outstanding foreign currency contracts as of December 29, 2023:
Notional Value of Derivatives not Designated as Hedging Instruments:
(In millions of equivalent USD)Sell contracts
Australian Dollar$3.8 
Chinese Renminbi10.2 
Euro13.3 
Indian Rupee5.0 
$32.3 
Schedule of Net Investment Hedges The following table summarizes the amount of pre-tax income recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:
Amount of Loss Recognized in OCI on Derivative
Three Months Ended		Location of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)
Three Months Ended
(In millions)December 29, 2023December 30, 2022December 29, 2023December 30, 2022
Cross currency swap contracts$(2.7)$(4.0)Interest expense$0.3 $0.2 
    These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying Condensed Consolidated Balance Sheets where the instruments are recorded:
(In millions)Derivative Assets and Liabilities
Derivatives Designated as Net Investment HedgesBalance Sheet LocationDecember 29, 2023September 29, 2023
Cross currency swap contractsPrepaid expenses and other current assets$0.8 $0.7 
Cross currency swap contractsOther long-term liabilities$7.7 $4.9 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE (Tables)
 3 Months Ended
Dec. 29, 2023
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.
Fair Value at December 29, 2023
(In millions)
Quoted Prices in Active Markets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Total
Assets:
Money market funds$— $20.5 $— $20.5 
Commercial paper— 8.3 — 8.3 
Corporate notes/bonds— 10.3 — 10.3 
Government agencies— 20.1 — 20.1 
U.S. Treasury bills— 21.8 — 21.8 
Derivative assets
— 0.8 — 0.8 
Deferred compensation plan(1)
6.9 — — 6.9 
Marketable equity securities3.6 — — 3.6 
Total assets measured at fair value$10.5 $81.8 $— $92.3 
Liabilities:
Derivative liabilities
$— $7.7 $— $7.7 
Total liabilities measured at fair value$— $7.7 $— $7.7 
(1) The assets held under the Company’s deferred compensation plan are classified in Level 1, as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.
Fair Value at September 29, 2023
(In millions)
Quoted Prices in Active Markets
(Level 1)
Significant Other
Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Total
Assets:
Money market funds$— $45.4 $— $45.4 
Commercial paper— 6.0 — 6.0 
Corporate notes/bonds— 8.3 — 8.3 
Government agencies— 6.6 — 6.6 
U.S. Treasury bills— 28.6 — 28.6 
Derivative assets— 0.7 — 0.7 
Deferred compensation plan(1)
6.3 — — 6.3 
Marketable equity securities4.1 — — 4.1 
Total assets measured at fair value$10.4 $95.6 $— $106.0 
Liabilities:
Derivative liabilities$— $4.9 $— $4.9 
Total liabilities measured at fair value$— $4.9 $— $4.9 
(1) The assets held under the Company’s deferred compensation plan are classified in Level 1 as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.
Schedule of Gains and (Losses) on Marketable Securities The following is a summary of marketable debt securities, which are included within the cash and cash equivalents, prepaid expenses and other current assets, and other assets balances on the Condensed Consolidated Balance Sheets.
December 29, 2023
(In millions)Amortized CostsFair Value
Commercial paper$8.3 $8.3 
Corporate notes/bonds10.3 10.3 
U.S. Treasury bills21.8 21.8 
Government agencies20.120.1
Total marketable debt securities$60.5 $60.5 
September 29, 2023
(In millions)Amortized CostsFair Value
Commercial paper$6.0 $6.0 
Corporate notes/bonds8.3 8.3 
U.S. Treasury bills28.6 28.6 
Government agencies6.66.6
Total marketable debt securities$49.5 $49.5 
Schedule of Marketable Securities The contractual maturities of marketable debt securities as of December 29, 2023, are shown in the table below. Actual maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations.
December 29, 2023
(In millions)Amortized CostsFair Value
Contractual maturities:
Due within one year$60.5 $60.5 
Due after one year through five years— — 
Total marketable debt securities$60.5 $60.5 
The following tables summarize the balance sheet locations for marketable debt securities:
December 29, 2023
(In millions)Commercial paperCorporate notes/bondsGovernment agenciesTreasury billsTotal
Cash and cash equivalents$8.3 $— $— $— $8.3 
Prepaid expenses and other current assets— 10.3 20.1 21.8 52.2 
Total marketable debt securities$8.3 $10.3 $20.1 $21.8 $60.5 
September 29, 2023
(In millions)Commercial paperCorporate notes/bondsGovernment agenciesTreasury billsTotal
Cash and cash equivalents$6.0 $— $— $2.2 $8.2 
Prepaid expenses and other current assets— 8.3 6.6 26.4 41.3 
Total marketable debt securities$6.0 $8.3 $6.6 $28.6 $49.5 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORIES (Tables)
 3 Months Ended
Dec. 29, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current The following table summarizes the Company’s inventories:
(In millions)December 29, 2023September 29, 2023
Raw materials and parts$223.5 $217.5 
Work-in-process19.5 20.0 
Finished goods46.7 40.0 
Total inventories$289.7 $277.5 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 3 Months Ended
Dec. 29, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill The following table reflects goodwill by reportable operating segment:
(In millions)MedicalIndustrialTotal
Balance at September 29, 2023$171.5 $117.0 $288.5 
Foreign currency translation adjustments1.1 0.8 1.9 
Balance at December 29, 2023$172.6 $117.8 $290.4 
Schedule of Finite-Lived Intangible Assets The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the Condensed Consolidated Balance Sheets:
December 29, 2023September 29, 2023
(In millions)
Gross Carrying Amount
Accumulated Amortization
Net Carrying AmountGross Carrying Amount
Accumulated Amortization
Net Carrying Amount
Acquired existing technology
$73.5 $(59.9)$13.6 $72.3 $(57.8)$14.5 
Patents, licenses and other
12.6 (12.4)0.2 12.5 (12.2)0.3 
Customer contracts and supplier relationship
52.7 (44.4)8.3 50.3 (42.7)7.6 
Total intangible assets
$138.8 $(116.7)$22.1 $135.1 $(112.7)$22.4 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.0.1
BORROWINGS (Tables)
 3 Months Ended
Dec. 29, 2023
Debt Disclosure [Abstract]  
Schedule of Debt The following table summarizes the Company’s short-term and long-term debt:
December 29, 2023September 29, 2023
(In millions, except for percentages)AmountAmountContractual Interest RateEffective Interest Rate
Current maturities of long-term debt
Other debt$1.6 $1.5 
Total current maturities of long-term debt$1.6 $1.5 
Non-current maturities of long-term debt:
Convertible Senior Unsecured Notes$200.0 $200.0 4.0%4.8%
Senior Secured Notes243.0 243.0 7.9%8.2%
Other debt3.2 3.5 
Total non-current maturities of long-term debt:$446.2 $446.5 
Unamortized issuance costs
Unamortized issuance costs - Convertible Notes$(2.1)$(2.5)
Unamortized issuance costs - Senior Secured Notes(2.7)(2.9)
Total(4.8)(5.4)
Total debt outstanding, net$443.0 $442.6 
Schedule of Interest Expense The following table summarizes the Company’s interest expense:
Three Months Ended
December 29, 2023December 30, 2022
Contractual interest coupon and other$6.6 $6.9 
Amortization of debt issuance costs0.7 0.6 
Total interest expense$7.3 $7.5 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATION (Tables)
 3 Months Ended
Dec. 29, 2023
Business Combinations [Abstract]  
Schedule of Business Acquisitions The following table summarizes the consideration paid for MeVis Breastcare and the amounts of the assets acquired and liabilities assumed recognized at their estimated acquisition date fair values, as well as the estimated fair value at the acquisition date of the noncontrolling interest in MeVis Breastcare.
USD
(in millions)
Consideration paid
Cash$0.9 
Fair value of total consideration transferred0.9 
Remeasurement of previous equity interest
Carrying value of previous equity interest before acquisition1.1 
Fair value of previous equity interest at acquisition date2.0 
Remeasurement gain recorded on previous equity interest0.9 
Total of consideration paid and fair value of previous equity interest$2.9 
Recognized amounts of identifiable assets acquired and liabilities assumed
Cash and cash equivalents$1.8 
Accounts receivable, net 1.2 
Intangible assets, net2.6 
Accounts payable(0.1)
Accrued liabilities and other current liabilities(0.6)
Other long-term liabilities(0.1)
Total identifiable net assets4.8 
Noncontrolling interest in MeVis Breastcare(0.7)
Bargain purchase gain(1.2)
Total$2.9 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.0.1
NONCONTROLLING INTERESTS (Tables)
 3 Months Ended
Dec. 29, 2023
Noncontrolling Interest [Abstract]  
Schedule of Noncontrolling Interest Changes in noncontrolling interests were as follows:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Noncontrolling interests, at beginning of period$13.3 $13.3 
Net income attributable to noncontrolling interests0.1 0.1 
Business acquisitions0.7 — 
Other— (0.1)
Noncontrolling interests, at end of period$14.1 $13.3 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.0.1
NET (LOSS) INCOME PER SHARE (Tables)
 3 Months Ended
Dec. 29, 2023
Earnings Per Share [Abstract]  
Schedule of Income Per Share, Basic and Diluted A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:
Three Months Ended
(In millions, except per share amounts)
December 29, 2023December 30, 2022
Net (loss) income per share - basic
Net (loss) income attributable to Varex$(0.5)$3.1 
Basic weighted average shares outstanding
40.6 40.1 
Basic net (loss) income per share attributable to Varex$(0.01)$0.08 
Net (loss) income per share - diluted
Net (loss) income attributable to Varex$(0.5)$3.1 
Basic weighted average shares outstanding40.6 40.1 
Dilutive effect of share-based awards and other— 0.5 
Diluted weighted average shares outstanding
40.6 40.6 
Diluted net (loss) income per share attributable to Varex$(0.01)$0.08 
Anti-dilutive share summary
Share-based awards and other
3.6 3.0 
Convertible notes9.6 9.6 
Warrants9.6 1.9 
Total anti-dilutive shares22.8 14.5 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE STOCK PLANS (Tables)
 3 Months Ended
Dec. 29, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs The table below summarizes the effect of recording share-based compensation expense and the option value of the employee stock purchase plan shares:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Cost of revenues$0.5 $0.4 
Research and development0.9 0.8 
Selling, general, and administrative
2.3 2.1 
Total share-based compensation expense$3.7 $3.3 
Schedule of Share-based Compensation, Stock Options, Activity The following table summarizes the activity for stock options under Varex’s employee incentive plans for the Company's employees:
(In thousands, except per share amounts and the remaining term)OptionsPrice Range
Weighted Average Exercise Price
Weighted Average Remaining Term (in years)
Aggregate Intrinsic Value(1)
Outstanding at September 29, 20232,862 
$13.61 - $37.60
$28.08 4.8$871.4 
Granted— 
$0.00 - $0.00
— 
Canceled, expired or forfeited— 
$0.00 - $0.00
— 
Outstanding at December 29, 20232,862 
$13.61 - $37.60
$28.08 4.6$1,159.0 
Exercisable at December 29, 20232,249 
$13.61 - $37.60
$29.01 3.6$937.8 
(1) The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $20.50 as of December 29, 2023, the last trading date of the Company's first quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their in-the-money options and sold the shares received upon exercise as of that date.
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity The following table summarizes the activity for restricted stock units, performance stock units, restricted stock awards, and deferred stock units under the 2020 Omnibus Stock Plan:
(In thousands, except per share amounts)Number of SharesWeighted Average Grant-Date Fair Value
Outstanding at September 29, 20231,277 $22.30 
Granted785 20.17 
Vested(142)28.04 
Canceled or expired(16)21.91 
Outstanding at December 29, 20231,904 $21.00 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION (Tables)
 3 Months Ended
Dec. 29, 2023
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment Information related to the Company’s segments is as follows:
Three Months Ended
(In millions)December 29, 2023December 30, 2022
Revenues, net
Medical$139.9 $160.1 
Industrial50.1 45.5 
Total revenues190.0 205.6 
Gross profit
Medical38.9 46.3 
Industrial18.2 17.0 
Total gross profit57.1 63.3 
Total operating expenses52.9 50.3 
Interest and other expense, net(4.8)(7.6)
(Loss) income before taxes(0.6)5.4 
Income tax (benefit) expense(0.2)2.2 
Net (loss) income(0.4)3.2 
Less: Net income attributable to noncontrolling interests0.1 0.1 
Net (loss) income attributable to Varex$(0.5)$3.1 
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)
 3 Months Ended
Dec. 29, 2023
segment
Accounting Policies [Abstract]  
Number of reportable operating segments 2
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Dec. 30, 2022
Sep. 30, 2022
Accounting Policies [Abstract]        
Cash and cash equivalents $ 141.3 $ 152.6 $ 81.5 $ 89.4
Restricted cash 1.4 1.4 1.3 1.2
Total as presented in the Condensed Consolidated Statements of Cash Flows $ 142.7 $ 154.0 $ 82.8 $ 90.6
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details) - Customer concentration risk - Canon Medical Systems Corporation
 3 Months Ended 12 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Sep. 29, 2023
Revenue from contract with customer      
Concentration Risk      
Concentration risk (as a percent) 14.70% 20.10%  
Accounts receivable      
Concentration Risk      
Concentration risk (as a percent) 8.20%   13.80%
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investments (Details) - USD ($)
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Accounting Policies [Abstract]    
Equity method investment, amount written off $ 0 $ 0
Marketable securities credit loss $ 0 $ 0
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Supplier Finance Programs (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Accounting Policies [Abstract]    
Amounts due for supplier finance program $ 2.3 $ 4.2
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Environmental Obligations (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Accounting Policies [Abstract]    
Percentage of liabilities obligated to reimburse 20.00%  
Accrual for environmental losses $ 2.6 $ 2.8
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Movement in Standard Product Warranty Accrual    
Accrued product warranty, at beginning of period $ 7.7 $ 7.9
New accruals charged to cost of revenues 3.7 2.8
Product warranty expenditures (3.4) (3.0)
Accrued product warranty, at end of period $ 8.0 $ 7.7
Minimum    
Product Warranty Liability    
Warranty term 12 months  
Maximum    
Product Warranty Liability    
Warranty term 24 months  
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE RECOGNITION - Schedule of Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Disaggregation of Revenue    
Revenues, net $ 190.0 $ 205.6
Americas    
Disaggregation of Revenue    
Revenues, net 62.4 66.6
EMEA    
Disaggregation of Revenue    
Revenues, net 66.0 65.3
APAC    
Disaggregation of Revenue    
Revenues, net 61.6 73.7
United States    
Disaggregation of Revenue    
Revenues, net $ 60.6 $ 65.4
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.0.1
REVENUE RECOGNITION - Schedule of Right of Return Assets and Refund Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Right of Return Assets    
Balance at beginning of period $ 26.0 $ 25.4
Costs recovered from product returns during the period (1.9) (1.5)
Right of return assets from shipments of products subject to return during the period 1.4 1.5
Balance at end of period 25.5 25.4
Refund Liabilities    
Balance at beginning of period 28.9 28.2
Release of refund liability included in beginning of year refund liability (2.1) (1.6)
Additions to refund liabilities 1.5 1.7
Balance at end of period 28.3 28.3
Contract with customer, liability, revenue recognized $ 6.8 $ 4.2
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Assets    
Operating lease right-of-use assets $ 28.4 $ 29.0
Finance lease right-of-use assets 1.0 0.3
Liabilities    
Operating lease liabilities (current) 3.8 3.8
Finance lease liabilities (current) 0.2 0.1
Operating lease liabilities (non-current) 22.9 23.1
Finance lease liabilities (non-current) $ 0.6 $ 0.2
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Property, plant, and equipment, net Property, plant, and equipment, net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Accrued liabilities and other current liabilities Accrued liabilities and other current liabilities
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List] Other long-term liabilities Other long-term liabilities
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.0.1
LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Leases [Abstract]    
Total operating lease costs $ 1.5 $ 1.5
Total finance lease costs 0.1 0.1
Operating cash flows from operating leases 1.4 1.6
Financing cash flows from finance leases 0.3 0.1
Total cash paid for amounts included in the measurement of lease liabilities 1.7 1.7
Noncash operating right-of-use assets obtained in exchange for new lease liabilities 1.5 0.0
Noncash finance right-of-use assets obtained in exchange for new lease liabilities 0.7 0.0
Total right-of-use assets obtained in exchange for new lease liabilities $ 2.2 $ 0.0
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.0.1
RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 12 Months Ended
Oct. 30, 2013
Dec. 29, 2023
Dec. 30, 2022
Dec. 31, 2024
Sep. 29, 2023
Related Party Transaction          
Accounts payable   $ 73.7     $ 64.7
Prepaid expenses and other current assets   75.1     64.6
Purchases | Dpi X LLC          
Related Party Transaction          
Related party transaction, amounts of transaction   $ 5.0 $ 5.0    
dpiX Holding | Equity Method Investee          
Related Party Transaction          
Ownership interest (as a percent)   40.00%      
Income (loss) from equity investments   $ 0.5 2.0    
Equity method investments   26.3     25.8
Accounts payable   $ 2.8     2.7
Percentage of manufacturing capacity 50.00%        
Percentage of fixed costs   50.00%      
dpiX Holding | Equity Method Investee | Fixed Cost Commitments | Scenario, Forecast          
Related Party Transaction          
Related party transaction expected fixed cost       $ 12.4  
Dpi X LLC | dpiX Holding | Equity Method Investee          
Related Party Transaction          
Ownership interest (as a percent)   100.00%      
VEC Imaging GmbH & Co. KG | Equity Method Investee          
Related Party Transaction          
Income (loss) from equity investments   $ (0.1) $ (0.3)    
Equity method investments   2.0     2.1
Prepaid expenses and other current assets   $ 0.7     $ 0.7
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivative Instruments (Details) - Net Investment Hedging - Designated as Hedging Instrument - Cross currency swap contracts
$ in Millions
Dec. 29, 2023
USD ($)
instrument
Derivative  
Number of Instruments | instrument 2
Notional Value | $ $ 58.7
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Income Recognized From Derivative Instruments (Details) - Cross currency swap contracts - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Derivative    
Amount of Loss Recognized in OCI on Derivative $ (2.7) $ (4.0)
Interest Expense    
Derivative    
Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing) $ 0.3 $ 0.2
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives at Fair Value (Details) - Net Investment Hedging - Derivatives Designated as Net Investment Hedges - Cross currency swap contracts - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Prepaid expenses and other current assets    
Derivative    
Derivative assets fair value, gross $ 0.8 $ 0.7
Other long-term liabilities    
Derivative    
Derivative liabilities fair value, gross $ 7.7 $ 4.9
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.0.1
FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Balance Sheet Hedges (Details) - Short - Foreign Exchange Contract
$ in Millions
Dec. 29, 2023
USD ($)
Derivative  
Notional Value $ 32.3
Australian Dollar  
Derivative  
Notional Value 3.8
Chinese Renminbi  
Derivative  
Notional Value 10.2
Euro  
Derivative  
Notional Value 13.3
Indian Rupee  
Derivative  
Notional Value $ 5.0
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE - Narrative (Details) - Level 1 - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Convertible Debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Long-term debt, fair value $ 234.0 $ 228.4
Secured Debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis    
Long-term debt, fair value $ 244.4 $ 243.6
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE - Schedule of Fair Value Inputs (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Assets    
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Assets Assets
Liabilities:    
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Liabilities Liabilities
Fair Value, Recurring    
Assets    
Money market funds $ 20.5 $ 45.4
Commercial paper 8.3 6.0
Corporate notes/bonds 10.3 8.3
Government agencies 20.1 6.6
U.S. Treasury bills 21.8 28.6
Derivative assets 0.8 0.7
Deferred compensation plan 6.9 6.3
Marketable equity securities 3.6 4.1
Total assets measured at fair value 92.3 106.0
Liabilities:    
Derivative liabilities 7.7 4.9
Total liabilities measured at fair value 7.7 4.9
Quoted Prices in Active Markets (Level 1) | Fair Value, Recurring    
Assets    
Money market funds 0.0 0.0
Commercial paper 0.0 0.0
Corporate notes/bonds 0.0 0.0
Government agencies 0.0 0.0
U.S. Treasury bills 0.0 0.0
Derivative assets 0.0 0.0
Deferred compensation plan 6.9 6.3
Marketable equity securities 3.6 4.1
Total assets measured at fair value 10.5 10.4
Liabilities:    
Derivative liabilities 0.0 0.0
Total liabilities measured at fair value 0.0 0.0
Significant Other Observable Inputs (Level 2) | Fair Value, Recurring    
Assets    
Money market funds 20.5 45.4
Commercial paper 8.3 6.0
Corporate notes/bonds 10.3 8.3
Government agencies 20.1 6.6
U.S. Treasury bills 21.8 28.6
Derivative assets 0.8 0.7
Deferred compensation plan 0.0 0.0
Marketable equity securities 0.0 0.0
Total assets measured at fair value 81.8 95.6
Liabilities:    
Derivative liabilities 7.7 4.9
Total liabilities measured at fair value 7.7 4.9
Significant Unobservable Inputs (Level 3) | Fair Value, Recurring    
Assets    
Money market funds 0.0 0.0
Commercial paper 0.0 0.0
Corporate notes/bonds 0.0 0.0
Government agencies 0.0 0.0
U.S. Treasury bills 0.0 0.0
Derivative assets 0.0 0.0
Deferred compensation plan 0.0 0.0
Marketable equity securities 0.0 0.0
Total assets measured at fair value 0.0 0.0
Liabilities:    
Derivative liabilities 0.0 0.0
Total liabilities measured at fair value $ 0.0 $ 0.0
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE - Schedule of Marketable Securities (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Total marketable debt securities $ 60.5 $ 49.5
Total marketable debt securities 60.5 49.5
Commercial paper    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Total marketable debt securities 8.3 6.0
Total marketable debt securities 8.3 6.0
Corporate notes/bonds    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Total marketable debt securities 10.3 8.3
Total marketable debt securities 10.3 8.3
U.S. Treasury bills    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Total marketable debt securities 21.8 28.6
Total marketable debt securities 21.8 28.6
Government agencies    
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share    
Total marketable debt securities 20.1 6.6
Total marketable debt securities $ 20.1 $ 6.6
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE - Schedule of Contractual Maturities of Marketable Securities (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Amortized Costs    
Due within one year $ 60.5  
Due after one year through five years 0.0  
Total marketable debt securities 60.5 $ 49.5
Fair Value    
Due within one year 60.5  
Due after one year through five years 0.0  
Total marketable debt securities $ 60.5 $ 49.5
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.0.1
FAIR VALUE - Schedule of Balance Sheet Marketable Securities (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities $ 60.5 $ 49.5
Cash and cash equivalents    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 8.3 8.2
Prepaid expenses and other current assets    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 52.2 41.3
Commercial paper    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 8.3 6.0
Commercial paper | Cash and cash equivalents    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 8.3 6.0
Commercial paper | Prepaid expenses and other current assets    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 0.0 0.0
Corporate notes/bonds    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 10.3 8.3
Corporate notes/bonds | Cash and cash equivalents    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 0.0 0.0
Corporate notes/bonds | Prepaid expenses and other current assets    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 10.3 8.3
Government agencies    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 20.1 6.6
Government agencies | Cash and cash equivalents    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 0.0 0.0
Government agencies | Prepaid expenses and other current assets    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 20.1 6.6
U.S. Treasury bills    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 21.8 28.6
U.S. Treasury bills | Cash and cash equivalents    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities 0.0 2.2
U.S. Treasury bills | Prepaid expenses and other current assets    
Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value    
Total marketable debt securities $ 21.8 $ 26.4
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVENTORIES - Schedule of Inventory (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Inventory Disclosure [Abstract]    
Raw materials and parts $ 223.5 $ 217.5
Work-in-process 19.5 20.0
Finished goods 46.7 40.0
Total inventories $ 289.7 $ 277.5
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details)
$ in Millions
 3 Months Ended
Dec. 29, 2023
USD ($)
Goodwill  
Balance at September 29, 2023 $ 288.5
Foreign currency translation adjustments 1.9
Balance at December 29, 2023 290.4
Medical  
Goodwill  
Balance at September 29, 2023 171.5
Foreign currency translation adjustments 1.1
Balance at December 29, 2023 172.6
Industrial  
Goodwill  
Balance at September 29, 2023 117.0
Foreign currency translation adjustments 0.8
Balance at December 29, 2023 $ 117.8
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($)
$ in Millions
Dec. 29, 2023
Sep. 29, 2023
Finite-Lived Intangible Assets    
Gross Carrying Amount $ 138.8 $ 135.1
Accumulated Amortization (116.7) (112.7)
Net Carrying Amount 22.1 22.4
Acquired existing technology    
Finite-Lived Intangible Assets    
Gross Carrying Amount 73.5 72.3
Accumulated Amortization (59.9) (57.8)
Net Carrying Amount 13.6 14.5
Patents, licenses and other    
Finite-Lived Intangible Assets    
Gross Carrying Amount 12.6 12.5
Accumulated Amortization (12.4) (12.2)
Net Carrying Amount 0.2 0.3
Customer contracts and supplier relationship    
Finite-Lived Intangible Assets    
Gross Carrying Amount 52.7 50.3
Accumulated Amortization (44.4) (42.7)
Net Carrying Amount $ 8.3 $ 7.6
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.0.1
GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Oct. 31, 2023
Finite-Lived Intangible Assets      
Amortization of intangible assets $ 3.6 $ 3.4  
MeVis Breastcare      
Finite-Lived Intangible Assets      
Intangible assets, net     $ 2.6
MeVis Breastcare | Customer contracts and supplier relationship      
Finite-Lived Intangible Assets      
Intangible assets, net     2.1
MeVis Breastcare | Acquired existing technology      
Finite-Lived Intangible Assets      
Intangible assets, net     $ 0.5
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.0.1
BORROWINGS - Schedule of Debt (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Sep. 29, 2023
Sep. 30, 2020
Current maturities of long-term debt      
Current maturities of long-term debt $ 1.6 $ 1.5  
Non-current maturities of long-term debt:      
Total non-current maturities of long-term debt: 446.2 446.5  
Unamortized issuance costs      
Total (4.8) (5.4)  
Total debt outstanding, net 443.0 442.6  
Convertible Debt      
Non-current maturities of long-term debt:      
Total non-current maturities of long-term debt: $ 200.0 200.0  
Contractual Interest Rate (as a percent) 4.00%    
Effective Interest Rate (as a percent) 4.80%    
Unamortized issuance costs      
Unamortized issuance costs $ (2.1) (2.5)  
Other debt      
Current maturities of long-term debt      
Current maturities of long-term debt 1.6 1.5  
Non-current maturities of long-term debt:      
Total non-current maturities of long-term debt: 3.2 3.5  
Senior Secured Notes | Secured Debt      
Non-current maturities of long-term debt:      
Total non-current maturities of long-term debt: $ 243.0 243.0  
Contractual Interest Rate (as a percent) 7.90%   7.875%
Effective Interest Rate (as a percent) 8.20%    
Unamortized issuance costs      
Unamortized issuance costs $ (2.7) $ (2.9)  
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.0.1
BORROWINGS - Schedule of Interest Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Debt Disclosure [Abstract]    
Contractual interest coupon and other $ 6.6 $ 6.9
Amortization of debt issuance costs 0.7 0.6
Total interest expense $ 7.3 $ 7.5
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.0.1
BORROWINGS - Convertible Senior Unsecured Notes Narrative (Details) - Convertible Debt
$ / shares in Units, shares in Millions
 3 Months Ended
Jun. 09, 2020
USD ($)
Jun. 05, 2020
shares
$ / shares
Dec. 29, 2023
shares
Debt Instrument      
Contractual interest rate (as a percent)     4.00%
Convertible Notes      
Debt Instrument      
Face amount | $ $ 200,000,000    
Contractual interest rate (as a percent) 4.00%    
Borrowings under credit agreements | $ $ 193,100,000    
Conversion ratio   0.048084  
Conversion price (in USD per share) | $ / shares   $ 20.81  
Number of equity instruments for convertible debt (in shares) | shares   9.6 9.6
Convertible Notes | Maximum      
Debt Instrument      
Number of equity instruments for convertible debt (in shares) | shares   9.6  
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.0.1
BORROWINGS - Call Spread Narrative (Details) - Convertible Notes - Convertible Debt
shares in Millions
 3 Months Ended
Jun. 05, 2020
shares
$ / shares
Dec. 29, 2023
shares
Jun. 04, 2020
$ / shares
Debt Instrument      
Conversion price (in USD per share) | $ / shares $ 20.81    
Number of equity instruments for convertible debt (in shares) | shares 9.6 9.6  
Warrant exercise price (in USD per share) | $ / shares     $ 24.975
Percent increase of strike price over sale price     50.00%
Maximum      
Debt Instrument      
Number of equity instruments for convertible debt (in shares) | shares 9.6    
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
BORROWINGS - Senior Secured Notes Narrative (Details) - USD ($)
Dec. 29, 2023
Sep. 29, 2023
Mar. 18, 2022
Jul. 15, 2021
Sep. 30, 2020
Debt Instrument          
Long-term debt excluding current maturities, gross $ 446,200,000 $ 446,500,000      
Senior Secured Notes | Secured Debt          
Debt Instrument          
Face amount         $ 300,000,000
Contractual interest rate (as a percent) 7.90%       7.875%
Debt redeemed     $ 27,000,000 $ 30,000,000  
Long-term debt excluding current maturities, gross $ 243,000,000 $ 243,000,000.0      
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.24.0.1
BORROWINGS - Asset-Based Loan Narrative (Details) - Revolving Credit Facility - Asset-Based Loan - Secured Debt - USD ($)
Sep. 30, 2020
Dec. 29, 2023
Debt Instrument    
Maximum borrowing capacity $ 100,000,000 $ 100,000,000
Available borrowing capacity   $ 71,900,000
Minimum    
Debt Instrument    
Used capacity, commitment fee percentage 0.25%  
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended
Oct. 31, 2023
Dec. 29, 2023
Sep. 29, 2023
MeVis Breastcare      
Business Acquisition      
Ownership interest (as a percent) 87.10%   37.60%
MeVis Breastcare      
Business Acquisition      
Purchase price $ 0.9    
Remeasurement gain 0.9    
Gain on purchase of business $ 1.2    
Business Combination, Bargain Purchase, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]   Other income (expense), net  
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.24.0.1
BUSINESS COMBINATIONS - Schedule of Assets Acquired and Liabilities Assumed (Details) - MeVis Breastcare
$ in Millions
 1 Months Ended
Oct. 31, 2023
USD ($)
Business Combination, Consideration Transferred [Abstract]  
Cash $ 0.9
Fair value of total consideration transferred 0.9
Remeasurement of previous equity interest  
Carrying value of previous equity interest before acquisition 1.1
Fair value of previous equity interest at acquisition date 2.0
Remeasurement gain recorded on previous equity interest 0.9
Total of consideration paid and fair value of previous equity interest 2.9
Recognized amounts of identifiable assets acquired and liabilities assumed  
Cash and cash equivalents 1.8
Accounts receivable, net 1.2
Intangible assets, net 2.6
Accounts payable (0.1)
Accrued liabilities and other current liabilities (0.6)
Other long-term liabilities (0.1)
Total identifiable net assets 4.8
Noncontrolling interest in MeVis Breastcare (0.7)
Bargain purchase gain (1.2)
Total $ 2.9
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.24.0.1
NONCONTROLLING INTERESTS - Narrative (Details)
shares in Millions, $ in Millions
 1 Months Ended 3 Months Ended
Sep. 28, 2018
Sep. 29, 2017
Aug. 31, 2015
€ / shares
Dec. 29, 2023
USD ($)
shares
Dec. 30, 2022
USD ($)
Oct. 31, 2023
Sep. 29, 2023
Dec. 31, 2018
Sep. 30, 2018
Apr. 30, 2015
Noncontrolling Interest                    
Business acquisitions | $       $ 0.7 $ 0.0          
MeVis Breastcare                    
Noncontrolling Interest                    
Ownership interest (as a percent)           87.10% 37.60%      
Joint Venture In Saudi Arabia                    
Noncontrolling Interest                    
Majority voting rights (as a percent)                 75.00%  
Noncontrolling interest, ownership percentage by noncontrolling owners (as a percent)                 25.00%  
MeVis Medical Solutions AG (MeVis)                    
Noncontrolling Interest                    
Percentage of additional outstanding shares purchased (as a percent) 0.20% 0.20%                
Cumulative percentage of voting interests acquired (as a percent)               73.70%    
MeVis Medical Solutions AG (MeVis)                    
Noncontrolling Interest                    
Percentage of voting interests acquired (as a percent)                   73.50%
Annual recurring compensation (in euros per share) | € / shares     € 0.95              
Temporary equity, shares outstanding (in shares) | shares       0.5            
MeVis Medical Solutions AG (MeVis) | MeVis Medical Solutions AG (MeVis)                    
Noncontrolling Interest                    
Noncontrolling interest, ownership percentage by noncontrolling owners (as a percent)       26.30%            
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.24.0.1
NONCONTROLLING INTERESTS - Schedule of Noncontrolling Interest (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Stockholders' Equity Attributable to Noncontrolling Interest    
Noncontrolling interests, at beginning of period $ 13.3 $ 13.3
Net income attributable to noncontrolling interests 0.1 0.1
Business acquisitions 0.7 0.0
Other 0.0 (0.1)
Noncontrolling interests, at end of period $ 14.1 $ 13.3
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.24.0.1
NET (LOSS) INCOME PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net Income Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Net (loss) income per share - basic    
Net (loss) income attributable to Varex - basic $ (0.5) $ 3.1
Basic weighted average shares outstanding (in shares) 40.6 40.1
Basic net (loss) income per share attributable to Varex (in USD per share) $ (0.01) $ 0.08
Net (loss) income per share - diluted    
Net (loss) income attributable to Varex - diluted $ (0.5) $ 3.1
Dilutive effect of share-based awards and other (in shares) 0.0 0.5
Diluted weighted average shares outstanding (in shares) 40.6 40.6
Diluted net (loss) income per share attributable to Varex (in USD per share) $ (0.01) $ 0.08
Anti-dilutive shares (in shares) 22.8 14.5
Share-based awards and other    
Net (loss) income per share - diluted    
Anti-dilutive shares (in shares) 3.6 3.0
Convertible notes    
Net (loss) income per share - diluted    
Anti-dilutive shares (in shares) 9.6 9.6
Warrants    
Net (loss) income per share - diluted    
Anti-dilutive shares (in shares) 9.6 1.9
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount    
Total share-based compensation expense $ 3.7 $ 3.3
Cost of revenues    
Share-based Payment Arrangement, Expensed and Capitalized, Amount    
Total share-based compensation expense 0.5 0.4
Research and development    
Share-based Payment Arrangement, Expensed and Capitalized, Amount    
Total share-based compensation expense 0.9 0.8
Selling, general, and administrative    
Share-based Payment Arrangement, Expensed and Capitalized, Amount    
Total share-based compensation expense $ 2.3 $ 2.1
XML 87 R76.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE STOCK PLANS - Stock Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands
 3 Months Ended 12 Months Ended
Dec. 29, 2023
Sep. 29, 2023
Options    
Outstanding, beginning balance (in shares) 2,862  
Granted (in shares) 0  
Canceled, expired or forfeited (in shares) 0  
Outstanding, ending balance (in shares) 2,862 2,862
Options, exercisable (in shares) 2,249  
Weighted Average Exercise Price    
Options outstanding beginning balance (in USD per share) $ 28.08  
Granted (in USD per share) 0  
Canceled, expired or forfeited (in USD per share) 0  
Options outstanding ending balance (in USD per share) 28.08 $ 28.08
Options, exercisable, weighted average exercise price (in USD per share) $ 29.01  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures    
Options, outstanding, weighted average remaining contractual term, (in years) 4 years 7 months 6 days 4 years 9 months 18 days
Options, exercisable, weighted average remaining contractual term (in years) 3 years 7 months 6 days  
Options, outstanding, aggregate intrinsic value $ 1,159,000 $ 871,400
Options, exercisable, aggregate intrinsic value $ 937,800  
Share price (in USD per share) $ 20.50  
Minimum    
Price Range    
Outstanding at period beginning (in USD per share) 13.61  
Granted (in USD per share) 0.00  
Canceled, expired or forfeited (in USD per share) 0.00  
Outstanding at period ending (in USD per share) 13.61 $ 13.61
Exercisable (in USD per share) 13.61  
Maximum    
Price Range    
Outstanding at period beginning (in USD per share) 37.60  
Granted (in USD per share) 0.00  
Canceled, expired or forfeited (in USD per share) 0.00  
Outstanding at period ending (in USD per share) 37.60 $ 37.60
Exercisable (in USD per share) $ 37.60  
XML 88 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1
EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details)
shares in Thousands
 3 Months Ended
Dec. 29, 2023
$ / shares
shares
Number of Shares  
Restricted stock units, nonvested, beginning balance (in shares) | shares 1,277
Restricted stock units, grants in period (in shares) | shares 785
Restricted stock units, vested in period (in shares) | shares (142)
Restricted stock units, canceled or expired in period (in shares) | shares (16)
Restricted stock units, nonvested, ending balance (in shares) | shares 1,904
Weighted Average Grant-Date Fair Value  
Restricted stock units, nonvested, beginning of period (in USD per share) | $ / shares $ 22.30
Restricted stock units, grants in period (in USD per share) | $ / shares 20.17
Restricted stock units, vested in period (in USD per share) | $ / shares 28.04
Restricted stock units, canceled or expired (in USD per share) | $ / shares 21.91
Restricted stock units, nonvested, end of period (in USD per share) | $ / shares $ 21.00
XML 89 R78.htm IDEA: XBRL DOCUMENT v3.24.0.1
TAXES ON (LOSS) INCOME (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Income Tax Disclosure [Abstract]    
Income tax (benefit) expense $ (0.2) $ 2.2
(Loss) income before taxes (0.6) $ 5.4
Deferred tax liabilities of undistributed foreign earnings $ 0.1  
XML 90 R79.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION - Narrative (Details)
 3 Months Ended
Dec. 29, 2023
segment
Segment Reporting [Abstract]  
Number of reportable operating segments 2
XML 91 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION - Income Statement Information (Details) - USD ($)
$ in Millions
 3 Months Ended
Dec. 29, 2023
Dec. 30, 2022
Segment Reporting Information    
Revenues, net $ 190.0 $ 205.6
Gross profit 57.1 63.3
Total operating expenses 52.9 50.3
Interest and other expense, net (4.8) (7.6)
(Loss) income before taxes (0.6) 5.4
Income tax (benefit) expense (0.2) 2.2
Net (loss) income (0.4) 3.2
Less: Net income attributable to noncontrolling interests 0.1 0.1
Net (loss) income attributable to Varex (0.5) 3.1
Medical    
Segment Reporting Information    
Revenues, net 139.9 160.1
Gross profit 38.9 46.3
Industrial    
Segment Reporting Information    
Revenues, net 50.1 45.5
Gross profit $ 18.2 $ 17.0
XML 92 R9999.htm IDEA: XBRL DOCUMENT v3.24.0.1
Label Element Value
Cumulative Effect, Period of Adoption, Adjustment [Member]  
Accounting Standards Update [Extensible Enumeration] us-gaap_AccountingStandardsUpdateExtensibleList Accounting Standards Update 2020-06 [Member]
EXCEL 94 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

V$)KP:OQ72\:P81I*QOPVX9-:*ZEK0!_C G^;>M3>&RY=M?Z0IO! M$AR43]KSW)C,\7EX/7["&L,>:6J>MJ0B9'S?!$ !'T3D?O)^=QH;[62 !)#< M#'--JY;]$L(G :!>%R 8/]5G8^K./0H//25(HQD\HH^!"M9N\B,A I@PX 9V MT;A+.3WI2- :;, K]-^YG_&VTA_9Q=AF^I\7^@P6^TY?/.LO#M)GF!B!$L, MW-Q[X@YGL\/LL .T28 &[HKC@/!D",LY_?V'7IJU:',;A<'?C-YXTF>=\50? ML$ZWW6$ZT_OC%FM/)[-N?]1N_N\ ")?HP)H!G0+FF-B44[^4'>,&I@OQ .^Y MZ-22V&BK73P?#:!#;WQGN(#YDPB\!E+L##4<^,C&KG8?;S>P12+T#[F3K53% M!6W\OT(M^+9>PGLGFWK IMS_K!OF%\MQ[LQ0T]P'>.##PIK\&4C[ =2Q9C@:H/]Z"?!Z05Q:!J">(JB#S@YU MP8V1#QOF9+%&COULN'/@O2@M)KH#%\TI_P,;0SR!/@)+K0.39BL=E 'V$\4& MP!=OLY"M:_!VFT9 D02JAZX(F3360;X@B[=,(90P%]&!;\-?I&. 6)EJ'_AM MVOV<<>X? ?$&6<@)@D-K.Q9QR/C\GA0>P*:%OG+8.^^/]UXY/OM17HH7;>])ML9'5BCM)\>S\A)V@K>9QO8 :&!KYYX@>E MC\P'.BQDPF^NXR@N*/'ZS.L(V9J*OA5]^\X.&8W+R'I4#;(NMCRSBK)?3 M3,MESJ]C',2N9CXFDT>[6/$W:%*+I;+TR2V+_-I5RF6I=U5(G(3$.7G\H%4J MW#UW,ZZHX;UGTDZS4S C;]*17NGD%5 MT6<+%F,N*;#ZR,S)ML;\^^V\X@C>+9A+=P'3FY+VQU4.BQRZZ\O98%5>MMG+ M@DPJ+'.8L,SK+["L=Q5J"'7*+4AY[6UR4M2.GD9Y$K7RA.\+F9.1(47K)?W: M9;_9Z!7K+]_KK)35N4N03#$.Q3AV81QY5<_!2?"+S$5#*KE7)?>JY-X=<@7O MVU5V;R[RZ!^Y&G,KMS44""=V/=V;CF-L[W']TK\KM5;F]>R-Q7C[>*17NJMQ>E87I(7A" M3^N=N707C=(XHEPM"JKQBI!+T]14C! M$; A]O@>53Y3KZP<467V*L91;L:15_,\&/1S& MNT$/A_)NT'@?HL&:%")7O'-[-VCLZP\W>,U=^4:\'- Z-8EVYM:SJ8GNT/PE M8[:PGAO:5>Q;2_U%FQJS&;.UF6TMDY8T9A-][)9V:4JY2MTN0"*KZ,I]J MGN^.F=LJ0WJ?#.FLSI%RD$I2/H],ZK[;*;R0EGR5!Z]V"O$5OKA"L[WZU4L2 M^+AFWKP/L(ZU%Z9G3_;.FAM3-HK(/=GN-&W/G.7H7SGO>+E:@$V"XUFNS.D] M0&7!O"L?X=-.6MT%&2BF3*L[57)QDD MD3M3-NMQU"P5810:2:JHK*01>;ZHU-PY;/AQKLUP2B'^HE+L7D7>7.&Q !$] M\//X!,>!9+49:>^P'PF^KDDL&29[WV><>@B(7.N C'-HA]U"C50C')?YR/,IYC9CVA)>-7[R]]MLLM =QY@9 M\&IK[>(+],EDO5PO:$JWF/EM+5DB;6FZ2&=S_#H! MU!$#V&%%!'HQ\EQS<):Y1G8D!J_1.-QR#.\DB)TQMZ5S"EDL[4&CU\J78I*8 M,-)N]'OR2Z^8Q:(6]1J+ZO1ZQ2UJ>Y+5/DE([8'*0BJ'3JNRD$*2,ZT[G$I# MV@*Z/,UU%/PVX;=CG;2"'D$O8S,0!;@8X- M>W:)@[HSUW03]H=_L+_6QA.8 MCV8\[73GC+Q3]F*=;;? 43&>JEXU9H$?KY90D<\YD$^KN0OYI&08- .RZA>= M8:!(JQQ8ID@KE;1:!R"MD,0:*-)2I'6FI-4^+&D-%6DITCI3TNH48T^-JF%/ MG4&OQ^_8OP#@Q7ZNF(GA>?2QB"#ZVK;)M^DX;$MYKVI8W=HI'R:KP.DWFX4) MG/(4I2GT"="GD+X[_6:K=MEJEJ;AN<*10G&DD)[X_2;V 6\V6@I'3A%'"NFW MW6]BO^U68ZAPY!1QI)#NPOUFMW;9:S?:)<&1TE<-G<-=ZA!*<)I0RC!76>0F*2ZO*MFS:^3V[13!#FNRA\BMZFTQ;&JB[HBS(,3YD[QYSAA M]HOQYRK*5)2I*)-39B&%Z_WFH!@ONJ),19F*,CEE%I)8TF\.BXE=*,I4E*DH ML[!6+_UF04V5RS<3Z!2:6N1M9;"E 4'>_A@5:]6@%I7U=]74HB 6+F_V<,]6 MKNIJ(5.23J/&6W6U4%TM5%>+"D)/=;5072U45PM5A770),Y"NEKT6SC0I=$L M?176\;QABGS.@7S:!^UJT6\5/JU%D58YL$R15BII';2K1;]5^$@:15KEP#)% M6JFD54Q640NKN_8OW%'D4RI,4N232C[%)!BTNI@M6W[R49TK5.>*+%1QV,X5 MK9[J7''2Z%-,YXI6OY 2!(4B94218AI7M ;HJ^PK%#E%%"FF;T4+N4^A7C-&H?(GM)5?HIPCQ?PBS&5==NJ88RBC 5819(F,4XO]KM0GSH MBC 582K"Y(193.2BC3E90T69BC(5919#F069F-W:97=TBETK<$,(,<-#.)Q:TG\!#"CTE-MH,'M''L*VUF_Q(K$*Q M:%1K-=-PC8H16T/_<#F\0O_%Y2*"&+WQI,\ZXZD^8)UNN\-TIO?'+=:>3F;= M_JC=_-\^X(]X:&Y[6UCIC^QB;#/]SPM]!CM\IR^>]1<'#RK<2\0P+\)0WP18 M(EAFL\. I=/\A:,FE68LVMY$)_"W]? :URP=R?5HS M[1KY!Q5>ZI>RLY?W>6D-J='+85%47B\[:&B"(WY;+^$5DTWE9)/IW9I/L$'+ M?OEH.).%Y:QM]@"W?UA8DS\#EM?CK!38 )M>N>(W?!D#]KA"$K77<-ZWWWZ_ M^?9P]^/VYM[CCF(9&]#;8"O!=^"=V[OGO ;=<\8>_V\^2-]/YFRZ7K"[F0_S M:YZ12N@F@7I? O5^'.H/@9YH(GV0NLE@ [VZ&@N7+ZVE@"W%\JZ M'+QW-$.L "3/+BH81%M M<$JE_!;3\Z4J?0YH"OM:U)T=09TE>(OVINNJ"WQH )T=09U@_^R[#\OP"I9V=:$.:HZ<&]A M@P"]-;]S<*:2PJAVV2K IZJJ-,J',%FY:"Z$Z31IV,+>B5['*=DX!;ODDV$: MSIQ-M4?+VM(YNB>E3]Z\/R,X$Q%]U;MLMMO# K2%$J@9RN$R,3E&0TVE^R%'L\KZ2T*\I4E'E\P9Y F5V@S$$!WJ'7I\QHJE$\R2@A^2A' M2LW 3ZDI74;&,&]&!NIWS\9B<65.;TU7-Q\-@-L5]:S:EJ/1D>1H="0Y&I_O M[C[^Z_;+%^WJVT?M]MO#U;?/MQ^^W&A7]_@D;I5S42&615#][XBN;XDK.-'?DUIRN'1>C<&<*@+,1S C=\\,*R)E"(WS#1KLGP7GZMV%.T0ER,8J[(5XU/<*R MX9^F:#(_>=%<&UZVX)X8??H'6"9+V0@_E2<4B):4,4$>G0A07PM(/P2 _JP; MYA?+D07$NTT0/HU62?*%5()9H8B3,@1G/\1IU2Z;C:%"G!-$G$.B31OYS:@D M:'-6[4-/V^G5WG!ZI58.9M0)55+#(8%S.CRSDS(R:XLUT^V@UZQ]G)9&Y4@V M.E17(T67BBXWZ#(E$7 ;77:Y8VYO)5?1I:)+19=YTG.W466O=MD>-?P?L-E7XPG%LOK2V@ U)6DE77SII5A^Q_ !\?1)KIMO^ =^A+0 MPZ7>$OIDLEZNP9IE4_P9SN_?W&5IS:2-@V:TB8L%[D(S_&V(F9KPRV2QGM(E M,733OR!>A]Y;!VZ OPC!Z,N>.7,_9W!SW@2W;H42W-K]1G\P*"9M"Q[HR2^] M8BX9O*J=;W_)OW=ZO;(MJM7HY'S348ZOA) J=%&MWO:DR8SYB5(W:*M7S6RO MPEM&5140^_6,VM7K%U=7A/AH8SM4_M(+?,.[-H]F>K^1KB1^+%,.+*_"2,:= M1/50HB&6&V$^DSIT[:E#5Z0.9:">3!!(22C=%8J'Q\7XF;W.Z5R%5-*KD$I: M+*(>Z)C*A^S?F+L#JI\=F!1/4#Q!'=,!>4UP0L>.SV8'\6@K?$.99Z_C=[R: M_+4V;" !]M-PJ"3099.Y"1]_?)%3PL[Y@&?EKRU0!649>PI55"16 5)[%@4)E<%>UBLTZV& ^/8LQA.QGOZ M7:=1CG5M84PP!XT/5Z(LM90P@BJ4ZZ2,M-Y%4\1BD )J051A92F5H-T1)H<2 MU"44BB=(9U>"%/:<%K=)D.\]K.%N*U9SBL@R+%XT]8FOJ&E$%<&7G*)I=X3) M(9H&A$)QEJ-$4]FPYUC(DR":ABB:]O:7'J=/A$K-24*BZ[4#RV8VX0N>(;U>18#D5J=E,:VRUU8#M*J"+SE%^NX(DUVD M]YNURVYW+VM38<]I<1NY2.^W<.I'42%0A2QE0I9N2OO;'413OPVBJ0 54.%+ M&473'@B30S1U0#3)M!LEFLJ&/<="G@31U*U=#@I+>5-="=5=>3HOOOX"U5T' M;J5YM&2#?F/P6D7UV\?^;K3$R5F7I0:-JD&C1?<8V\4FZ6%N_+"PMM<5Z BX M)?ZAJ%51:X$VX>[DFL,BQ!!VJ[^72:AH5]'N&=#N<4@WP1X?U"[;[<+&DBA2 M5:2J2#73T*U=E&*<7]?I*6I5U*JHM6BE^!C]$_I8\=W:+TZB:%?1[AG0[G%( M5ZX4#YJD%._=]_[U277'OOI.^&'V:W&?JZPJDZ;6;:D,?RS[FA_+W V M6_C3=[--O*KA*I:Z^Y\UXZ?[SEPO+Z:6>R'>)\.X5NU2U@G$ZY)+N9RYEI\R M)*G@Y;=Q^7%Z\9>/9X+M]]VYS9BVA)7.'8V9V*@_UD6:]NK]RL^YTZ1+[;IF M,V?%X.5/;/'2T&Y-W+7).#B>#7=.7QFO'4 A'#A@+<>&R=%C:CB3M>/PT0#? M+)=IK69#^^#=>AW0#[VZ*0CFK2RTL!^P MDD<3Z&9ZB]G&QLS00TH(;\UW94Z_P,_& I;*'+BV7L;9WAW6G#[,=3.8_I'S MP#O (;?@:QWA\3PW)O.\4$F9I%ENJ'01*DG6F4<+E(D-Z.1:VB1'TK:3GP>T MNBEG_<8NWI9-;MC]K-_T6M23PTM[TMK/1'=C&VF?[GA3Z#';[3%\_ZBX.Z M25CM TC#/5-@"6"938[#%@ZS5^XEC5%YD\H\@X4.V;C7; FO31KT4"B K'_ M+ 0-,-;8EU!TU-#RC3WZR,;N1Q#Y M"\M9VY+11@/):*.!9+31A[L?/^[^=?OM\WW24" .L8310/R5D@^UI0,%EJ,)! 99!MLA2(&P 7[,N13HARYJ#:7@"O69+$7%CF(__7%):3 M=[03K>FR&J.=NMW&H-,I9N)-M]'L#,LVAJ>4BX*C:N7]^%$6M?U5^PPLRC2[ MIGP3%@J?5U11.*2,*RH$$ >Z[4"CE%[A$,(CD.I@L4S@4,A-LF(VH@SHS4XL M*"!SNY_, !0U&D9!)B]DKH7?9*TOM%M<''-<[8?N,@6L.+!N9C/N.MT"JF/W M7W@-G%G;-IR-MM3=M4T>++2(HV9"%L:[5_/%-*3;J5Y-+:XTBU.%2*];\,,# M__'A5&4+_I.77,IR\FSX-/,<3C-9H=5-R>'] I+H 001>L^$K))%1S 7\)2: MERI\/U5\3TG/R8COF#IWDAT1J_C\&9@)O)QVLH.QL+,F668>)P=2<=,"2LG] MY)LNL%XG&^\;-N6RW@/^*TB @N<2E*'MBR);1;89,XHSDFU+KK(HLCU(MZ8J M/B_TJ(W,LQ;O(?+:2IYZ7BG9!^;)WRSS(HN*_6X?AWSIJ/[4 K(L>3PY4<9< M8U9G"N^\_?9)5BMQ:SJNO5["9KWD(,P-NG>QN.J[GY+H8\Y%.T"=;NVR*T&< M7W;2V=6!9CC0R R@SC;OU+_H.VQZ!=N%\PN?[1W\A+N0GFD/SS3>?/&70R2+ M544=%2KH_38%U >#ZAW>31AK48"PZH.PZG;V%U:JYWP)\::7T'.^ +P9G"[> M[.<7/ &9.#JLDC/$N06C@I0<=:#I!]IK'5S)&>&8I/B$S#V5G&K[W)(34C.) MJ*P>AFJ+J*04SOU%U*B)G734H.B3Q)J$K(("L(;:1ZGDR'(\?P9Q6YX<:>X: MO56I5BK5*B5#L@"FV,9QJ7V),%4)6"IO4A'S$?,F"R#F#B=FE4U9/G]2:9Y7 MV93J^7/6RG\#;DMM?;')K>.L=7/"8*^.FQRFJB*9G_OS*GU2I4]F44^2V8%V MH85S*U4J9<63R').A$_(I0PB93,&:OGTDV$BREPCQL@')8P2&E[GGF92 I>C MPO>3Q?>$K,D=\+V'^!ZW0:N([Y5^_LPRS[9* M)4PD4AB2F(&V X9@QIDD;:C2&%+%YPLR_;+8WU\LJOVN4R#+.>11X=[^G48.@'NC MVF5/,JOM1'&OBL^?0:B")Q!A5TSV:[MU$YL5FRQ"0BG,BOV MJ W9XLP3/H]I"+(*DJJF(91Y@/3^24>**2BF4&R[-QE3:"%3D(U#54Q!>2A4 M5/]UH_JOO\"RWK7CFA-KRQVTI6HIS@E)C;C&E?X;ZYH]V84S;-D#=Y?.B&M(NLVEBYX;[+ M8,[TK9\9[#I-@EW[8"C[JIF89?9P)C:O]$<3^B)]8JU7(*EQ+K6%A?:%U8Z4 MW'&Q;X9:[NV7Q#510-5X@#I/.N7A/*R=P6G=IE?_\)4GF/IMP. M0T599T-9G<-15AP1)8'+[XHH?424>+/IH^[T#BEBNWO"YF2ZNY_UHR?[CMSO;R86NZ%>)6,6XRVC]0!^"TH;3 7AX#LW&2^J:/G.ID?5T#:O# MW!L;$%- <,9@)12$F\T 4^&JL$.TE?Y">3/CEW!N3EU[!A!I^@I6\A/@ZK+% M2UZT2Y$^W\4>/\$60[OA*:?Y$*^%-F6X'!IKN$B!T MT\1 IHTX6D*4;">A9-T_48"O=T*L#6!;,<>"-]L* !R<: M_(FPT?&7L6%RWS@&RIDUJR,NTOU^JAQ;,#IGNJ0C*S5< ]"4?];!ASV,[0X; MS>XP].7(-U=P.G]OU0%\4@XL82_/

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

.=(*=S27B>H& M,*$<<4BF#&#&>N-I&H>/-1YW6-A$HE9_8TR0PU/0?]KGB$PC&U?@OGJQAYHH MU.39'FIR#Y[E#^8->;D"CZ(\/RC/?X1X;(Z?'CZ#L1#?G$@@D*M"U>20II[I2J.FQ)<;[^'^Y;'.ZHE\ '"W%U*H2X^T&_M4&_5J"#$=Y(L+.?AUN;!^G: MI&1(PQQWA)UK%EV;@99!0&7#YT8%D]$[<6MR1!JE:;O]G/T.YP/ ) &8R%K- M)BSDO-NF^C?+&SM6+![_4EKXVV1KZ9W=S^"MS6#C\G_CL8[)H%E:%,.<8E^G M=^]IW?X\A)2*H:_P04O>B"L0@G\EG@DE$0-PR/83RM)!!50.Q$7 L543"3' 5.$]0F69';&0?U*(L\(ZUOA%UQ]HP1?9GA28F#B0)WRU6+7-!+)WWNH08TPG;CAVLR MA?EB:90A'"RN<#!BGCA2!WZP,4&Q+YQ(WR$P;6-QA8Z)H#4W["Z-4(AF01!Z M0VKSP*4@):]^9J87(P58&\97W#Q*^'NNE[&@#4P/$ 0P "F-$,F4/6[3"V>% M0&1@3/D>')=$KZ.@]"7XCU$O9]3^/ $2?LZM,S@^QL;T]AE<]%\=*5P&ROGM MY2@#HA[V@:2LM82(!Y8D,@SD_FO^=[2%6T@ZYL*%#BN_+_.2SX?K_XKX:4"K MUO"C1Q7$48>C3VZG@FOT2]2R&&:'0F]3I(=WM:CX=]+'WWM*Z3KN"&MO5)>I MRNVGJ9.5QT0Y/8J.ZU0#0PDT,?WJ+'$QNR &LAT]'C[TR2+9CF.3>B[,2>$T M?79\]/#B$4S< <,-P#@*XC $8@S1S8-@#&,1F<>R1[%V&NDP+M-_5E9S)@)H M,]#P59$VS>0=@PWU2! R&9)@H-9R?F9]-N)QND*%+=%!41I\>LP&D'9-XU], M).OX?N_X3K;>W[\^4$86U#T-O7&.&$SPG(AUJ2RX!(R\/3^"CD5Z_4''3>#/ M-#)E>O0:PTP@:2CTQX.W3%HZ];(1])X(-I!U8"F B@%]QGEG< M,+Q1V/C B4 $ 7@=:6-1CB'3^8)Z"M[2M$3/]$\]%6SS%?)U,2<2,9W"0"2& M+BI18]18])F!I%5]_XUE(ZP,N2O1H"I]$ZPKI!Q 33P:)NHP$Y.-<*2*U+0- M="5*M9@$"PFF:SMI/.0]A&@8*&=4Q*T 7+ LL/;Z.XG=/GN+P\D'_"U$W!F"& MLCSP=V-]/0%RL/%0$P/KP%CG\.AXN; ON&C?E5F'6M7^I"=OCMH7FDH['L-C MI]H)0GX#/C$X#A&7A"B)[C#([-0N:C2=F4O!>-1*;R]D]6B75&+& M<9!UA2@SM9) E58()U-T^:U7AP>EM1\T;$2LN@9R&%G^0B6&737JSF-Z4KWY M5(8V<#:QRA! 4X@9AAJ,>4;$2BM,?AK/OO<"8'.F',\4ZX,4Q#PY?S :5(29 M$?.,'/HB]LSRX0)UE:4".YJI2L-TJ!Q:1H0+2QY M6CI;1C9@;!%<2\0YO$N1,N<:<-O/860UJAD*C(ZFF\S(C/1RC7('_EDP:]]9 MUC]%XVOL.D)B1AEMTT 781()4P@]SC/BLO+^$F.=80BY2\\Z(*H_8E,#+*CA\-YPD9$>U/Q%T.@YU:T\=MQ@.4 5?R; M0,6&]?C68;CW;^FSMT DD&&"AWG..^WRV=SAHRWA?)=#Z?60C/D,]C80UN04 M180="?.H!R$XF)=Y95[,OW#4TP!(]YZZ34(AG@!;T/7&U)_=Q?X2'<+TVT6D ML4/DO6ISP\T/ 877!(W'*Y799KIZ>;4HO+LDBEM_F_6*2&W%N.]IT (V]:L] M-O4>/,M?E0;M5T?)(^G^"((6YO1!)[E()2%$_E:O ;,7A$4=U;WFO_/ A3EF MPL6QOD0IX[4V^^-Y%]]4>HIBMS)$\X8W(=Q3(WCT,/TY2T&.IN'LEW?X#)6V M-MM[XD;F&4Z!NNK.%U$CA- F2]GR\1(8:P^\8YD%W]"/X'E::LN6J'5/^ MF.3AK23V(C[T44\%CTZD$6#7;4[C"LXZ1)O3M/87I;9-;"_!QR+W4ZOV*/25 M7L)9CSK&0#'D5_^Z3T?1;^X"'4-*>0Q[Q20?8@E9T5*>PXXZB(8ZC_)OJ)A= MM(XKF1"8VQC%'UDB=Q-=A/.QT"1HO6NMO-F,) Z"!L44D\R0K::2TIKKE1][ M!;*HV$&34*%F9WE9%9>2ANF_J.:,HW$EQC,#5Q&+([9E=('2<_<[_Z-8#:*K MT#*&SAYF]T,&.;PCWDNWE[B]42>XT?# ;;!S'7IOQ#I3'(O1JJ&9)Y[#>.?B M;.3+J8\JN;Q+'$;D 9/45+&^H:[9GXY][6PT9P."BV_>!SIT-L,-:E;9T2/6 M=A@E$4955?5X\,$R1*'-J+)5O'$C-A\MS4O09H01(H4"B47\M<[K=!F+>!V> M'3*K2DT&E?XCS\S7AUQ5YL-5[8^T-KI/D9:-,F0O4RQ;<;G '(\LJEX+12&K M;=3QM_PAF/NMWK4;QG&@][=U&%74IJ;"H9FXF)&$/2>M0&Q-J6U4&QY5)N93 MFD2N=G23?-^W-$RIB6#I,I1IX=S"#+U?!"3YXE)JXQFMQC)="R:P9=&%$]HJ MD!EE&&S$ NV488YX./V8[> MCZ=%EHT^ZL1[(-U2ZO0\J(-%%9K#O-GM@IJHKC)C#MEBWSQY^!L/NOOD.PS# M"LXE)I1(3*(L,/KJ9/J%(43'1--\9" 1 T99,L1[]4"(%INC";H^BLROB\)' M2(*%L\F[7!5]:.O)O2U3]$C+9ID9%]I ."%)CJ=!]V=K\/^=,=4;E]OX4Y[Z M&3\P&DQCP=_=H< ?_&TLSL:S"7RCM[P+7M'S3W[257%J%<32HD-'#E)%LF;>YC544I(+< !*>T^),HV^>R0@A$--EM.% M4G48CN"8OO/^$LFEJ(2=8T4XVMKJ>S>&&2(%=FFJ3.!\'*),.K';G?O?!,,% M/JI";-PGO^RR@75#W,NY*7H-Y(-K87AES2?$ ,RYM,SK =;+)0RUG[&?O8?L MESCQW;^+JM[N\!^'"1'7V#^757G@C\-YSE S?/EF@ZZ&&U1\I08(&/5JR=NY2>*J6BB\BE/AE J>E<2#Q:.HZ70 MA1)*! DV8TN"A@$7T:MX7F=#_C:N)23"AJ7:T/P"V,2ONX/SNKK"2"MH=/T% MRJ+WZY![):!QSL-2AM+4R6&6[]LI)T"SV74>7BQYCX)>TJ9BU3EY7I'$+92* MB^Q0F%HWIHSCBRJ*#,T]QCYM-8F9C8, &!L2S#QS4$&X,*Y-RX,#D P["$CJ MLX?$*,6R(8A4U<_C!Q-%4$EZ<$\+0,)F"G6VJ55ZD*8375#08 !P%?&O8OL) M>@^AXT >#QT(P-)FZ=);$TRTBN4UB1BUS1R02O\*@I8#1 CCOPW/_ 6Q$-@U M?*Q>8P,NLCXJWW2!*N V&N]RD%08^OW!K]H! L7[[H7=::BCBMP*"&MH/FH!ZDV=H(- >4LJ\6^31O MH_B<0!1-:W!4ZRS$/7B6/YBG:^]G M;7G*'R1YX-H%Y@H)31CR4WC$R"F(7G:LOHPUAKOWQ,#X5;-9VG#B:Z3LK%CR M^-''X0ER'ESE4*HKS^%L'O]UI5Z,(%JI.W9+*8A;!=!7N[/*"LKU4A' M)F;V0"MOY2\IMS)%\ 0PZ0TI;6%3:<)?2.L:NZRP>H0T)"C8G'&R8<.O-^EZ M6Z1PD%[BUQ??: G^-?D#0QAG?%4NLTFB:'2"!$1 F;5PP"/^/+%$K &,"?WC ME?1HA:AXRHU"$I!?^%E 9S'X!SQ>C'URP5NGW;9]NKP[W[)&A QM/2BWXONL M37$_]#$OJBL$:6B*(&BF5P"I%WTBR2/Y38)Y&XM(#>W7)(^03*#\D-KP1SD? MI,HIKT(N8T&CZ3TEE_J7H :O".LZ=^[ 3_^!((/LH,73!:D#D)J'I$ -PGXB MSH$;@MCO(WA+YKR%\\")O82V44=E4DW11HB@'_LDUE(2BTE3*!3*$P?"'6-"@L(U: M%VE#8Q0@FS+1'6D6O*V:IVO%V\"\T]-"#%-[Y[\KL)Y-(8V??NAV'ND[X*X4 M-N*8?<3G@HJ6*N(CDN!?+%+,1J\JRU8*-HR#^D>9F0Z025 MY+XVZ(*,FJ(D H.V;RAB96"2#K %-YC;P\D_**/O;[+M7(7Q_]RBAKD*Y37B MNXBI @?!(>')3"T@8E )QAGP%)2OH1SF#$0O_6%1HTXK2VOAXA\YKG#0(HZ3 MP\D;:(E-05G.=.YJL6\0\M]"G0_$+[$^L[W&MZ6PVRM--NX2K0Y@V@#W?^!' M%R5"R 1A%,V&B;R?L+ D@?8^;9ITYI_&M9RI_0<$V&6KR!2]Q$]ZY/S$MN;, MC]T"[/XI=/9ZZR4Y%O]C?XUS7MH@C0.'H(]GJ%<9#K39A60Y(D#.?.)G.9U" MLV"OH0[FO*@:[O6'^P#LZ,I;4?\,*TJ7BT\'QL2<]6-^)QL4<0XBE1=-)PC0 MDK(>6AS YPFE *%O :<@+A<0,G1VP5-*?8R\[>W#CCT@/]'6_J5H'$-;K=&T M[N4H+<]75/@!%S[$AH=W&=F-I-AI2VZL (?\N:1( M0TKZK07A1(I7B30JH7BNWYY=Z>\ !M5@9H-/#U!#;K["3CJC"@4/Y;Q!$MZ MI#,PSQ [X7=5@"Y2QH+4>N9=!K M35/-EQY/8DZ0[AJ6-56?2K.R7/[F>TXWI+\U;))2)K?CD;X?0) F:Z$ 2^0V;NQ MV%_HEF3\'U#&52G1ALD8#84N P%'3] DW21&(DI/X>;PZ[] 1?>4[%2(1K@( MYEW$FC;:D+=/_JVL?4KDATC--B_R?\N?9;*FZX/ KR;S=D4.G!7T54V4N&FH MJ@_X\>.K0-\1XF'X M%_7:C-(I:*!B$V[*^>/"$,-[0LLOIEQ5A%M[P TD;PKQ+IP6&-DHKY M'$/<45E%[,JZ@;3B;MJ?#]B\A)Y SLFEOLG9/LA]L^#WIB%+0K,MO9:QT*/$ M?I9AC9A,"F'ZLEU<&ZW/-NY36F?80"+2JO@-B%/49-!>8]0;H>?,,PUV3.E_ MR330B22J!,.D;#EF2*\YC.#X#NTY;BT>MX8C+.6V"X@-[P( RR?7RVV#9".4 M5XV+MI#9(V?2R#D88.M'2Y=ZXV:RJLW#B:Z9U=!_J\UD&LFW/S*[# MM9G(=G/O0:3A34U62'AM+>WX0%+.!H&%L)I[^R>A'@[*7HW:[(BTQT;JR ]! MBSALTL/):[D.LK8J?1K'.O8NX1DI[=P:;J[1)\22$QWLF-@<>="R\N>YM\FU M:#_3^N1,WBRTU##D@MEHPI>7V!U1SM/+BHV^CYJVF.J_'MKB^1YM<0^>Y:_* M//$FXMRAC)%021E>[V;((\6'V%I.2"D(7(->YEZ?"2,CPNZ,H\Z!E)HHQ5[: MULN0>H=/Y&2!!J<*J(82R.66#7GZ_>-FD?X[K3, Q@;K&L=H(.$+?F'/?]#\ M$V0(V!S/H#510\I-O/E<\8;R#$ZBS+QW'LMNI3/9*U>QWB6. G7;-1!9Y64' M.21S\1_R"\<15* 84PIA?_+@ '$51AIMB=D>@20C T*D%GFY70Y *!I**)W0 M0G9X95=@OJ^E"9O)-9TSMIL'.[^GDA"IV_"',%,+S7^ M%-*52QTLXEQP,1(7"6%>I91P:+A%UNH; L2W@;%1U.;C(5@3O8<-^1\W7/:] MD'' H+5(FU 05CHMK%-#C8+ILF0UD1'IN4^+'+8&!CO5C)B7<=D'CFND!?XD M:PW+2"DJ-P]XO @%W;3,^8OCAW.UA%TO%HI;1=?BL423OZ,FZR>@[ ,GDGO( MSAR$V(HL>6U%CT^!21GK6\(!B!O*_Q*7P3]\I.9?[#U'H&?2._NNG!U.'CZ@ MCQ\\@@I"B9"850<9S3F-*WV<"*$O)Y,56.66WMU=RSU@OOQK27)_Q.I0_M.Q M\D1.'4X@((\AIE3@>G4'A?0"&0(0VP);(90[4@!9YX( H(=@]E%NR6JLN)KW M'Q'F 'B@\ /-Y;O"+TF_832FLPU1[7_O:P.#BD^_/3J23?"&J0UQG!EASSV4"2/Y-Q1AH;K;$C.V0@R"7ZDS_WJS<=7/YR: MO&'+00TL/LS9\1-SC&.5[FB-&*9*G!X[U#"8/-%%X;R@;D]\&# M@Q@"98L*M5,H!@'3;>WO+:>%+"WT0RZ@-C6K._1,,"V! "?-_HM6<%["_L8LT(KE'4T-T48$XJE>YS,@N(/+'07E) MWH!0A0T8MS7DN4^.3IXD\CZ$Z$%6T;_LNG+[=.04%XZ(!0,9!<4QE!HI%B&1VB=0^,*'XI+-)5$Z\7R*\1A&:TY[.C#>_H .&HY-FU:IUTDI+[!CH^0 #/W-B6S50H?'G MFJ(\_JC';:#3% 5EO?2/+5[IZZ)YQI<0,Q">#2BC*PDDTE)J+($#WMR_#[*; MNN!R=JN*- (<:)VI?%18)T$HC>8#=A^BJ*TG2?UK,S2"E7'WL:T5P(U%R,OB M9;B0&EQ(2P];1X:=SM61E5WU*NJ"$KL)"=:U=O[QR1^P]:^16D@F9P!Q\/]+ MG-HXMQ^AMWG7RO@?HF;])BJ) '4=++<-KP[KQKR^^G-GWZD_%S%W$V4,KL(1B)5>2$K4I^87I%L52#OQ31-*@)E9QY6&OF!E+T MCO!1F%SJLZS;U]*F(0(E5O( "" M CKK'G%2@O@THK%_1X>(O^:!SDW:IDF@II0RGX @>;HYM\*9)$9L$PDWRFM MS@.;;F:+W/L"!!F&_=O/9?'M^15&U!J+HO1M7DK1,[1 MEAGPQU.TOZ7/7NW)]9\15H<^&U?CV+T'CX7P/B[XIR-%2#JL E_TYNCH8IO=%/@OX%F[JOK2,NF**&&) K'.] MN0_M\Z4[Q\>\CO9A58\A#_Y&)-J_VYA+51/ULU#DRX'3[1S!)A73-6PE[@$LHRA@/F>8/W"&T)D1 MDZ>0_XM?'V9V"(?+0JIQF@??4J4NHQ,^=+%YSQA-AWHU MA=>$5DH2FP89K1;FT)6"1HH"&4O74Z131-J0\N@EY^Y7:=-B4E.AMHNTB5*1 M(7"X2L^E>9ERPC0LSA^NU5K>.?@LL 9RX0/D+P7P#V/M4 3T@E)5S)AC.XAK M-ZL[P.0NJ'D,APCW6(L 3^1LPS8[R_HB:&$ +<6MV>7DES9="$=?5])C!8YQ M5CLLQ#$HJBLFE.&2A089E!UB$1T9H>!<6"]0/D_Z.<:X:0]V0P1./9CB177H M^EB!QL]Z-=A!"8H>*>QX$ !"8,X:]8Q@GR^50%2XI\P:?AK[V7# MR...Z!J@R@+J>G@:V#+ARZ)$/D&)7$9M<^X=TF+>:O$S4.D1OT/=,."OAPM1 M,3T2R&;<\E"&#@LX-LV!?;[:%PPXA1IR>T!@@;YK2\VQW@Q[-YE8O5= 69Y2 M)RFM;7 [O1=,G:8FK7@X>5L[]V^1<15_C4HHV.-#.41E)*Y*;0M=Y.@1]RRG M^^1F'NU;YO*FS&&%W!W![;P1G-2PTCC>:A0\U MZ!-D"U3&I,0TTLJX3[P%*]% ] KOM*ZP! _I6PP!E/XY$0IR><1(_TUQ^&*- MV X9[K-8C1%:W@N7G3MBZJ0&BJ"B3GIK0%8Y+@;+1L*_.BZI<.2$T^,W'^>3 M,Z(1845YFS((N!2*%G%R_)MQ2ZK2-A#HQ*^DVD9&$U6SIQ*;I1/72:)13G3 M<(K90$^:BQR[NLT[\JH+G1$]RC"11V9S+&WU?L9J/6ILF GH4G('[GM.&3/& MWEB%MBAP:=[YX9CZY0I3>>>.V0V]72CEG'[[P^0M%;O7BLJ'.2[158MIL,_H MI#@#^5B_+'ZLX*@; 12'XL> :"W4@4*5"%O=2\\%902IW1 M<3QP'I7NVM3X\(3P=J):KH6S5'P'IL7!LT:2BRHQ.BJ$$"PDMKLXP4_'KV.> M"2O5@1*('J>LL.=47 _XR2MBE4=\! VO/R@ZS#1._MO[&5 S?I98()6:%^AW MA%P*JF9[US+C&7U<"550SCWPH_?I'?4;K^LHT5!$)('@XE]\$@[8/V]OW[VG^.[F"_S=81$ M&?MF0*2\%7)*6R<-G IXR%5UC9PS "=U]$03/X#WJYG^6WW*.^VEY]H\S0?[ MM'XZ,PA ,M3?])Y2AE'#6]UAZ.*S59G3.4\EBAW=W%P_/P.I\CO]*]^;^*+;0G*:&R.GQX^@[% [=H$@\TE%=I6$"EQ8V . M36M!"3HRR ^#B3WOH$>Q=>@;^P.\FC]ZN7'&]E-TPRE: =%M#DB9DN" ,165 M[:G4[-\L1:(871!(1=7\1C]?^2^@L/P447]IVSM_]_-Y>_.)0XUB4LXM MD][L* +-#_U^T&_/S@%:)+ YJ6R<;@"A'V6J*G0+,4NRGX3;/6S\*>_(4 %B MN=V/[^V-[]+&W$65EHJT8J( P$EM\P%&K;]/-S:/*1% 82JXD')C(P!=PU\ MG-, ,B^ G,VSG @7B&\S=@-PMAF#9=CINOU,WMY,,A4V9+R@X3,B!D_G (># MFM!^P&]QZ[1#35FD)H25:8'BYV9CO MY^N&\Z4DY3AE %AJYFM)L!N6UG[-BO9@^'R_A6YM2BZ[ HP66S\MR(H%P_8. M-FM:U0Z@&#M14K!&H)KV.=.WIDYT;9E%0X*\4,>;B!0+0KDL/ T@+T2WAX]9 M"WNRW'"_&FYM-5BEP0S1I,!F&,N-QQ,X2YN%GVQO:TG%+Q3L*4Y77(+L8P$^ M7#$L )6),/R_3/.BEP/8>G6PZ(CYPF98RN(GFL['/@N_3*$+RVJ(\&(.I!NK MKH8BWMZHW&+DVB(Q2>/-B5\UD#4@AE21L RJGHK5D9X@7EX$:R@(S#WU@6Y5 M[Z?G]KU=@94KZJZ(,$MA_H#LWJH_1^#)?9N1SOBSHWV;T3UXEK^VSN0IRQ\H M"U5U"2HUK5$_N!G,A;F+(KS, -973MPE"B3/02\HA3\;"J8@)&]+Z8>3,^R: MD5\H=S;='43_4B#X2;AANR!QMLD,NB]%!QZ(+@J1S':A QZ=#1+#D8TX)IDR^CJ!)@"@)>@YJ M.Q_1V(+]99 ^,C]AEWK>:EV#FA:\ U13XA%'8\/%>N+#! 2_YG0ISRMAMMF^#4$.A'H1(9=KHUSM:$ M4?J5,H&4-JI*IG\.=,\1;<( !@V/1:3OUP1>"_QPAE_'1H=5#?SIT%]!Z'7H M Y]"0SE\KP4F;Q2(8))UXI!:+H$B X G5A PW,% CGACH,T6SPNXW<74<&4PDT/28LM MQ78NMHES,:E\A 'V1?3:-B=Y ^(EX1:89@&$"\J.)"]E*,8C0&"@PO!FQ6]) M5\?ID0#JWTP"@0AHOTB1]R87O'8I(_5L320*9^XZOUFE"-KX+'A?F-J0+ M1SG$D"44E5B3+=PY4:4/<2[;YL)PK[:1B%_HR3 5B6@A<#-BH&4A!6#JD;6" M#] =K$1$* &:FS$_ YUQX<26YRZ1'*9G@9D<' VMR$L3 MZ9^>]C,6Y.HE OE"@U4LY$*TBE&.A7Z@RUB3TZ3ZY_T&,F=,GX+G:.A.EVA) M;H=D>9'T*"U8N%] ]=M&>&^<*Y*4"3,BP\!.DXX:Z4K)=+WL,VK:@A2G-%^R MBPL9TTVC]/(:;;OKEQR#7+IBD&C5QC0A@+6V0N6^,[?$W@9^*6%(?#G0;$NW M[LV@58\K<72+OF36@$W%!:)'(#YR)N6Q7JR^9>_\97] .L_F3#D;)J#__7(D M2>U'^OP<&I/:,%EQU&&?;AH B=K&;GP0S;VK:X$T "$R5?\D":KD]#@856OL M%@J<\-#@JT;.*\#B, XDYW5'3>"@Q93M/ K?Y66^[):3M[CT7M'2>R5+[R,N M/>!Q/CPZ@N&@_^6E"*IG0"4!5.#N$[*)1',>!\)1H -_E(#)7_YA_FAR?'08 MV)%_J/R77J4KZH2#W_$7TT>TMLQ:"N'^AA0!;(J'T_X/@W4!:@9JT'N8^P?Y MCZ\/G]' 1K1 M>V4'WJ.L8X^V[Z/@#X$P&%E38C9NFI%WZ)"6S$FOR\2&B:/CDPR4 M!F3T9^:K$$'A=+@(,RMT=<-/T'G0/ O7*HMUV%6&#B/+BRZJQ)K9(%J5M* )DBQ_#YI[T5-KJZYA7D[>6"MOMN[ =^A(46:(T13,H,D$2Y8'^/ M0%R;LWL4G0A,?N#/@\LJSR('&_ZH8:D<9CRB&S-JXC..&\O^^35F:J]O-/]Z MA=/C?>'T'CS+'UDXO7>4.Z]H:Y[!UMPU9Y".P5*C26.7YXX*#IM]&1\,MG5^ M?@[>#)=:QT31Q[3ML:*F5#J<'-Q=9S!4'UL[H,125JV&@[OQ 7YG2D46MJ6=&J1 MO6N(#QW_);C9WD]-H.JWX=PE11K.KF%A.3!YPP3#FI>A$T4V>70S.OE( 8]J M7U+A4=^8>:0#4 !D@[J2]D57.*XDSXJT:<#!''OE?G4SN-6; S7(> B_E=^& M"RG7!BJI@9+/U69*)N-TSS7X[H$LM7@%^\_[N\4Z$%@%]KG^>H"I=MLGM?&7 MX:QIS^\:5 !@-3]?B)HOB&!"%^1C6C#&@F$=.>N96-670/N^ [R:1W]G*/]F' M^7S7/(H?QC4+8WE8U4Q$1%$L*YCTE8.\X0-Z?\RO2J:E@=$9:"W2VA"C5'!= M:,S&CPE4Z+&=C% M)$* &LLDCOQ=W*\U\V_K'Q5O MDC"604C5C0\H2U\% M:6+"8-MT82]O$'PV+S>0(B6A&/Z/Z.O$-$;POR3^+= FO\EQ?HU V&8UBE%] M&#Y$MNT^X(Z\X0:\0\/^'3>-[*2VU]L12L_ LHME3HYIVKIB'6Y$WF30.C.< M?2[,=+MJ-M^%FA9Z\@I_HUP2ZW<2=3!H%Z)P'HT;,F9?>^C "8R_0;3VEA%0 M-)^011D$GSZI18IWY MU0G.=MU'U_C2#(PM#E:UU)\XQ+ARZ04+WA)2D&KC*+E^B<=9/V>>8$U5<+X"'/!*W;GR(TA/JH*L_UV6T@O(SZTZ27$FD"7Z: 3D6T M"T^Y>2'I8&L5>SKK$6:O'T)HH57UT75;3@#O+U$4U3GEN1C'@HAN'$KD*S0][8^VZLPU*HA>[\B*W(L_]Z\/DTX_&3KQY\YESX M(_J[-JBZ^!%@\M[#R2\E>2>X@L\D\GQ#B-(S193BZ/Y"R9^?&.!XOPWICU7Y M6^;OFUV8OR>'D]?4N]%,?@$)5ML'@_/V9YZCIR>[,$=/#R?O_<=^;\T!Z/][EIS2F\K_F%FM_)YIK?35;OLP=_FDKADWM4*=S^++==*;S&^OS;_YO6 MCV]28+P/5NO9X>0#QM/O0F+C?MNK38'3:RH%D7O9 /#\7UU:MR@&#H#337(& MI3^;Q'\DP?2J%MB1=PWKAG,^4$/1.M;_RS^]\#_\$5H%\AFE9SZU'V')S0Z. M'TS*=.F'Q,VR%_[H^^BCF>.CZ;/CT[H^);W3MT5Z_F!"(^ZMR*?V!4+__(@5 MC5^\8%KF!\^_.7KP-]1 Q4F);ODW>,+K/X5]A)_K9=E>]PF._2Q_Z;O>Z$;^ MC%?EI^';#M]^[F,%EFN >T[@I@?'VGB6UC7$F! !L'(##!C_P%_HX#,_2N17 M" *#:BA#E4%B#=JK*.OW496<)V<'?T\FL+$F3X^>)PA 6V'O'P&,FNLRX]^S M;;5]]K_YVL[_^[8N?H9A^C#_N"NP*5]TNY^A%A[NYX/,5XO^/Q4 MN'LP>*?G#U![:^FMR7\]>/?CV^%PAB#I]/S\%(JDI\LV?LVR6QYD%;H2<*4' M$S@__$6.PEL_?_"WD^/D^Y>\F.O>@Z9G%M%3'Z?D7A MZ8\BTW.07H'W,;/Y:VYBK@$&K(&$U@11A00\=V_CCKU\V@$[.N2B2 MH5PJ)7_\;=ZZ:=T!-/7XJ8!3H&4E]?ZBPUH$JH':HLOV)T]KQTE1GM/&AW M'IY%C^L^+?)IWKZ\\P>\KS';V.2^O&^!W%>']+]O:#;O3=)I_+FAJ>PN1<=D ME*(:]10.MX(*[&9@CX[Q*(P\?77FJ6M13:T_I^L#9)-9->Z%_.,E\ (4Z?I% M7N*CX(]D!;%]?N:?&P%+WO/@E8J+ECX.AN?PB(Q/6_O_S^3._/&A_^CQR-]/ M#K]^_GSTHZ/#XQO^_>DW3V_TBTT/]?SIX9/C[0_U&%^27M2/)8SX?SWP 43, MK/?B9/5IC1T0"C7'TX:R3_^*#LR"P[-S8^FF:_-/O=V1_!N/$H[/@BO M$0.SBG),, "?F6?9/9"IV3P07_:M_:WWM][?>G_K_:WWM][?>G_K_:WWM][? M>G_KO_JM.96!Z:U5.T%AL0E$B"]W*>!\Y'V[0_)74!XCNY[CGC[ W*. M>-&VJQ>/'U]=71WZQSP\KRX?G]:S!5":/';9>5H_SM(V?7S\U?/CKTY.'OO' MY7\>?PW/?O+D,;_1D^.#XZ-/%X>+UD_(Z9**8U"!^N@00IQ-7L'DS4EKI)I/ MWI6BS8' YPR_\]]IB:6EDZ^AM'3\]>1A"HCYNB:FG%"4/J;/'Z$FNVA\8,(1 M=8X1Y=Q6$\X63?SZ%;Z45RC?M]9"UVGI;UGXQP2@._2)OJWJY>3XZ.#OG,3\ ML;JDF_)#/7]T.$* 8-(OO3+3$TP.WTINZJ9?^Q/E_9X*+F(HVT2T< M_W:K\HH[]7MFY;E:E7#/K^B>>ZMR%U;E^/#X_^[MRN[:E4OHMOW7\F(Z>-Y^8F^QTUN[W MZEWLU9/]7OU3[=43NU??:L_A?J_N_%X]\>?J?K/^F3;KB1RLT::T2-OCYY-? M#L\.7QW"1L1/CY\\.T)'FV#.T;?E.]\F:@P^? ]^2HSM)T=' M)_LM?!=;^&2_A?]<6_ADOX7_2EOX^.CX\-V/9_=@$]_%V[]#C.CD?[_]^,/D M70D<2S,W>5W-.FPF.&")*OY[)G_/*O\$);5RN[06H@VD>$F)]^1UVJ;>6_4> MJ-#R 0 6[].FK' .&>,L8XX3O49X(+G?&'QOOQ=^I[UP]NK[_5Z8_)Q^(M6/ M-R OBE2/9[.%6Z:Z.?:+\@]7H#4S7Z)WL42 M??WF[7Z)CBW1U]# GN]7Z)VOT!].O]VOT+$5^D,Z=<5^<=[IXOSIXYO]XAQ; MG#_5K@'1G[T!O>,U^O0ONCY1+'+R$]#PCP?X!Y.'1&\!J:^TB4)X4H,RS-4" M"_%[_M%.+]X[A,MN63TUC-J]6CY_T5WS%@%,0%0+R:W#FW2@[M;T_E7GMZO+ MO%E\Z1S_[M;C,;;]WR6ORRB1Q;TA>WEZ*V0OSX[_/'2;>V&^.Z0D&B M]F)-TJ5 PIXWS+0OA%\DIP)$[ZC^M$B+N_H+7=*U^ MIY#A6F[-!/[WR>')L\][.'[]_?&6!]?=/TX_OOG?R;OWI]^]^_&[R:L/'W_Z M\/'TYWW&#(&*7WDT;6*A_Y>D- M7Y->;W+=0/#NWO/;]1?,X+V.[QXWCR=GW__R[?>G[R?O3[]_<_;]KZ'-D[5U;=Z.XEG[O7Z'QR]19ZU"Y5557LCIUEN,X MB:<=XS%.JOOI+!ED6ZNP<'-))>?7SY8 Q8@L)TSS.!^Z(I!^Z+];4E;6Q=^ M^\?KRD8OQ/6HPZX[9Q]/.X@PT[$H6UQWGJ9WVM?./[[]\LMO_Z%I?]Q,ANC6 M,8,583[JN03[Q$(_J;]$_I*@[X[[@[Y@-+:Q/W?G MYY_B8O%;]^I\;EU>?)E;&CF[/-<^?3F;:5\_77S6SN;S\T]?3TW+)&=_7UQ] MMOEC;[-Q:(BBG:BL3=F/3.G7F6O' MY2].^.L9]DA<_ 6[F=+PF[Q^-)T5%#^_.#L_OXQ+%L^:[F MOZV)=Y9/!.]/^'LNZ%0[/=/.SR12->6Y=GJA70 E]GV7S@*?W %PMV2. ]N_ M[@3LKP#;=$Z)!5YA$XY[ID#JM8_=!?%'>$6\-3:)RBS??D&((T57:\?U$9/H MYMB;"7T]UQ=D'12B.G1,[ MGY24]*"JJ)I4_(;;O\5\:__7QU;,Z)]6E!IZV MP'A=2W*:)I0>/:FC0N<_E:Y#K2**\QO_4SLX!VQIBBSRRNFSX MI<5TA] A:6_U=(CI]M0AMY$5^8**4OSV]E5CTV)KJQ%1UE)#,/*(^7'AO)R8 M3L!\]ZU*D\@CB7_4:0Q99H'KPM!43X$TS>;7SBI8A-:1'A?G?^PLDYA6'9EQ MOXD>K9>4S9WP@?PB+>>J[@)3<@\'L*DP3&GGQ+_7&'7=!U; MT:F=K%UG35R?$B\]L H&2Y?,KSLP;FCQB/'/M4L^@B)Q"8E_MAO@KT$ \6#( M$M4=)O6)6?"6<-WQ :;A!9J;Q/; M=>L-)&9@[^+RG'P*[Q&UKCL]!^8$'<2?/4T&!=&<$!B6C%G%S!+?^W8J_CM# M6C)WT)"@^NUDN^P6E\ CELZ^B;^W&W-$'!4I(=RR2&6Z;//))8L>QI8KLZ<^ MNNV/C/XM_&'HP\%M=]J_-:;P_\?^:&KH=_JX/^E.!_#VB>' HCX/JJN8?Q?& M2K3. 2(#;$UBN&(I*"T&)7*0?H<22>C#1M;?CB G6/3TQ_&D_P!E!L_]H6X8 M@Q$\ZA\8<:44)?P7N\"?$8L^<,%_0Z'HHS\D5KOI#KNC7M]XZ/>GAVCK!?R4 M&'^JAG'$'H7\CT"J##\&R)B_)#X%S0^-:I:Y$N+/^T*,/F0DMA[R="]K3/7> M[P_Z\+8_,?K__328_GG@;KQ,@!+Z+[OTX&F)_XE"F<<67S#(=HV'NZ'^_=#A M6@Y?)=B_[C1<@R D)+448N/I\;$[^1,:VN!^-+@;]+JC:;?7TY]&T\'H?@QF MZPWZ1B54*[)2 OF53Y*H9]J.%[B$HQHR%HTS88T2WBAFWB+@)OWG_NBI/^GW M=# )GW!4 BF'3 G(Y38@$1.4XM(BRP_[7:-BDXB*JBQ\=KIMX9"P14:=](>\ M>QYW)],_IY/NR.CVQ"2ZHE,7$"L-?R:[MF"E"5XHS:Q%8-P-1A +#[H\!AH\ M=Z2Y.WSJ5\-G4UH)P(4$ - B0=PB\PY&,/I-]4G5!I NKS3QIVT3IZA;9.-[ M7;_]/AC"E/QV %'DZ'YPPX=$ Z;FE6Q>1J_$X/,V!C$WT;4D_%#(L$6PW.B3 MB?X=.M9J**2**XW^9=OH"7&;#/QD#$9]P^CICS*9?$HE"-(D%_ALK=\ ,R2XM0B'_N-XJ/_9[XNLZ!C&TVIM(8=,A<"Y M- F.F80I6238M,CTT^X??4,?)+! MZ$Z?/'8K)]=RR)3&ER:U$1.4XM(FRU=*(H\=FYJ4> ?,2V]8EB!V>?GYTZ=? MI>92/3^-/L1BCFL,VP!,\<@NL@6 M(;R,B!4GU&JB4!YL2>B4RTKR])&/?1G#D''P-9 J)E;!($_6\-'X;\9"S MPW527D7$2CRD&7Q.@KF5<%1*(AIDP?>33P@_I4[9XI;XF-J'3%,625 "*TWV M:^0MH7 H%FWDH@^1Y*,32!"92V(%-G'F/>PM,;/X/_V_ OJ";:B[!T\FQ/-= M:OI$O'L'+]E5!:4;2=F)>FX4Z86<.>)B$2@2_I%23CQ,U O?']VM".M>X/G. MBK@]AYE05UC\.[E5*4TGVD)$LM]XGEHXP"B&MP=)!"U ;L!1H3[[Z] MP[M$#G.E$^QQ9(>GY1*)1]"+1X!@O;8I<>\HXS=+C5UGX>+5.SB 0I#2&:2< M4KT!)9*.(O$HEG]TC4+$^NR%N@[C+0C;^LRF"Z'V._B&2I+*.2ZE1%)PH$*%UAGWTT&HJDHEAL*SU WDZ1S!/ MM'BQ<$G80ISYA+P0%I Z^._!7HF^E+W+V\^1G5]D1?(GD= C]EO@3/A-LQP3 M/W!9U_-(-$&\23-G>W\'#!^C[70?A]_V$>>TD&D M5&BN@VQ4B%R%*R%\(ZU&F)SBBJ"4)JUTF:)C]U MQJSVP+*O%*5[2"G.XE/^F70$H@QM1&M<-MH(;Z5'5-VOF H3B; ??2$#YOEN M4#MI=6"12E^1\IFUME!N!:P;35!*E:/G5()QP, 'R(28SH+1?Q'KSG56_PO> M5%L-I8=)R=(]/"S4#B7J(:[?T?$.TV5YV+_#U'W&=KUY\Z%E*EU*2KD>I-." MP-E'7!DDM#FZ3R4H;[#-\];&DA#_@5B+>M'0(>4IW.;SJ92,W<-M(C60T .% MBK338^+C 2.>F>3MJ!;^A=1*-*5\:NJ8@88V_-H-2M)N-KWL@*V#FE%$96Y* MT.0[K=*@I1M8JB,.91R!#$W_B-T?8(B930QB!F[MS%5-EDI(2V[)VH(T$8,2 M.4=8HWU.#M\.8OH!MA^Q'QGG7=#>09+2":249:$3I*2C1/S1/13ND0Y[WL$G MJK)7.H)\)+/($;(1U!'\G/."Z6GY"]3(<6NM9U?CI(142B>FSQ5NS\\CYJU$ MKN2HX+WC6#^I;4\Z(=1:1 52* M+2AT9>%ZW(& +F*K1+GN\5.^)!"+BI<4CQ!GL-AIKEN'GQ)4*06F!+7=,^+D MH&\Z"SGSZP"HXJ$"3;[W/'7\>#LK.?./.&U"%I] I?S^ZYHPKU:;J\%.B9Z4 M<"I$+Y: (A$M1Q*F?"_\^X=B1L&HXSZ!32#&)];(\8FW4V>Z.W+\ MVXYASBWGN^%7A9$2._G.^KSKTX]3C1QC)]%G.*'NFG\%%+JJ[ YA>!>L2*W, MT,&$*=&O=GG^5B0['!N(%_&<\ "H5A6A!%O^"$ QV.E6G16;3'=;Z09Y=SKQ#8K,A$XN M.BTV@DX.FHKC0O]W2YBSHHS_FCLNQ#K4Y$^I'?@0'1,_W.,XYI<4K%8.,Y;@ M$[6*L.4R4"@$Q5*.@ KS)%<+"2M! M[P<]G3B[Q;=P\$?[X5N=OQ+N:K?C:>G;DD+D>9>>DAH];2/^TA=NZH!;2*Q$ M3DJXY7\EIY60R+<3[C1IJ\!&"9-\*U[.=8=MGZK)A@XC1 ,J),[![GCH=Q>^ M2D3E"^IR$8UBW(VH-AW?_>WDU;O"ZS6%*O,GX6_&G%!W\0B>D/"0LW !0.Z? M\=;3[]1?QC>QB?/S4X?/.UZ(&]VRPD]*>]$C8G40GGF"\+HSQ[9'.HCA%;GN M[,R/4=OF6QVO.[X; +O7F6O3JS5QJ6/Q6EYWK""\&BY^-PLW2\(+,J-^!WD! MJ$3]@)>Y=YU@?=T)"U+PA@[R!9/P"4Q_P!G2063/WL1[*: M$3==ZU#+L-);A>I4I9+2EN]J_"_O[,IR5I@RM=X0)_#+]/""Z/-4\?URW(K+ MOQ^$E1%,+:J+M;ORJA25;H(OYL^ N_S2IH4H>?.6%!GC-_ZHRW=1AE,=3P]\ M<54$98LQ!,3%#GMX0>_KU4(9M?UN H\RXGE0J1G/\X" Y+3OP.+7(\PIWFR" MC!<6NGE+&[W =8$@_<(TH6J9HLS2_25QY;*%EF^2BC4PVQI(3%#I_4:2G",$ MT6&/MZYM.R;O4J%>!GB?3>(WM_#T3X)=G16[_0$X[VZS]QQ\!\P*^!P8V]%5 MU>5]8&'Q)G2"]U!*9^/ -9?0^^CSN,5 S&H'O,>90'D,X2VGXH6'CE?0]:YM0]X-4XYTEP>2*HIFU##G.[>\,E: M=.N>F+SPJ[_]MW@5;,"B'I_ N.JX4R=5LLZ8LH>0IKI^S\:>I\^C.RSU<+(4 M1=[0FETBVK(\ ]ND/!3:EVT3PGEE..?-RN.Y>UYW<**Q4'O/ MV'$G8>_96*L'D/G7.8OO$+]-R:M_ S'"CV++5*-^QRF3'TM15S6*+S-QY1 Z M$4+$YTW4M:W.X#VQK5'CN)M,]79=Q@)L3_CPZ$(LD'9H96];E4TS/'M";![< MCK'KOTVA 7I0L6AUE2^=]5'$16(6WJ ML/E?#F7^,SR!"'# # Q!;]>%!HO+ RPE61.BJY[CKAT00FX<9A7#MUVLJ7.X MK9-%,S]UW4'\M@?22CJG>DP:VE)S4^.9"Y+?NI8E>MXRT.LP:6KKS0U=!6Q?N"";$(/+7NL$G &0)6[#]%Q9OI-#W,'!;G ]X\*._%O3Z( 12A M]=MO4\=;TAG.EE,L%^S/N DC97X$4S'2KT;*JHA%6O TIPR5Z!(%4#[FA/*8U!^'3X$-314^%"IB@.);\843R0_;WC" MRC>!H$("52[< )_9?9%F$G90/.+C27^Q:+-[L'0PF4T=,;WE&%,K'>%LQ30E MP74EXJ8&U>GM&H^8!7,^.Q*)&[S&9EF\6('RG?N":@GAM)Z;X:T8SJ+BC:A+ MLEA9=5&S28/WOD-0_Q7L1#U>C?<=ZV1!C=C2<4OFQ'7YE(SO6)SBURBS<4,8 MF5.?=T2#%;2]LHE,90X-G;EMO@*3[E_+6W0925-KZ; %S"Q6?.()T^]P=3[: MMI+<]0GB2E;[:_%HZ/:7G/6%7K 2.V1?2+JG?G;\U'1LLU6HSL)%3<9-6.N, MY]A5]KGDEVW"L)#ZEK30VXL_\$1YEC+<#>TMZ5J5G:C+I@EUC[]".86&6NBL MV4('5SM\$A-5&(;6](\'Q^;=23DB.06;8/-H= ^']@D/"?C$Y2Z\@[.H+@JB M=P*%QW#0^QQDE4#D+*$A\-&OYE;\-QGL3W&:PZB2>@+UZH$^T**AL[;JYX;B=8V4A\:Y9\[,F T$!G. M_0^F* 4TM)'LG>SISB$RTAF9+D&EQ?(.PB>>]MEC8>X]Q#?3?>,MMCHSB.^' M+_6Y^ 1.^"U!7L'PQ';9-OJZ;)J:BGKN]P8KO !M[U>SAY[S\??[\OBBA* ) M<4;VAK<)>7'L%SX%$S:\PZ883,MK6(M%$^J\>X,6+3DZ6I!JS>_0=11*:F8O MP:/HX;"G#K53A?Z]KB!.C7KFDJSPMU_^!U!+ P04 " F@4983>W&?? C M #?50$ % '9A&ULY7U9N@ MC7WIZ.H;LBR[-"%+#DFNNO>)@25A<9HB=0])V9Y?/PF*DBE*LKG@4$>>J @7 M-QTDD!]R0R+SG__Q]7+PZAJ:<7\T_/TW]G?ZVRL8QE'J#S___MNG\W?$_O8? M__K;W_[Y/PCYSS>G1Z_>CN+T$H:35_L-^ FD5U_ZDXM7DPMX]=>H^7?_VK_Z M./"3/&HN"?G7[,_V1U??FO[GB\DK3KF\_=GMM\T_>$Y.Z)P(,,>)U"P0*X4B M+&O?W]MXO)Y.H?KU]_^?+E[U]#,_C[J/G\FE,J7M_^^K?YS[\^^/T7 M,?LU<\Z]GGU[]]-Q_[$?XF/9Z__\<'06+^#2D_YP//'#6 88]_\QGGUX-(I^ M,EOUG]+UZLE?E'?D]F>D?$08)X+]_>LX_?:OO[UZ=;,@O7,!A=%5$Q?WHO"AJYMY9H9B217GGBDK(D1:D2H\(RK2K/ M\(<$W9_M J#VFOAJU"1H4"#^]NH+%.$UEXTWU.$C'R#M_KZ<_^+U>'IY.7LF M02A=WOY];D:7-?$P&;7%AQO.X[.VA<89#/"KS^]AB!,=(&%[Z;(_[(\G9=K7 M<$N;YSC)2$3@)(FH>OC$R!,^68Y961\7WT;>=QB";5)90GO4-N M[H^&R+TI+OJX;?#"4*E M\.MP.($&QI,>U5Z*&!FNB46.2PW$@J1$VPR0K1 ^L,H+T^)TNB24-T3?\@;K M"O.K[RX0V*#ERHGK?,!O""..9$(281RPT0XTP2%K1/SK6"Q >DK"FM MR+1J"!K$@EMP5DN]6P?LF>56;9YOM^35.'\, MDX4)>1X4FLXHD7TL8:7LB%,JDB@4SJV@]6]R:3IA^G$AP&F!IEUG5,+6H>HTQE$E M+[Y0(9FAQ$HJ$./":RIRTK0V6IXT<#8)-U[#< JW7E7CX^2O_N1B?SJ>(!>: M@Z]Q,"T'&7MC5#9C2&@[]T(4C@86"!K+B4BA<++H.Z$^2TE*FSGGM6>\ 9E= MDJ:;XN5A4+)=;E7;(/NC\>0DOQ^-TGAOF,Z@N>Y'&)^-!JD'POMH,B-""]RP MW"7BO?$$=(XLR*A2KNWA/DU-I\1H+9146OS*L8YV@C=.2D:]!D*M"43Z!,1! M%$2Q;"FC3EOY8B-W=4(*'GD:/<_$28LL!^9(H((1YRPZAEYE9NVN0PK/*XV[ M@L< MNYV;%M$%1BGQ#%6MC"(2FX$28Z1R/E.56.VHV!():TK?EKW%*B!X&-K??-'K M140G%]#\8,]%Y@57:&YY5HRZB-:7HX:@TRJ5"EJBLUQ;%?^0HBZ)T'9@49$C M%>WA:P1J22>Y(>9.T@>?D@@ZH*3W2 WE&O6\P(F"XSQ:"DK4QL=3M*R"#/&B MD5&%"TN8^.?KY>4ZPO?MY!#NGWSX>'KP!_[F\,^#HY.SL\-C_.B@U83"GX[9 M?G;A>M.NE&JX/[J\:N ",=>_GMMPQX ^=HFO>"Y\+,!- M:2:UR[6U^P_(V3YP\^2C\=U-=.GCJ)E)@E7"L]FS;+0/Q IIB51&H?^2-;$T MQLP3CY'63CFJ/(4N>:ZU229*@G45M$@6Z M6%QZU^K!Y8L[Z&D+?^VRKF)4N^XV,:"]\< (5>4\5!M+7$1+0VL3$@V@8ZB- MOU:%XU9'[U0!V B9))&0HSPH@FX:)3D)M,NEEFA__7]Q]/Z<*/O!X?TZ_*GK M4#^R(+-(VZA!=@SWITT#P_CMO/'#L8^S91FFV;LY"]/_F=X8^G>R"AA0*5(D M@AJ-)OXL$1O_T9"$\M*YZ*M?%&EE)EURX+N$VP[@9L>NX9N]H[WC_8.S/PX. MSNO?*GOBZ>VX>ZM,I9)C=S89Q7]?C :X4<8'_SWM3[[UI+(\2 XDSF(*):LD M9.:(D\S[P+2RH?KUF0=4;*]7(0/B.\T>_:'" O&:>P+":IVI]#;6OPCR(XJZI'^WQ,1#%5J-%34-V(J=+"JXR,&HQH1HJ]A(*6EP&/_CH^^EP MN.^O^A,_Z$D1G ,)."O4=9)F),8:2IB7V5C'F,NU,PB>(*5+4>G*:*BQ^/60 M$./TLBPMI!]94G=VD8Y9TUQ2VH5%WT#81)PWD5BOP FAJ):U'=DU25P%.?*% M(J=%9E5#U"E,?'\(Z< W0Q1PXP6BWT+NQ_ZDEU 12L$-,0Y)0D'GB0\"99X* MUGBG14RU3[]^3M4JN%$O$S>565(-*D=]'_H#%(8P[C%04J*V(S0&C@0813QH M1:@32GO'9,BUTT(6AJ\XDQMO<]++PG%P29'( GJ0V?N;! 4JN9(NHSQ/HKT) MS:GHDK6]*;>7T;SE6M=#[VCX^1R:R[<0)B6P<4N+CD'HR(GCLER*P/GY3%G9 MJ(X;GK*KGC/_."5=,JBK\7[[-:]_*?((_!AN9_AM@2Q+#82H(^&LW-4,V1"K MDB,A,1 L*:2M=J#[IT1UR;"NA8JZG*@;TEZ8XP(]3E-!C1 $C?IRM9UEXEV0 M!()PN!!,H,'61ECZ46JZ9#%7@T2=M6_#U+E56NCYF:&UX TZ%\08Y= '!8.[S5K" MM*'1.T]IJEWGXDEB.FH150)#!0:T;1O=TI1DRF RDI-0$\M,@;@LD2:J3/;! M:03Q;@RC-9#Q#%91#6149$4KKM,M(5QJ904Z;:Q,5%*#YKOA%"=J([,^>%_] MMN@C9'34%JH!A&T7O>*9U,,+S0]PZ50JX2[46\S2DH2"QGHY,I."69NRMES4 MUANKT-6E*&%E?%1G2SWK8CR&R=T<>2CGJ.CL"U7N^RBK2#!9D" +-,!/?_J MAU2+!&P-?S\NM4;+_TIL]]H/\*'COUJ6BL1UB6#>G-V1!_\@T)Z9GD M1'!&D^P%4I"9Q5EI1TP&38T/Y1ID90PLCM\ET[D>SS=>X8K5?.'*]]/\ AP* MIUE(Z_X,'0_,&JW*H2!JXU *;F4#A-*22N Y,Z*V'[4"65VRH>LAHC8_*EM' MO2PE*B.JB!)>$ D\$V^<(IH%AH*(9QMJ'Z#>C%SA$KT??NZC6+UY'NZXN_)& MI;3-E_Y@T(LI!4@T$&]+_5ZC@ 2.C@HW+BHM:0JQ?O67G]/5/6MH+1P\/ #R>X^8J5-JO3CZ_?]8>E7<@LOG%:%OHD?QK?S& O3W"/ M+J8[7#40^WZ> [YW6;+4_^_L;2]H% ],)Y+ Q^([ 2X<6)*C2R)0I62N?6#? M_JRZ9Y%M!=".P: E#]?;G%.$0!RJ)%0C:'F$Z/$?%FRYEQ")%&*@FB! MYCPWE@B94I8F&5:]?MJ3MP4ZDU2V/1)^D&J_UI+7:X3X8#X;%1B(.F>>C2,L M14ZDBKHTS4DE9,6BL-ISJ'UKK0[E70K?M(JT9V!TUT!JJ% 4F"!9%46"*T:L M4YED'D"'6!H[U99I;8"TQOKU0C)H$,E,4,RXTN8ZHU_& XF!!:.<\\S6#O?_ M3&%UK51!ZQC[^19=BTW5MMN'_G#4S!;@M@:=C)8))8F@,: 9)X%X%02A(N5D MT9 +U;-)EVGHDISN %2V8M%S5EK=._OCW=')7^TV:W]DE!U44_W)U"J5V2F9 M,7Y\\;$97??Q:6^^?1J7L,M="'8O3OK7-P9EI-XRSQ,B@:)!6;PGGYTFD=E ME8REG6'E;;LZ=14ZH30EVOP6;OY_.'R8H=]CFFFA(^XN36FYX,2(]_B* 7L-KUV :!6ZNJ3W6L+3(^UBZ[*K9DN=AY0MI:/U)-,42N%[69J,2^/+U5=) M"624X0&"%*[V=<)5Z.I41=/G1-(V_-H!DN8WR'K9"XTN$R4*,A3OR=[T'W'H M4TGJT'VJWN#NIT1UZ2SZV2&T":/JY2@L9$F M,DN2C:(YX'JKZ@U5?TQ1ETZQ=X2%ME:SVME6CU/2IT=(V'#IMV;]M6\>IF[,0?@&AH!$ ME>D?7E[Y..EYGU7(",.XQHJ?7L3=SS TPN1FDA7V-6&?%MOZS1,(U/FK?]\4TD%%=XW-/:" 5!$:[E M+!6(HE>&2E"D8&U(7IM8.SEB>ZI70:'[Q333CGG=H@=^>\VLK @5^!>>&Q*$ M*Q>J4;]:%+"$X\9.$)R!31\11 0K*)B&QL%C0J+VL?0:Q) MXDI ^\6BS6URL4J(Z;WO#T^&'Z=-O$#R3O*;Z;@_A/'X+FWJ%"Z1\&E3_,KR MXUDD+*,'"3(BF9IZ(O&1Q L'I:$FI-=1*9VJ?<*Q.785X?01(LQ#- MF1\43^:#GTQ+6N!)WKOV_4$YRGXW:LJ79Q#+-S.(*&6RS(%H&F;W#-"1);8NZ1TX"6F=JO1,C_VT6"3P?[<7_GO8;^.";?\,L MZW61-&Z9XIZ32'DYS J&H"JPZLZQVH>/]XA M_P](G^&QN7,9D!PJ":H==,2T10/9M8>MIZV_4G"\5[II*ZY+UQ57FLIKAZNB,\D"E/).:V%JQXC7)/$EY'BU MCK**7&P/:K?>/]P<\L^*-]]\DWI")K THXR593.@W"6!"4J VR00(DE ]9*H M:]"W9O;8KPFR6ORK%OTKT:*3X1E,)@,HI)[D)VW&Z*+(VN,.X*$H-FI9Y4J^+!:[!4KWX4R@I1G$":5Y/_OX' M"[_\"$V_9"LM1\;GT? MWCQ]WJABAS&^K&1:8O]S' N T%YY%0AZB;:4FT\ER8>2*+W/ 26:JYY.L>FQ MP/-6.GCY\-R6_6W#\Z:F\M+VB31&#ZHDS.9BH6D22N4/11W'=R&R4+N8TNK4 M=2G4^?+AN2W[GP.>5C@1+&Z?2'.YEX(BWG/A"?6:">FMH[$K\-S<%3Z%61WS M\]&Y_UJR*$JY%QRH..U/W.W3P29-#4FVW.U#S[THV<36E= MTP!Z%F=G6^ ]Y2*WRM=JN_$4KN;TGN3;KH)'Q:-'7QY]^/ZDYXR6(D(B24># M9/E,G-*>6)F$#*# R-H6]D^)>@D'JK5Q59=3K1RF+IRDS$Y/'EL"2HU7*G-B M3 D[HDU4:JRB 1]8@,RRI+%V8M^:)';)[MB5S&J1B>W5 #O[].'#WNE_G;P[ M.WQ_?/CN<'_O^'QO?__DT_'YX?'[CR='A_N'!V=G\0+2= "C67#2/^@,Z)33]2R"F(%!QQ@J&>@.*5@K5$E#X)%-U2Q=J(/[ZH?J2[ MP]UF_4O7X6%%8W%QPCVG.*,!069VMJQK"W([8(J[@(^'\C:'2&@GLI>@>#'EXE&C:MA+(DI)]0> M-).0$B7!4H.JQ0HM:MO.&Q/;!4/@I<)U>^Y7R=V9A3E\/RVNT-*:C'LJ614S M%;AG#%*5I<>UP+!E5Z0820G+D/8__*#^Y(4C$I M;140HQ1'!6$%"3Q+? LV9A Z5J\A_D."NB)56X=(/;:TYU"]VSL\_7/OZ-/! M=T?BG>\WLVC X?!J.AEO[BZM_NRMG:$-IU$IFKA0 OYNU+?]<1R,QM,&>EY( MYB,* ( M8*"X581QQ%%KT<"@5 ?(!>&D%FW!%,A)5O6_5CTGJ@O'6+FQJ M\J0:4&XJF'Y'[[OKXWX/(F0-UI#L!*H0$&A!JJ"(\5E+'H3*R_5EMD;'8W1T M*;&A'4ALO?H5B^K=*OUYN4>GDC,A1D(E1/0W(Q OJ2616AD=2S)6+W2^3$.7 MNFBTP_^M5KU.&&O47(W0184W(Q1)/1HD$Q3M1IHE1=\1-99#;45"8HX[IZQ- M2[V;'P]8W7MJE]I$ MGID6I;>7<*I$W3FMW\_O1Q1UJ5=%.\*[(D"L98=P&D8RVL7H&S(\IZE(CB[94?#6.[#18^UCYJZH1VQ\-T$;8 M=N4)54A3>6RL>ERCE03K0WZ.RY5"Y/!"#)H(G'=?).K&)H_72@ MK0,)CU5!DPXB$Q9W@0QHXZ1<>@!21D*$A!:.SR;6KN^_:9FZ71P)UN7V@[#! MMAS8J=BXK:\[]8-Y=48D=P?29(-QVQ RVTZ_TKG1HYA)/C*@L00BLT%],SL3 M<)((IR-8 QS_V_FNW5ZNWA8!W1O,_A;2WC"=]8>?!W#[S5O\]+_ -R=#Z(%/ M-D,LV2'E=,2:0(+2AN >9(%Y@_M4;RAWUR*D"[*K&EH6W:;=LJB*![TYR7MY M LV<[O.+9C3]?/&N?XVVO]8R![3J$I,>Y;T/-UX =2&P8*.B.K6*LB<(ZU*0 MO2.HJ\'"UE!XWXK@UGDF4>D+CBLT"PP[QCS1@><@N1+T&;=CQ.EH@ _\ M7*X>EX+K,W%P?_Y,Y@P\*V)2]P5'F=;26C.?5.;*D2A+ZD0I_Q,XYR0I"AHR2PQ6N6"P M&VJ[H"(Z#N'Z7&_/13L\_O/@^/SD]-X]V;M.7IN[8*L]=VL7:P/R*[E0=X/, M6A!Q*H,.DFC)%/)2E(MO-I#(G!340_:M1-=OQZ_61>_4?T$\0]/W@_'>_!)7 M?UX*\Q3&T%RC#6:H\DJX4F@59;'4QA/+I2(\6!KPE:-@VYKL*@1V0WA\OG?\_O!-N8M\=G!^ M=CB<^.'G/MIL-^=FFQLN&PRRM16S[<0JF30% !,X0G,U+0];0&9D*C?T!&J1 M(BP2!!) 9<*2$!!<]+QZF?P?4U3A]M)33W_?E"9MI?2/18%(LI<6P2Y*I%&B M&^%\:6?*$\Y\=S.>T=0EXZ8B7AZYP52/-36ONSU%U5Z,T\OIK$+>8O/27HE8 M2$LSD:7#B@SHY3FM@3 6&401A*S>779]*CM5?NYY4%6#?^UIOC MOU_PN+5.6XOD6M?AYF4$9_U HN4IZ]* /AA:)(0@UHI('/H_ M/'NN1*K=/&]Q_&WBCN4YD_ES#K[.R^KN3YL&#;7OQ\8W@I")7(*?@4#.L51A M4"@#J2#@G-#*FJP]^PD6UARR2RIH8XXO!OS:6NYJ>F=QEG.Z>L(GFD/,)"E5 M.I(H3WQF%.U^&23Z^@*JW\%XA(PN>KDW3+.?CL?30!%RLP MS99O%W0+?)LG5\_++]RM!/5!9^I16&2.T)%HO'J;+*%11I\DBI#J#0R?(*5+ MJGN7^'HJZ7H;3NW6VD=_!1H8HWU2LL2AKN'_Q,-;\0%6F4BU([I[0_6SP^.#L;/_DPYO#X[WSPY/C!9E\&P*[Z7/IAVFAL M^APHZ;:%P M:@V]O3IJ91$J*:O;QJ/[H\N ""I30U$S[J=9@;#1\+SQP_&-U<)ZX*0P(FEB M=52EO'(F%E#HJ"@$.@7<45N[/,NSZAJ.G&-Z7]O6C:KM'&K%0Z'\_G 'S!( M'YO^J#D?+3R.];SD$:CR)"OT#Z0%3T**.$\N)/4Q6+N<:[S+';CIM%I8^;,) M7,U&'??+VZ<(.H5+\.4R;<%3Z;%;[D;,K_X"OF/46J8ZQMA>Z MN>Y^7B/]!0*W#M^KW%[8?%O-UVGAE[W('5>^Y'T%ZHDT&4A@$@B7*C,'QAF3 M?^((U*:I2]EX747JL^*@3?EZ"G'T>5C"Q8<)97\_]_U"+L>-#[?WF \WRR$) M$E _>!(IE*L7N9B\U!(&N(J"><]V(8*WF4*75G1^1+KX19P%\,?H'LP*(EFN M(\O.DZQ9ZU -=)0V#>PVZQ:QTW.;-22D+X4A7=^$Q"2??Q@NK /#/2U3XO:7=& M'3>1?PV]M!V..KDWEK.C9T+@_,(/R]V@+_W!H$>9D,IK(%24[ LEYM4+$P01 M&,N('?=H- #96**D<$3ZB,X\ MY-+CA_NDM0 A:^>$[6)>72KE_*MNFRJ8ZN1N.1X-XP-+IJIE8#K5SB;=S_DYQP?G1R=G9X?'^RG)[]L7=Z4*8[C$CM[-FC?(Q3:>/'_5@^[0^F MD]G2'P[QV? 17;?1Y>5H>':!XVV>P[-3\K;.\WF^Q:R4"_37;+,CEJ^1Q,^ MI 9H3O*^.0BZ%ZH\4U M2=Q6RSPQW(-Q9KSK!2' 4H?^5\D/EQ%WMU6VCD6-PGE)@8+ LF1*FMI1I.VI[M*Q_RXAN6-^KVA!S#\O_P0< M]E]_^W]02P,$% @ )H%&6,_R=>'Z8@ QF8$ !0 !V87(M,C R,S$R M,CE?9&5F+GAM;.R]6W=;1Y(N^-Z_PE/S.E'.^Z56=Y]%4;*+N MO$HX10(J )2M_O43"1 D18+DWD#F!DAYK6HW;\+^,K[8F7'+B'__7W]O7_[ MP^M)N+Q(X_D/A]/DYBG^\/MH_NF'^:?TPS\FTW^.OK@?WIV[>9Y,+P#^<_'/ M#B>?OTY''S_-?V"$B=6?K7X[_1O+T7*5(R1J&0A%/1C!)=">+;X]C_^ M\FD^__RW'W_\_???__J'GY[_=3+]^",CA/^X^NN_7/WY'_?^_G>^^&MJK?UQ M\=OK/YV-UOTA?BS]\;]^>7L:/J4+!Z/Q;.[&X>8!^/@XO_Z'M]'('Y>_Q#^= MC?XV6_S[MY/@Y@N"GES"#P_^1?D.5G\&Y4= &7#ZUS]F\2__^6\__+"4G)N& MZ>0\O4_YAZLO?WU_=!_I:#S_,8XN?KSZFQ_=^3DB7GS"_.OG]!]_F8TN/I^G MU<\^35-^$/UJR064+'#^[_)I/VZ-Z1,"F89+GP!_FL9%Q2MB7/?IVV.^_BR( M*;O+\WE%Q/<_NRK>R84;U13PO8^N@';Q07"1+GR:UH3ZS>?>PKD">1=A^<@O M;IK^^&N87/RXP'9XG)VZ/7!Q_>O#[]@/_]Y["3R\%'X9P&:>,V07DK1YW:X6H M2J/QJ.Q.;_';JV>6!0VSUO3'/(UC6NY@*TSGD_#-'YV7_7-R3?BY\^E\\=.S MRQE\=.[SV>D<#[-RKN$BTA%^.3LCUC$E50#)/1XXL9Q+3!%(-A$JN&=!D_OJ M,ENI7W8SOU"8JT?\6*3_8SJ?SU8_6?"QX.)A%$M)5UC7!^?/TYF()."!F4$9 M)D X:L%)SX$%%1@C H_1V&I-"P3?KN=&=PZFJY5=O:J]3IP\G5Q4Y7,^J2;& M)5,(^B\_3*8Q3='(PE\M]H^_A?/)+,7_^,M\>IEN?C@9SU&KWYPO'HAO<_I8 MOJBF"6_^=3F:?SV<7'R>C/';V<$?H]D9UYDDR3S8:'%%2G)P@B?P(BH2+,G4 MFU:*L0Y013UYQ IX1&\V(/HAG=E:X.M4:$MMN(/I]>+\Z@3J[(Y=4DD;U@*J MJ 4/VE6/Z,#VQ$U:27TPE<#=T7GO'$CM(KI=P8"UP8$)S":;K9>B]HDQH"I\ M8[+N7A/Z"+N!!KQ#(VT\_V5AQ)XE;4(T5 +/,8$0'+&D;" +3=&(S :77YGX MV\^OR?X83E/Y!KG=RNV'P7TC)FO)^C[6L"VUH(0+B\N MSTMH]F3^*4W+?C9-G\J!]R4=C=$#3U= /67X/YN!*Q% ,./ $4&!21Y,$I0P M6OO][PSN.6M'$P+N:PK?5E/>ISD*)L4W;CH>C3_.5FL/E%$F$^Y=V:++$]"^ M"4:#=2*01*,4GE=6B_5(GK$.5!#M?<+%MH0?3\8EMH 2P;_X>#2>IVF:K9;+ MO#&1>H_ND4)LG#FPS'G(.?%$C*%4L1=T5B83>=GA\O]";>C M-_BT,'^7IJ-)/,D'/BW%@=+17&@%<$U9\Y@FZ.#! 8XK8\*SS4NN@# M/O"6+N!W-WK0%;#^CCJ#/AP:[X_@*"(N&H&.>@=8END<3R[%^.4 -Y,/K M6U,%N9=E'9S=!K';6\'DTT\.$9U# M@R#QC?V/&!=9C ^3#^Z/?XSFGXJ4\J$X_"R%':R*# M+*,!82*ZLH[AM]QFG;/25-:N%=D"[LO6OJ%XO*^"A\D#J?T%) "4Y18M%QU@]YE9[ M#2];HW?*^'T--HT#PXETY$V.E["NJVL5T+9(& ME0/:ED7#A$T@@U-(+O?@LQ!@9&0$#P]#I=M90'NCDMO)Y7B.GW1:/A%?B=FO MGR.ZW&_*W=39",7\=H3*H)U+6K((2<@ (B4+/N4 +N@L)>=!J08%MUV@/?N4 M9 L*'DSS_/N/=\2$:_CG1E>^3W_]Y9>#]_]]\M/IT<_'1S\='1X'AT>O3D]1&\$C34TX,8!)39=NAJCV3]?ES+3\]FW@#M=_J[T MX&VO@;=8?Z4+X?<>=J.H00::A3)X-G$\[VR)520?@(MLI.!<12:J;U\/H=E^ MH[[SR2 FLU48)'*VBGPJUMUCCHA?%*?-]/)VXM MWGVY0'YO*:^^?L!_NBABP]TT.JKP"%?,@= ,_4$?+3C!J';&.UQO:W6Y@;.K M@N$:9#^E/QL*O4G-PMW5XC^\JD[K JW11?)'8.WF.GDU"I_<6K:3_] JXI4( M3"J@A)0\9XBEJD*!]-FKI-% :W^*ME:-)ZZ7[T0S>HB]A48\9,NMKDA%E1)G M%'2F!AUFI@<22X9:8GGJ+8:[3 E\3 -+"6F51:RO9'Q#::7;6EL+OX&Q6_W M\:W0K:[J=< WE,UQ!]O>&!Y;,/JDNE2@8P@3Y"Y.;9/B2B,Z52I_:<#7A<@ M.7(E'('$S!.P8TH0DM)?XR=KJN\<0MQOM/?@'& M: 615JS#+VB.W44ZR=]@6MW [ "JXH7X!X$,?P=^6X8FK<1;^>5^&)PU5CM/ M,P0B2M4*[F7&1P&,HM)3&M$XJO&.#\SY(U?9!Z&\CU0K4OW%3<\.W7@R_B7% M47#GIU]G)>]S.)E^GBPWM9\F4T1Y_O7#9/9IY-VW?[?JYB2EL8)S8%:43C%) M@LTN J6EF8M34K [*G$O*UL%R+"WU2N1.=D5$T/$L=[A48H_P[,'%F*C/.NF0G]0(8:N^G@WG<1+]'S< M=.K&\Z^M:ST>>-PP%1Y=UEJIKN/.H]Z.G!^=C\H7UVK(C4HTE#87EH#0!A4R M"PG';YI"9""X*2UH6(!DF:691A6K MU^,]"FBHFH^ZNK#F'G$EF>^Z J0<]._=^.,R,VF"YR[;TMR6HE\7N ?CL@84 M3I0D:Y]"I\3M$[;O]0-WY=96Y&^RK1PK.S8+$%?64A<8%=W86X\>WG'=4/AW MZ=M"<@V)S%[&Z!0#8]$+$X00\#806#2I9"8%XSL%'G=-X"->:%W^^@BL=M@0 M)75Q>;%JL44YNB7HJR1O'8B4.5AG.;K3$8\8[2)+-7;4;QXZK)NXL=@G-616 MT-9D[>QS"H' M>E;'^8HJMC@=F, F%H#3M;IHA( M1[FF(7A5O]%;%V3?NSYMQ%"3!H*/[J(Y,8>V&P?N"SI4>C":.2#<\JA3R%K5 MCOMV.=?J95K>O_GMS?&O;]Z_.3SY^?CHP]')<9G''B_/TR2_'LW4(8\S'5+J1\"M.VK]H#G[\,%E.5$Y&X2J=,,5(\&M:2,2#.6R6E(J[Z7:?' M\ R57ZFJ!W=WX&H"WX?LRG4[A)_3Y./4??Y4JAJ65=?4)B62!E<(+ST(8%?9EWKT3FJ+N7(L^'2I/K$XI."^9)2%:*6O4DW[[U&&S")5H MF%2188, ]9M?WAQ<(;'.H NE$ 31>#PIS]#KXPZTEBHJJHPUM4>%W#S].;.Z MI2QKOZ.SD7OGPBB/PA48[36C1%K<QS 0E!/^/>];)87[J-;W[ MX.?,Z?:2K!A@6UP@FGX]^_7T+,3 6/04:"D%%59(<(Y18*4^5 >:$=DC7,Y2 M^.O'R9?5-S=LWCSO.5.XH=2:S"Q^]&K@FS^N.AT>S&8)_[?H56M9 MV?^E!$.3!\%( J.U A*XE#80Z4+M[,T&,()1FV\00 MMWWF]J'$JJNN%%&\&F'QSDWGRR[5J$_+=5WI*O-"RG(Y/1A7;JAK72I41)G9 M@Z9?#,*[VOWJGL*T=?#^*H1;WLRU3YJ]^OK-;Y9UJ3IPAMLZ<)EP^9HJ?&E5 M!);03PHDE>+4VC']38 .%8.LJCGWLD#-*=J+X.3U*I?]A'])\T^3>+,AW/]I M2N5>V,)K9UR[4,;(Z!#1T&-HQ'MM";C D%O'J7?::[\4P&,+3#N;+YX>^V9 M[(#%RE[80[BN[-DNR"K&2!]'LX- Z6"L3II2,JS2Z,24+$5##&U9$+E8MIF6 MUQ%4QX+H"\_;MX160H'F46:5R M^T.!\"*#<2$"_LP@OF1#8AUYN_[0%\/99F*J_*[]]N;PZ,)]1-WY^<+__7#R MU__]\Q4H*8(7"E?%-).EBX0%3XT (VB@TG))XU-.\Z,/>!$\UA%?Q3AJ6>O) M[^,TG7T:?5Z<#X03%173>#0XBLX3HG%E-A2G.2L68M:D1FC\FX=^'X;[YG)N M1?B5-G>!4M'TOO/XX6WM+8A81^<64JQL+=^%A$]D01D#DJE2%RI+H8WC"$XK M%[B.J4J::Q!"'[&'V_#91WC-+5H3#?>,$8@\X**T%N66I(',@F!9>Y>RW'^+ M=BL1/VK"]I%/4Q-6TV %);[T+#(@B+5@/9'@4\I&"M0 MV16J>LC*FU2[1]TC<+Y[ZZ(W)_?51312EU64H0.X 2R+>\#VRLCH3V,W]=B" M@^%\FBN0#K@I/*@LS1*R]Y#+93O<9^*\AF9D=C_>@C^LJ1 MHW>7T_#)S=+J+@4E6?'$'3"72G@RS+SZ$-*=VIFUX8C[GSL;HV% M+04^J2.MRE&DGT9_I'@XF]"A=$@KEHMQB8-,02O! M$B-WYU"LY?#A)[P4.BO)L')0_K 4W:?IY[+6ZRH,:71&;\" MLF8?UZ[ AL_3;<_A9"@":K>#[0S6*^6LQVV2&XM@@Z;HVW)T=:W),3JT8U1Z M_EKR2/)O1TK21^[-LX.*!!7+C&&I2]LCQ?!T"]%"3M*E+++T]AG4NS42_J-Y MPSZ2:YHW=$*'TGX3/"$6ET1*'V3$99E"T\4D$NZ6U^];WG 8^C:36.TV#ZO> M!J/8YE6O1*:ZFGG4 5;/ERT- =MCR97.2)JTD7'L?>!!< MC)XK'G!WBPI=V%"26#Y+<)HB.AVTCU6Z/0U+>Y=V+XU9[R/81FS_-)FFX&;S MU3E$@D5C4T,,L53%E X(2ACP5GHCG>>$=)H[W9'J;Y\^<#>".K2L(7H+F;9H M ;/V6LUU8=3-2+(S%FPT62?@F976HXXA1K1G#$O.!5("3;6C[)W![4U8[VV5 M.[IM2&F@/4?C,+E(;R>S6>F:L![V[(S0Q"+S!C2W"H30$CP5'&*4T1CBHPJU MQ]5W O;"M*8^&8,4B5QU'9;9L205)%+J(4PL S 3A9!M,$+RE&3U_E/?A5;4 M$'B#=N$/I2LO%N/23_*MGYTEE8-4'@_&Z$M3%Y/ $5;*GH../B;&>/UN.)WA MO3!]:45,@VK4@[#H\C1[Y[X67_OPE*; M@M2*>%N[V&P]DA>F&17$7;&&:)'4OC:$RCSG\67&Y5Y.1^./A^ZS"[CMG3E1 MZN]U )5*+3XC$7P)OV@5*1YU+(3<95K2DP]Z(537%VK%W.)=<-6^N8/]+KQY]<@ MSWQTN#KI@$<:0&1 M]4*4I141]W7%U&Y\^-/1\<'QX='!V]=OWA_]=O#AZ+FO&2%IT!!Q]24?CV7QZN?"*-N^"6!G MBT16\JCUL25ZP?> M:"W%3892R?$@\L4IM1YLB!HBSU*3E')4M3V]-3"VGJMR_9%7HQ^LT-+@H1JE M=V55$3TD%D':3(V11"5=>V;1'0B#34_9DM-[ U.VD.2NVQ#>7\.M%^MGW.1+ MI.[5U[^G6)JD+#;TDD1>W>W/FN@8\/0EHDPL=;C5&E,"O5;YTFI:I%A]WM!& M2'!+6;:S-#,#MI2D.L-#2( M"-F6W*8H'D#0#HS(E!!EF?6U._$.K"]/W*+9*W7IPT8#-3E.\YN$P17*50LO M;:-,64%*1)0[!ADLUQ8R&OZ6":D"KWTX/8QF>.^K$F63)O)ND.:] O,ZS48? MQ^[Z6AEGQ9LLC=R2U"5L1$NS_8PN)_?$>:ZBJ6VMKT?R$DR0"C)ND*:[CVHU MDZ,#KK86QCU,NS$P:O#VI"IL(?1V]L-]?,YDK7B)'N/&A-L4XG/:"HBX$=J8 M",%M[%DKPQ/6PY"ZT$?6#71@!2C%@]D5QAN+Z>K42CX0:XE$?[]$'IUTX!+N MB4FKD),WA//:'1\ZP-J9N; EA_=S?RY-9FZ3L$R"TM&6 MYMRT&$D6*%>9$Y2*8D/$-U9X7H()44W>#6HU;K"M9BM]P'^Y\HL[8&MD3#R& M:W\B%INQ^*!Z5**@R;'R"$81 M>J>$$17Z[%<"^?E )E?:2&)LUX[1K!X=5C M@P!%>^WH(_D&6G$XG\GL\^U905ZT/O+7&*0G,: Z",@^> M,P)63>5C$F1;3N?%G;>I:R=DSH M"%3G,AM$9;#>9%"2.:$)PZ77=U?68WE1:K"YE!\\2G99.+*\9O$^AA_ M4BR7+79>3-(;U/ %)MO)K6'12=11$1T\)&5*8X282MD;@VRM2DEXZG*G"ZS[ M57220A")BPB>4 (B4@F6E[Q4QA?,6!=RJETIMT=%)WTX?:KHI(\D][GHY-I- MP-,6-UK+T!=%PT_P,M*'"@8V:\705Q!,U<[R/H?02R^>^X1>^LA[:)^Z"[8_ M0R^]6>SC7&]"P=!J0HWQG"NTU'-)0">*SISC#%2V/"N=T6.L?87W>85>FFE' M'\GO,/3"A"0J9@;<9 >"A0B.4@HQ^.2TBC;YVL[3\PR]].)SP]!+'S*:=06X M;I/RMOR#ZUPH<;8L$X03K@QT)&"5LA $SXQQ+82NK2>/P'D)IDH'GD MVJJ:H0.X1J;'H\!V8WM4H[&;>FS!08-3YG&01J9 G0N0LU0@;)(E8%CJ+&G4 MAB \4]M?V8&"/&%][$8_^HB^B5XLS[BKJVA7QQMGCNIRK TE,:*M0/W:X$,;UE4).N>&FPKZ0:&Q.+>X>'DXO,T?2JO2;&\5SUN#MWL MTT_GD]]+[4NZKM!.>3(M,<9S-YN-\NCJ'1G'#^Z/,V>\M02%$BQE>,@&#D[: M4AQ#/3>:1DMU9;6INH#]2 IL$UG;'9_[H)QWE[%<7%F)LPN9?9K1O9SMS\)S>:_N;.+]-N[D6O0[#+ MB]%/2J1ADLIZ)0+)"G@N@T)RE.@<)@;&)\F%M;[^C*,!DE0\)VJB8.!H\B"8 MS^!9*8#5?E&#(JELEWK;>9*J#Z=/):GZ2'*?DU0=+ML9:KSAFD'D"<7&<9=F=!^.!KWAV@78GS>C:S';^:KK)K0,JC>< MAYR9+#VQ: 9!/06OE >NC"IE^9K)3L-G]E=?VMR,;J,N?=@8]F8T(;T7WD/=S-:,H"'KB9@9<$M=Y[ MA6X@_D<3H8UESEI;6POV^V;T-B9(!1D/>3.Z"Z[O^69T+]ZZWH;=1.A#WHS6 M25DG5 0;\"40,J#^1QM!$)%]#,X%]3W>C&ZB"WUDO:.;T;BPG(V+P)PN$'D& MZS3BE,Q[J5/.M--,U%XN['.Z&=V+PPUN1O01AL%SX8-")(N6"KX@4WXH8T/D))A"7DG&ULP!# M*\43AL30.M%'X@UT89F:7/9<7C9@OCK ;"*69LX@:XO+E65B6"R]YV*P4BNM M4JA]U?DA+,.;#;7X6IL'WE+8K2H-CB?CL(3V=N3\Z!Q%G%;XB'8!H5A0KDP! M(]:563X>F*:H]I$2YVH7R#V%Z64I12WA-[VVL>96@D3>?/86 HD21!("G. < MHE_78YJ97,^WH(_D=WO3R*KN0I05* MM2R3/RB4P3!E:JV@W%C!<^VK@,_SIE\Z=6'C*:]5*X+XTYN%$,-!$FRYMQ$;]OM* _CVH^ZU3HU8)6D/[R&K,SIK^B_ M,Q*CHY M+W'>J,I0N0R1&$V3X$F+=MV8'L?VXC5E,Q;VLG[YMA>XJ-D>M W/ MPT\?OFZYHR0:UBPG[W@NK9X$+8V^N!)@DR+H9J5L;!(IZ7;]&M^VJED.VGL1 MRRTK46X:Z%QZYS$!3 CELPK!\7;=4W9>L]R'TZ=JEOM(19@-N3S]-IBL/63!O2&8<%(^NM+I%_X>AAYRSELD3'JRH M?>OWUN.'=QVV86)21XP5W/'WR+2OSNAL:[SWS.Q^Q6\JM8-1NN,)P=G)]?X1FA0W+5>[X#I@X' M[2R%OWZ!!)NBR?ZQFMC]I?N!0[<]VWTDVH3E7U^?)95R,J6=-S>((5O31FTYL^?.9+H*^OZ%J\?6]^?7\6HY6:6 G9F% Z09ER MRTH#)3%S;Y+3[+$"P=[TX3-? GU]1=?",CHZ?G]FK374HFV=31D?BNX8>!G0 M(W,I26>\R:+JVX?/? GT]15=T_E6:TH&M")4<<>!4.:*ZU4JCX($CB:[\"HP MKMKU8M_?,JQMXH;5Y#WTK+,NV/XLP^K-8I]"FTTH&+H,*Z;(F4#?@!G#0%#M MP(E,03.2@M?<9=YNRW@.95C-M*./Y!MHQ4^3:1I]'+_Y(WQRXX]WZWVJ^8D%2)ZJU0'P6T9R57O;B;M!+\D$.K5/8R*V&!2<*+ MV5/JR[0%KS,GR2A#1+ML]#X.K:J3H-Y"R@^R7[$LYN#H_6\';W]]<^RFTP7> M+8I<'ORLK4M6NJ&L5(!R7=BTO+ES,([?7-5PL\MIBB?C]ZEX#:/Q1_R#X\EX MNOKVE9N-9C=:Y(UQB4?TX)V3( *CX#Q^*[1)/E"'XJM=Y%IU 5N?0A7 +(U\ M(PCARE*0N605%1[6CDFT]%FB2O%89+N'DARTT&9WNGOO$-P)[_M2W/-V,OXX M3].+U\DOK(IE!RM"#0]E>D9V>/)+(L"85 ZFD!2X"34#MMV0_9]FX\-V&O0 M4O(:VI5<%BUV[^-=72;O +:1G=D+Z&[,SQ:,/Z14S>AJN8]U BT\-5[@2Y:# M*G.D MIJQ$2(1!(MN$A&U^YZO0>Z]815NW>JU8>EEBIU-/Y\.9\M)$"O3NW M%/-%")DR@ZEQ&70:JH#;7U&Y8] F=XTZ@AD0^IS)8L-+"3BWWXX(?OUY&=7RX;U6\5>9L>(T"D:-,6Y#J7I/DM@O)*096:"9RYHVL>-^7[%A'NSP?X9 M:C*^E9^Z"5T[US%GI=2\^&0Y6_3)T)>WI=MK+I5_RJ)_QFN[*7N@6W5"(,.I M5A^6!@Z!<*%T9JETZPJ\M-1B8%A@I3]PD,:@6U^]DOL9AT!Z$=DC!-*'A08A MD'70V!4TQ;1T442@T>EESS7G!(60+ HB1\:K=^]^!,[WIB";L##0#L)7[><] M3590"8&4JO:8(IB@T&]!5X7EJ%P.M?NH/0+G>U.035AHF1Q\]?66&'Z:IG]= M7C<4B#I2)DQ$/DM# 8'^@?/2@18Q9^5%4NUVDH=A_>EWU>1MH+SS-<#5S9H. M$ =TM>[ V[F#58?:#B9P#5X&\JGN0;66)6LC9.TB>@.X,?N(R)W-FIE$&&6U M"^)VICK=_:?=:4X/.H;RPJ_WXJLS5SL>O$L!'*6F]-IW8$K7?70?.4O<)NV; MQ1(?P;4?)M!6A';QMK=AHX$/=76,^]GB7N89\=+8H"5$7"^(; RX$#F^'Z'< MRE.2A-JUEM\B>.Z)XVTR(5MPT4 S?IF,T]=?W/2?:?[3Y3C.#N:';CK]BDM> M)K2=C$;B*YVQ,$J\XDQ[0?U_4_IIR9X2!4Z4JG'DJ MN.M$WNU/?<:,;2R?(E3&H CU*6;@ M+ @0/$3PCF1@#!6*ND"MJ7VQNA? 9ZD4[:FXKS=;#ZL[&G])L_FWL;S7HUFI M:$ SYBQR$V) $U.Q5*P3S\"'C$KN*,DHGR1C[:E!CR-ZUII14=CW54'6ZVZR M7/*9-,RCIU&&%NF2K1$!/0V:04>FHDF:H%]'2$Q.EJ%UYM2WF9ZU)@Q*V)NZS_3VCFV#H MM4"R0*O'E5O#M@Q(=043M44@-&9/LTFV]CZS!L;W'"K>EI6FG5=O@3M30;$H M+0.IR^S+2#DXI3QPJJQ/7C%BVTT@O05D!PT)YY3CI&)ZFV^'D7T_-6@HL0;5+VL&7_;_\ACQD:9 M:;EMJ7!C9)Z"95P#KD"@LAM#JS>'JX'[^>O6X.P]&#EO>M%UF64KV9@;QZ[J M;=?''M#@RFOG]=2^]WHK /IF/%\\]\,G-S]TY^'R'/7F.,T7EM+BC]^EZ>DG M7,N- :115P7G$@*S:%QCL WTBH7)&\!8UD]:2@.Q M,D*VLI3.>@O6&0>:)*LB(;@)-"Q@WA3VX/=;!]311PJ?!V%Y7^ZTWBSWNC\A M9U(Q*P3@28!B5-J"TZ7BV*.Q0JC3V;5+/.U-M]>A].#!/-5&?#1P&[Y%=(A+ M_SB9COYG84"L[A9U0-BH-OII=+LIC=Z6QT?5HAH)NU$7QG+"?5JCXVL70RI* MEQ\=P"JJ?9"&1UH[V;$K-7FB#'IX+>DC^R:=8K^IM5I=/2M=F 2N5$D60!@2 MP7CB(=IH$6((EM5V(M<"&=XKK,W8O:ZQVXJ[0;'J-]5;-U[0%3@3DZ<$3\N8 MDD9P,8.3.4,JB5K/I"6D=GW4HX!>H$[4$G^#_>'7TP_316S^ZZO1^?D]="(Q M1H-R((5.($@N5QL)1_75Q@FGC$RU9]D_CNC%:4=% AJ$+-?5]Y76;?=P(IFEX.T,@R:'=15&J],,.DSI)'2\.=L=UK*ZR??- .,Z$["*_4 MEWV+VS-K )X1R2A-&5\&(4K!H$W@N)' )1KG,DJ:>.VKY.MP?%_J4HV1!TV3 MILF*5^[2\,V2&9O#KI;(N(%PDCN"6 8V2792 MTL#!4H=O(+<6Y8:;-;J1/'DB<@[-A@)N"GKP),9 >OE@ F,0=O=&+Q_YA MZ4U(V(VZ!,\\=8H#54Z5H4X4/!,$T%^12@7/A38O1$WZ)R\::TD?V0^6O A$ M2T6B!UTFG CA4KDZ2(%PYCDW"%!^O\F+7HQU2E[T$??@R0NN!#&!!U"+S#]5 M"ASCO#1^8(IQR7CUR]W/+WFQG4[4$G^3Y$7'0*B-0J7 #7@C$FZ3,I9 JP#) M'7>12J)$[3L9SSHZO8W&-"&E26KCT<0+FM^4T*C!VG(!106%9KEE8'VVG(D< M4JY]0_@99KZV4Y1J!#1H,G([Y/:V_'41]7+*FM/<$0$4'380>"J"39[B\1A8 M\$81F7UEQ7@(R_?I]%9AIL&&L@[7]2C&IY$UQU48@O1-S!5 M'D'H<*-+3%$((@80H>1MO"/@12(J,"J8J-UR,*Q'5HG^DB\A5OK9I]P MHRS_K[10^.+.2\KOZMASO%0RHQE$2XL,83*:U+PTQLF2FECZ0E=O3/$8GN&M MCEJ\W75D:@F]@8_[;IH^NU%\\T?IGI+*U>F3^:;>-;451_WW1W=BU&61H0TV$O6)NZ9YLSPL]3HDIH+VLKR9Z54NPH)[@U&P]N+O7**'X^.7G]CZ.W;P^.7Q\= M?S@X_OGHU=LW!Z>G;SZ@XSZ)OZ,O]GYR?IXGT]_=-&Y>0;'9<[8MGJBPNDIU M$ZO'W6@62=1SERW(Y% 1E#1@-3K+@I,22M4Q5Y]3> _$MOO-JB;E)*\^>NG0 M*5F:@B8!/C)<420&3U#"4-V9]E322&CMZJT'H Q5?[ =OW=WCAIRW9<:@>MK M\:\N9RBQT^;FSA4VO,GKZ*FO($0U[$4T&8TL^P6O%3 H"-\O:FO(8H%T% M4:HP?E>+JDF^@:ERA>7*/.L"IE%(Y!L@NXF"5"3JK@IL+>7FU%M/= RT%+L' M!4*B<64R&L_1Q1;"'=20S(5HPT%R-$X7L[FT]$- M%D%DS(: (D("NL9E="IS8%.,B4HNA,L=6+K[N<^5J*WDTV#CO.VS_+3T6 YID"<)SRTX;H&][:2;1 &7$%"I3F:S,^%EU*YT+ IIRZ)E+O'J\Z.^W0$&B3<>C>=N M_+'TR%N&U)L$&Q]Z2,-(8Z=UU;J>59"GMZ,O*=Y][,U!:=%*\=+A.\-#*!.* M,WBO;+G^*9GDF9E0N[%U%USU@I&//&T95>&,1A;PQ8Y!4'RA(IJ&5!A0N)5( MFF3BKG9*I#NZP:Y,U=:5AZ.850G9E\#F(XMZ]?47]W\FT\-S-UMZ]#Y$(31C M0(5WI34YA=+0 R255EOBD[GK_K9\Y>["VWW0LZZ"W+V;UXBH!F;B(U!O@!Z[ MBW3EV7:!VVHL=C^H.QJ1W8KZ[BI6C;<]4#G!)HHMMT,^VRBBPD1#. M'(V*U^[KLA=J]M0X[3W5LCYT-1ES\"6=3SZG^"&%3^/)^>3CU_>CCY^NBV6$ MQ7U/ II!S4J+2F]U[.\'A\- EZX_G1^ MGL+\TIV_FR+.Z?SKZF*!"YQ2K2%[(]'?)QHE+P8.'U""ID6,WG2Z& M#37)B=S[](;)D,=7,F06A-I,I&860J*E*(09M()X )^L$DP*C]O&R\Z"D*BD M#-:!DYRC_L<(GAH-U#"I@B-"5Q\X^$RS('UT98LL2!]"]B4+LBI@/ C_NAPM MAYTMXERE:IE:XX%P:]!9# Q\)@PX;N;)@V? TJ.ZC']CSL1&$\B5&6XA=!E4:@T8,/ MA@)A&DTYHZR.M0NC=J0H3]V0WXF>]!%_]5KRWT:S5Z4_S#R@J;GJ-Y49,RP9 M\&40@A"RW.DE'**)5HOL.+5=@GQK/WP'EY?K$C"I*;UA8R_W5$]PEY3QD0&+(N..:SC@IFV EHD,V3NAQ8!)AV=9/3&DEO6A:\?ISJBY M-H9:,"1+$#E1,(8D*$DXJ7![YYYVL(1>7+JS%X5;I#O[R+^!+?5D84=(S-HH M(+C@05A$YM$? !N5M8P*9U3MD<+/OM!F$]5IP4>#<^MVENPDWY7&&5&*J,0T M,",<&HLD@[,Y@TF*1VJH(+EVLH$A2M2T& _6;FBAY,+/QHO0+Y/ M8?)Q7$:&'<4TGH_RR-U*P"[/#?[U"=NFX_MA;A2#K9\_M%X-I]>EBS3C=JQQ&DBQ(.CLDRAY*AV M/&:@-H@D-)$QUIXA^P"4[:VNVQ^[#+08JG2Y,PI*%?\DV0A>< 4F*I.$4)SE MVB'J-3"&RIW6X/B^[;2=5/.*VG#VJ EL* M?$B%2%8;ZM#J"BDG$$Q(W"E5!NV3%B)IHJKW;!E6$9Z(^ VE!WWDW(#_A26[ M=M@))88S:3C@#D= J%ANVO RW")R$8SRT=8>)_(@F.'=DSI\35H(NW*#K=,T M'DVF"T0I'D_FUYB<"D%3)8!E56X!HJUDM'?HX#O'!%54W)V2N39@^]#G/W-. MJXFNP4O]=C+^.$_3B[+@Z\%[01IIO$C (T>#5R8T?5E(X$VB,M!LB:T]]'0= MCI=BVVTMXP:YY;N8KM2["ZI&MMUZ1+NQ[+9G[ D5V$+< VP"5^@H=Y0;ZD$+ M@T:,,P2<"1JR9L9SZH6BM;W_(97@":MN*!WH(^4F8TC'7])T7@*6!=BJ,Z11 M49<;),1ZW.Y,\."5, @O"D>B#]+6[BBT%LCP)W\-ENZ-F=Q6Q V2(E>FR"U MS&7&'1YL(1>?15L!GI>LGE549B:]E;5/_7L@7@3?VXFVT?[^X6J-JS$O?K8H M!3CC/%EEG0":"1JTG&KP4E/$EYG7D695O1?!(W!V;>G7"?K6DG>#UWX-M#,; M8D:O40+)I5&&)JB=QEI(G@3MB"5_"DU/T]]+QDTF*)Z=4;%1\,FAI!$T-D'6[LK[U.87L9>4%7RE>OR;I]] M;_X(YY=Q-/YXI;$WN)>]#9S)B@OK(-$RK9#Y#-:'4M)A68PTX#EYIVA];8BG MQR.'Y[\N5Y/V@FX>Y2_MXS2H:@"5"#6: M_^O8+6L-T;\:S<+DIYSPW(X_C<:WX9T9 M0Q2-7((10I2A[QY\QA>4*:\24T*16#L'^@"47:O+0-3>4Z_M>6EN3O46S5GT MQ)# &'J?JLQ^H27@G VD0#5NO8KQZB.1MX3\O:K?<#PW-MK.GH.,!A#H. MPF;$8H0$)JU04:&-? MLA$$C;.RD*P3NI;X%0^JN):XO[+:G3#VO="H%[=="HWZR'BXVI(NJ+[70J-> MC'4K,ME$W,,I@Z!>.>$BN%S: 7&7P41'@"9):>;:>%Z[N=Z^%QHUT($^4AZL MT,B%P"@/97AMF4F82P=WDS-H0YGTE-!0O=1TOPN->K'4J="HCXB;='.X=SM" MKUT_I("3' !G"YQ9A6S"+7?]_V^.;;-H;^E?)N$2!\HGN^"ZWN] M.=:+LZXWAC81^) WQX2.C 06@"F"CE&6'"QC$KC.$CV%69^$0A\X:U%BK;C968X;8%9:*ZH837?#'NM;/*W]]%U' M$#>5_*2JV"J>Y;/I_.R]&W]<%<$3IK+T0&ET()+FX&3PH%S,3'C%">_4?PD_ M]=8;B]_=O*W?//"YG]2;2Z]B.OT:Q&KZ50<8?<[B+F36?SN?/G*W$/Y=^K:0 M7,5-]2Z<&+UQ049@,B^R5@0<6OKX58I4)FH[&M.[)O"!H[(^?WT$5IFW7]P? MHXO+B]4-$(UX?4)7#_=T$%8X,,HS"%QZ035GJ5L#\">8^^:APQV-6XE]4D-F MS9W9GUQ(!Q7SL%KCEE\4<>E^:$-(S);-)VF:T;\I(-V$)&&8B>%*N)^&IF6/MZ'AG<"]# M3=IPT;P,>BW0=]-12/2,4XN"0,7VS**+F@(#A]^#H21KPR3+OGXE:D=PWXW2 M;,#%?:41S93F^+)([22_^=?E:/[UYD]F9RE[;Y31H DMC4[0LC*6(G:A@_*I-+$-!$#_K(>9B" )&I#1R=:E0^"B)(/!D=BQ"S)#P2 M%37OTE]B[PL">DG^Z8* /F)KU$[H7NUJEH*B:Y+ >%V:'ZL +GD!3N1@B4Y> MZ=HO\;Y7]6]SGF\MX^':AW9!];U6]?=BK%M%]R;B'O**AQ;6&@Z4988'EV3@ M4.DA&"4E]XZZV'H;V+>J_@8ZT$?*@U7UAQ0",5K@(5[G M6 FXR9&^N?0:5@)V@?'R*@%["?^!2K)-)->P$A"5SCCO%022$HA8)D-$7QHU M<4&HU9F23E&T71/8J1*P!G]]!-:V$M %GDDI"P^I= %)C<>#2*9T$4'?/V?';3)!$-LV MN/TL\O'U,B.UN!A2:1[.^'H6\*U ,\,9ZT 8Z<%DGH$Z$JT1F1LZ6 G0,\C' M-U&C.NRT\+[*E.^3_(^2MA[/3Z:+L=QO_D##=C1+"Y6__N7LZKB8R0G;" M@/.Q-(]4'(].;8#31!DCVJ;JU^TW OHRM*H]1Q7C>XM(\SK 5X6T1^,P36Z& MD$_GT]$_K_#C>W+JSI??G"D=L\F4@U>6@F Z(')E0'(1 R-&*GI'N]8'\K=" M\;Q59V 6!NTX=G\06M6"H0X?7W'\=,^UM&XE)EQ,6C(PB3%TB4Q"]K,';AGG MT4>TB=M.:W[;=!8U0TN-<@LL*HNKP_]X3B5D8LK(]RQ)]0D%>UA U(?C3K.H M>TAUCPN($FYVSE/O#Y=0-1'OD/6 MBW3!];T6$/7BK/,,X@T$/J1">)>RLKDT6$@>';(DT373&CAAP44A-$EM[]SM M7P%1$SWH(^?*!40/CM(E20O*581(&2X448 +N.>)0,J4)5D*Y#MX'L]@"G$O MZ7>90MQ'=$.5$3F6T$G!(Y!;CTA\N:4GDRT7'A13!J'1%H-!]KF,:)M3?6L9 M#U=&U 75]UI&U(NQ;B4DFXA[N#(BFB+//C,HXZ]* "6 IR64HK6ECEFA1.WK MC/M>1M1 !_I(N0'W]T>F.FL2=Z5Q%BL#&%4)8!FF07/I W,DU+\2LL?3:/NP M\^0TVCZB';*'2M!)&44\GFX9<]E"I%O#94-*[ M[:$2J-$BY0R4EML/UE(PW@8@#%6>,[1ZPO_E:16.;O8:Q2J-%;E MP(&X,A3)E<[5CFA@(B1/N#3D[LO__&;.UF:\E7P'31(>S&9I_LK-4GP[<>.J M"<(G/KI>\#)@9E5H$J MGB%[D_%-B8L!;@H(?A]42$G0MOUN]B(QV(?C+HG!/E+=E\3@(?HYHV+GCLY' M\Z\+5UFH13Q3R'$7KS>+67:3KXM M"N"^0;3JN=T!4Z/PX3H\NPD>;LO5H]1O(>BAE*#,.L^&*3!.HXO+$):308"B M:-Q&2I0DU:^@#4;^$T'#(;CO(]\&G+]/7R;G7XII^PVXU0T#F5,RTD'(!E?K MM %7&F9E8IB5""^3VI50CP(:WJW8GK-)*X$W#R@M%-Y*S8)2!FR( 43.Z.+F M;"#H)$,BY9AK.^[])1W\6\JW>0_56ZGQ+KB^UXJ@7IQUK0391.!#5@1)PY5P MZ [)7&I@O"=EDAX%SCC/*I>Q'6VO7^U?15 3/>@CY\JQX6]#+8^?5$0;KJV- MY>1#/SDS!M:R#)0G1JD(Y7<=8HH]'KGKF.*F'$W:"WBH4B(KF4,C1X!CY9J6 M++V;)6?@!;?>HTU$]??D(6G 3=H>"3DH:42YNUD\G[7DK40 ?Z2'F04B+K%SI.E1'U$VZP+D0O2ENF'H)Q $+G, M>#%$@ \N&!T-M>[%SB/P M"Y%U/"=K'"ABBOWO];+''?/"2V^I2O[ES".LP5\?@=7N0H22NNFHDPC+EF@& M7.K2S,)RL-$8T-K9()1W3'=J-?)4%Z+;#]U=%Z)>8I_4D%D+;WGIXJ>;SU>4,29_-#L*_+D>S%>PK70J,\LC0'E7:%_=<9; Y2F#& M*AJYMDG4KH-X#,_6H9WP*<7+T&AEJ3L2V7IFJ4M_#_OE42++0)-UN-F M'0EXSSDH[T.PAJC :UM%#T#955"J+?V3^C0T,(;6P2I?3M-UPX8. !NEH9X$ MMYN,5!4J.ZC']CSL1&&!0=4!Y,-"PRMQ)>A*$]DK7:C M)WW$7[F8Y9?TVVCVJO1WG >T,5=Q)H]T,:-QN5* 8-&#*14\7(?@;=#6"/F$ M'?S@AP_O^U0F8%)3>I735#?GX[)[\"]I_FD2C\9?TFSAU=__:4JE8F@!%:LDBVX'\*UR@-W0%8Q MW_8XFN%3<,.Q.FE*2>6$T%,(@R4B)0N1*U_BU1H,8PRI)BSBUJHM[V25[*&R M/)+NVTM=Z<'$( :*R%D%72Z/1QX!H7GP61I(CFO.HTJ<=+FKOV,#I;;DG[1, M^HBM009HO4*?_#Y.T]FGT>=;^09-)#4QEF5[7H:V($#=Q3)-DN16A]GV: MSN#VPH"M$TUK0T@#S7GGOBY&8'R87%GN*Y&LFDL8E7%[4PZE)5?$WC' <3B[\:.S*PD_GZ?,M.:R&J2S;#1U=.X#O MTP7ND9?310#WYT51,5UC]H!E_<=J_)02O%@77?;XHZ58SW)BPN&LZO3(KIQ?#MROI2OC-(,?X>K MBG4+0#9Z=(LBD>UE,$0AB7&"T^AP]Q0)G0W&\*"6Q 'QCF5%94ZFE0FV%X4D M&E<<)DI&L-11D-JBUZ]E9M5[C#W+0I(^>K)U(4D?4O:]D 1-X1A\ MH&@.4X>[M4W@N9*@++'HP!'E0^TQG\^]D*07_1T+2?K0L).Z@"X _RPDZ4UE M[P*!37C8B<(D'[-+28,0W)7&7QR);3%/V' S^;3UV8GTGJE"W&%MS.<>J5K#Y5 M80.8>Z$Z=>S8UB3M(ID3C(R42 HJJU) I2D8EBTDH42V,=JL:Y]V+;S--K2#6?-# M:U,SMH;)SFR::'J++\IQFE^+T-)(&-%HWTF/[XP7$FP0%$)2S$7&E!:UKP2U M6\W+/C5W07EE&WSS5;V;CB;3JYU_^9=GE ?G+&[R1*(!*X3TX-$@!8;O9&(R MQI1,!].])J:]V#9WHB>3/2!YK^HV?G*CZ6_N_#+1,RT4=TY[4(9FW >D U?J MDX),S%+F>0BUH^4U<'_WRKPS)=AO$^+,*^)C, F7PFTI)8A@A77 4LS9.I&] M;749ZUD7(+T8M=Y.)8:I+GG(F#\:7PT!>VAQ?T_G\>H@NO5Q]$S1E+W2&:)( M*.I$&!@E#'J7T5BK9&!B *VOO:R7;3+O5 F&V<5OJF..(KZ-HSPJV97EKEW7H9I_P%^7M_N+.2]#P3(6@E% &-%^DQQ5!1T(H\#Z(R#GW M1@T0<*NXHKVP8W:G@'5>CA;:,XP;NOGJEL-/EW^)GY)PD?@O9V>$>R88UZ!C MN4%#2H4DQX66:<8A)^L2JST;<(AU_?F>[+4F[8^5M':-:!JZ\A6_MN MDBTWB]N_"*'<3)F]M"PZYG+V8H P:;L% M_ODB/0_=JMC5_X%T2-V%3B_3-W\ZCHN-Y/[?GFE&N*560A:AW*X/N)W88"!: M(Y4Q.;EXY]I"UXS9CE;TYROUS+7L_KLF]^G0.IZ,P[T%+M9]EJ7PFI4>)KZ4 MA 2*'J$3%K3W7"=FI/8#A(,;K.S/=VK/M>G^.Z/VZIU)\S.M!!=12T"'#QW M+!,>MTQ B$()(YDSIO: P;:KV MQVI^]/0I;]GZ]^I,>4D)Q[V?E48,@J!LG-(7K->HX/CD^/#G^\/[D[=NCXY^/CC^\>?_F]$.-02Q=/WG;-AL;K:!2 M%XU?1N/)]%:%S8U&.A^(U]J (T4C3::HD1I/U9 ":BO-J)B5=X 'P6R[>=[] MX.6%_.1P*\>W"S6W!.]-D% :S4'4/-O$$F[OM6W"M4"&ZH11A^N[N\_VLMWW M7A=XU#OC501B(RO2*:W[DP(I#>-<2]PQ6N4]]J37106..S:TZ"/KG?0GZ +P MSX86O:GLW:A@$QYV,TK'6JO+M1AC2ZU%$!J_XAZR)S$&*BWCX64HRH8-+=KJ M21_QMVAH\4N*H^#.3R?GEP7=[.#GJQ\O9V$+EE3. :3RMHSC9> Y_H<73Y-$ MY@WI/";ET2?MA;NS#35W6UW4DVOE 2K7O:^7 [<-CQH].4A$XAD9?0##J 5 M'0F4>JI4I^*C)R80?//0YV\E;"?'RH-)KH&L1OUT@%)Q$LF=QP\_>F0+(M;1 MN844*P\/N0O)6/1Y%(D@C=0@&/5@K4A 0E2.HKYJULD?W ="'QD/TH;//L*K M?,[^OQ,4Q&_H %Y.T]'XU%W&T<'4^9&[.@PL<9&;9,%K&4%(9Q&:":!HTESH MH&.G%E)//&;8H1];B7_21G85#]*.QSS7*NE$+9!L_O_VKJRYK5PYO^>_(!?[ M\I(JV:.9ZXIMN23?>RM/+"R-&58HTN'B6/GU:1Q2$K50(D7@D)(]4S7E17/0 MRP>@N]&+1Z[1B+3&&>*XIRPQ%:B@K\Q\JJG;.55O<%)HNI2-M0]FN<7 6M;C\B["4J MZ7>%&>2)60:5M+Y*C'R>TD^6?[D^XBM@9]).]?E8_,+7MW M]<67C-!!"L9D$)1(*+WL HO$FY(.HJR(5$6A0NV,B!W(ZS^^U\]K8BV-' H\ M=W,HEC\RL%P$K6PJPZ/0GK<:42^C1A?<9B6" TMK%_*^F-B?"EA[:ZN?%Z9; MDL_R/R?SM>20;166VH2 >%15BPC_11WB 5A!6?,1->J6'PW2M\*P'K0 M4\7 =KF2U\D[2:DCV8_.%O/9W(]+\YV+O_"@G5UG1:8!5\ 8PXO:6X\^I#% M+%))M(G40@Y>&[>%D;/KNJ\=(SIE[-/^M1R'E9)*@B>EM9BOO2\=;P$VONFA46+O^ CP>+_SH'$J9%9); MAL.A![H< (>N@)#:)<(=T/)F"TBDU0C[%+1/B>?[70NW1.DB:R;U#FN/TT<0+Q[&[2T MT4:#E=HN1^+B7D*F+R?C[DC> MHV2E3_+VKGLYF"PK%<^B!4.0&^J(RR )SY$KQ[RIWZNB%NWU1MON2='R MF=LJ;J+!X\)RIXF,1I(0R@PU!M(JS1SUM:>'U>6@KV*@@V!W\PC=WI5_+$5' M>S+^[NKQ#W2/KQSE80U/)&@TQJ1REMA09@ER"E)9SFRN77K0D)W##_KM'Z23 MXP1+@V>.QRE;>WC>AKY&A5?/T7:8NJNC <-6(-U3DX= 7-!6<\DD\3R8,CR5 MDR"](%$HI:U@21KQ)I#V3.'6JP7:+@IL +!S=&^GPXB^R<5\$O_[.N/60:32 M4H*%%@&,)T&%$C_GN@QL%R13%FE*/D*H';5XDJ!C04+/X8AZ2FIPE]S$ M-\N(N8'5,0D=* &6$9A"(,:(C,,9%U[?>O.P3TCY"*RKG_,/%BR;:X M$F#XYU]HQ9S@O>7_A,^+(I6S_."IMF,?T[2/$O*6 M8+&_I!L,!KE/U.J-[(9AH3QRK- &LK2, RVM-Y3T)'NTA$S6'.JG3SQ-TB^3 M8V]%-;B-[ER-)]_]<%1BV-W,S?+ 6CSMOR8C7&NV(GS AU*Z] MV9'$GQ2*+179GQ4W<)(QSJ(DC*I,I#22>%! 6&;,.2>=W*ZIV/[6VT^*HQJ* M:3"$8$_9K!K=FQP (&5T52U#P3!-0F2,\$AS0@ZR=K5]@RJ$_Z18[%_I&XM" MZJ79GG[Z\O'LOTY/+[Z>O?_/+Q]//E]TQ(9B(*P7LYS^*+_<(V'VA0OMF_I: M@[]*2:RG**7)%2!VIM^'$6X-L74Z3D;=ASH$W8ZK)0+Z6U#F'+O+$4D_+HG9&@ 7"'2DU\ M% XOF,04&&$]Z,IR;<)(7PFNA\3UYCS70R'B6-)=EY&*"[R-NN]^7/'9Y0(9 MR2$[RPDLZU4C(TY&O ]5$"[@%:2JYUL]0<[ATTT/AI6'#GP5G;4))3U&VBI[ M8!OB&J6,/DG88?)%JZEQ.WCLH8/>@6*5L]DD0;A7H8QQY\2J8$B&&,H81/"^ M=L#F !Y)LWS,/C81?0-<%&.R+-\X4"+2M:;SHI1RZLQH,Q@4%B!1Z6KF1]9(=_H81F5-9.Q=F) MP+<$GG:::?!ZM++05^\+#PSX%;$#JKUB#(]!HWTH8$?CW"1-3$P)_\CRF*J' M7;>B[ "OY4?DNC?0WL8[K6G\M.0!G'WK)!=QDPSG5U6CIIL_WR!6NB4OE2*D M&_!W^T#][NKA\_7_^FFZ12!W,3&#R&!*XQ%DE";!64MX1.LY:A.DJ&U/[$]U MO3CHL[3,-A&SBEY ]%Q(2A3*"T]P98DS:$ *%"<53F4KV\4^]R2^KWAGSRC= M'.+L4]F'#FN6AMGGA:_.2U92ZIB%($+&2*3CF83L/:%,<>V" >=J](>_6?#P M(=3W95^:5IP5T1%PW,M^"C(KS)-:6[G]XQ N%?U]]>TBNH2)I1/_#,T=4 M,IE(E1PB,BF2J/=:N1 %V^JJ.;0"GQCH4%=_NPBLLMX^H:0N%Y?7M9P:CPM' M*9'>R-+I%-T\KS*A-F5AA-(>M@KB/J.Y.XOV.YKAQ6*?U)!9Y3F9G_R/-4), M\BX[ABM+!273SI?Q1)QH):UVR*Q@-:[..XN^0N6]6&8MPF,O-3B7GMMZHN7Y M9#3Z?3(M?SF0UD7MC2*QU.U+E6DWC(QPR[C,VEBCV+&X2D]RTG_"YH")7RWSC@;;6!\TH;E01EM5F5@E-HL)_0Z"0:>T.(-69>$7@KHBN=H!_ M 32.\$C_HS1LUI M S9^X?T(X-'@<69?EE"L&89E>N[L9)Q.?WP;3KLOW' YX$$Y1I&CDE]-)..6 M.$'1T9*!H_1YRNEH0K_;,O5K-QP==!J4']6_WI(.%FU*3[1+C$B7$O%69&+0 MM!2,)AY]]3A^6\NG?ZF>_H!I',Y*^'0E5<8 S0,#!$QQXGG7VB@+XCTU+BD/ MF1_;#?N B5=THAR'L[0?#"K/1%T1 U^FPPA=H&/]D(V6!@]<$9MHN>*9*$WX M%!')9NZU#A'NE2L^.MCGR45^&OS4%7?EB7*/%S$]E$EX_K#M>!L$'SQ/WB$' MLDM;Q\N/)E?>)U2R226$^A;0J4U7?VBKK.[)D>BJ\OGS+"^S\#0S2\]DN#*\ MEOPD)EDV: S:$A:7DGMBF16$>I:TC]V$V1K8>P%M/P7^6NNL[[/O&7;6W %_ MQQVXRR&U+$M #IEQ*&ZE([$4+WV1(!FIF8I\FQF<_5#[4^"T?[U6GO=9_29( MV0D\^@5)*5LBO8QHUSA/3 (&T0EA[[>X/L"MW>_N7C/7ES("K;@,AI=&QR-^K=V2RY]F4[P2(#5HG=,3QX.@//D+I83;53A [Q!ORQI3@1U\)GV0U>I]M M!D7 L)(!Y1FJPW)B9<1_ #2M7Q?0'WN_=M2^.^I 4'N-[]1/,B_+S-^L+?%) MH4,GHD;G5&J2J42?#D3FL793WX,R_&OG-;[+^H/CZW6S!H$ZZVR(R)<71#H\ M] W]20VPP!FGY2'5%J Y6J*',A$/W)=V!)GY MZC7]_;#VBDZXXW!I6T!F8R/-P^V,DY0Z'/C1;\-9J:#LCNCK-O6NC+1@Y:*@ M98A6YF6HB3/$S7>2^XM\7/H2@7__S] M9-RQNO"CKS"]Y -@$GA6F7!&/9',.A(\^-)JQ/AHJ(JY2?RS7S9?T3ZI#]3' MMM 1HZQ52&-9IG@V++!S9QGH! MF[\VUNM!V1%&==;.D@_(V7 \&\9_^M$"!I2S1!V71#.MB8P"%6%<(H)+IPWG M0,T1O\O=9>;7)CDVQ+0*JM39_7<98P/*0LH4,AK,I?=Q%I+@GK=W:[^ MBM!6T4'>7? /(6!JM_2[./WCT^GGKQ\^_WYV_NGDZX>SS_?Z:WX8Y\GTE"$:W"5! M!V8Z+#71$6'[J5WP^?UMG^WF*'@9K,51[.N9158 ME@*EBIC,2T]H%!Y*M*1-)YD2U4'EZH]B3Q%T!#WXVJ#A/OJJ::5)I^Z.EE5G MZ6V(:33VXPXAAQGS45%1#[IN[ROEYJKWX"FUV9 D,B>2:4F\"8YPF7RI\]?* M5W?UVJO\F<$=?6E\%^%6+O#[!&D8_6A%SW7GR""C5LB4H+NI)13E5;*!5Z/DP3@MT](?W28H"$N46"&B*_ 7D M-,2DB'?,VD098Y9MH;H-GW^MVJLAK09'[#E\A_$"EJ-$EP'T?PWG?[U'6M%+ MFRY'C:+A<3*;X>$#Z:O_,7#2T)A<(-9 24+FA62T;*S+/@LGN RU)RJ]@,R# M :6=E]!:60TZ['6-H+Y,)WDX'WCJ11).$V$\0ET!Q;.*XM;AC,H 4=(0*^-F M;?DWB(>7"K?!.7*&[HTO3%[/9QG8A"<:U1Y/1B:(E%XABV5\-K?6*@T!C[;* MVGY Q!O4^7Z";O#.^7DRGES3M(SM7<]-L4D;1]$;Y5+IJB-Q+Q!)-01?(/GOB4Q'_%LNKZIAN,%$KF"[F0\>P=:)"[$H-"B8^6[YDPA5DYYGA PT@39:@AD@,GP1A!6,K<:*[P M2JL=(FK(SAM$Y;$HO\'#W0W)JWWV#L90KEZ%!RS5DJ$7'O#JM5X2!R@NSKA2 MTAF3[C.N(V$G #[5M]TKW>*"=3DX Z?)OIR6W839$G)Z.%YW$"A+[Y;748&%2FD<7_'GSO))FG1)7I_NH*S2SGAT MB7W'Q,8X611+^,^+DJ#IIVGVCV_)SP%7Q].F"1_;K=G[SG]*@P_FL^XBM@9! MK1)'G=\6E%76S]V/[V^/HH,UO_HR\N-Y*;O^G\6PF[J-O_X=':MQA(_@9W!> MDN?/\C]FT*U_DO$^1#$O+A>C,@CW-_@VA3A40" M&\'Q0K^DXV8&\=__G'S_&\2T-.H_C-/P^S M_&AV-AY=[>B'K']NJ8V8;I5P M_]L[^2 O('=/GP,7&9R,1FM+/&NG/\W_Q@_ND83SG\/RA1%<_7TRABN\J*[S M2KP(4D0&Q&CFB0R.$J]2)LQ*%I.C&7WH+;)P-GV_O]WSG!K6DVRJ2&/C#;]A MHZW^N/RG%"/]Q[_]/U!+ P04 " F@4986\&, ;E0 0"_SNQ[D>WG]TS;6\7_OS^7J_KQB_&*/ D1L:6AH $WB<9SH/ (P!0 U@ MWK-G]P\\6,"_O?OW[F5AVN3088[#!P\>.7Z$ MXQ@G%Q<7.X2;YS@GSU%.+L[=AS Q@_>P[#VP=^\!SD,'#W'^EP_&5X!C_Q[Y M Z^9FSB8F#F8&'4 % "8]C+]/H!_.9CV@'/)F;F M/2S,N[,&?_4%?P=8./8>/2VELN^8_CW6,RZO&;4,C8Q/3.V;6#VP>VCZR MLW=[ZO[,P]/+.^!%X,N@X%DIJ5G9&9]^E)06%1<4EI6 M7DNHJV]H_-;TO;.KN^=G[Z^^_K'QB7MG5RXF@)GI M7X]_*A<'*-<>%A9F%M9=N9CV>.Q>P,&R][34OJ,J^JSW7(Z=N?1\/Z=JY,?\ MF@."T@9$KONN'6S'A63&SI)V1?LMV5\3S/__2+*_"_:_Y>H'V)F90.,Q4D=;T@;/3*7R5&$?'\TEFVB(&^@?O M+NW]+!T0UKYW7GRT##^:ME-4V<:)ASBFQ/!D-^Q$OS20%PC@9I5I(WL59S MU;T9=/8!!A!N@NYV8 "2XQ'PW(YEWQ5U) <#@%SN9@"S5PL90,T[-.D3?&RZ M'TO;?QQ+EG:FRVK^[?J A:<^6)\.!-LLGF@PEU<4RN,NR3+0-]>I^\K-A?_# MCPX-TWU/JA$M5YL:D?>KIU]Z+M_32G:/$N544$A\:7!IOVR;<>"-RS/&944* M[=DH#2UU3N-]->J. ME(X5;]ORW)WWFG]9E''#/:WY4,N\8;ALJ^""F/@HY@_"Z?])EOF=,VXJW^ \4$]6Z@#Q# M'&ZNV_RY8/VD4\O9XX'0&JSM$K_)LWTJ!CGRL[55)TK3N/=-2'3T\(J>%>+4 M5]=24>>*&0]=TKQ)',[R2NT[EY8U,* E4?2N3$4I)#7'QT]^4$,ZX&?2#E.V M.O+H"/&VLKYIMN>>[HOR O/.D0S@==8_3M)R1!]'Q8?(TTLTR[:JN(A_GC0# M"'IGCUX7,$./MN+)/=#?UT/^Q;YR8QBRJ**]U9DN"5EG5O.Y+8"#YE2^ZUY^Z\T^)@,WJAY0/-5J6Y]];N/ M0;& OS:NMW >U07F'S$]PETN)U=:E\;(C. 0&3S^,U\11]$#0.(Q!7$67=EXJ3 TS5RM#T3# #?2!7YAW^)HG/* M$%0J VBRH:LLIOU:GQ=OZ1U?7[WT:>[&G0C@V*EH!H#L31DH#&=Q%'OQ)O/" M)U>F1H$3Z\0[2=P777<*<G MG'T[RC3O,.'K06=CW_0>HE6_&Q-Q+B1G/"TIC]J.3 ^38IMZ=NK!W0GE>8LW M'O+Y\M]Y9-[;FR1HGH#C#&#" M'=8IS+KYDW6; ;#2-0=D_G1#AAH#V,O6<^'<]62B;&64XEY#2Y57]W4!YN:4 M_FOPXL_P-C)\%=:;G#4G;3EH9VPP,I";ME8;[N)\HM< MB*-B=B"G_M7:$-&HZ_F"BE^219H>R@/>"8 O%RD=#[YDGX^$VZV2+N390\M8 M]A6^JNZXEG"9>\$F8DN"YFC1^OQY"';)<%!$K_[<]U! M4!8&(+B4(#[N3/9\^1&,._42.KLY&'<=8-P=Z8;/7B\&PRX432I73E6G%3VG MHW?-NMG*1;J&(-ZJ,O Z*D\]Z"P4H?KIPH?)?"6 ->YG]?>.Z8JRSL=IW1*= MG?3K''D2$[X+IP)5; X]+V6.3'0S3$W+'PALO-6 ^%4QT!3W",R(E;^-MCMP M_M7GZ0,CQU&GR>=IT?BV2 M--T/=8P!?-7&TJ_C5.5/=&IEG]+CO7&AA78F&2^''IO$'H//LH[!J2QE#& R M!/['$[C%G?&=*<'UD!#J$*BC*.1-T(VA+Q@ \>@, X@2@1(-]%YY\;97BFC2 MO"T8P*HZM&^#L/ &TRDF'D]VGLB%CSL_?XK@M NB'3,HON-O>^[R+ GK?O>[ M;TU>0N5THF5\?X+]+"B8&IM(LM]_;>#>P!TD!XX9DT]/2"@2K+B^=+J?)#EN MOEXDD/_#\T&NG4&,G2O!32%&\(92)PSWET1?HK?EN=)< M(W?4U5%.#(#0!#N';H?4HLD'W,!0Y$3_Z81M+R3/ 'X]$]F-ZS?F'U[M.3]Y?A:D@ M,QM@$^[?-+?*5TT-$\J0S_V[^?QB58)25U#LX^S, =ED, MYTW!V&F6U9S^;Y3297J$J18_; MT@"J, /PBX-3(S7_>,(J:-/7#?,W(ZYY_-&-4OYT@@(K]?UOTE,&+0IO)\H M'DFRSV>8^G]OK$MX,*KG?#\G7^D"W.-,T$-E-=')5::))USA-\^:Z<]$M7#W1O<+C:EN@CWN&)JWJOL.O,1"Q] MS]]\_H\G/!B ;>\56-GUOQAF\(*%H%Y1:*KA7S&/YJ;OD_\H)O_9.="7H1:I MJ,B_-/O_'<+_=ZV/^=.)Q9VQC>^:6A3#/FWL62 M.1CL7:08/ULY!1[IP*U.2UE2$)^6@-#9>(G9AOV2W!8=&#>/^WDI=)IB(@H: MZ(UXR0#LH8'\XF+GE3Q2Q4N&M.=TWD'OGMOO9GHCT'3EN,.)[JG"R'E#(Q_Q M!4>-(2>)"V?*GU)DYG&]2!S=/ZN M=9]O[@>UA&.*Y&TB \27F)[=>,NST>J@F_BI.4HQOCOKA,MT;&/WF[^B7$M\ MW\8/Q/^;GO$_$?G_HMYQZ6CKD7[!.FSAX7?C/I@C?7;/]-*:G5Z'7Q(59.>S M>#\PB:35A%E7V=P^8/S&8BH_34E'(6HJ8J9#1E_=A4_E-PW\3077,$OBI.QQ MVQIEU8,TR1OM19)L0_<$RY,ZG\4.6[A&Q;R55(H18%^5BOSNU)_X*^S:D^ZA M.QDVOW840LC,='XF$H3N-\P+3LH<0X>#*F(>A]*8*J5!%95 J2@029,80,EG MRY%!7P:@CF0"+020@T +.;.#%I)H9 #0E#\]I3 8[7RW E]*H?^5=V#LCM"' M:SS0+ELTKC7;Q3Z*N61]N($C<_V17W,*E*A-C?9+*JX?7/T4\]=8A7DG;?FN M[.CFRIY]ZL.#U%$R@MMI#>WEU+\Y]Y=0GSB! =CI]=_H'8V(WQO[GJ\Z9;SB MJY#_#^3;L5#Y2]\Y P+\ 9:CKCXGM@E_G/>MZ>C\B7'IQQ>.IZ3)?5K\Z^K0 M[K\V_7V5Q MAD09#VJ$')7'7B?2,"]S,#ONZ\8%04+K(4H_--86_#E=??:(9B1?3DF\E\_% MI>#AN W5UU?G^KBTRW+V_IL!C8.6P&NQ9!/$":7\@@)QDQ@"O&V?M1/J)QI^ZONIU]VV\-JB<*#- 7?8$XJT-'.JLP]:=$0YU5*_609%'-Z M\7)3X5%O<647:U$?,]V!7-U*"3U;?<1#5"XHTVI0QV]ADV,M.OH4T(@XW M-UR^M8PGKK]SNHQKV?QRY&2&)::0LL\-<:?GD(=Z >E<*#IU_F)N:^#Z47,+ MU2%^.8,<^!D'>UD^L1"'CS'7Q5Z[V(YM<'4C#8B'9FH90+#95B#NR\,NIX2S MK\.\\CG>SRW!+SQVLN$->N_7164LSY95_^=,D1;:WD<7E-TC"2 MY]+GG2/BF]9CSI@+WI4=JTO_,*= M3Z%92W?MW=2[? _GA8C@!-9K04@*^8X9T![3I(J!W#+A37&^E[=&Q7N#+F:V MG$7DK\:.K2.*XA*>LJ@4U. (&WS,FLI=UKUT>DT6?:C _L@2[\,@GO?P%3_H M @_7MAO"*"![R4Y\N1#FP:77U_VL#_0;RT8!DWG#L0'DSXZ\Y#,>NO3("^F7EW>S0H*^)?]T,V\ZH+RZ8-2TXD1!]'[J=M4 M\3Z'!#(:I.SWR<_X%HI],"-:C4KK4+_&:8?2*MQ7P=#PFL?OWY>V%?G?C&X$$& M,"!M=1"1-O)%CP E&S. _3*;94'-/46)]G)WH)>"F+^KC;P8>.TM+6O!U;?\ M@(S(&8_VT33900D7@0'U$Y6TVY3B&ALI8@!U(V03]'Z<8V[:ZH;ED_>P$3N" MV$5P?@<:?+C-MDY0^VB?JX71M;7D,@];1[GXM$=7YXB.5XQ?0T?D=_#-RX)F M/UR_*%F EB(E]1+@ +PGU3G-!'=?@("0J85:#Z6 "?KP2Z8V\M).7=287NI M9:=X"X*Y%TJY&4#Q0_QU\7KX \Q+S3%\+9_R\GUP#K8GPG^.O;SUU>LZZE5 M1'U"55[YAS+]G8C;@3MYQT6I!CT,P.JY.J=Q4.&_=M>0"# Q<)-5W1$0.\21 M0C)3:=?^_.Z0B)N'1\K=%O-N@-K2GT-@-R@>XYA#O\@$@G=Z4%;]C-U.>&%L M0>-\1.HI;WY7R'TF7 /F%3]+-XS7<\&,6)V.G_-V)*@B>(Y*&K[VN11S;[%G M_8ZOTR,?N7(JYMA)[5B+A:S6#G6N!?Y'NZ)NKE"/Q8T3BZM[JOGLC[TN.5G$ M=_[*A">T.LS7D)69%J>\L*) O4ZT#96%,)$+M$B'8R1C,NU*1-T./CNK^PQK M)"@0,1J)*(#M)<5B20=K=C2#US/6SLN*/RC%),9\FX)0;KAF#)[8;JG%"-&2 M^^BV9?[9K8L$,0^U9 >JN8G?-R]] 'ENL31 M8M;]\'[K0/Y)DPF3B$KK3*HJZ67^N(X1M9EV8VI9:":P:8R5(G8QY1<;19S. M)D7"T%6PA];G&$!%IGT%A+8=3,_3I+G)$NM]^1&:4?P=RPQ D-#0,XT]TP>F M<*NLF=U$SB=,0.^QAQY#NB>3$3<1ZU4WQNY!PH)[L[_YQJA);9K18HFXESG( MDV/O)56[!%<+:9?[%4VYJ^MN?< :N$3Y1.D@05#*,D56E7@Z!*:)CZPK3G<* MEZ2]U\.OKZ5!C9F8EO(;O2FNU1!CEB&!FZ>75AVCH!R.J(.4R_V M*NF[Y$\7A]JD2C( B;R34Z]@[X*%^3BEEA 1"1$?7;+MN4UZHV7KA[IS9;K@ MPQ[WM:6VA*+)O?EQ'=/1GW;XK11RD[/RTKS!9.)'^GL_HLIDTYI<.+*/?O%1 M_V !3V'\P*+9ZT7'5 %I#GH3&XA.V58_B0ESR9=6Q>M'A[V)4]NZ?.6X:4]' M0 I[MN@W@76!KH49Z"_$.(D<241)G-E$RYD1^\QY/4X5#$QL'4:/"F30"MJ\ M=Q2J%=+D=)T@']?7IS^I:[F#"BB0^4O :EN3SJ8%PG4Y-0:0'P&AG2O'96=/ M0*=;QB%LIO5SN2UQW1&LQMOP//=@Y8 M]_=M.?:LQ7"]F5/-:,BS.Q$=5+N(>DN5I.'I4'+'QT(2FX6GHCZ2?0BKT)Z_ M>$Y_=6NJY^H&+NWID$';G7Q_BEZ%_\YW]Q&N^L)0(5?)^SD'6'S%B=,@B0&I M 5^E'1%AP WC[9GT'WKWM/_I=E0G"HNZY)(D5?:$D,\U];,Y>2-UT9N3U&EF M: )_\ B'90"VV %6 O3D"P6=403$LX"'_B-^C>\'ZSE6NJ1E!KOB _;>=JYQ MW<2LYEC[EHV/\MT6'?? Q&;S1PBW%^6+KKD)G_0BVM("TAE 1]'.00060;P- MV>9'@@CT[AQ^W=&;!SJ!BZ\/HQ_O,H-D@8;L8P"STB;[%&G#",F6Q1H&P MUW,5JC>U_ M?ZN-YSN"MW.8S,FEDZ:%$5LZE6'U,I<.[U=N_,CZ6E/ 3]V^XVJ"@;$/-!8/ MK6:=1[ @K38OK91W.(5J92 BZ<47O30:-2W\?#V5#WF%HXJI-\G.*51C8N!, MT$9FB?D/.4VP/.:4O&$NOJ8%E CNXTF:8]%%!#C&KA1T)_WZ_+YVBU$ MSBB^Q0Q%0C[2]@NLBL>Z3,$OMW[I#< 69A#AA&9JQ(T0D9RVI%WW/ONEJK0+ M=[JB*$';X2W?@Y!'B=DIS*^_:PKX*_3.MBU64#142$&J]*:>J0CH\5\:2E-C MZH/6F"NL.!U"OD#$8=:90W:>MG7E<0$;"Q*VFA51S08%K[79.Y)4^#"9@@(! M-2P!1KRN!3W-I+6O/=-F],UGO>_SC$$K*RMMOINK)9GN M)'WU$.X20F')D*\[F@0,VR]/]+42BG)@LB/OU*3SN(=R'T:(LLG#U48]1E9, M0QXG/CBA['=LN.F5\THPP:(UHOJ[=* 583#*=U_Y1WY#5'S,5/->O03TR9'F M9BJ(N',A3_]8.1U$;,2^'M'8KWP(I8;JPK/I@;X?EC =R@XSCI.F5>A^W4:U MG3YKB"[W$*;NP5LM3$'((IJU:+(VBK>?7/W]T XFZ %M6W]--O7%OITEQ_#% M@UBS]2>RON_-E>,)H1E+HD-.F-9Y,'$F$O?$F&;O,U!C?JVIKZ4.H"KI+7"N MH 9(@#=_D4RU4_8>WR#]IIDE#C]>#&4T&R2B"ST+:\[T RLD!)T#^JK7BJ/R MW,*[M$/SNT_4PHZ#I M0[[G$"9)6,$AE&9@>$8SS+T[!82)F5YC"%?0O/*H\XZ.SF-3ZU^=?F2DOU0F MWTF!DB>8%J>K3^1AQS 8210/F0&HDM1?ZC2\=51C"OGJJ S?I2CZ>:..!C7F&A8/+O(:194J$3VZ4M_J0WAN:JHIV7^> MKV!M0&M-LVG>D ^L 5XG\/>S)T%[8D%[7E_G[$N5#N>&]82FQ1I)^! M[[/K&JRI.3XF*<^S%^=7J^)KPC+:].*=,#_^9E#5]^R=YBU1=4NG,FLBVT>S M3OE#K!,<.9DH$(HBU0 S :E59JVSZ<'U2Q:,?")]F8;'ZBK:!O'_$.]T6"N@ M'^C;->P*O[T5:U5B;FP%;VF!L9)$M[TVTUSU131/MP>N0V'[U*YIZQ_[7N#/ M*$K'@GE"_,WL7RGN4DC+7/3=63DY@?'[2J7X$67X!;TQJR-:0E&N#J7DK%Q: M@3%&+[R *[-YH@)+Y*&VNG"1\<>LJTO"GX[3^KV1.PP@[MM2VDD-4+TF32?W M.I+EU.C#I+V5[!4?U*:;Z;-+Y$1(0[[XSVKN1]B['0D[ZG6]MN))'UGU6B;I M1BN3GE#R%J71C8B9IOU'E77 MWL0L%@LDZ=3%[]?,&T;P!SMT9(\Z#U2 =$S(2ND+,3RU(J=0GMH$6IR3U_4->5["PEA2+CAX)&\@>YI>_L@,O69Q_WEQK-O)Z/G[<#D!/F^ M"\8TTU$_$.QM];D[/+Y]XNV1[=RYIS\1>XY\E& M)"_W:&#O.0 ?RX!U4(IO"%&/@W&0?>9[PLCU2I67R6WK%H68^LLB@Z^PSE M^'Z\.O_59$1[UTPOM5H%Q!2V/P*]3187B"U40W)^BMW1^NFYS_@!R;4M9/"W M\QFTB2+XJ/MTT=;6HB2QDE#_+^HQFNG_O#8WGC3 ML]&>XO^YTF64 @GFA_Q4NI*5YC^,D$4^+PIR1+^CO7S547 MOU]*\@S YB6/#X>IT>:!]#S,6[N,AZ#?7&2CX.@'FDD^2&\\(5=U8ME6OY.0 M5#?NV3A1]'7K=6]M3#L21BK^2!QIZ)=[59@QX)MND3-;]O6)_ /XXI?8VXL- M923.JB(Y9GM9Y3?=F $V<6@M3.0SJ21P/1>M_48G8]ZXR>V@1__74U!5!8Y? M >9C3@AL"9=#%!I^?ZZ(* M/9SL#H:&'R:1B(F5$PCJ-5)ZT;CES>FMV^4^0;=96B^^; M7CCB*9BDKZ @7R[DDD[>"F(*L"NWVECX)GT#+N"'V7DDCN4P^=7E=CE%K[_U M&D6N)NE8%_7 F+(PH=_0RAB;/G"V4'PPD&?0US1QE[Z!.!$9X%A1,!?UY;HS[G**C[^\_BZRZ$9$Z^!:$LOEO_\W2 M%M,B_$M<_319D12JU7WAW&JAI7WV,*G3#,#%O]I[S-0#]W-4#5#Y MAB.PT71IK^B2V! TJZ.CY,,U=SPDIBLO]++9]5KZM-J&2HEP5GBX9WPX'Y?1 MFO+C0Y9S!;-B(#L5[/V_P,/6,>2'(R'8=3VJ"@/P.XH.O)G&L[QH$!K[;I0%.Z9)E7:NU]L1I@N 8.0 O!9C!YE&>/I/F/+'NPN#UB0KE1,ITJVSN.L,X*4C& M55QS4&(KG@L^BR4', ! B &P_>%FG^OH2Q1"7UN!TO"?E?NGFY5W-3BV.-.7 MY*SNL04O6*FCW-D#)XQP'M5 >Z3J"5![]G_R@.]%G?X5*,?/3)(M=:Z8GMTZ MB$TWP-@='FNZT,BK[C#/#^DM?-U N=;]V#_JY-+Q*$U_A8#(_B]BRTEUN^LD M_QI)K 29V"Y-F4LR!@TUG=>$+GV^PL+1WCN+6/2AW).+&.ZMX9JKKB@4>FHDK1&3>?U7]GBS*]5^/;+MEF] M<&B,U>AVN!&6AQGL%__* *P90/]!.G<086U?EAB6ZU'-7?SLH=K(55U6BNEI M?#_K!P&3:I.F[A=93;7F*7.G90W$]'=[#N?_+:H67UN@L]T#*41; 'R13XX> MCFLWHX*8PO\M^MO::!N%58\MU1J9'EU&V7[$$+^1K$'WQD+>_$/SVFA M*R$Y.NF7/576%\)CRZM*[61H5W$7FS#EC;PB@_N@:MULZ]]%E9]>RK[!]6&N MV^0FU8=D$K@!WTOVIUS[Z6C5;/#E=:.,Y*\-%OY1__V"_OMEXQ"IZ"+6Q05G M4C0!U*V"A0MA? D&7[<[T'\AA1>FEA00'6/=3FI/H(Y5%H"<]5Q1^4N0LUJF MQ/(:@IS5/P<"<]>K-7!5F8$1E@/J6+/1KAID(=\V97'0^M M6O0K,I\M_."*H=8L[Y?=EK4*)&I.P'*)MQLX[(O/YLEL%S>B,V)K+=2Q'8UG MS?,WA4Z^*--#B[4DL2&CR?QT*_0T*EO?%'60%!M-8B9<5MA\];3$VWW<60/J MI??T7M_S;X+Y7&66MG/Z45$&H>7WP'G>^F=[#(SE0I%WTCQ/$DKZIPN>QGJ[ M)S[4>F#=]B5SN6X4N"+TW&3CD.J 5GYI555IQ,\?PY=C[:;O9IT0:;JO=Q7 MM8+J=-@,+B>WC@M:9RC%TH]^?DV+/18C=ZB]56!CH9#?;R?Z;T#1A?BU<]J[ M:1&?%R1-&IAXF$6J:(!D63H5=^9N:6;84;X(A"5E] P ^9O,'[BFU_4M*N91 MEL8Y"SK=FM:5)-, ;GH@,@]&T=.KT/K?")G][K OT 6^QC ?N4P MF#1)-F_DR-"YQ[GG#$Y\/P-;8^[48*7OD9^_#M7O59Q[Z@/"14@RY1 M&I/17L2"\7-58PY##9:7IU*T>*Q;@ZD=8&#L4I[2C!82]OO6W2XA^(A M\YL*:2]:G7UM%"QJ+FUH<02(0S[NP=O0.9%7"\D9Q 45DDY2!W_:XR]:)Q*# MTZ#GP63/]*29;#(^Y0M& LL8.<^ZK!?&/]RZ^NUP1H83O.YB@!@KY8)# M,>4I[3?<45KP/Z]&ASK5F6_Y;Y&W"[Y5#L(3L+ZD+E>2]HUZB1V+W MN7 YXNC\12;80+3=EM@T7C.[&6^G%V@]P5TSY*$2<7$G07A 9F+0HN' 5?CP MR6A8A /NH,FO'H-9M_NB%#-'=[B 2-K31WTQ;[*S:HQY!'8,3'YB+^^^#Q4. MHB6E:G$&4*M/G*;4Q'U9P1.I[Y9*^,U^JE[GIR">;++[5Q?A&E?Z<.,I2'YR M_8>%SNO6769Z7^P%\XM?^TWN+"DB^#/%-VA\#XQL3L>\5!/])OBSVII/NZ]G MVEQZI*9[)L.VG ]D6HD>>VW(6$*QE21Q.N/CO/Z!=9I&O_:=">6.[JS&CS6C MF[)9ZLKOVYU0(D@UHLX6 7/* <7;K<+M;=,U4&"]1YUUZHDR[XW/F_\R8Z"K'2J/'L"-V%,9P&?_:D$<[J/)P.W;L/M% MP-QE4*CDM(FW>=794]I#"MF.TE]9J/Y]*D!^^IB V*+'&E M81-^%'DHV1.K(]!O_RSK"?<5J7P>SZ8-8_:,(1V4:.\P@J@+#84^ZMK !Y5T M/=1V=5>6!X%=[&/55IX=*6, [=OJ=2?P@C=RX:FWO%ABP:2O7DEF*\X[C!?A9: O=:'+Z M;4_GZZJ@] ]$5@RN[L+6Y MG#]V9SC7X4$\O]OH9SK7O-XH$P[MSUG\4OZ^963#1R[-N_L G#)9)]DQ8L(H MTLMYL!ZKFX-^33WD+8LBU/Z"9H_!\L^N&%)C1V:V3AG9>-P%M;G$K@KFC<-N MX\+A$C ^,M2,Q+?,?L*]0.=SHA>FXQ@LI][0)X$:^W,C%,_A(->?1DUW&.@; M'O>"D!3S'\+C93>YE[9)BH^]Y9X_GI[*SYQGTG,RYH1'; KLG,:%.22D5.1O M#_N&;/;T\"Q!=I#"*&R>3!,NP#%FL_BEROTD<:1U MX3YN#$>G]<\F6":]MV$;Z.N_]EKM: 0'E^HGS(<]>?KJSZ Y:38/P"!A9IM! M"9"_=XVM^!=A.4;3>]41)U$CV&-*I4_1>_J:6]YV M.V\F$<39H(T^'(LOT_5B+$8;[QL?@XA5>7NOPV"]117XHPX>.T74:O>-]14W M)>RPQ_TZ^L/,#G47;-3E@=VUG^=\D@0]YB'D==)TZ%B%>E?/'V&:8UDDL+IW6]KQO%1SRT1#R84^U*NTYC&];[2ES(2-V[I%T,'%)W0P^NB6(/C*U4O_HRO" M(""@"4/R';&T0W.LSSZ)7NHJLDPA?X7=S)C_\!&^V*#82]B@&)$$OY:CZT;V M+%AQ=S?NG$M[W![7<-.Q1XA_OL;4)X1J1S)YB:L\.>YHHM(]ONI^Z/*T]IW> MXO7[J9A;+J]]_'<;;>;_TF@+2VN"N1= M_95=D[LVPYFN[9;M0W@6L@:E<5BR@ZJ8?HZRI#NO:%HJ)'J?R1HSIA\K_'D? MWH9Z<'0(/K82L(XY-*PXZNO'?/HFIV MW]V^-Y0Q9]Y(XJ#,:;8?\6, 10)+"$^3'P^YRF86?S:O*;=P73!UJP)A ]<4 M?_ _ STF,P@JI_0$E"HT+/N%> X+6U)4I=&6NPA#Y<0,6IW\SK?1=5PIZB+R M^A>R)G'$@F2TW'O\XC&6\RXS-T?.Z],O7)6?O>1C,N&4GVWET%^TG(%6M!BQ MNKEUK(4!>&OQ@20XZUP5LAHC\UZS?4VJR.M^5E[:#9 TOB#MIJ,]U=5D<0I_ M"0;^$,OAL&7\BW0Y)WE&Y1#AC%H4:TFB!TZY6!9)(TJ.68XT.+_JEWLI$9!S MK&EZ^ =VM;;O^B5X[RF(L0W?PJ:P=I=CH>/E7KW\YQ(YN?>O"[R4"HR0O?4I MY1? .F:EJWADSNR(][*W_ VVM"D)#"%+T#/UT= -A?@+.$_A7%ZZU*QWV8EG'PYL&UF^;-*C8/SUMK0C-L8- M#7794BW.%H@=?1(5-8N:U;?BIIRBWH=SPP[_>M=4.>2AWO >73J%M<=CMD*AY,+$]-/V/=\B"QOP.)QKH;9\NA]+"GJ#G M9'M\+1$@7ZW1@D^^G$5O2M4P@-1>HYY NI*O[F--8BK*"80R&XVMNPMKQ^8V MDW?H_8/%-3+9_(NVO *V&[C!!*IR.WKR2@:ZMP6]OT2 (IL+= MYI])L'?-W[<2_CO#-&'$OU)QW,:F9YU/VLCXQU1U0<1=MU[%-S^'.)=_UHZX MU5?>!I5QAF16%E=[?.=Q:Z?E!_:G/ M(=(?0BL.O908,6IR#%&J,!V4X1EWHZQ+UN&DKZ9NF66TV9"&4(3Z MNI@GK@W;7[(I[AP4&X>2))YWL_1T56KR29?FCJWWW&Y/LI(:48 M2-%?[>Y(LD2>3"_[^ EV#4Q#/4JCNRFF$V^+"+U-Y2;GIWCZ76_.D/'O-0A[ ML%+DRI+H(>XW,;075:,FXW$D-5^A^5CF@Z=7V"$" 8,F8^]1N:AZ]!%,'<1/ M ?I>-):B(9$Z>%R)/@N19 "G9=#!LN,/#0N-N#_.C]K;SQ4,@1"%B+G[WT=T M>XF!B0J84!EM[3='!]I\6 PTM)AB4F]I\G_HG<=2I7IKVG8XEN#$Q!7:"T<&L&[?N_3>,_[%#"N_B77/U]I+!M,F2K9TGH71&=K^32SY M&&BMQMVVB0(9!%ZJRAETED$TZ?NFO?BWS1YT/&TF8S&+ 8A1,+Q_N@8^%E%] M&-V.L6, S^6@5->JA!#E(L0TVM-'#/V]>J(!_8??,61K7 !V7; ?/:K3R !. MX1XF8QQ-MK'#_-^QJ[A2$O8/OZ?\89;B?9DI T9TVZV@+QG4[.6_)(7(;R'& M_D>&_XLRB!>1/8B86OB!L:K06N_S9C(>.9@G^5J"VX$J;+J;RLS\246_.FZ+ M%0GEBEZNTLBJO3 G $:H]-4_+6C'PAW:^C+HQ\2O4!W&?&XN;,Z5TW]P36]> MA.WX78G4I*WO4_"#=*\;.,3?27R;(ZMD*7PCN8/.;SNA#.;-I5<4F?#C#CA^ MLEG7"63XM'WQ1=Q.D'!\-_II]!K3EI[R@8%599?"\<6V9BE/L[<*>3%Z9/=! M,-HTC_QN_.(+G)<.>!'UZJIU!K3G]\PKN+1ZQK]!<9/XFJ%L MPUJ4^,DK%)8AUK@#:Q0]C35Q@-RAX&P'Z*R3J!?Z-R/4 M8[@Z8CI^4\#NVPNI-)8_=K)$#[!=\N0L(I6 DFIOBWL10=Y9@JB\$FJ"#ZQ> ML7ZRKI_=""\O(SWTE7RA)>6#9^YOH M,1X'7=!B27X1^:)S?<%M5].K'R2'3#HM+U(+CKW*"OTTW^V-GP>+B<&5WRW& MZF):!/HA?JDYU)F?G-RE\/0\]$9^/+JW5$F70/'#O$%SS'PX6:K7A]AT>S>^ M7"G[_B$WIE8!&= BQ+'9QPJ[@5UF )X1 L45D"?-]+C?D7$&'5 NTK2,F\>058RH&2;AG**PFG M,W#"&2ECZ%M92@ B<82H#]G]("",JOJ9E/O&_#%2!1KC7OBD1%^$5_DE>1/K M&N'0VYSMVMKEJR?-IY<@YO!Q59U3'Z'J^=%2DH#@LZ)*DY:#QD/9W[V_-&?; ME^CUJF-"^/.#\QE]V0G)T3=NM-@5+F,&&,#AA9]68NU/EVQUWNAES!\G#9DW MT6:'U$2IP;DGMKGI!T9("/I11-!.D#_NX9#OAZ89LY=*13EANJQY37*0N[/B M"Y_(\]U#8A&[N[D^^5P7W0V@8[N[0YA7"S9_D751/%2'[@N.]U;7T4>8L_J7 M>(R>P:O#GGU#%K.JNW.-&NW$49[\WO<=0S1>I7=RG,L?Z^R/*6.>?N1'HUK_ M^C 2,2W+M6WW[^X6#EK4V=TM;%MC?M \JW+(FC!I5V(><2=2<_D!W+!V%+?GEB8PHY^-#ET6.K.:GTL;:.'X.;1Z7R3MG\8

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var-20231229_htm.xml IDEA: XBRL DOCUMENT 0001681622 2023-09-30 2023-12-29 0001681622 2024-01-30 0001681622 2022-10-01 2022-12-30 0001681622 2023-12-29 0001681622 2023-09-29 0001681622 us-gaap:CommonStockMember 2023-09-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2023-09-29 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-29 0001681622 us-gaap:RetainedEarningsMember 2023-09-29 0001681622 us-gaap:ParentMember 2023-09-29 0001681622 us-gaap:NoncontrollingInterestMember 2023-09-29 0001681622 us-gaap:RetainedEarningsMember 2023-09-30 2023-12-29 0001681622 us-gaap:ParentMember 2023-09-30 2023-12-29 0001681622 us-gaap:NoncontrollingInterestMember 2023-09-30 2023-12-29 0001681622 us-gaap:CommonStockMember 2023-09-30 2023-12-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 2023-12-29 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 2023-12-29 0001681622 us-gaap:CommonStockMember 2023-12-29 0001681622 us-gaap:AdditionalPaidInCapitalMember 2023-12-29 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-29 0001681622 us-gaap:RetainedEarningsMember 2023-12-29 0001681622 us-gaap:ParentMember 2023-12-29 0001681622 us-gaap:NoncontrollingInterestMember 2023-12-29 0001681622 us-gaap:CommonStockMember 2022-09-30 0001681622 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001681622 us-gaap:RetainedEarningsMember 2022-09-30 0001681622 us-gaap:ParentMember 2022-09-30 0001681622 us-gaap:NoncontrollingInterestMember 2022-09-30 0001681622 2022-09-30 0001681622 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2021-10-02 2022-09-30 0001681622 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001681622 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2022-09-30 0001681622 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:ParentMember 2022-09-30 0001681622 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2022-09-30 0001681622 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-30 0001681622 us-gaap:ParentMember 2022-10-01 2022-12-30 0001681622 us-gaap:NoncontrollingInterestMember 2022-10-01 2022-12-30 0001681622 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-30 0001681622 us-gaap:CommonStockMember 2022-12-30 0001681622 us-gaap:AdditionalPaidInCapitalMember 2022-12-30 0001681622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-30 0001681622 us-gaap:RetainedEarningsMember 2022-12-30 0001681622 us-gaap:ParentMember 2022-12-30 0001681622 us-gaap:NoncontrollingInterestMember 2022-12-30 0001681622 2022-12-30 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-09-30 2023-12-29 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-10-01 2022-12-30 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-09-30 2023-12-29 0001681622 var:CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-10-01 2023-09-29 0001681622 var:MeVisBreastcareMember 2023-09-30 2023-12-29 0001681622 srt:MinimumMember 2023-09-30 2023-12-29 0001681622 srt:MaximumMember 2023-09-30 2023-12-29 0001681622 srt:AmericasMember 2023-09-30 2023-12-29 0001681622 srt:AmericasMember 2022-10-01 2022-12-30 0001681622 us-gaap:EMEAMember 2023-09-30 2023-12-29 0001681622 us-gaap:EMEAMember 2022-10-01 2022-12-30 0001681622 srt:AsiaPacificMember 2023-09-30 2023-12-29 0001681622 srt:AsiaPacificMember 2022-10-01 2022-12-30 0001681622 country:US 2023-09-30 2023-12-29 0001681622 country:US 2022-10-01 2022-12-30 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2023-12-29 0001681622 var:DpiXHoldingMember var:DpiXLLCMember us-gaap:EquityMethodInvesteeMember 2023-12-29 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2023-09-30 2023-12-29 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2022-10-01 2022-12-30 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2023-09-29 0001681622 var:DpiXLLCMember var:PurchasesMember 2023-09-30 2023-12-29 0001681622 var:DpiXLLCMember var:PurchasesMember 2022-10-01 2022-12-30 0001681622 var:DpiXHoldingMember us-gaap:EquityMethodInvesteeMember 2013-10-01 2013-10-30 0001681622 var:DpiXHoldingMember srt:ScenarioForecastMember var:FixedCostCommitmentsMember us-gaap:EquityMethodInvesteeMember 2024-01-01 2024-12-31 0001681622 var:VECImagingGmbHCo.KGMember us-gaap:EquityMethodInvesteeMember 2023-09-30 2023-12-29 0001681622 var:VECImagingGmbHCo.KGMember us-gaap:EquityMethodInvesteeMember 2022-10-01 2022-12-30 0001681622 var:VECImagingGmbHCo.KGMember us-gaap:EquityMethodInvesteeMember 2023-12-29 0001681622 var:VECImagingGmbHCo.KGMember us-gaap:EquityMethodInvesteeMember 2023-09-29 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-29 0001681622 us-gaap:CrossCurrencyInterestRateContractMember 2023-09-30 2023-12-29 0001681622 us-gaap:CrossCurrencyInterestRateContractMember 2022-10-01 2022-12-30 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:InterestExpenseMember 2023-09-30 2023-12-29 0001681622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:InterestExpenseMember 2022-10-01 2022-12-30 0001681622 us-gaap:OtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-29 0001681622 us-gaap:OtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-29 0001681622 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-29 0001681622 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-09-29 0001681622 currency:AUD us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2023-12-29 0001681622 currency:CNY us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2023-12-29 0001681622 currency:EUR us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2023-12-29 0001681622 currency:INR us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2023-12-29 0001681622 us-gaap:ForeignExchangeContractMember us-gaap:ShortMember 2023-12-29 0001681622 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtMember 2023-12-29 0001681622 us-gaap:FairValueInputsLevel1Member us-gaap:SecuredDebtMember 2023-12-29 0001681622 us-gaap:FairValueInputsLevel1Member us-gaap:ConvertibleDebtMember 2023-09-29 0001681622 us-gaap:FairValueInputsLevel1Member us-gaap:SecuredDebtMember 2023-09-29 0001681622 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-29 0001681622 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-29 0001681622 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-29 0001681622 us-gaap:FairValueMeasurementsRecurringMember 2023-12-29 0001681622 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-29 0001681622 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-29 0001681622 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-29 0001681622 us-gaap:FairValueMeasurementsRecurringMember 2023-09-29 0001681622 us-gaap:CommercialPaperMember 2023-12-29 0001681622 us-gaap:CorporateBondSecuritiesMember 2023-12-29 0001681622 us-gaap:USTreasuryBillSecuritiesMember 2023-12-29 0001681622 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-29 0001681622 us-gaap:CommercialPaperMember 2023-09-29 0001681622 us-gaap:CorporateBondSecuritiesMember 2023-09-29 0001681622 us-gaap:USTreasuryBillSecuritiesMember 2023-09-29 0001681622 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-29 0001681622 us-gaap:CashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2023-12-29 0001681622 us-gaap:CashAndCashEquivalentsMember us-gaap:CorporateBondSecuritiesMember 2023-12-29 0001681622 us-gaap:CashAndCashEquivalentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-29 0001681622 us-gaap:CashAndCashEquivalentsMember us-gaap:USTreasuryBillSecuritiesMember 2023-12-29 0001681622 us-gaap:CashAndCashEquivalentsMember 2023-12-29 0001681622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommercialPaperMember 2023-12-29 0001681622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CorporateBondSecuritiesMember 2023-12-29 0001681622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-29 0001681622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:USTreasuryBillSecuritiesMember 2023-12-29 0001681622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-12-29 0001681622 us-gaap:CashAndCashEquivalentsMember us-gaap:CommercialPaperMember 2023-09-29 0001681622 us-gaap:CashAndCashEquivalentsMember us-gaap:CorporateBondSecuritiesMember 2023-09-29 0001681622 us-gaap:CashAndCashEquivalentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-29 0001681622 us-gaap:CashAndCashEquivalentsMember us-gaap:USTreasuryBillSecuritiesMember 2023-09-29 0001681622 us-gaap:CashAndCashEquivalentsMember 2023-09-29 0001681622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommercialPaperMember 2023-09-29 0001681622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CorporateBondSecuritiesMember 2023-09-29 0001681622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-09-29 0001681622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:USTreasuryBillSecuritiesMember 2023-09-29 0001681622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-09-29 0001681622 var:MedicalMember 2023-09-29 0001681622 var:IndustrialMember 2023-09-29 0001681622 var:MedicalMember 2023-09-30 2023-12-29 0001681622 var:IndustrialMember 2023-09-30 2023-12-29 0001681622 var:MedicalMember 2023-12-29 0001681622 var:IndustrialMember 2023-12-29 0001681622 us-gaap:DevelopedTechnologyRightsMember 2023-12-29 0001681622 us-gaap:DevelopedTechnologyRightsMember 2023-09-29 0001681622 us-gaap:IntellectualPropertyMember 2023-12-29 0001681622 us-gaap:IntellectualPropertyMember 2023-09-29 0001681622 var:CustomerContractsandSupplierRelationshipsMember 2023-12-29 0001681622 var:CustomerContractsandSupplierRelationshipsMember 2023-09-29 0001681622 var:MeVisBreastcareMember 2023-10-31 0001681622 var:MeVisBreastcareMember var:CustomerContractsandSupplierRelationshipsMember 2023-10-31 0001681622 var:MeVisBreastcareMember us-gaap:DevelopedTechnologyRightsMember 2023-10-31 0001681622 us-gaap:OtherDebtSecuritiesMember 2023-12-29 0001681622 us-gaap:OtherDebtSecuritiesMember 2023-09-29 0001681622 us-gaap:ConvertibleDebtMember 2023-12-29 0001681622 us-gaap:ConvertibleDebtMember 2023-09-29 0001681622 us-gaap:ConvertibleDebtMember 2023-09-30 2023-12-29 0001681622 var:SeniorSecuredNotesMember us-gaap:SecuredDebtMember 2023-12-29 0001681622 var:SeniorSecuredNotesMember us-gaap:SecuredDebtMember 2023-09-29 0001681622 var:SeniorSecuredNotesMember us-gaap:SecuredDebtMember 2023-09-30 2023-12-29 0001681622 var:ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-06-09 0001681622 var:ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-06-09 2020-06-09 0001681622 var:ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-06-05 0001681622 srt:MaximumMember var:ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-06-04 2020-06-05 0001681622 var:ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-06-04 0001681622 var:ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2020-06-04 2020-06-05 0001681622 var:ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-09-30 2023-12-29 0001681622 var:SeniorSecuredNotesMember us-gaap:SecuredDebtMember 2020-09-30 0001681622 var:SeniorSecuredNotesMember us-gaap:SecuredDebtMember 2021-07-15 0001681622 var:SeniorSecuredNotesMember us-gaap:SecuredDebtMember 2022-03-18 0001681622 us-gaap:RevolvingCreditFacilityMember var:AssetBasedLoanRevolvingCreditFacilityMember us-gaap:SecuredDebtMember 2020-09-30 0001681622 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember var:AssetBasedLoanRevolvingCreditFacilityMember us-gaap:SecuredDebtMember 2020-09-30 2020-09-30 0001681622 us-gaap:RevolvingCreditFacilityMember var:AssetBasedLoanRevolvingCreditFacilityMember us-gaap:SecuredDebtMember 2023-12-29 0001681622 var:MeVisBreastcareMember 2023-09-29 0001681622 var:MeVisBreastcareMember 2023-10-31 0001681622 var:MeVisBreastcareMember 2023-10-01 2023-10-31 0001681622 var:JointVentureInSaudiArabiaMember 2018-09-30 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2015-04-30 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2017-09-29 2017-09-29 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2018-09-28 2018-09-28 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2018-12-31 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2015-08-01 2015-08-31 0001681622 var:MeVisMedicalSolutionsAGMeVisMember 2023-12-29 0001681622 var:MeVisMedicalSolutionsAGMeVisMember var:MeVisMedicalSolutionsAGMeVisMember 2023-12-29 0001681622 us-gaap:RestrictedStockMember 2023-09-30 2023-12-29 0001681622 us-gaap:RestrictedStockMember 2022-10-01 2022-12-30 0001681622 us-gaap:ConvertibleDebtSecuritiesMember 2023-09-30 2023-12-29 0001681622 us-gaap:ConvertibleDebtSecuritiesMember 2022-10-01 2022-12-30 0001681622 us-gaap:WarrantMember 2023-09-30 2023-12-29 0001681622 us-gaap:WarrantMember 2022-10-01 2022-12-30 0001681622 us-gaap:CostOfSalesMember 2023-09-30 2023-12-29 0001681622 us-gaap:CostOfSalesMember 2022-10-01 2022-12-30 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2023-09-30 2023-12-29 0001681622 us-gaap:ResearchAndDevelopmentExpenseMember 2022-10-01 2022-12-30 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-09-30 2023-12-29 0001681622 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-10-01 2022-12-30 0001681622 srt:MinimumMember 2023-09-29 0001681622 srt:MaximumMember 2023-09-29 0001681622 2022-10-01 2023-09-29 0001681622 srt:MinimumMember 2023-12-29 0001681622 srt:MaximumMember 2023-12-29 0001681622 var:MedicalSegmentMember 2023-09-30 2023-12-29 0001681622 var:MedicalSegmentMember 2022-10-01 2022-12-30 0001681622 var:IndustrialSegmentMember 2023-09-30 2023-12-29 0001681622 var:IndustrialSegmentMember 2022-10-01 2022-12-30 0001681622 var:KimberleyHoneysettMember 2023-09-30 2023-12-29 0001681622 var:KimberleyHoneysettMember 2023-12-29 shares iso4217:USD iso4217:USD shares var:segment pure var:instrument iso4217:EUR shares false 2024 Q1 0001681622 --09-27 http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#Assets http://fasb.org/us-gaap/2023#Liabilities http://fasb.org/us-gaap/2023#Assets http://fasb.org/us-gaap/2023#Liabilities 0.048084 http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2023#OtherNonoperatingIncomeExpense P336D 10-Q true 2023-12-29 false 001-37860 VAREX IMAGING CORPORATION DE 81-3434516 1678 S. Pioneer Road Salt Lake City UT 84104 801 972-5000 Common Stock VREX NASDAQ Yes Yes Large Accelerated Filer false false false 40600000 190000000.0 205600000 132900000 142300000 57100000 63300000 20500000 20000000.0 32400000 30300000 52900000 50300000 4200000 13000000.0 1900000 500000 7300000 7500000 600000 -600000 -4800000 -7600000 -600000 5400000 -200000 2200000 -400000 3200000 100000 100000 -500000 3100000 -0.01 0.08 -0.01 0.08 40600000 40100000 40600000 40600000 -400000 3200000 -1000000.0 0 -1400000 3200000 100000 100000 -1500000 3100000 141300000 152600000 600000 600000 139600000 163600000 289700000 277500000 75100000 64600000 645700000 658300000 148300000 143600000 290400000 288500000 22100000 22400000 28300000 29000000.0 42000000.0 41300000 28400000 29000000.0 37100000 37500000 1242300000 1249600000 73700000 64700000 61600000 82600000 3800000 3800000 1600000 1500000 9400000 10200000 150100000 162800000 441400000 441100000 22900000 23100000 44900000 41600000 659300000 668600000 0.01 0.01 20000000 20000000 0 0 0 0 0.01 0.01 150000000 150000000 40618590 40618590 40529573 40529573 400000 400000 453200000 450400000 -2200000 -1200000 117500000 118100000 568900000 567700000 14100000 13300000 583000000.0 581000000.0 1242300000 1249600000 40500000 400000 450400000 -1200000 118100000 567700000 13300000 581000000.0 -500000 -500000 100000 -400000 200000 100000 1000000.0 1000000.0 1000000.0 3700000 3700000 3700000 1000000.0 1000000.0 1000000.0 700000 700000 -100000 100000 0 40600000 400000 453200000 -2200000 117500000 568900000 14100000 583000000.0 40100000 400000 469100000 100000 63800000 533400000 13300000 546700000 -34600000 6500000 -28100000 -28100000 3100000 3100000 100000 3200000 3300000 3300000 3300000 -100000 100000 100000 100000 40100000 400000 437900000 100000 73300000 511700000 13300000 525000000.0 -400000 3200000 3700000 3300000 5100000 4600000 3600000 3400000 -800000 -200000 400000 1300000 -700000 -600000 2100000 0 900000 2000000.0 500000 0 -25300000 -15600000 13200000 18800000 -2200000 400000 9000000.0 8000000.0 -22000000.0 -25400000 -800000 1700000 10300000 -3700000 10400000 5500000 0 300000 14200000 4000000.0 24500000 6300000 0 2700000 0 7000000.0 -900000 0 100000 -100000 -19900000 -3700000 1000000.0 0 400000 500000 -300000 100000 -1700000 -400000 -11300000 -7800000 154000000.0 90600000 142700000 82800000 13700000 13700000 2700000 4500000 2500000 2000000.0 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Varex Imaging Corporation (the “Company” or “Varex”) designs, manufactures, sells, and services a broad range of medical products, which include X-ray imaging components including X-ray tubes, flat panel and photon counting detectors and accessories, ionization chambers, high voltage connectors, image processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. The Company sells its products to imaging system original equipment manufacturer (“OEM”) customers for incorporation into new medical diagnostic, radiation therapy, dental, and veterinary equipment, as well as to independent service companies and distributors, and directly to end-users for replacement purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company also designs, manufactures, sells and services industrial products, which include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, coolers, imaging processing software and image detection products for security and inspection purposes, such as cargo screening at ports and borders and nondestructive examination in a variety of applications. The Company generally sells security and inspection products to OEM customers who incorporate Varex’s products into their inspection or irradiation systems and processes. The Company conducts an active research and development program to focus on new technology and applications in both the medical and industrial X-ray imaging markets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements include all adjustments necessary for a fair presentation of the results for the interim periods. The Company has consolidated all of its majority owned subsidiaries and entities over which it has control. All intercompany balances and transactions have been eliminated as part of the consolidation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended September 29, 2023 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on November 16, 2023. The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures. Except for the change in certain policies upon adoption of the accounting standards described below, there have been no material changes to the Company's significant accounting policies, compared to the accounting policies described in Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the Company’s Annual Report on Form 10-K for fiscal year 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has two reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its Chief Executive Officer, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance. See Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further information on the Company’s segments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Year</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The fiscal years of the Company as reported are the 52 or 53-week periods ending on the Friday nearest September 30. Fiscal year 2024 is the 52-week period ending September 27, 2024. Fiscal year 2023 was the 52-week period that ended on September 29, 2023. The fiscal quarters ended December 29, 2023 and December 30, 2022 were both 13-week periods.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, valuation of goodwill and intangible assets, receivables, warranties, refund liabilities, long-lived asset valuations, impairment of investments, valuation of financial instruments, and taxes on income. Actual results could differ from these estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company considers unrestricted currency on hand, demand deposits, time deposits, and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the Company's Condensed Consolidated Balance Sheets. Cash and cash equivalents and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total as presented in the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities, certificates of deposit, and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. To date, the Company has not realized any losses on its deposits of cash and cash equivalents. The Company performs ongoing credit evaluations of its customers and, except for government tenders, group purchases, and orders with a letter of credit, its industrial customers often provide a down payment. The Company maintains an allowance for credit losses based upon the expected collectability of all accounts receivable. The Company obtains some of the components in its products from a limited group of suppliers or from a single-source supplier. When these suppliers are unable to meet the Company's supply needs, the Company's production is negatively impacted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Credit is extended to customers based on an evaluation of the customer’s financial condition, and collateral is not required. In certain circumstances, a customer may be required to prepay all or a portion of the contract price prior to transfer of control. During the periods presented, one of the Company's customers accounted for a significant portion of revenues, as set forth below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canon Medical Systems Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Canon Medical Systems Corporation accounted for 8.2% and 13.8% of the Company’s accounts receivable as of December 29, 2023 and September 29, 2023, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in, but not control, these investments. The Company records impairment losses on its equity method investments if an impairment exists and is deemed to be other-than-temporary, which is based on various factors, including but not limited to, the length of time the fair value of the investment is below the carrying value, the absence of an ability to recover the carrying amount of the investment, and the inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. There were no impairments recorded during the three months ended December 29, 2023 and December 30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's marketable securities consist primarily of financial instruments such as United States treasury securities, United States agency obligations, corporate bonds, commercial paper, money market funds, and equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's marketable debt securities are classified as available-for-sale. Classification of marketable debt securities is determined at the time of purchase, and the Company reevaluates such classification as of each balance sheet date. Marketable debt securities are recorded at estimated fair value and included in cash and cash equivalents, prepaid expenses and other current assets, and other assets within the Condensed Consolidated Balance Sheets. Any unrealized gains or losses are included in accumulated other comprehensive loss within the Condensed Consolidated Balance Sheets. When the fair value of a marketable debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in the Condensed Consolidated Statements of Operations. When the fair value of a marketable debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss, and are recognized in the Condensed Consolidated Statements of Operations only if the Company sells or intends to sell the security before recovery of its cost basis. There were no impairments related to marketable debt securities recorded during the three months ended December 29, 2023 and December 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Marketable equity securities are stated at fair value as determined by the most recently traded price of each security at the balance sheet date and included in other assets within the Condensed Consolidated Balance Sheets. All unrealized gains and losses on marketable equity securities are recorded as part of <span style="-sec-ix-hidden:f-334">other income (expense), net</span> in the Company's Condensed Consolidated Statements of Operations. See Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further details.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    From time to time, the Company is involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, and other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. When a loss contingency is probable but not reasonably estimable the nature of the contingency and the fact that an estimate cannot be made is disclosed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplier Finance Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company participates in voluntary supply chain finance programs with a financial intermediary which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. As part of participating in these arrangements, the Company generally receives more favorable payment terms from its suppliers. The Company does not receive fees, payments, extended payment terms, or other direct economic benefits from the intermediary. The total amounts due to the financial intermediary to settle supplier invoices under supply chain finance programs as of December 29, 2023 and September 29, 2023 were $2.3 million and $4.2 million, respectively. These amounts are included within accounts payable in the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport, and disposal of hazardous substances. Certain of those laws impose cleanup liabilities under certain circumstances. In connection with those laws and certain of our past and present operations and facilities, the Company is obligated to indemnify Varian Medical Systems, Inc. ("Varian") for the cleanup liabilities related to prior corporate restructuring activities. The Company anticipates that it will be obligated to reimburse Varian for 20% of the liabilities of Varian related to these sites (after adjusting for any insurance proceeds or tax benefits received by Varian). As of December 29, 2023, our estimated environmental liability for these sites was $2.6 million, net of expected insurance proceeds. As of September 29, 2023, our estimated liability for these sites was $2.8 million, net of expected insurance proceeds. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranty</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience of product failures, adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table reflects the changes in the Company’s accrued product warranty:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product warranty, at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New accruals charged to cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product warranty expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product warranty, at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represent the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate. The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its Condensed Consolidated Balance Sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its Condensed Consolidated Balance Sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray imaging components including X-ray tubes, digital detectors and image-processing tools, and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X-ray imaging and sells its Linatron® X-ray linear accelerators together with its image processing software and image detection products to OEM customers that incorporate them into their inspection or irradiation systems and processes. Service contracts are often sold with certain security and inspection products and computer-aided detection products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company determines revenue recognition through the following steps:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract, or contracts, with a customer</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when, or as, a performance obligation is satisfied</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts and Performance Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price and Allocation to Performance Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current, and forecasted) that is reasonably available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. For sales with a right of return, revenue is reduced and a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding refund liability and right of return asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation could be sold separately.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recognition of Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Service revenue is generally recognized over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract, and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report, for the disaggregation of the Company’s revenue based on reportable operating segments and Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the disaggregation of revenue by geographic region.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Contract liabilities are included within the deferred revenues, and other long-term liabilities balances in the Condensed Consolidated Balance Sheets. The Company does not have any material contract assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Deferred revenue represents the Company's obligation to transfer goods or services to its customers for which it has already received consideration (or the amount is due) from the customer. The Company's deferred revenue balance primarily relates to contract advances and billings for warranty contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Deferred revenue that is estimated to be recognized during the following twelve-month period is recorded as deferred revenues and the remaining portion is recorded as other long-term liabilities in the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain or Fulfill a Customer Contract</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The Company adopted this ASU on October 1, 2022, using the modified retrospective method. For further details, refer to Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Notes to the Condensed Consolidated Financial Statements of our Annual Report on Form 10-K for the fiscal year ended September 29, 2023 filed with the SEC on November 16, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs, which requires entities to provide qualitative and quantitative disclosures about their supplier finance programs, including a rollforward of related obligations. The adoption of ASU 2022-04 did not affect the Company’s financial condition, results of operations, or cash flows as the guidance only requires additional disclosures. We adopted this ASU effective September 30, 2023 on a retrospective basis, except for the amendment on rollforward information, which has been adopted on a prospective basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards or Updates Not Yet Effective</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    There are no new accounting standards not yet adopted or effective that are expected to have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, these unaudited condensed consolidated financial statements include all adjustments necessary for a fair presentation of the results for the interim periods. The Company has consolidated all of its majority owned subsidiaries and entities over which it has control. All intercompany balances and transactions have been eliminated as part of the consolidation.</span></div> These condensed consolidated financial statements and the accompanying notes are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended September 29, 2023 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on November 16, 2023. The Company considers events or transactions that occur after the balance sheet date, but before the financial statements are issued, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosures. <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div>    The Company has two reportable operating segments; (i) Medical and (ii) Industrial, which aligns with how its Chief Executive Officer, who is the Company's Chief Operating Decision Maker (“CODM”), reviews the Company’s performance. 2 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiscal Year</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The fiscal years of the Company as reported are the 52 or 53-week periods ending on the Friday nearest September 30. Fiscal year 2024 is the 52-week period ending September 27, 2024. Fiscal year 2023 was the 52-week period that ended on September 29, 2023. The fiscal quarters ended December 29, 2023 and December 30, 2022 were both 13-week periods.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Such estimates include the valuation of inventories, valuation of goodwill and intangible assets, receivables, warranties, refund liabilities, long-lived asset valuations, impairment of investments, valuation of financial instruments, and taxes on income. Actual results could differ from these estimates.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company considers unrestricted currency on hand, demand deposits, time deposits, and all highly-liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div>    Restricted cash primarily consists of cash collateral related to certain leases and inventory arrangements. Restricted cash is included in other assets on the Company's Condensed Consolidated Balance Sheets. Cash and cash equivalents and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total as presented in the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Cash and cash equivalents and restricted cash as reported within the Condensed Consolidated Statements of Cash Flows consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning of Period</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total as presented in the Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 152600000 141300000 89400000 81500000 1400000 1400000 1200000 1300000 154000000.0 142700000 90600000 82800000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk</span></div>    Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities, certificates of deposit, and trade accounts receivable. Cash held with financial institutions may exceed the Federal Deposit Insurance Corporation insurance limits or similar limits in foreign jurisdictions. To date, the Company has not realized any losses on its deposits of cash and cash equivalents. During the periods presented, one of the Company's customers accounted for a significant portion of revenues, as set forth below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canon Medical Systems Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 0.147 0.201 0.082 0.138 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</span></div>    The Company accounts for its equity investments in privately-held companies under the equity method of accounting if the Company has the ability to exercise significant influence in, but not control, these investments. The Company records impairment losses on its equity method investments if an impairment exists and is deemed to be other-than-temporary, which is based on various factors, including but not limited to, the length of time the fair value of the investment is below the carrying value, the absence of an ability to recover the carrying amount of the investment, and the inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's marketable securities consist primarily of financial instruments such as United States treasury securities, United States agency obligations, corporate bonds, commercial paper, money market funds, and equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's marketable debt securities are classified as available-for-sale. Classification of marketable debt securities is determined at the time of purchase, and the Company reevaluates such classification as of each balance sheet date. Marketable debt securities are recorded at estimated fair value and included in cash and cash equivalents, prepaid expenses and other current assets, and other assets within the Condensed Consolidated Balance Sheets. Any unrealized gains or losses are included in accumulated other comprehensive loss within the Condensed Consolidated Balance Sheets. When the fair value of a marketable debt security declines below its amortized cost basis, any portion of that decline attributable to credit losses, to the extent expected to be nonrecoverable before the sale of the security, is recognized in the Condensed Consolidated Statements of Operations. When the fair value of a marketable debt security declines below its amortized cost basis due to changes in interest rates, such amounts are recorded in other comprehensive loss, and are recognized in the Condensed Consolidated Statements of Operations only if the Company sells or intends to sell the security before recovery of its cost basis. There were no impairments related to marketable debt securities recorded during the three months ended December 29, 2023 and December 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Marketable equity securities are stated at fair value as determined by the most recently traded price of each security at the balance sheet date and included in other assets within the Condensed Consolidated Balance Sheets. All unrealized gains and losses on marketable equity securities are recorded as part of <span style="-sec-ix-hidden:f-334">other income (expense), net</span> in the Company's Condensed Consolidated Statements of Operations. See Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further details.</span></div> 0 0 0 0 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    From time to time, the Company is involved in legal proceedings, claims and government inspections or investigations, customs and duties audits, and other contingency matters, both inside and outside the United States, arising in the ordinary course of its business or otherwise. The Company accrues amounts for probable losses, to the extent they can be reasonably estimated, that it believes are adequate to address any liabilities related to legal proceedings and other loss contingencies that the Company believes will result in a probable loss (including, among other things, probable settlement value). A loss or a range of loss is disclosed when it is reasonably possible that a material loss will be incurred and can be estimated or when it is reasonably possible that the amount of a loss, when material, will exceed the recorded provision. When a loss contingency is probable but not reasonably estimable the nature of the contingency and the fact that an estimate cannot be made is disclosed.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supplier Finance Programs</span></div>    The Company participates in voluntary supply chain finance programs with a financial intermediary which provide participating suppliers the option to be paid by the intermediary earlier than the original invoice due date. The Company’s responsibility is limited to making payments on the terms originally negotiated with the suppliers, regardless of whether the intermediary pays the supplier in advance of the original due date. As part of participating in these arrangements, the Company generally receives more favorable payment terms from its suppliers. The Company does not receive fees, payments, extended payment terms, or other direct economic benefits from the intermediary. 2300000 4200000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental Obligations</span></div>    The Company's operations and facilities, past and present, are subject to environmental laws, including laws that regulate the handling, storage, transport, and disposal of hazardous substances. Certain of those laws impose cleanup liabilities under certain circumstances. In connection with those laws and certain of our past and present operations and facilities, the Company is obligated to indemnify Varian Medical Systems, Inc. ("Varian") for the cleanup liabilities related to prior corporate restructuring activities. The Company anticipates that it will be obligated to reimburse Varian for 20% of the liabilities of Varian related to these sites (after adjusting for any insurance proceeds or tax benefits received by Varian). As of December 29, 2023, our estimated environmental liability for these sites was $2.6 million, net of expected insurance proceeds. As of September 29, 2023, our estimated liability for these sites was $2.8 million, net of expected insurance proceeds. 0.20 2600000 2800000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Warranty</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company warrants most of its products for a specific period of time, usually 12 to 24 months from delivery or acceptance, against material defects. The Company provides for the estimated future costs of warranty obligations in cost of revenues when the related revenues are recognized. The accrued warranty costs represent the best estimate at the time of sale of the total costs that the Company will incur to repair or replace product parts that fail while still under warranty.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The amount of the accrued estimated warranty costs obligation for established products is primarily based on historical experience of product failures, adjusted for current information on repair costs. For new products, estimates include the historical experience of similar products, as well as a reasonable allowance for warranty expenses associated with new products. On a quarterly basis, the Company reviews the accrued warranty costs and updates the historical warranty cost trends, if required.</span></div> P12M P24M The following table reflects the changes in the Company’s accrued product warranty:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product warranty, at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New accruals charged to cost of revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product warranty expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued product warranty, at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 7700000 7900000 3700000 2800000 3400000 3000000.0 8000000.0 7700000 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company determines if an arrangement is or contains a lease at the inception of an arrangement. The Company's operating lease right-of-use ("ROU") assets represent the right to use an underlying asset over the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. ROU assets may also include initial direct costs incurred and prepaid lease payments, less lease incentives. Lease liabilities and their corresponding ROU assets are recognized based on the present value of lease payments over the lease term, discounted using the Company's incremental borrowing rate. The Company recognizes operating leases with lease terms of more than twelve months in operating lease assets, current operating lease liabilities, and operating lease liabilities on its Condensed Consolidated Balance Sheets. The Company recognizes finance leases with lease terms of more than twelve months in property, plant, and equipment, net, accrued liabilities and other current liabilities, and other long-term liabilities on its Condensed Consolidated Balance Sheets. For purposes of calculating lease liabilities and the corresponding ROU assets, the Company's lease term may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company’s revenues are derived primarily from the sale of hardware and services. The Company recognizes its revenues net of any value-added or sales tax and net of sales discounts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company sells a high proportion of its X-ray products to a limited number of OEM customers. X-ray imaging components including X-ray tubes, digital detectors and image-processing tools, and security and inspection products are generally sold on a stand-alone basis. However, the Company occasionally sells its digital detectors, X-ray tubes and imaging processing tools as a package that is optimized for digital X-ray imaging and sells its Linatron® X-ray linear accelerators together with its image processing software and image detection products to OEM customers that incorporate them into their inspection or irradiation systems and processes. Service contracts are often sold with certain security and inspection products and computer-aided detection products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company determines revenue recognition through the following steps:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract, or contracts, with a customer</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract</span></div><div style="padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when, or as, a performance obligation is satisfied</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts and Performance Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company accounts for a contract with a customer when there is an approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and collectability of the consideration is probable. The Company's performance obligations consist mainly of transferring control of products and services identified in the contracts or purchase orders. For each contract, the Company considers the obligation to transfer products and services to the customer, which are distinct, to be performance obligations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transaction Price and Allocation to Performance Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Transaction prices of products or services are typically based on contracted rates. To the extent that the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method when there is a large number of transactions with similar characteristics or the most likely amount method when there are two possible outcomes, depending on the circumstances of the transaction, to which the Company expects to be entitled. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current, and forecasted) that is reasonably available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company allows customers to return specific parts of purchased X-ray tubes for a partial refund credit, which is identified as variable consideration. For sales with a right of return, revenue is reduced and a liability is recorded for expected returns, and an asset is recorded for the right to recover products from customers on settling the liability. The Company recognizes a reduction to revenue and cost of sales at the time of sale and a corresponding refund liability and right of return asset. The Company records this estimate based on the historical volume of product returns and adjusts the estimate on a quarterly basis based on the current quarter sales and current quarter returns.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    If a contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation could be sold separately.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recognition of Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Revenue is recognized when, or as, obligations under the terms of a contract are satisfied, which occurs when control of the promised products or services is transferred to customers. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products or services to a customer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Product revenue is generally recognized when the customer obtains control of the Company’s product, which occurs at a point in time, and may be upon shipment or upon delivery based on the contractual shipping terms of a contract.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Service revenue is generally recognized over the term of the service contract. Services are expected to be transferred to the customer throughout the term of the contract, and the Company believes recognizing revenue ratably over the term of the contract best depicts the transfer of value to the customer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Revenue is disaggregated from contracts between geography and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors. Refer to Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report, for the disaggregation of the Company’s revenue based on reportable operating segments and Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the disaggregation of revenue by geographic region.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Contract liabilities are included within the deferred revenues, and other long-term liabilities balances in the Condensed Consolidated Balance Sheets. The Company does not have any material contract assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Deferred revenue represents the Company's obligation to transfer goods or services to its customers for which it has already received consideration (or the amount is due) from the customer. The Company's deferred revenue balance primarily relates to contract advances and billings for warranty contracts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Deferred revenue that is estimated to be recognized during the following twelve-month period is recorded as deferred revenues and the remaining portion is recorded as other long-term liabilities in the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain or Fulfill a Customer Contract</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has certain costs to obtain and fulfill a customer contract, such as commissions and shipping costs. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred if the amortization period of the assets that the Company otherwise would have recognized is one year or less. Incremental costs of obtaining contracts that would be recognized over greater than one year are not material. The Company accounts for shipping and handling activities related to contracts with customers as costs to fulfill the promise to transfer the associated products. These costs are included as a component of cost of revenues.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. The Company adopted this ASU on October 1, 2022, using the modified retrospective method. For further details, refer to Note 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Notes to the Condensed Consolidated Financial Statements of our Annual Report on Form 10-K for the fiscal year ended September 29, 2023 filed with the SEC on November 16, 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs, which requires entities to provide qualitative and quantitative disclosures about their supplier finance programs, including a rollforward of related obligations. The adoption of ASU 2022-04 did not affect the Company’s financial condition, results of operations, or cash flows as the guidance only requires additional disclosures. We adopted this ASU effective September 30, 2023 on a retrospective basis, except for the amendment on rollforward information, which has been adopted on a prospective basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards or Updates Not Yet Effective</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    There are no new accounting standards not yet adopted or effective that are expected to have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div> REVENUE RECOGNITION<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Revenue is disaggregated from contracts by geographic region and by reportable operating segment, which the Company believes best depicts how the nature, amount, timing, and uncertainty of revenues and cash flows are affected by economic factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table disaggregates the Company’s revenue by geographic region:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Revenue in the United States was $60.6 million and $65.4 million for the three months ended December 29, 2023 and December 30, 2022, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Our products are sold in three geographic regions: the Americas, EMEA, and APAC. The Americas includes North America (primarily the United States) and Latin America. EMEA includes Europe, the Middle East, India, and Africa. APAC includes Asia (other than India) and Australia. Revenues by region are based on the known final destination of products sold.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Refer to Note 15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the disaggregation of the Company’s revenue based on reportable operating segments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Right of Return Assets and Refund Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Right of return assets are included within the prepaid expenses and other current assets, and other assets balances in the Condensed Consolidated Balance Sheets. Refund liabilities are included within the accrued liabilities and other current liabilities and other long-term liabilities balances in the Condensed Consolidated Balance Sheets. The following table summarizes the changes in the right of return assets and refund liabilities for the three months ended December 29, 2023 and December 30, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Right of Return Assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs recovered from product returns during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of return assets from shipments of products subject to return during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Refund Liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Release of refund liability included in beginning of year refund liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to refund liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Balances</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the three months ended December 29, 2023, the Company recognized revenue of $6.8 million related to deferred revenues which existed at September 29, 2023. During the three months ended December 30, 2022, the Company recognized revenue of $4.2 million related to deferred revenues that existed at September 30, 2022.</span></div> The following table disaggregates the Company’s revenue by geographic region:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Americas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EMEA</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">APAC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 62400000 66600000 66000000.0 65300000 61600000 73700000 190000000.0 205600000 60600000 65400000 The following table summarizes the changes in the right of return assets and refund liabilities for the three months ended December 29, 2023 and December 30, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Right of Return Assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs recovered from product returns during the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of return assets from shipments of products subject to return during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Refund Liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Release of refund liability included in beginning of year refund liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to refund liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 26000000.0 25400000 1900000 1500000 1400000 1500000 25500000 25400000 28900000 28200000 2100000 1600000 1500000 1700000 28300000 28300000 6800000 4200000 LEASES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles, and equipment. The following table presents supplemental balance sheet information related to the Company's operating and finance leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394"><span style="-sec-ix-hidden:f-395">Property, plant, and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities (current) </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities (current) </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-400"><span style="-sec-ix-hidden:f-401">Accrued liabilities and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities (non-current)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities (non-current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-406"><span style="-sec-ix-hidden:f-407">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table provides information related to the Company’s operating and finance leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash operating right-of-use assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash finance right-of-use assets obtained in exchange for new lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total right-of-use assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes variable and short-term lease expense, which were immaterial for the three months ended December 29, 2023 and December 30, 2022.</span></div> LEASES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has operating and finance leases for office space, warehouse and manufacturing space, vehicles, and equipment. The following table presents supplemental balance sheet information related to the Company's operating and finance leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394"><span style="-sec-ix-hidden:f-395">Property, plant, and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities (current) </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities (current) </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-400"><span style="-sec-ix-hidden:f-401">Accrued liabilities and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities (non-current)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities (non-current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-406"><span style="-sec-ix-hidden:f-407">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table provides information related to the Company’s operating and finance leases:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash operating right-of-use assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash finance right-of-use assets obtained in exchange for new lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total right-of-use assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes variable and short-term lease expense, which were immaterial for the three months ended December 29, 2023 and December 30, 2022.</span></div> The following table presents supplemental balance sheet information related to the Company's operating and finance leases:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-394"><span style="-sec-ix-hidden:f-395">Property, plant, and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities (current) </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities (current) </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-400"><span style="-sec-ix-hidden:f-401">Accrued liabilities and other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities (non-current)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities (non-current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-406"><span style="-sec-ix-hidden:f-407">Other long-term liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 28400000 29000000.0 1000000.0 300000 3800000 3800000 200000 100000 22900000 23100000 600000 200000 The following table provides information related to the Company’s operating and finance leases:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.651%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash operating right-of-use assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash finance right-of-use assets obtained in exchange for new lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total right-of-use assets obtained in exchange for new lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes variable and short-term lease expense, which were immaterial for the three months ended December 29, 2023 and December 30, 2022.</span></div> 1500000 1500000 100000 100000 1400000 1600000 300000 100000 1700000 1700000 1500000 0 700000 0 2200000 0 RELATED-PARTY TRANSACTIONS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately-Held Companies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has a 40% ownership interest in dpiX Holding LLC (“dpiX Holding”), a holding company that has a 100% ownership interest in dpiX LLC (“dpiX”), a supplier of amorphous silicon-based thin film transistor arrays for flat panels used in the Company's digital image detectors. In accordance with the dpiX Holding operating agreement, net profits or losses are allocated to the members in accordance with their ownership interests.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The investment in dpiX Holding is accounted for under the equity method of accounting. When the Company recognizes its share of net profits or losses of dpiX Holding, profits or losses in inventory purchased from dpiX are also eliminated. During the three months ended December 29, 2023 and December 30, 2022, the Company recorded income on the equity investment in dpiX Holding of $0.5 million and $2.0 million, respectively. The income and loss on the equity investment in dpiX Holding are included in <span style="-sec-ix-hidden:f-432">other income (expense), net</span> in the Condensed Consolidated Statements of Operations. The carrying value of the equity investment in dpiX Holding was $26.3 million and $25.8 million at December 29, 2023 and September 29, 2023, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the three months ended December 29, 2023 and December 30, 2022, the Company purchased glass transistor arrays from dpiX totaling $5.0 million and $5.0 million, respectively. These purchases of glass transistor arrays are included as a component of inventories on the Condensed Consolidated Balance Sheets or cost of revenues in the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of December 29, 2023 and September 29, 2023, the Company had accounts payable to dpiX totaling $2.8 million and $2.7 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     In October 2013, the Company entered into an amended agreement with dpiX and other parties that, among other things, provides it with the right to 50% of dpiX’s total manufacturing capacity. In addition, the Company is required to pay for 50% of dpiX's fixed costs, as determined at the beginning of each calendar year. In January 2024, the Company's fixed cost commitment was determined and approved by the dpiX board of directors to be $12.4 million for calendar year 2024. The amended agreement will continue unless the ownership structure of dpiX changes (as defined in the amended agreement).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has determined that dpiX Holding is a variable interest entity because the at-risk equity holders, as a group, lack the characteristics of a controlling financial interest. Majority votes are required to direct the manufacturing activities, legal operations and other activities that most significantly affect dpiX’s economic performance. The Company does not have majority voting rights and no power to unilaterally direct the activities of dpiX Holding, and therefore, is not the primary beneficiary of dpiX Holding. The Company’s exposure to loss as a result of its involvement with dpiX Holding is limited to the carrying value of the Company’s investment of $26.3 million and fixed cost commitments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In November 2018, the Company (through one of its wholly-owned subsidiaries) and CETTEEN GmbH (“CETTEEN”), formed a German limited liability company that governs the affairs and conduct of the business of VEC Imaging GmbH &amp; Co. KG (“VEC”), a joint venture formed to develop technology for use in X-ray imaging components. In accordance with the VEC agreement, net profits or losses are allocated to the members in accordance with their ownership interest. The Company's investment in VEC is accounted for under the equity method of accounting. The Company has determined that VEC is a variable interest entity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the three months ended December 29, 2023 and December 30, 2022, the Company recorded a loss on the equity investment in VEC of $0.1 million and $0.3 million, respectively. The Company's investment in VEC was $2.0 million and $2.1 million at December 29, 2023 and September 29, 2023, respectively. As of December 29, 2023 and September 29, 2023, the Company had loans and other receivables outstanding from VEC of $0.7 million, and $0.7 million, respectively, which are recorded in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets.</span></div> 0.40 1 500000 2000000 26300000 25800000 5000000 5000000 2800000 2700000 0.50 0.50 12400000 26300000 -100000 -300000 2000000 2100000 700000 700000 FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As part of the Company’s overall risk management practices, the Company enters into financial derivatives to manage its financial exposures to foreign currency exchange rates and interest rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company records all derivatives on the Condensed Consolidated Balance Sheets at fair value. The accounting for changes in the fair value of derivatives depends on the intended use of the derivative, whether the Company has elected to designate a derivative in a hedging relationship and apply hedge accounting, and whether the hedging relationship has satisfied the criteria necessary to apply hedge accounting. A qualitative assessment of hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate the hedge may no longer be highly effective, in which case the Company would test for effectiveness on a more frequent basis. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period income. The Company does not offset fair value amounts recognized for derivative instruments in its Condensed Consolidated Balance Sheets for presentation purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions that meet certain minimum credit ratings to help mitigate counterparty credit risk.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives Designated as Hedging Instruments - Net Investment Hedges</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company uses cross currency swap contracts as net investment hedges to manage its risk of variability in foreign currency-denominated net investments in wholly-owned international operations. All changes in fair value of the derivatives designated as net investment hedges are reported in accumulated other comprehensive loss along with the foreign currency translation adjustments on those investments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of December 29, 2023, the Company had the following outstanding derivatives designated as net investment hedging instruments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions, except number of instruments)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Notional Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table summarizes the amount of pre-tax income recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:28.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.090%"></td><td style="width:0.1%"></td></tr><tr style="height:48pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of Loss Recognized in OCI on Derivative<br/>Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)<br/>Three Months Ended</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross currency swap contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying Condensed Consolidated Balance Sheets where the instruments are recorded:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Assets and Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Net Investment Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Hedges</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company also enters into foreign currency forward contracts to hedge fluctuations associated with foreign currency-denominated monetary assets and liabilities, primarily cash, lease contracts, third-party accounts receivable and payable, and intercompany accounts receivable and payable. These forward contracts are generally entered into at the end of one fiscal period and expire by the end of the next fiscal period. These forward contracts are not designated for hedge accounting treatment; therefore, the change in fair value of these derivatives is recorded as a component of <span style="-sec-ix-hidden:f-462">other income (expense), net</span> in the Condensed Consolidated Statements of Operations and offsets the change in fair value of the foreign currency-denominated assets and liabilities, which are also recorded as a component of <span style="-sec-ix-hidden:f-463">other income (expense), net</span>. The Company has not and does not intend to use derivative financial instruments for speculative or trading purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table shows the notional amounts of outstanding foreign currency contracts as of December 29, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Notional Value of Derivatives not Designated as Hedging Instruments:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions of equivalent USD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sell contracts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australian Dollar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chinese Renminbi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indian Rupee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> As of December 29, 2023, the Company had the following outstanding derivatives designated as net investment hedging instruments:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions, except number of instruments)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Notional Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>The following table shows the notional amounts of outstanding foreign currency contracts as of December 29, 2023:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.872%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:17.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Notional Value of Derivatives not Designated as Hedging Instruments:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions of equivalent USD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sell contracts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australian Dollar</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chinese Renminbi</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indian Rupee</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2 58700000 The following table summarizes the amount of pre-tax income recognized from derivative instruments for the periods indicated and the line items in the accompanying statements of operations where the results are recorded for net investment hedges:<div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"></td><td style="width:28.171%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.090%"></td><td style="width:0.1%"></td></tr><tr style="height:48pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of Loss Recognized in OCI on Derivative<br/>Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)<br/>Three Months Ended</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross currency swap contracts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 2.12pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    These derivative instruments are subject to master netting agreements giving effect to rights of offset with each counterparty. None of the balances were eligible for netting. The following table summarizes the gross fair values of derivative instruments as of the periods indicated and the line items in the accompanying Condensed Consolidated Balance Sheets where the instruments are recorded:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative Assets and Liabilities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Designated as Net Investment Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross currency swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cross currency swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -2700000 -4000000.0 300000 200000 800000 700000 7700000 4900000 3800000 10200000 13300000 5000000.0 32300000 FAIR VALUE<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The fair values of certain of the Company’s financial instruments, including bank deposits included in cash and cash equivalents, accounts receivable, net and accounts payable, approximate their fair values due to their short maturities. As of December 29, 2023, the fair values of the Company’s Convertible Notes and Senior Secured Notes, as defined in Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and measured using Level 1 inputs, were $234.0 million and $244.4 million, respectively. As of September 29, 2023, the fair values of the Company’s Convertible Notes and Senior Secured Notes, measured using Level 1 inputs, were $228.4 million and $243.6 million, respectively. The Company has elected to use the income approach to value its derivative instruments using standard valuation techniques and Level 2 inputs, such as currency spot rates, forward points and credit default swap spreads.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value at December 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quoted Prices in Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant Unobservable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-507">Total assets measured at fair value</span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-516">Total liabilities measured at fair value</span></span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assets held under the Company’s deferred compensation plan are classified in Level 1, as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value at September 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quoted Prices in Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant Unobservable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-553">Total assets measured at fair value</span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-562">Total liabilities measured at fair value</span></span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assets held under the Company’s deferred compensation plan are classified in Level 1 as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following is a summary of marketable debt securities, which are included within the cash and cash equivalents, prepaid expenses and other current assets, and other assets balances on the Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The contractual maturities of marketable debt securities as of December 29, 2023, are shown in the table below. Actual maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual maturities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the three months ended December 29, 2023, there were no gross realized gains or losses from the sale of certain marketable debt securities that were reclassified out of accumulated other comprehensive loss.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following tables summarize the balance sheet locations for marketable debt securities:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial paper</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Corporate notes/bonds</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government agencies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Treasury bills</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial paper</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Corporate notes/bonds</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government agencies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Treasury bills</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 234000000 244400000 228400000 243600000 In the tables below, the Company has segregated all assets and liabilities that are measured at fair value on a recurring basis into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value at December 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quoted Prices in Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant Unobservable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-507">Total assets measured at fair value</span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liabilities</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-516">Total liabilities measured at fair value</span></span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assets held under the Company’s deferred compensation plan are classified in Level 1, as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value at September 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Quoted Prices in Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Observable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Significant Unobservable Inputs</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-553">Total assets measured at fair value</span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-562">Total liabilities measured at fair value</span></span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The assets held under the Company’s deferred compensation plan are classified in Level 1 as they relate primarily to publicly traded mutual funds for which there are observable market prices in active markets.</span></div> 0 20500000 0 20500000 0 8300000 0 8300000 0 10300000 0 10300000 0 20100000 0 20100000 0 21800000 0 21800000 0 800000 0 800000 6900000 0 0 6900000 3600000 0 0 3600000 10500000 81800000 0 92300000 0 7700000 0 7700000 0 7700000 0 7700000 0 45400000 0 45400000 0 6000000.0 0 6000000.0 0 8300000 0 8300000 0 6600000 0 6600000 0 28600000 0 28600000 0 700000 0 700000 6300000 0 0 6300000 4100000 0 0 4100000 10400000 95600000 0 106000000.0 0 4900000 0 4900000 0 4900000 0 4900000 The following is a summary of marketable debt securities, which are included within the cash and cash equivalents, prepaid expenses and other current assets, and other assets balances on the Condensed Consolidated Balance Sheets.<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized Costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8300000 8300000 10300000 10300000 21800000 21800000 20100000 20100000 60500000 60500000 6000000.0 6000000.0 8300000 8300000 28600000 28600000 6600000 6600000 49500000 49500000 The contractual maturities of marketable debt securities as of December 29, 2023, are shown in the table below. Actual maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations.<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amortized Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual maturities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following tables summarize the balance sheet locations for marketable debt securities:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial paper</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Corporate notes/bonds</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government agencies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Treasury bills</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial paper</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Corporate notes/bonds</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government agencies</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Treasury bills</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 60500000 60500000 0 0 60500000 60500000 8300000 0 0 0 8300000 0 10300000 20100000 21800000 52200000 8300000 10300000 20100000 21800000 60500000 6000000.0 0 0 2200000 8200000 0 8300000 6600000 26400000 41300000 6000000.0 8300000 6600000 28600000 49500000 INVENTORIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table summarizes the Company’s inventories:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and parts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> The following table summarizes the Company’s inventories:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and parts</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 223500000 217500000 19500000 20000000.0 46700000 40000000.0 289700000 277500000 GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table reflects goodwill by reportable operating segment:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Industrial</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 29, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 29, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the Condensed Consolidated Balance Sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired existing technology</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents, licenses and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer contracts and supplier relationship</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:6.75pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Amortization expense for intangible assets was $3.6 million and $3.4 million for the three months ended December 29, 2023 and December 30, 2022, respectively. In connection with the business combination discussed in Note 10. Business Combinations, the Company recorded additional intangible assets of $2.6 million, of which $2.1 million related to customer contracts and supplier relationships and $0.5 million related to acquired existing technology.</span></div> The following table reflects goodwill by reportable operating segment:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.511%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Industrial</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 29, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance at December 29, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 171500000 117000000.0 288500000 1100000 800000 1900000 172600000 117800000 290400000 The following table reflects the gross carrying amount and accumulated amortization of the Company’s finite-lived intangible assets included in other assets in the Condensed Consolidated Balance Sheets:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.156%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Amortization</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Carrying Amount</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired existing technology</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents, licenses and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:9pt;padding-right:2.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer contracts and supplier relationship</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:6.75pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.4 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 73500000 59900000 13600000 72300000 57800000 14500000 12600000 12400000 200000 12500000 12200000 300000 52700000 44400000 8300000 50300000 42700000 7600000 138800000 116700000 22100000 135100000 112700000 22400000 3600000 3400000 2600000 2100000 500000 BORROWINGS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table summarizes the Company’s short-term and long-term debt:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions, except for percentages)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current maturities of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current maturities of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current maturities of long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible Senior Unsecured Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Secured Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current maturities of long-term debt:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">446.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">446.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unamortized issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized issuance costs - Convertible Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized issuance costs - Senior Secured Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total debt outstanding, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">443.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">442.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table summarizes the Company’s interest expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest coupon and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Senior Unsecured Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On June 9, 2020, Varex issued $200.0 million in aggregate principal amount of 4.00% Convertible Senior Unsecured Notes due 2025 (“Convertible Notes”). The net proceeds from the issuance of the Convertible Notes, after deducting transaction fees and offering expense payable by the Company, were approximately $193.1 million. The Convertible Notes bear interest at the annual rate of 4.00%, payable semiannually on June 1 and December 1 of each year, beginning on December 1, 2020, and will mature on June 1, 2025, unless earlier converted or repurchased by Varex.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Convertible Notes are convertible into cash, shares of Varex common stock or a combination thereof, at Varex’s election, at an initial conversion rate of 48.048 shares of common stock per $1,000 principal amount of Convertible Notes, which is equivalent to an initial conversion price of approximately $20.81 per share, subject to adjustment pursuant to the terms of the indenture governing the Convertible Notes. The Convertible Notes may be converted at any time after, and including, December 15, 2024, until the close of business on the second scheduled trading day immediately before the maturity date. The maximum number of shares issuable upon conversion of the Convertible Notes is 9.6 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Call Spread </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On June 4, 2020 and June 5, 2020, in connection with the offering of the Convertible Notes, Varex entered into privately negotiated convertible note hedge transactions (collectively, the “Hedge Transactions”). The Hedge Transactions cover, subject to customary anti-dilution adjustments, the number of shares of Varex common stock that initially underlie the Convertible Notes. The Hedge Transactions are expected generally to reduce the potential dilution and/or offset any cash payments Varex is required to make in excess of the principal amount due upon conversion of the Convertible Notes in the event that the market price of Varex common stock is greater than the strike price of the Hedge Transactions, which was initially $20.81 per share (subject to adjustment under the terms of the Hedge Transactions). The strike price of $20.81 corresponds to the initial conversion price of the Convertible Notes. The number of shares underlying the Hedge Transactions is 9.6 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On June 4, 2020 and June 5, 2020, Varex also entered into privately negotiated warrant transactions (collectively, the “Warrant Transactions” and, together with the Hedge Transactions, the “Call Spread Transactions”), whereby the Company sold warrants at a higher strike price relating to the same number of shares of Varex common stock that initially underlie the Convertible Notes, subject to customary anti-dilution adjustments. The initial strike price of the warrants is $24.975 per share (subject to adjustment under the terms of the Warrant Transactions), which was 50% above the last reported sale price of Varex common stock on June 4, 2020. The Warrant Transactions could have a dilutive effect to the Company's stockholders to the extent that the market price per share of Varex common stock, as measured under the terms of the Warrant Transactions, exceeds the applicable strike price of the warrants. The number of shares underlying the Warrant Transactions is 9.6 million. The number of warrants outstanding as of December 29, 2023 was 9.6 million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Varex issued $300.0 million aggregate principal amount of 7.875% Senior Secured Notes due 2027 (the "Senior Secured Notes") pursuant to an indenture dated September 30, 2020. Interest payments are paid semiannually on April 15 and October 15 of each year, beginning on April 15, 2021. The Senior Secured Notes will mature on October 15, 2027, unless earlier redeemed or repurchased by Varex. On July 15, 2021, we redeemed $30.0 million, and on March 18, 2022, we redeemed $27.0 million of the Senior Secured Notes. As of December 29, 2023, the aggregate principal amount of the outstanding Senior Secured Notes was $243.0 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Senior Secured Notes are secured by a first priority lien on substantially all of the assets of Varex and the assets and capital stock of its subsidiary guarantors (subject to exceptions), except for assets for which a first priority security interest is pledged for the ABL Facility (defined below), in which the Senior Secured Notes have a second lien security interest. The Senior Secured Notes include negative covenants, subject to certain exceptions, restricting or limiting Varex's ability and the ability of its restricted subsidiaries to, among other things, incur liens on collateral; sell certain assets; incur additional indebtedness; pay dividends; issue preferred shares; consolidate, merge, or sell all or substantially all of its assets; and enter into certain transactions with their affiliates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset-Based Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    On September 30, 2020, the Company entered into a revolving credit agreement consisting of a $100.0 million asset-based loan revolving credit facility (the “Asset-Based Loan” or "ABL Facility"). Borrowings under the Asset-Based Loan bear interest at floating rates based on the Secured Overnight Financing Rate ("SOFR"), or a comparable rate, or a base rate, and an applicable margin based on Average Daily Excess Availability (as defined in the Asset-Based Loan Agreement). In addition, the Company is required to pay a quarterly commitment fee of 0.25% annualized, based on the aggregate unused commitments under the Asset-Based Loan.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The ABL Facility matures on the earlier of September 30, 2025 or 91 days prior to the maturity of the Convertible Notes, at which time all outstanding amounts under the ABL Facility will be due and payable. The maximum availability under the ABL Facility is $100.0 million; however, the borrowing base under the ABL Facility fluctuates from month-to-month depending on the amount of eligible accounts receivable, inventory, and real estate. As of December 29, 2023, the amount available under the ABL Facility was $71.9 million and the ABL Facility remains undrawn.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The ABL Facility includes various restrictive covenants that limit our ability to engage in certain transactions, including the incurrence of debt, payment of dividends and other restrictive payments, existence of restrictions affecting subsidiaries, sales of stock and assets, certain affiliate transactions, modifications of debt documents and organizational documents, changes to line of business and fiscal year, incurrence of liens, making fundamental changes, prepayments of junior indebtedness, and certain other transactions.</span></div> The following table summarizes the Company’s short-term and long-term debt:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 29, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions, except for percentages)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effective Interest Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current maturities of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current maturities of long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current maturities of long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible Senior Unsecured Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Secured Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.2%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current maturities of long-term debt:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">446.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">446.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unamortized issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized issuance costs - Convertible Notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unamortized issuance costs - Senior Secured Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total debt outstanding, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">443.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">442.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 1600000 1500000 1600000 1500000 200000000.0 200000000.0 0.040 0.048 243000000.0 243000000.0 0.079 0.082 3200000 3500000 446200000 446500000 2100000 2500000 2700000 2900000 4800000 5400000 443000000.0 442600000 The following table summarizes the Company’s interest expense:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual interest coupon and other</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total interest expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 6600000 6900000 700000 600000 7300000 7500000 200000000 0.0400 193100000 0.0400 20.81 9600000 20.81 20.81 9600000 24.975 0.50 9600000 9600000 300000000 0.07875 30000000 27000000 243000000 100000000 0.0025 100000000 71900000 BUSINESS COMBINATIONS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    As of September 29, 2023, the Company, through two of its consolidated subsidiaries, Varex Imaging Deutschland AG and MeVis Medical Solutions AG ("MeVis Medical"), held a combined ownership interest in MeVis BreastCare GmbH and MeVis BreastCare Gmbh &amp; Co KG (referred to in combination as "MeVis Breastcare") of 37.6%. Because the Company had the ability to exercise significant influence in, but not control, over MeVis Breastcare, it was historically accounted for as an equity method investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In October 2023, the Company increased its ownership in MeVis Breastcare to 87.1% for a purchase price of $0.9 million, resulting in the Company now holding a controlling interest in MeVis Breastcare. The purchase of this additional ownership interest was accounted for as a business combination achieved in stages, or step acquisition. As a result, the previously held equity interest was remeasured to its acquisition-date fair value, with a gain of $0.9 million recognized in <span style="-sec-ix-hidden:f-737">other income (expense), net</span> in the Condensed Consolidated Statements of Operations. The assets and liabilities of MeVis Breastcare were then recorded on the Company's balance sheet at their fair values in accordance with ASC 805, and a gain on bargain purchase of $1.2 million was recorded in <span style="-sec-ix-hidden:f-739">other income (expense), net</span> in the Condensed Consolidated Statements of Operations. Because the purchase price did not give consideration to the other assets of the business, the fair value of the ownership interest acquired exceeded the price paid to the third party partial owner and this resulted in a gain on bargain purchase.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table summarizes the consideration paid for MeVis Breastcare and the amounts of the assets acquired and liabilities assumed recognized at their estimated acquisition date fair values, as well as the estimated fair value at the acquisition date of the noncontrolling interest in MeVis Breastcare.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.055%"><tr><td style="width:1.0%"></td><td style="width:87.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">USD<br/>(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration paid</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of total consideration transferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remeasurement of previous equity interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of previous equity interest before acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previous equity interest at acquisition date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement gain recorded on previous equity interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total of consideration paid and fair value of previous equity interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recognized amounts of identifiable assets acquired and liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest in MeVis Breastcare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bargain purchase gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.376 0.871 900000 900000 1200000 The following table summarizes the consideration paid for MeVis Breastcare and the amounts of the assets acquired and liabilities assumed recognized at their estimated acquisition date fair values, as well as the estimated fair value at the acquisition date of the noncontrolling interest in MeVis Breastcare.<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.055%"><tr><td style="width:1.0%"></td><td style="width:87.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.090%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">USD<br/>(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consideration paid</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of total consideration transferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remeasurement of previous equity interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of previous equity interest before acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of previous equity interest at acquisition date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement gain recorded on previous equity interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total of consideration paid and fair value of previous equity interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recognized amounts of identifiable assets acquired and liabilities assumed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest in MeVis Breastcare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bargain purchase gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 900000 900000 1100000 2000000.0 900000 2900000 1800000 1200000 2600000 100000 600000 100000 4800000 700000 1200000 2900000 NONCONTROLLING INTERESTS<div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In September 2018, the Company entered into a partnership in Saudi Arabia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has majority voting rights with an approximate 75% interest. Accordingly, the Company has consolidated the operations of the Saudi Arabia partnership in its Condensed Consolidated Financial Statements and recorded the noncontrolling interests. The noncontrolling interest related to the partner’s 25% interest is included in noncontrolling interests in the equity section of the Company’s Condensed Consolidated Balance Sheets. Income representing the noncontrolling partner's share of income from operations is included in the Company's Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In April 2015, the Company acquired 73.5% of the then outstanding shares of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MeVis Medical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a publicly traded company based in Bremen, Germany that provides image processing software and services for cancer screening. In August 2015, the Company, through one of its German subsidiaries, entered into a Domination and Profit and Loss Transfer Agreement (the “DPLTA”) with MeVis Medical. In fiscal years 2017 and 2018, the Company purchased an additional 0.2% of outstanding shares such that the Company now owns 73.7% of the outstanding shares of common stock of MeVis Medical. Under the DPLTA, MeVis Medical subordinates its management to the Company and undertakes to transfer all its annual profits and losses to the Company. In return, the DPLTA grants the noncontrolling shareholders of MeVis Medical, an annual recurring net compensation of €0.95 per MeVis Medical share. At December 29, 2023, noncontrolling shareholders together held approximately 0.5 million shares of MeVis Medical, representing 26.3% of the outstanding shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    During the first quarter of fiscal year 2024, the Company acquired a controlling interest in MeVis Breastcare, in which the Company now holds an 87.1% ownership interest. In association with this acquisition, the Company recorded an associated noncontrolling interest of $0.7 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Changes in noncontrolling interests were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests, at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests, at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.75 0.25 0.735 0.002 0.002 0.737 0.95 500000 0.263 0.871 700000 Changes in noncontrolling interests were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests, at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Business acquisitions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests, at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table> 13300000 13300000 100000 100000 700000 0 0 -100000 14100000 13300000 NET (LOSS) INCOME PER SHARE<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Basic net (loss) income per common share is computed by dividing the net (loss) income for the period by the weighted average number of shares of common stock outstanding during the reporting period. Diluted net (loss) income per common share reflects the effects of potentially dilutive securities, which is computed by dividing the sum of net (loss) income and any adjustments to net income by the sum of the weighted average number of common shares outstanding and dilutive common shares.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net (loss) income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income attributable to Varex</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic weighted average shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net (loss) income per share attributable to Varex</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net (loss) income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income attributable to Varex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dilutive effect of share-based awards and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net (loss) income per share attributable to Varex</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Anti-dilutive share summary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based awards and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total anti-dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying stock options, unvested stock awards, purchase rights granted under the employee stock purchase plan, warrants, and Convertible Notes using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net (loss) income per share attributable to Varex when their effect is dilutive. In connection with the offering of the Convertible Notes, the Company entered into convertible note hedges and warrants (see Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Borrowings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). However, the Company's convertible note hedges are not included when calculating potentially dilutive shares since their effect is always anti-dilutive.</span></div> A reconciliation of the numerator and denominator used in the calculation of basic and diluted net (loss) income per common share is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions, except per share amounts)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net (loss) income per share - basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income attributable to Varex</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic weighted average shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net (loss) income per share attributable to Varex</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net (loss) income per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income attributable to Varex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dilutive effect of share-based awards and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40.6 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted net (loss) income per share attributable to Varex</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.08 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Anti-dilutive share summary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based awards and other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total anti-dilutive shares</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> -500000 3100000 40600000 40100000 -0.01 0.08 -500000 3100000 40600000 40100000 0 500000 40600000 40600000 -0.01 0.08 3600000 3000000.0 9600000 9600000 9600000 1900000 22800000 14500000 EMPLOYEE STOCK PLANS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Share-based compensation expense recognized in the Condensed Consolidated Statements of Operations is based on awards ultimately expected to vest. Share-based compensation expense includes expenses related to the Company’s direct employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The table below summarizes the effect of recording share-based compensation expense and the option value of the employee stock purchase plan shares:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general, and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table summarizes the activity for stock options under Varex’s employee incentive plans for the Company's employees:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands, except per share amounts and the remaining term)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted Average Remaining Term (in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 29, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,862 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.61 - $37.60</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.08 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">871.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.00 - $0.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled, expired or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.00 - $0.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 29, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,862 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.61 - $37.60</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,159.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at December 29, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,249 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.61 - $37.60</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.01 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $20.50 as of December 29, 2023, the last trading date of the Company's first quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their in-the-money options and sold the shares received upon exercise as of that date.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units, Performance Stock Units, Restricted Stock Awards, and Deferred Stock Units </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    In the first quarter of fiscal year 2024, the Company issued performance stock units ("PSUs"). PSUs are awarded to certain officers and key employees in connection with our long-term incentive program. Each PSU represents the right to receive one share of our common stock, provided that the applicable performance and vesting conditions are satisfied. The fair value of certain PSUs are linked to the achievement of performance goals based on Adjusted EBITDA margin. Share-based compensation expense for these PSUs are recognized over the performance period based on the probability of achieving the performance targets. Certain PSUs include a performance objective based on our relative total shareholder return over the performance period compared to a predetermined peer group. The fair value of these awards is determined using a Monte Carlo simulation as of the date of the grant and share-based compensation expense will not be adjusted should the target awards vary from actual awards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The following table summarizes the activity for restricted stock units, performance stock units, restricted stock awards, and deferred stock units under the 2020 Omnibus Stock Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 29, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 29, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.00 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> The table below summarizes the effect of recording share-based compensation expense and the option value of the employee stock purchase plan shares:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general, and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 500000 400000 900000 800000 2300000 2100000 3700000 3300000 The following table summarizes the activity for stock options under Varex’s employee incentive plans for the Company's employees:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.987%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands, except per share amounts and the remaining term)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted Average Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Weighted Average Remaining Term (in years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Aggregate Intrinsic Value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 29, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,862 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.61 - $37.60</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.08 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">871.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.00 - $0.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled, expired or forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.00 - $0.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 29, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,862 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.61 - $37.60</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.08 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,159.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at December 29, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,249 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.61 - $37.60</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.01 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">937.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The aggregate intrinsic value represents the total pre-tax intrinsic value, which is computed based on the difference between the exercise price and the closing price of Varex common stock of $20.50 as of December 29, 2023, the last trading date of the Company's first quarter, and which represents the amount that would have been received by the option holders had all option holders exercised their in-the-money options and sold the shares received upon exercise as of that date.</span></div> 2862000 13.61 37.60 28.08 P4Y9M18D 871400 0 0.00 0.00 0 0 0.00 0.00 0 2862000 13.61 37.60 28.08 P4Y7M6D 1159000 2249000 13.61 37.60 29.01 P3Y7M6D 937800 20.50 The following table summarizes the activity for restricted stock units, performance stock units, restricted stock awards, and deferred stock units under the 2020 Omnibus Stock Plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.483%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 29, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,277 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.30 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.04 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canceled or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 29, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,904 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.00 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1277000 22.30 785000 20.17 142000 28.04 16000 21.91 1904000 21.00 TAXES ON (LOSS) INCOME<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    For the three months ended December 29, 2023, the Company recognized income tax benefit of $0.2 million on $0.6 million of pre-tax loss. For the three months ended December 30, 2022, the Company recognized income tax expense of $2.2 million on $5.4 million of pre-tax income. The Company is unable to recognize a tax benefit for pre-tax book losses in certain foreign jurisdictions but has recognized tax expense for profitable foreign jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company's tax expense for the three months ended December 29, 2023 decreased, primarily due to decreased pre-tax income in certain jurisdictions and losses in certain foreign jurisdictions for which no benefit can be recorded. </span></div>    The Company is maintaining its reinvestment assertion with respect to foreign earnings for the three months ended December 29, 2023, which is that all earnings prior to fiscal year 2018 are permanently reinvested for all countries, and that all earnings for Varex Imaging Sweden and Oy Varex Imaging Finland are also indefinitely reinvested in those countries, but post fiscal year 2017 earnings in all other countries are not permanently reinvested. Due to the level of earnings available for repatriation, the treaty benefits applicable to jurisdictions in which those earnings are located, and the now favorable United States tax treatment of repatriated foreign earnings, the amount of deferred tax liability recorded related to the potential repatriation is approximately $0.1 million. This estimated liability is for United States state income taxes and foreign withholding taxes that would apply if the foreign earnings were repatriated in the form of a dividend. -200000 -600000 2200000 5400000 100000 SEGMENT INFORMATION<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company has two reportable operating segments: Medical and Industrial, which aligns with how the CODM reviews the Company’s performance. The segments align the Company’s products and service offerings with customer use in medical and industrial markets and are consistent with how the Company’s CEO evaluates the business for the allocation of resources. The CODM allocates resources to and evaluates the financial performance of each operating segment primarily based on revenues and gross profit. The operating and reportable segment structure provides alignment between business strategies and operating results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Segments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Medical segment designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. These components are used in a range of medical imaging applications including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Industrial segment designs, develops, manufactures, sells and services X-ray imaging products for use in a number of markets, including security applications for cargo screening at ports and borders, baggage screening at airports, and nondestructive testing, irradiation, and inspection applications used in a number of other vertical markets. The Company's industrial products include Linatron® X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, and coolers. In addition, the Company licenses proprietary image-processing and detection software designed to work with other Varex products to provide packaged sub-assembly solutions to industrial customers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Accordingly, the following information is provided for purposes of achieving an understanding of operations, but it may not be indicative of the financial results of the reported segments were they independent organizations. In addition, comparisons of the Company’s operations to similar operations of other companies may not be meaningful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Information related to the Company’s segments is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.0 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205.6 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.1 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.3 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other expense, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to Varex</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    The Company does not disclose total assets by segment as this information is not provided to the CODM.</span></div> 2 Information related to the Company’s segments is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 29, 2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 30, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenues, net</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190.0 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205.6 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Industrial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross profit</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.1 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.3 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest and other expense, net</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) income before taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income attributable to Varex</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 139900000 160100000 50100000 45500000 190000000.0 205600000 38900000 46300000 18200000 17000000.0 57100000 63300000 52900000 50300000 -4800000 -7600000 -600000 5400000 -200000 2200000 -400000 3200000 100000 100000 -500000 3100000 false false false On December 15, 2023, Kimberley Honeysett, our Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement providing for the sale of up to 21,821 shares of our common stock that have vested or may vest to Ms. Honeysett pursuant to previously awarded stock options and restricted stock unit awards. The arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c). The first date that shares are permitted to be sold under the trading arrangement is March 15, 2024, and subsequent sales may occur until the arrangement’s expiration date, which is February 14, 2025, or earlier if all transactions under the trading arrangement are completed or the trading arrangement is otherwise earlier terminated. December 15, 2023 Kimberley Honeysett Chief Legal Officer true 21821

<<1P3JYY''?--;6MOQ 6T*2]82H$M:_IVX&RVYQVB M-S ';(';$Q4H60>HUV"(BZLBOAVSC5O(UTSUHV*^AH_UO"2@3YRMY_Q.?,D7 M^8I_E6S%;J4UN'C,)6==ER5?E0?%->/45U4((^@AFBA_!X,9]R(8"B8\[DEA[['LMCZ'(?%O2A?>;&> ]2-]4! MB*[IUY@=6PZ,\_46*X.*-W*V3LP[ARN9M3E *V!Z:D/4#W:1K;" MX*QIY.E91FX9V:KJ<WQ/Q*_]X+1X7.3_5U(0DY/D(L=;$JK#.]CU M@GV5O\[G.J9#_FW]S-FG]5*E+C7_0.ERS?<^NF ZAOCXLS-I9''*XPB2*(DA M2GT!"P-?_'2$G1#9GXYFWN$"FL!LK-(--$"J"!IZ@1J=*U#KW/RC*IY:?1'WGI C M5(D?)Q[YC_PBFE]^3$?H"5ZY_&=^,:WN?Z:W_BVW3A,2=K2[K@GI?.*&;8+2 MV9=RK8.&W_R /.2K.9_)[YP((P]!&H5,VH4AA82C# 8TPP0GF&1A;%K!]7#P MJ1U)M5#*"^0''\AOFUCY-_-ZK4?HM5M!EV(RL"UB"X=54=9S>O>JQ7HTV&@E M6,^IT:R\>O8SSO(V>_.,2BL]H@_-*C/*TBA*4@[#-)$;GZ8))$%$%0\(+PNS M" >H1P[3.-)/].A7&3#S8O$()9\]VQ_R1OX.F+G0)K2D_PF'-'S.%M[IOF\. M:_4'358=<+F&RV\=0NCW3HD=<"$,LFB'G-V^;^5ME=+[L&2Z*(H<4?6>UX6# M.?LRQX^F_2L[!YJ:'5H+K-+6=4.NC=B:.I3LG*V7BCDJ%B.([G/C 3N2!JF3;P33<2>O4I.]]4FH!PN"DT_;TICGY"Q38YM&(DAO!]=I.,W8 MY6*0!B:3!CX; 1TXU8VT=YXP,_H]H)&:YY-G+K\E4Z>7Z\?'UUP*?-2>\V!E+Q8\&)=[E<;D9H J0K8Z6+N MI# "M]M/X1K7@4FA!Z2.K0Y;T'KY+8PF&,UU8:-NTWMA]=R '3&4W[58K*2Z M'6UP]>K8T3K@R"4.;_YWK<4M5TL=B5G=?#T\X45=7$H*^RH5X>R@ MM-3OET!PA_S MQ4*_ 2H) ,?\@7XX^=G]2,H%7*6[X$I+,C,HV&(O(!#CX<4HC0-898$NIL6 M2[*4)0SQ^KMVLV#_?_ZF;=1[U^\97[#_OWW#S(R6*8@Z)?OG\A*>%3"@@4P= M.[^2V.P*?'[???F.RGMJB(#"""B0@$9I J4]!UCS]R[VZ5*E_XSRGP,LHK." MH$/(UL\@O5F\YLMBH9-[YKH!9]4=:I91$43$)_)-351,/I?O;!SXD!*<(#WY 1W9)X_ZE6UO%LXBZO9Z\H%6@._0O:!TC*.TQRN"QM' M5'MVFE'IKTO90TKJ_/PE=24>\*_=I>:V!@+":1)Y*(8Q]D*(0D_5\8ICR$(F M$&84IV%F7UOBY%Q3(XNZ;(*4=>^B_J(B$Z=!-J,-1] -S!R]4>M9<:(5#Z=5 M)T[/] Z5)UI5/EU]HOT1^_O++U*#8L%5O+>T7=X^K_E#43>5NQ,W"U'(;Y,V MB)Y7IM>8%D-.C2EJT<%&=L#67#7.J<57A_*& E?@^EFU[#2_T+1!N_M>?QGJ<=O%1.UO*>+_7![',^7Z\: MO0P1$EC$*(4Q)]*4H3&"A(<9Q'$<9H*(E&96UYH=\TV-I+[S%?@@7P#E;R"O MWM%;SR" @%7"6YZ#.A W/ ZYPW'H4U$MJ;I+K+QG5Z"6=A +QQ 95V>BCMG& M/1J9J7YT0C)\K&=(!5[5#='NQ-=B\?C E\^J-=KV"T\BQ$D4^3#THP BD0J8 MA7X*4IFL31*F$9*=@LBV7V0#_;Z_>B8'_G\_F78LGSQT55(H^^/D$.KI\<(/;WB.AKI&U\]%>Q6QQWI+3CS_82& M G,H(N)!Q*(8D@0CR&+B>4&"@M0SLF\ZYID:1=6!C<]:3I#O!+7T?)]!U=#C M?3E60YLT%4R5B.#6 "9[YW8["*Z9W:[JD1.[X^-]HWQ>Y2C%\NT[ M7\TR1 /.? P13Z3-XA$AK1<1P0QE0>K[*JS?,JQG-_C4MOQ&-NL2 GN(B2C% M:49]B9-*BL1$I4<2#%,BN)/EO MOE(%)^MZR:K@AY_ZE(J)08[D<'/;DBM M&<0*(D?48C;GJ)QC!<,A&=D];,=2Y7(U^Z&N,:Y_Y>4,"9][2!H//%&]L6*! M8!I(XX&*T$NI2*)(&)E;>Z-.S_?H.1PIK>(NV#UL[ M6_0&8^@[K7XX&%/ 2;W;MKA\H+&]Y4^[K;T_UBA;]Z3XFZUY^H_V'?)^\D5> M+/4N5L6E5[RL^V4'(4H\RCV8XD":\0GQ($GC$(HT"U"((DHS([='VR23VYA: M3E +"K2DYIVXSD+9OCM= 33T9CV!37>C<7.0S)N'N0!KI%9>5E\HJPY:72"T M]+,Z^^AHW:6ZA&_V>NK\;,^BME@N%.4_GSA??2VJ^["ZZ'*$18($QC",PQ@B MEF!(6.S!0-HF691$@C,KA^_YJ:;&?[6D0(L*-K+V+&?=@K#9X<8-;@/38E_( M["O4=J+AJBKM^8G&K43;J?!1]=GN)^S/)I_6S^NY+FAY(P2GJWM=-.1.Z +Z M*L]=V=\^#TB0Q1GT_-"#""&L.CAYD-,XXTS^/T$"TV.+R813(XZ=S* 2^@I4 M8BO7R49PZ_.-$?3=1Q_7@ [,*$ZPM#HCV0!TP?'):)K13E8V2C=G+$ R2,8C:OV<(@*E361A!#Y3(0D8B*FS"[4[O1$4Z.7 M.FZL(:PJEX,W_6EM ^W.H-O.)"XQ&YA!^L+5(\JN'8L+@NS.##QRC%V[>LHSCB*! M_=B_L(_'@.)/C;KT#?$H'2?[KK?A86RRJSCT >^2#I178!>->+89I8+AL-#N M!HAW[T5YX0*^;T_*OL*_=\>5$1;&48_*2Z7HG>^'ZR+^4LX[\8._\L6:/RCY M9BE/$,=9"'V2Q!!YC$(2)PQR[ON(!Q%.$JN(K;;)IO:VV9=5'1AK:<%?6E[[ M%+WS.)N]-URA-S#+]P>N3U9=)R+N;[8(W[S8[/FE?;4Z?-G4.\%,QEX_\6"TL"LN=?GIJM%7%7#?$ ME%_"U7JYL"X6=P:L=B)S@]/ 1-87(JM:;^TH]"KK=F;(T2JXM:O4+-;6\'FW7I4KO% MU6=^P#R>B R&091!A.6_L)=&,!&Q)_P@ M2FA$[+S_;=--;=O73NU*9*!EOJJ^XB5HB&U[%]"*N.F-@"LZM$VD_WKH;CGA:H3\F5AWRGS].-3XX3K;:8\ M>"C _K!;%ZGPS#6/9B&+J>9 @7[*$D 21QED(L] C*:,^EL<*&Y9H#CXU6J@.Q7]*"7_57;ML M\S8;P)EM_;YP#+S7*[&ZDS=ZY%H>Z^LLI;(Q],B9D\=*'2=(GOA,S]ZH_%&9 M:'6D?!RD 2:AJK_)J,I%B"#.*(59H@K/,$&0E]ILT+W1I[9#:^'*G@D'^\B9 M[=#>> R\1$IE5XWY]L8>MT/>*;6.6M6=_%#/( 0N^'*YW_3N7BYB M%2 Q2Q.?ADR^2TF(Y:L590B2-!5R^S+D^9$7(V&U<]NGF]I6WD@+:+.MYHO\ MC&4$0CO(9IO<'70#[_HM:GO-2)6H=6"9PR@$(TQQ"&9/ MC=P._6N^X+C\FU#XH]OVW_^(^=+.=#3VU?^*G%528L9R4@@8@HY MI2I&586=>22#/(O"F(LXRD*KCA-FTTZ-DG?=SL%66!TF__WZ3ZMD44OTS;C4 M/:8#\^4E<%J3H!TZCHC.<-)1R"20-26!%2]Y13(Z.-Q(#7(MM1 MCP'&9K3C%KF!*6<+VK;AWX>&O* 6V&&!=7-T'%&.P82CTHTY (=48_&D?;Q) M7;Y-OUX-8TP:CTR-"VK1#)OO'>K?OL\O4'W@S5Q+YI_I@^KOR^5$T\ MTA11RE (?4HP1"@*(4:!@+Y/,AYQG!!*K9P^O<28VN:MPQM+)27(M39@_2)_ MH^K#J]S:0H#E5IFJKZ]\;^6+^I_GWU8NU\[0GS/XB@SMP]&K4&D *A7J:C:; MR%.52[U=C.KC6I,KH'5QZ+:Y"$M7KII^0HSKGKD(J".7S&6CV9LBC0#:32_U MVP7[+K^DII;)^1&FQG5*)G,CI069;IO%#2@#TTU#2+"1\@I(.?/7G*WQ'+0" M9F79=./1R]!I&78TNZ=;M:899/#IOFX+G>_[1XK4/#"GU3Y\90F [NZ*C@5!L%;$0'?TO9P49X\%ED'H,AHZ$D B_#R"B@V'"^J7'"MJAM0^8KH*66,(-: M-"Y@'PRCU$!8<8^K96!@G9YD:E=3B :R% M-;SE;;NC\C N]H<#.O-?%IG1[OX8/!1M^]IQ0[W[9E/];7_KQF3ZU[J%__=\GY9 MO.92V)D0A*/82V%*")>&OQ="@L, >BSB!+$XI*E1;&;71%/;Q+6A6@O;,%$W M MO:^6?P-37P+T=M',N^!V ][/EV-"XPY,\,/+(%WZ[>L>G>\7G[, :5P')- M5VL\G[_=XYS]69ZH.6A=V,MNU*DQPGX66*T&4'J U_*_P;FRE^81$I:@MS/' ML'@/S"4]H1Z@=E@_"'L%7UA.-5I 1C\(FD$:/4?HF\]<+#>%2 M)[1UEC.[&WGDY-5#26SDT@1&#J4PQ3Y@40 M>0F%) DPY"2*.,XH\2,C-\"Y"::V)YLRZN _^R:DIV!LWZLNP!G\]6Z)BUU# MT1;E+VD@>FK8\1J&MBBUUR"T[7/V[4JT;U#GJW\M\.('?RWF\FCQ^&G)6:XN M'U7+I;?Z%>*A( W4QHY\FD$48PJS@'LP(UXH./&B !MY"BSGG=JFUZ+7!2&4 M\.;=.VS ;N> 2$*C;[LO1YO-]1Z3M??<+ED_87,+Q6O62KGGJ;VXC82T,6DQB&+%"I^I$',:$19 $/D/"3@'.K$Y6]"%/C>R4^ M$//B[[**SRXVH@.\E=WREK?'NIB=WX9%>^!7@Q0>:+ WXJOR2Q^4!B!?_ :V M2H"=%H-<._4'T='IL8< HQXR^P-T>!:]8*2><2J+5<[R^5KUT-[%V=[\HO.U MG+\*T']^6:_JIH";:@;W?*F=65^W%=-0XD<>$1FD)"0092F".$PPC%./LL!+ M<1);E31Q)=C4V+.I%]@I!C::;7)>MKJI!.IMO0^I7N4&OJ \GK,E-Z/@]UC( MH6WV,=?0/N3',>"NHH1E,JH*Q;EQ[>]O^B>Q)Q%6990"JGGJQS0C$&2>ADD01#3B'I9Z&.KVX8^ M4DR-X#=*5%V-J\I,6EK05.1*V7+[?^[5,[K?PAE>?@R]'$-?DPRU$O87*Y<@ MZ>H*II<,XU[67 +3T;7.18/U3#7=V.DZ5*VN>%K. ASX*1(Q1'Z02IX,I&TL M&()^&O#,\^,X9*%5GNG)::9&A+OS*3WK,9CKD#[+)-33()MQVN70#4Q:.]2T MA%>;&LL.2_.T8^ JZ_3T)..FG+8J>I1OVO[I?HS0VO T2;T01T$,DT PB (4 M0TP9@RF+:9I0/PBBQ(87_I,:S#;KAEW5M<"N0-&H*-.[1E@KYE'$F!=D!"9A M@B"*PQ02JB[G4T$S+XP\+_5G+U71I)5\+XR+_.'$[XB_M(OX8[Y0QPU L'R6 M\H&6A(0L3D.:0B]0S1,]DL(TI@1ZE,L_$^";!JYT*]D(=>[*5!:I6>93SS]-[" M&_G BQ)0L\H?/S\#R7L5NUB2B_D:F#'-(,@.3#M'12,:8F]^T)!KR8>,!E@,-[ZH?R__BR-4$1IA*1])!*(?.Y!$L8(AHF/ M<.ICAHA5P2KCF2?,6SI]WSE)U8 [(RE[&*="4C]:\1V"I/:Q&H^DZGFG1E+[ MVL\\$:5RCI,.3NI9:\LTMTHHR6('@G>S/T\_F/?FP,IAZJ-J^XJ?^3E MOZMX:/6O&<4HPC1BD(?*8YJ%$<2M)*V 53._*+G9QK9+=JI\K%7 MM/N1"YH=53GGYP2A!PI\M M^*.*CS CD3,S&6V(K-H0S?D&O&)78O5H.W0"13.ZN 29$1L'U1+^%ZADO +M M0/5K"70>!I<]?T[,,GY3G_.JGNS:T_+QOG[%9?Z*563IMMGIG=C]4J==S3Q. M?8Q$ 'F@6I&R$,,4IPQF?IR)2#4D%9F=2[%[TJG9%#OQZB*50*CFOJ]*^"OP MV-H8JS_RIKY%MW@.[E;<0JE%NP(_U^1?G*[ J@#?<"F7$WSGJRIM:=\2-=$+2$ MD70^ZC17_'91-S;=I6+.,DR1)WP*XR@3\BR59C!CH0T1_:*;4; M],OK]WR6B93@S$M@$C(DN2-6+N040^$C')/ RQ+?JC3.J4FFQAC?\/+??*52 M!0'7XH)R*Z]ED,W^7?/A2CZ+PJ;GD6S?\\[P&=J'8@R-56W3 M3M4O*'!Z?NS1JIQVJM.RS$5.]87U1^V[?\"_9EA^.2(/,1B34*7RH11BD2*8 MQ510'\7$CZUND]R)-C4JJ9I8J@ 6)?JF=8N^R3[4;P<9O;.T4T).=L-W.<&F9*.6H6L@O MVEMMTNOJ*;M6+3[!2<1)#&D@342$Y2$Q183#&*/$DT=&%7+0KS)4^\138_EF M":*MY-WGH,O -^/@(2 =F&';T:S+-@T3QFB+EO.B31W3OE.=)C,PSI=F,GR^ M;V.<*FN!LV9[I4;4R<>WW4?J>B_7?^,ENWO1]:$:F>D_BOG\2[%4?YS);VD6 M1UC .(T2B+A/8)JF"<0XI#BCGCP/6]FXPX@Y-2:LA;5MV#/("AH2Y+NOR]!T MJJ2O*^'O-R#;Z:BN&9N?J_4$6M$K4*NZ5U0#_*74!;6^3ML3#;D@SCH=#2+D MR$V3A@3ZN/_2H+.YR,G778C2,*8T"7T893R$R,]4I"R*H ABXB4HXE',^B?? M3[&=TT&.N%4SIQ8@S>CW,G@&IDY+9"[,DC=MZ-0['7Z\UD[="K8GN%_0WDDE MYS6XXOKQ<76SU,?JZ^>5:2[JV0&FMG>;+V0IZ5)GU@ I;['@Q;H\>.%KSZ)Y M+NMY&-OWMC,$AW;E.03/*B6V$YQ>*;+G1QTM9;93L68*;?>'+W5??>>K*M1* M<8IVG56]I'7)SSOQ)5_@!N<]M#Y,C MK;ZM^VTR:SJB]^[D9OF=JU5X//7WZRF*2I#SC,(U3U9,X%5"]KF M6>#.^2FF]AXYZJ/9XQA[ D@SGK\,GJ&#=NR0L<]Q.JN\JY2FXPG&S6 ZJ^!1 MPM+Y3_;;VE]S3-18*O$EXGY DBB!G/L,HBC-(*$A@5Z*LXPSQ GB-@E(C;&M M-O,(&48/:@XPWPEHMX^;J)EMX)Y8#+QSOQH 8+U=3ZCJ:)\V1QYU@YY0Z7!G MGOJ(O6=)?R^UG[JJX_!CM?BSO.=\^?NR6+_L3@>&?B;#X:;VJJUV9T-N\(.O MULL%^%,5^),_:O'-'4VFJ':[G08 =. M;H:E/.ZX/.CT@*J72\ITCM$<5)9* M-]U5MH_V3,%Y?ID7;YS_Y,O7G/(SMV;S>7V,4&VO-B&E][J)Q:>B7)5?M]T[ MTPPSCC(*&5$%H)(X@UG,&.2^H"A-4TP#J^8SCN6;&K-5E^!D_Q*\6<#DYI?2 M4OY5.2@^X9=?N>!+>0:MO^?7"Z:CBG7] MGG(F(AP'NF1%''"(_-B')"(93+V8^#ST8Y&P337 !_-W0C]IC&ACOV+@PPAO M@%ITP"N92\T4A0[ZKZJ&V3%\SY4R(_(!@1^'KS<*@ \;%51Q=;!9@UI\O015 MWL5U^Q)8$_-E"#KBWYY"C$JSEP%UR*87CM:/-*\I73^O=2O8K98Y65<5!U:%*DZFX\V<5]NP1L@1 MQ9G/.RJK6<-Q2&3V ]C['/N%L$T[;LUYK)IU@-IDH])&C41S&'[V7C%GW8%F M3J/+MO51O^DR/-JO\&7)_W?-%_2MKO6 ,I_QU,/0$Y$G[0=/'[$H1(S0@ 1) MZ@NK[S\Y_.;7YRN5>V'3_*E\%@L=X7G3$V!EC&FQAM25K 5%NRDM; $ MVA SL L<@36TE7 &)\?-FTS0Z&)6'R^7YVQ0_^4EU8E'?B M:[%X?.#+9^4NEC]6046S.$ZSB/$$BCA+5/A/"+,X0I#X*2:I'_@L]7IX;SLG MGJBC=B>WBB(FA326_U:9'.N%ND2G5$&W'$H91]0 M)2U4X@(MK_I5);$[N\,8'$=61_=\H]HB?SK MY?*:%2]R/W^9XT=3:^/\"%.S-:2D4(D*E*S0WTN(K\4V-SM:@.LV.MQ@-C _ M&, %_E(R.[(]ND'I97FT##N:W=&M6M/J,/AT__3WSWE)YX4ZN&Q;#V/A^R+R M.&18!!!E(H490QQ&C&28ASP-F%7,T.EIIL8&.ME[)Z9)8V(;4,WLAJ#4*RW^/ @.4^-/3#)Z>OQY14^ER+=\NN^Q0U]>W./EZNU!\GFI&G@4B]JK MYL41C4-YY.!^A%4_)@I)Q#$,"4:8(![%R"J+J'6VJ1%"+2S0TH*&N#W=F.U0 MFYXG' $X^%FB-W8]CA$&F#@[0K3--?+QP4#MXZ.#R4,]0YBCAF";&*03XST=0(1*4_?YCKZ(B\JA"K6K;1NL&; M[N6&#R[^_Y2_/%\%U@YV,T9Q >; 9+(1<=>?;1"SHPL)5]&VYZ89-VRV0]FC M^->NS]MQQBM>SN10JALV?M3ESA=K(8=;+^4DG[#\(N2KMUF2A2F.I=$1AI&0 MYD<8P92Q$'IAQD7LF'0[-AR?][NK\/H+5$U[)_W @/ZE^ M?L*E_O%QC:6UL>+2)%SFCT^Z3_"+E.Y)!?^N7^2/_WTYD5NA6[&Y?$0SM!\$ MF69ILS%&H6HK=39\;?=0C_MH576Q_"2M&OY0?%N\Y.I$>E :Q_1:NGNHJ7%R M)3+0,JM ]8?\69MMW[[?WS:\(N45T'I87%H;P-KM1G:,Z, 4;0KF(*5^+.'J M=\=M,/YX5]WFRN[=>%L\UK-<&W]4;[ ?_*58JJXF]\4\IV_5?W=??L_W<>Q1 M#CVDNM!A',+,CQ*8B@A11*/0\ZU"ZHQFG1K]U$*#K=26I=&,D#8[-CK';V"R M.8+N"E3"@K_J_QVFDI@-3*[J@!G-.6X5+QL8CFIP63W<,S=()QC5[0EF)"$I M$W$((TH3B++0ARG.4M7XFP4(>EB<5=I5=LS?VN!DTI]0ZRI(Y^:&^J<^;(GSE[>):B'R>XQ4O M?ZY)F;,6N<:-]G)1.VC-">CA_H& M(96K94Y7G*D^E[,L#9''200)\S!$OI!&&DDPC$F$4!@F:9)8M>#9'WYJC+&3 M3E.&;4S1'G)F3- ?CX&W?@.*3VU0] @1.J6QLYB@O<%'#@(ZI=AQU,_)3UW6 M7D-E&R@A%ZOEIN157O[[XYOZ[Q=,Y8+L?(J"(IJRE$.*Y(D+$1ZJB.($2G,@ M(&'H1]2SBBCN(NU^D5G)&'3OU3[G9-UM_&[67!G[*$ DA3U7( M=4)BF&6!@!1GW,]XX"7VX;Q3H\=:[.KHM!&\HL>-Z+TS-$R7PM2:<@[P MX&:6$VQ[6&%62#DSS\QF'=ENLX+BV*"S>[Q7W8G;!8#'WMM0^'^RH29Y7O6SWB>, QJT:<5>>@6L3YS_4\ M?*U?7N8ZY1;/U5GNR[SX^W:A&T[I L2;5U>0)E',>0*C"*<0I<*#64 BB'A M?89%Q%AH=> RFW=JN[PI]LXA"_*=Y/_'\C!EB+_A ^$W^47(<;^FI>K&8T#@4020Y:B$*((^Q +G\$P%#R4?Z0)]?I>)/66:FH4 M=W!=HO6"A8!2LZI:=J/?YD&[S5H_\-=.0Z!4M"W/YV2Q[2^Q1EG"<2^[+EV] MF\5:FO]Z)[NL#^@2] &NT_K+]&[7;A?#V'8]=_G@_5A?5T#^7BR*%_T=7#Q6 M!9#K6NZS@!,O$SR#7H 81#%/89JR$$:QAS(6A*&?6GFVVJ>;&D]7I=/K/. / M=7>)WZ[ @EOV#.I V8Q'W6$W,$%6L#4EK2O-@P^UL+^Y(SHS5!PQ6,=DHU*3 MF>*'G&/XE!V9,)[/;G3RX)=\SI=UE<6W&4UI[$6"04$2#Z+$3R!)"(%^QN(( M>5D2(:,KQ#/C3XTN*A&!EG%3WM,P8?4<@NW,X "7@:G #A+CS=^A>(M_2CY9 M;73YC]W^/C?>*!NZ0YG-#N[ZF'TR_^U"[@I>KNK-KVH5;3S3:SS?_/53L7XI M%C,BLB3VTQ!BCA"4F]>#. D0C D+/)9QD:5&>]EVXJEM\H:@TC*H) 54B[IK M.V6>I6ZU!NUL,"2R ]/$1K!-]Z@KH"2_ DVPMY^II!\(8O.: $-!/5)Y )>0 M6V7[]\&M)?'?:KC1:@#T4;)9#J#7\[TJQ][SXCLOKE\?=4Z99<.:<\]/C;15 M&=3[FSOP7?[_ZU=I^3YR4.707=3 YBQ\W7>++I ;F)3=@&9;/K85E;[%8T\/ M.F;IV%:U#@K'MG^VYR7DQJ&DP^%F'(G ]QB!0<"E-1>( *:QG\$$>VDD(AY) MBK6Z:]P;?FK;?^>.K:(!+9WE!]@9WA/V1F3HZT!C,.RO_$[J[.IF;W_P<2_P M3BIV=$]W^E/VOI0ZZ_9+7E(\_Q^.ES<+]EF./8LRCZ6>)_>I/(I!1+,49@'B M4 B4899PD:1&V[9MDJEMWEI.4 D*E*1 B@J4K.;.E;.0=GM87 U\)[NA9&5 MMZ4+A%XNE[.#CN9WZ5*KZ7SI_&R_-_/O1<'^SN?SZP63=KU<576S4V7?[PHJ M[<+\PU3$J: 1Q$$<0^2KE"M"8LB3D(41QCBFV.;-;3?]U,CA][N[S_^\_?H5 M7'__#&Z_/UQ___WVX]<;R;;*I;;7]M+ZE2N7[@$N M-\5LS\<.V.-L]@YWA=[0AX ]X*IDR)VD[M[,)G X>@^W3C7J6]=$Z<-WK-$S M]M>VW_B?>?EQR7&YHGA9]ZJ?(8)]K+M6!R2!"$4!S*+8AP'B<1J'- U]X[KK M)V>8&D]H(<%.2O,+P=, MG.!$U@&)H!#1+HS@@RA,;\4O1BBD6X_C;\\5E>; MK=JWW&&>?FZTR\I6L9NWDNT?M&.R]'(DX#P8W2!TZ./C4&N[Z__F2V-4^#U4 MU^O54[',_R]GLQ0QW\>>@(0F(41IPN5&%0P2GT:"ISSR(Z,SO]ET4]NY6VE! MJ<2]JCI#R4/*5F+P(:_[1966!Y8.X,V.+.[@'-K5L$7R9X5D)2O8">ONX&(& MBJ.C2\=DHQY>S!0_/+X8/M4S'D$-]Q&7G#6#21KMB3^^[3Y2EZS3?0UN_G>= MK]YN%^5JN:[Z::N RX7M0AZV\H+]DZO$&L[J !;]1W5I M\P7GRS_Q?,UG-*:8A2&"'DJER<&Q#[/ (S ):,(2#]. 6C'99#2;&FDV*L5I MU@3K1:[*=C]JM73U8JV8ILX_?G[6G?F/ MZ,MTH+ "&BR'83-36W]7$3N3T6O<8*')J'TN3FER EY6U?).;&XS&V$2%',< M"P)YE*@FMO+]3@3F$&/B!810$3*K.@0MFQ[I!]C?.Q5)\->TU7^FJ]R7LX"+PZ1Y E(HTQ Q B1!!*ED"51%&=8A&'(;/H) MF4]MQ2>*N"'=U8K(H9^PR#]>;/A$@]&GD[K.'T7 MQ/9;<-/\%FQ5'L21,.BRN/0,#"/H^$?]00$_>78?=D;[&-^;Y5))\X/30A[U MWZHT.<. WU//3HW,I8S%@A?KQ#1MA(;QX>?!*R=O)U@=; E&D,E+O< MPRY4>H4;GQQPM-CC-G6:@CD1K:+8)R%ODA0 M% 8085\''"*8A=2'OLU_W^O"IVR0L'-[O!P9JQ83CVI\V@-R:$SV&,'NM5)U**=OLYL_ M?LS2+/5)XE/(F2S B9\968W-0:?V*KA9+PLS7MF#IITQ M^BH\M+$G=055K*$J$*5.$ZJ9<2L$QKO^E,XMIMSFX]5^WORTV\M[PXVR2T\I ML-E_)__6H]^+LK ?GA__4?S];?&2?UJ43/Z\O:DS[?S2.LK4-IB6%CSDS_GB M\0I(F<&W[_>WJFI9F4O46L(%;>'K/HRY0V[@G=H)FN,<;G-P^G62:1]ZO)XR M1BKN=9\(^)VSWIE8%PW\I[U"Y*FT\U-,C1]V4JI+?:'D!%0):IX#=0;+=CYP@]# /- YT[U)?BEW3,N MP#'/$+L^.:H>/QM O(DR;C(%_IV%JSD9_'CDE=W JIB!N/RV_ZL M_XY7^N^$/^:+A;K E4-Q3)\ Q7.^8'@)WE2]GM53_4%>U4S.2[#D_[O.%3VO M"O""W_[;399:^PJTI*F=>7"T/+5VP9N):AV?O+"$WHF>#-LF4DQ^*P1).4Q# M)AG7$TB>;ZB 2>;SD&0\3C+2J[!>RZ13X^#.[B<]>X :+8#A!:9C6(>^BKP< MT?[%_ P@ M6Y(Y@M244BX!:FA?C1;H"ERO5LN+,M/Q3.1?*)H9'."US\\+/&BK#+V;A=TOF;2UMQ$ M[%>>W=O%-=46)?\'G[/[95XL'XK&L1U-.77?\GC/SRI239K,^(4OZXHG-&69%\0" M9F&D_)F$PRP-0N@E/I=&;^9A$MG5Q3LQR]2.TSLAY4ODQ;2Y4#N09F1^,3P# MTV\#&2V@PS(R1A XJW)W:HZ1R]NUJ'E1REV(H$S*>>&C,T\Q_H4,_Y"3V!$QXAB#B M00;32![,8QIA%E <)J$1RSF19FK$IQ4"M:2@%A4T=#*_T+Q\I;HOAD?%?VB; MJPMZ\&&C$*@U.OST;ST*DUZ^3.97U*,NUTBWV>,LF]4]M#.86ZZL+Y]CM-MM M9W T+\+=#=K/K-_5_-+N\'HK^MC#B4\$]$CF0^3'$22)QZ"(?3]%81:GQ"JM M^.0L4WMG56FB.B\/8!4'5MKV"VX'U&A7AL"59)/CF,91M[<:W&I7._DU' $YWF?AZL)[%TBE6/E>L&^YICDW8& +>@:FU]M1*F4%#Z"M0B6U3_:\_L.:N MB"$ 'LGCX YH*Z^"+6(MS@/CH4;S$=@JUW0%6#_;NZ^=CFS]9[YZ^K0N5\4S M7VYF?/O!7_EBS57%BL>%;F? _="+,NQ#H>[QD9!&/HDB"HE'_2#F64 RJRH2 M=M-/C?8WTH._I?B UO)?@?E&@RNPK'20_[M1PKH?GLWZF 8*#(7ZX!$$3< _ M;0'_N@.\%A_\Z :\3RN]'KBY:ZYG,_G8[?9Z '.B 5^?4?H17\MMXC?\KV+Y M:8[+4C4._5P\XWPQ2R*2?&O6U MWZQ? :T#T$KHWK3@KTH/2^^$[2J9\=^ V ],@.YAMR;!GN Y8D';V4>EP9[0 M'/)@WV'Z$:%N"J"\"TO^Q!>EG/5V027U?BW*\DNQY/GCXE-= $/'F:JRT<5" M&J;ZIWGED&#_DGRM3BG?^>I./.!?,\R3),4T@51;BACY,"48P3B-$D:SC%)F ME5DYC)B3H]5*$[ I.0)6.^D!WHIO6;%[H"4V(]OW7[B!.;GJ4K.G(:A4!!^4 MDK]=@V.^I_?'M08YT_2LO9Y[P@S1) LA2+X$H":5%[?D^ MP,NW6Q4-]5V*I[P)Q5S.]+C)@IK%&?RO".\D?X3EM?L;3:111OX;;AWP "*TL%.5;#3=;.4]>>U MNO)8L:?>-JO9W4MTA$5P]!(>4M)17^(C0'YH!(PQI7WD2F?/#=+>E@3/ M5VLIACR:W_QZR6ME\KI1YOTRIWR6"$&2*.409R*"R \Q3 -/Y?Y@Y-'8C[V( MFL:]C"/RU-XYGU1HS%S56>!*8L[D$@-1J<+[]Y4>\3O0'7(SO94=^,5D$L?: M&L;::,/44%Y[R1KJ-QM :P@F]]TPCQJ:WG=DI)BCR7U7K$*7QEVVEL"GD009 M+6QJ7&";059LYD>(>EF:PCA,,H@0CB'Q MY8\>1BSP?)[$J95+]?Q44[,EMI)6-06O*HM!;GTMK;8EJM]8]I%I =OL..H& MPH%?VCOT?E;H57*"2E!WQ\)N,!R=ZEHF&O50UJWPX9G*X(E^M/$/SA[E >LS M+_/'JNA3'3.3H<1C5%)%G"0^1,P+8(9\!(,LBJ.01#CR0AO2.#?1U"BCEA,T M!.T9I7066C.*< '8P 31"RMK>N@"PA$YG)UF5&KH4O:0&#H_WS,.$N=+W5'T M=O&R7I5?^2N?!W6.LH@H9CAE$!-&(4I]:4Y@C"'#84A#C.0/1BV@#.::&CG\ ME"#G(J=8'C6J (\[4O+EJ\Z"J,0''[0"(+ T*=H0-R,,1S@.S!E*RJIE\E6- MF,HFT8@-D"9N@(FK$,26F<8--^Q6^2BTT."1?CSRG:]N%Z^\BAZIN:K^4L<( M^90%#)*$>!#%Q(DB23AHD-C9R?:FHL\ETG_6U$!;6L=G31 JP9 M6[B!:V"R.(W4 #S1C88CFFB9:%26Z%;XD"0,GK#C",;SV8UNDW/SS)=JN-^7 MQ=^K)^5DP8NW&1;,XXF'(*99J.P,E4Q,,TA10 ,>!*'O&Q5/ZYAG:NRP$1)4 M4H):3#-ZZ,*TG1L<(C4P,512 ENLC'G!$(F6SG=RA(H/Y#]V-- U[B@<8*C< MA@!,/W[Q26-#+J6>+>?EPQ->?<)SNI[C%9?\H[,=](?O^5([0:H:(TGF8R]F M,>3*RXEPA&&&PAA2S@/JARQBPNC2U:%,4V.5?;-[J]45V.A5M2[;:J9CS+5N MU5/JJJ3R__4K*.-BF:V/06,LWJC'I4'7[9+#U:5(NS^$]9;HO0YKET+8.A^U/ZY]EE7C;.X;M\G)YL%<41BCZ8PHH*IR!@""0TC&+" ^XQ&!",R6_!' MU;W\P9RUSTQGM)FS:C,?33K5XY+/4X]Y/;G M'BVZJ%N!9D20P:?[F4S7KSB?*]/K2['\B>?\)Z?KI3;9U'OP&U[5 M/VV-NT;/X@0%%&K\EX:*35',/9;YL8^,"NY=+,G4&'9W@K(SK/HO MA9GI-0K 8QAG.\&OP%8I*(HE5&I)TFD<8;_DI2I&_S^J5WJMXML@C8\O1M>1 MV==?CE$-PXOA.C0=+Q^P;Y[H?FD4::[>_*J;W_U>%.SO?#Z?>7Z(LD @R%.L M8IN0@!G&(12)YXF4I"*,F%U&8/>D4Z/%1ID@7)<)6K28@'&>F63Q[:;W\^V7!UG3U M3ZSBQ%=OVY)U!V5DD?#\*$0)3/S @RA #!(F,"09)DGBA8QX5M%4M@),C9>: M19-K#\RKSA].]43-X.G/,U MXRW'<=;=?E>:\Y;QQ2H7.=[R;]U]F.W7,Y9_6S]SIIS8"RZ6K[[N)F]!>MI!FCON/Z#$RX MIYO,[Y0#3>TVG4@W^NG4Q8:&H%;1\47(0.@/USK^(NG>NTV\"V@-6L([F::G M+2RM;8:7[.#5VAS6=JSK< :&J^NX!K:4JWE/#)3KT E*_BK_M]AK%03F%R9I*USC6M_ MFJA]9&P:/61_:?P[SA>JG,S=XB=?K:HN.G="A2#7L2WR^'Y-5_FKIJ\9"A,/ M98Q DJJ+Y "%,$U\ OU$I"'WJ/S*Q1;A)?823#3B1"D B@4HMRJHTQ_%Y1,0 M\^)O\*34,;]*M5R5[JOH 4 >AZ*4X)N:6W<+L),>W F=L["-W5..P9T*@V%M M?I4]'.8C76\[Q][JVKL??"U7X98#CG8]WD_1YI5YSQ%Z5PM=JBOYS[SZW]N% MSIM_*N9RC/)&6KVKMQ_%?/ZE6*HZ';. $3]A(H2)\!E$7D(AYH1!&J$X%;'@ M@; M$6DS_]2LTXWXX,-& 54#$C1U^"]0:6%=!])J74SOC@9#>_!K)&.@P5]* M!5#KX-#"[8F>NT*+5K./73RQ#S0G"B+V&L:.^SAE,]7^@]W\XG0MB93?"9%3 M.<.7Q>YFPX#$C ::&F5I@<%68K 1694 *U:+8F5HV9JAV,Y+S@$/R1/SZM'@KE,'SER_H0 M/R-!*@^K\C3M!1Q!% 4,IE'&(0F9AV+?#X04]T67,9/G_^7*S$ RGM]FFQQ* M,: WOV[@BU> \,=\L5"'"WF8KB2XO)?CZ:7(:(Q]+X@@P2R35JIREJ) KHQ< M%)I%W(M#OUZ*FP5[]X78R##*,O %&WX!S,S102 =^!5PKH6FEANL"E!+OO'" M#ML]LQ6M 1MGGI[WW7MFML)ATBZS?0![A^PWO/PW7ZE[I%U8YR::]WJNUUQ? M*OV4M#CGF[]\EK_]4=7S5L+EB[L%5X' UYL\.!5 /PNR2& A/(@3GD(DC^4P M932&(O!)$E.?A=RH[MS #@37#VUQ2I?8T5M[< M"SV1;\!(+NM)?!.LW-PCK$^+3WS(V4=SH(\ 8=/;/L9T]M6>/M<;K,H"JFI? M?Y&_*V<88YY%.(()P_)H0T0,L<\HC&F82&. D1@)TUI/9V>9W#N[%G23%56) M"K2LYN6>SH/:_NIU!M7 +\Y>*%D5>NI$H5>9I_.CCE;DJ5.Q9HFG[@\[C0*[ MIG2YEO-4Y?++&8]IQ#,_4XXEU?>39S E"8*1'X8QRJB/,-]$;9BY-LPF[A&L M,3 M; *=_M[$X_-?+WS!J@8"3@+%#K$W\VLXQ/.=0\= +?,5V%S)J 9#FR8B M#EBE'V3#AI$=3CJ%>+(S0!@&EIU[NA]/?;(QZSG'Q4/NL'S"&O]1S%/B[@_O7E(,/1, [@Z,&I$8\D?_!:JD.! M?(,_Z]N@S]* G1>EM):N@!;>_.;_&*?NF_Z+(!J8/DZ@,T1*9RL,O>[OCT<; M[;[^K"+-^_GS'^I9]V>QRED^U[?].X]-E9S.6=5']?EE7;DF[\0-7BJ**#?5 M&C^^G1Y -5Z?\23%U,<>%$D:0$13"E-?)5$*CW@)#CSF604W#BCKU-BE*6G# M60O^4L):5L =PK# V/IJL:1 -*.FZ5HN$A/ZIC-,*4 M]O;W"_:0K^9&Y4&.GYH:UVJAS$VU PBZ[;3^V@],6 ]+K"L&-1J* MJIP5EK_F;(WGH!T8*R/M- :]++2#H48SSTZKT+3-SGRBI_=:[^*6WJ\?WW8? M.='[]6Z]*I7W2EVI<16&P]GU*U_B1W[SBR]I7O*Z;SSR/1JB 'H!0M)(BS!, M&8YA$ 8I2@(6)V%D'V8YDO3VL8%C!&G6.H!BIT0C6I/4L8-]^\F/_07AOA>) M.!.0"C^%2!KU, T9@R)D/!:>'_B$V09__G_MRW+B6+O@JB)B),ZX(H8,@ MP5N?7[(M5VN.;2ED5>WHJ1\9N,KLGS.^L?9]_5/6A_]H6$?^8V<= M^9;V5Z#1']0 @ 8!5W7DWVG,7-T_#23UL!=8PP[%P0W8P-W;^P2K'0_3OG-/ MXDZVDLGY4Y[$ M(DG3* \A"Q%3^Y9(XGA/R*B/FI_M\_"OJM9HK,4W9S!SI%]/8@Y/ ;KU<[8O) >[N?+0C?S M>:[]&R8HY)(E80IER!*( Y%"PD,&*:4X27(69(G5I>1N\V.C@T8Z\%>ZILBX/EY7F4JJ0O+ M)Y1A(=,0]##V*9M)6"5CLQ$DGN=M&PWP5R6>P[E[4G5G =_[[0\A?3-\ MX@G[0,9/.HQR(37." Y(& :1(2B"."($&Q@'$8DRC"$L4A-8U=;#<\ MMHFG90-:.*"E,P]0W &K>^9= H'OU<],>ZO PV.J]HHUW&EHL/#"8^*W(PJ/ M?FX_V="UL$!):SDS.Y ]/T_=X.5YUO:%RFH:GT>B MUZ3N:':P*7Y>M?:$-WBZWUYTWZUR&Y\1X8CQ!"_?CQ&[C]_NGNVPVXOWD /_[C^N'&;JMZ&ENS M+:L3Q'S30"VCCH2I_#T<9[0T!L/19O9T/X-N:L^JN[^Y/?]"[X3?\V?Q8T56 MY9W!5SU0VP-33#@-[O.8N,NZW='7T#FVSZM])*.VP4L];8TR M'_I$#G-(L%,IG=G+V.;X&T)+3WW;P&$]M(_6[+ '50,L*4+]MIWAWVX-,ZUF$;]SH%ZWQVO5HM"KHN4[L^SK5GI,[W7N5LO:V-[PE-11!'@80B8KI0 MA) PPQ&!%"5Q&(B 9C2R*9ON1BPK*AFL6OIRI]:6Z%'4S-&@(4YH*#.U?=8C GCPH1LNP/?'D:&[:D=T7AW&^[[+T'(629S% M&,947U,*I SQ/(@@#R4/XR!*, MR?+FMQV2?DV79]V^C'AW>*)S(K_+F^I/\UGR_FT MX.4O'\FR6-[)>]5K$Z3_<;TL9F*Y_"R6;%&4^3NN9_R:L?EZMBJMIFG!"K'< M.FHQ(:,P)1(&L?H'QS)7!$HP#$2"<9X*FJ%@,A.&1P9>936:\IMR&]Y/$/[X M]NWZX3_!W1?PX_;W[[=?;C]=?W\$UY\^W?WQ_?'V^^_@_N[K[:?;FQ]V_.IW MN,W(^/V'<1CF;NMY!78TO0*EKIK$V]JJ/]?Z@I;"9;&UKCGR< MRS )U7HC AE!C%.JW2L%Q(PD88B2-(Z,2K:Z$VEL=GRCT<:>PZ.:LRV#PS#VE8,YSB)Y6 MN5=0]UY3@P5U'U>A'=1]XHE^UM"78E:LQ-?B5?!;99#-G@HU=:^72[%:?GS[ M1OYKOO@T)28JVTVD@G$28PAY)I*R5*C.=JC[[%-XDIT M6,H.ML*#2GJ=9+>4'Y0*]*J>8C,P9O:+)[@]DX53I*T-DQZ8.;) ;'H>U-3H M 4U$WB1O"A%ORW*Z!E!Y7P/K U3[OK!>.!DNXZQ-HJ[:XU9AU)=\W; M&BSEKK5Z[82[]B_W+JM>!3_>2=WFE^G\[^7FNE:F/!QNLJ^OFZJ]^*:[)5:T]T(9'98[@\WT(UA^Y/I71 MST+BKA[ZZ:Z&KH)^5NDCM<_/O]-SLTN*Q9]DNA;;BKFEU7D]XTVJ\+?O\]4W M0?1'_'JU>>%K,1.W2JSE)*42DU00B-)@T0T07?"[>==RN^Q@: VWT<,.F._MM9.Q M G]IW4"IG,O=MSNH7>W*'4@T[&[='80'NWB'3=OO[C]IEVFU)/RC6/W\M%ZN ME.VY>!!RW>K\FO,R._1RDN<4IWE,M;\0AUBFRCS,PP1J#^@PD9)(ADTW^#8= MCXV9-X)597:TT.TR/.8;4ROTS^_[?6'JF3P;L8&6&S2"7X%*]#9U;J3W!+'Y M]M\7U .= +B$W.H(H ]N':< 5LT-=A#01\GV64"O]_O9\M5Q\69?BC"6E#(. M,Q9E$*=40!)B!%F6YT0FB*#,JKS&;O.CX_%2.CL+>0\P,V.W/PR^[Y"KZQ\? M._7C.KLJ3;_;^+#5Y(\J=E _OA3/9TW'I^?OLU>"FTB;OVM;/PXCC4PNNE8 M.C0\%L_:C?;;]_O;UE[*TL'C*%[=<]495+ZG; =*CGV.C2#I[Q9RM-5A/42Z M%#MP%NE\N-_R^_M\SO\NIE.UV=N_PFUM!S>K#>U)T?,$WVYPS"P!;Y![9AVG:%O;$KU0 MA*M+^:.G$5W'D67VMEZVUT\OKTO#_R-VGM<'7@8 M,!?7!OU ]G=I8"G/>U\9](//X,*@9\/]2+Q5#OJ(*),X#CF+90!9Q) R4D," M,X099'D2IS'.,,>I31*Y[NZLZ'>PY'"MRP#PW)JN4D_75_MKV3.0FY&F.R ] M,V)+T"MPE![=D9P9*(X8[$QG@]*3F>+[W&/X5L]2SU4 W?)!3*L2\X_DESX" MUTF@BMG3E_GB1$%S@4441,H*S$,=/HK2#-(\PC - YIEE" >Q9.9* O7FY%. M7U&,9M$F3<%6((^$I-V0P:+20]]7SI114>:! 6K%6$TWCEM5PCQ ]$F'Y9EX M[X$S(RZO@S%0[>I*A:O2U;8E^Q4X$T'JL,;UA2BZJH;=5XQAZV9?"-9!A>U+ MV^L;EJ;3B=^7"3@G61 122()<9B'$">Y@"2.U#\!$CE&C 7(ZFZOW?CH=L'; M-/6V\6(MQ PWHSUQ\+VOK""HY+JJTI*\@;_J_WJ)/S^&A+,XKE;3 P=J'2IU M&(EUY)F+=U>;H^44!9@SED-"> ZQS"G,9)A 27 293RC:LLU>14+.C>=NT=Z ML?GJMOL:9!_0>[NTO3L)<,@CQ7FLDAZ0'DY.)W$V(P$7Z'EF@E)$4,O8W&*ZR_QKBH2K1&NG MNADV1]H990_2FYU[ON2*RKE M(62IH"S) AI*J^J4/3$;HA2V,\PRGN:"QP+F(L.ZI%8$,Q&H[YF(\I (P@.1 MVQGH_5 ;QBYWAYOA^5\O+#PO(!J$.GS^@Q;MMU'4MCB$RM6QW;;A80_B#A0Z M.%H[?.*26N#E>?F]LJG4 $\0CA(,H0$E(G,P$1Y< MGX?9FF;L$7-$/Q8=#TI+]H#LTU6/%OK1V$'"H&H+K1=8FL11&BBRDC))(.:A MVO:*!$-.PS!**4YE:%4.YW178S-?VMG7>IU\=:!J1D)NL/),.L<2@%5R.K9C MSJ/AB% Z.AJ40,XKO$\8!F_TSO0UXV3!%17Q-5O]@VBODM7;-6.+-9E.$BYI MG!,&!8\9Q#@(81Z% NHBP%*D.:4TZE,WMJM3FRDP7#W84C@U&5XJF<'?M=!7 MVF5S6PE6[8$JF:SS@'4-0T8(2U"*(4IE#G$2J"TFIQS&.,I8'J,$I\2^QJO; M0?!?N[5S"(2^T_ "OAFENX/3,ZTW@H):4M"("FI9G>9A,\#$72:VKLZ&SL5F MH/B1;&PF;UWF-_MEOE#M,R'X\HN2N[Q>N9V]BN5J=S>59U02DJI=+B?M&6EW[: M\N2_YX"9$:/_8?#,CYM2@BT-KL#NN%1:;*X)ZV>5'NY8\C(<'9%E3R$&Y)SN#S?IQ82PJV MHH)*5@\^=8:X.#M8[.YMX--%(]4/CQC-7K-/'_N-+/XI2O>6'X*M%Z6=]XVL M]$]OU]-R+ 6_GO$?:CI-1?/)9_77A\H'YEJJJ7TW$X\_%_/UT\\OQ:O003O+ MZV?M0O/?.AIJN9KD) XSFA'(0[5MQ7DL*KD!U(I4/[%(JOJ0./>393C'$W/7+M5&&PUO@*-9E=@ MHW7I"U[IO?D8:,VO0*T[*)4'2GM0JP^T_F78G"XDVT - :C^W*8)^L=WY=D MH#2_X_NR6"4+'G;<.M(,#R3(8 F*AP6VG=IXX)[[;90>E(1J>\9OR$+?_&WW M1YP1G#.H[(\08A$E,!=I!GF4AWF<)NK/5FX5Q[L9F^702 D:,>WV0B>P--L" M78Z0Y]7X !P/^YUN$!QM'R\XEF"K! MH>K^&7 ENF5$\1%@S3C@0K@\$X"6#FKQ@);O:A-1^&V#G,/HXM-(N(HN/M+# ML-'%IU4\B"[N>-2'PU3]JQK1V^5R+?B$L@!%61A#CH3..D4II!$/8,SR-, R MR./,ZKC4KONQ4<9W\3<@E:A+P'Z2Q5.5;HHIS=@RL+_J?VWPP9?Y?#6;KVSJ M(75"V4W"3E'T3**6 /HHE62"5+]R29TM#US^F3!?)]Q#LGS.PV'('J>^P[PL]I9&"+3:V]QKNW!=A>&2K;W M%Z:OV/'"?Y,BMDDI93P((N@)()!3#"")$DQC$B @RP0 M 4F-Z@X>:7MLY+ 1#_Q5"6A8!/ 8;-V3_D(P?"_PYC@83^8.C;L6=/5::S%7 MOVVG\+$6!YFR':HT4[3KD9Y6^8M8$!V;\U5?@5)&=_3<"8$C6C[> MQZ!TW*GF/@UW/VP?FOM))YHG;*7+#'Y:+U=J6BQ*9ISM?6-$PFQY 32E,00A5P7.4@3%D>FP;>NA!H; M#Y7B5FZNY>%/90R6V8[ LA&Z3&)7J;<$RS7]+\'*N^KZ';Y>E$D'?@JK5'=. MQ[J;P=YK!#T37J-269@5-$K5!BIXG(-:L<;MMOGD3F[.^K1Z0.L'-@J^P^B9 M1\2^QR@.%/,Z\&A:!;2ZAKTC9-595X,%I;H&IQUVZKSMOAEXZ.IVMEPMRHE0 M^FQ.XH2R*,#*4$\3M1FB*59V.Y90)&F&48 EH59V^Y$^QK9:MKV;OVZ"RK3@ M8"OYLG9J-3Q][H+8S"Z_$#C/B]0!9H^],.N1;>9%(0I2CF5M6' M3G\KT;*$'42T6VL__ M>D:F;\MB:4]))]X?'?DL%O.9F*^7N^$EC=P67',*, -6<8"5;_[HALD'79P! MI1\QG&IT. HXH];.9#_WK/UM0GDE00]B ;=!JA_?MH_4,:S7?Y,%ORM99GFW M7BUU3+NVBA8%$Y.,41DDF4[$SM3F)LIT^2$I=1X-&>%$R"Q*SOL_C3B1A: ?N@X]O.\D:-K']6L4K4"NI M?MBJ>05*1=]Q5,TOD=YS= >Z3'JG4;:Z5/(U#!V72\Z['.R2R1=8[DLHA=VT.I>W2[!P+<[@Z'Z5D$+QW2](&)AI[G!PA6.*=&.53CZ>>\B M\U5!UZ_SY?+ZE113?5?TJ',@/,]G[6CES\5TO1)\$H9,2ID@& 4X5[:RU!%& MD5Y4:!X+SEF:6@4O6$LPMFG\_<"K\[@O)P2\4L"Z_+SE")E=%WG%W3-U:,CK MDM ?OI;(;Q30>%ZLRM/Y0A7YI&=[)ZK"#3^WE5&.OFUTK94(62[6NA:\$$ M*$]23B&*@A3BA#-(DRR"**=YFH=QF&(C*\:M6&,CSUJK)M9FH]@F0_$5V"BG M74HVZH%&/_#75D.@5;2\=WF9BQ^-W,U.[Y46Y#W'H#. 6=4?T M[4BH03G=+9#[1.^X=?L[P<<%5[O?S^OJ"VAZ$[C[UM@(MGT U,AH?NFWA\CY MJ[[^8'@FJL<%*4^FK?"PNM [KGJO:[R]I@:[O#NN0OO*[L03=G.-BV)R,UOI M4CJ?E(_WBT>YW_/)G&88"ED"',>A/J^C<",RQAF"<()8I3'V"B*IZ./ ML4W12DQ0RZE63OW;? &TK&93M0O0[CGK"";/D[<70L:3UP"#CEFLWJYFL?IA M.XN[VAQD.ALHURUW4]>6FSA02Q7BX*M!/]$EC^O9^5_M)_>*YGJ6(Y6&84, M\X3B"$8I0A#'*( Y(1SB($LEHA&W#.WO(_.@-KX:AWJ3/GJ MAY8V?2L?F(^4V6F%9_P]DX\QW -5);#&T'F] 7,)WJF2@#5$IVL$V#=U*4_^ M$$]Z5_D@7G2%S]G3[4S.%\_E/NGC6_WA=@:&. K"4!"H_M6)^G($":<(IGF8 M)'&0$IK;5>7J)\>8^;*6%6PT 2U5K@!]:Y[HRY=V(V;+F=[&P3-O]AJ"@3BT M%Z;.>=1.BG?BTEY0G>;3?LWUX]2/ZV4QT_O0^3,M9F4?/U;BY9HI^JZ/?,LP MD=N9HB3%\[>S\J.%$%](L=#!(P)-DC1#L0Q"2*,00YPS"BF-$>0$I3A. T9B M9D.P+H0:&]MJR<"K%JW*^2)>"QT"455; $6MB7;O)5LU 2>F,6I.!]2,?X<> M)L]DW*@#6OKH*S7Q EHJ7=6E'D"CE1H[T.AU!-EY&63\MC6G".)A%G$)99PG$$=Y##,6Y#!!@@LF MTR1/I T_=W4V-M[=D=6.2CLQ-:-(5TAYIKX=,:^J= %OX*_ZOUX,31-D')%5 M9U>#DI")TOOD8O2.??3>-[+XIRC=)G\(5MB%W6MP?+C?#FT3CG@>ZF M$N?P>>:2K:Q@*VQ9E;02MZPXZQ(^\^@DIS .%&YT&9Q644/&\'2$ 9UO8["X M'F-UVH$ZYB_942ZKXP@FG[[_YR0784YDRB!E60!QS C,,A3!- L1$K&RRF*C M \EVHZ.SNWYJDUB !S%[+F:T,)OQ.S!U\V)?Y7V;4DIO<@7^KZRCYK>M9;33W" 3\I@"S;P[^IF]F]/GFI ?%V16[;JJ$[0)RG 2 MR)S"(-;'4Q0G,$L9ABA(,>:<)UED5*&OJY.Q3;]&3K 5M#Y9-G=S.@EH]\1T M!9/GB=H#(2LWIW,0]/)S.MGH8(Y.Y]1J>SJ=?;:_J]/]0O#5XGG6R]-IY^6Q MS=P=1QXMJ="I4-5BVL/-:1>E[FGK!"#/<_8T-EYCPQ+$3 D='C0IC MQL,XQEPBN_!-6P'&QA)MKY#-I61;A=(;I/6'?FG1KH%BJYBM]77Q*)J: M:H,,RE!V73MU2#D>M?],I1)HZ70%=+(1Q;T;O73@V8YF+JU!5R@[,QTO%FA@ M.],5@(=&J;.6G3E%;BM$)(FV2)':KLJ40DP# DF:AVI !4^3(,ZEW<:UJ[.Q M6:;'7.3ZE^'HA-F,*UV!YYD%>^/FPE?05SF.SJ[>V[?O;$D.HW?ZYK5X+$\E MRT8_*Y/'+KW%WLMCXX"6>."SL7OR:6S.GTI?#(OGV7TLWX4Q2CWR7IQ XH+T M%_LM#IP%XX1"A\DP3CW8>U^VT EP/HOJO]HMMZS3L[PG;^6)!Y6(2XP(E$$: M04Q$ @FA#*H-5Y 3GN6(4;M#ZC,]CFVR-^*!ETH^ZRW3&8"-=T3N8/._X2EE M!!\::7^K(@1J(._/ -EG(V,&CKM]RIG^AMZ&F*E_9)=A^&)?C_Q-SL0RM?/R M>JVV, OM1S8)DH3A*! P"A+%*PCE.NVR@(+G.)*98$1:!4QU]#4V1JD3ABZU MK%=5P8(E(!MQRW(&U5\-ZQB8X&U&,XY0]$PP[8RK5U66^2782NK20_\L',X< M]$_W-+!__EF5#]WSS[]BGZ3]^EDL"D:6]1UOFD49Q2R (@GT\2_+8)Y'#(H\ M0Z',@H"$R#1-^V[38Z.'1CKS#.U[4'5/]"3.U[#0Z6 MJ_VX(NUL[2>>Z)FR+)9?BYFX78GGY40OZADA"%*:9!"'1 ?2Q!*RB$O!4,*H98YBE]*- MC06V4;17H-*OS";3TA T*H+2;;/6JGRJK28H];3,4NQTW,U,CW<;3<^4YG@@ MP5]:25!JZ3)IL0_T7>4N=BK;L"F,?JB'2[@H_-[_$@A5+O?&L MBFXE<8Z5<4>@KGT(L2 QI(%$,*&(QCR.@X0&)@N&#^'&MEZTY/-;#\]V$+O9 M_[V'QC/Y&U5*HV:5TEIJNJ^'9SNJ#NOA>1S=,=7#Z>M-W2Y-89C()400%P1'$-!8PB^,$!AE1>[0H M"=7FS731;3<\M@6SD0WH^!ES)MW!ZOS:UA0A)#%+(>;* MVL_CD,$D260L6!CAW"J+\\F>QL8_:@NFQFBE^IM6F2XK>>T.:D[C:G;HX@0M MSUQU BA/!R%G$7%TJ'&ZGT$/*,ZJNW_8#$H:)TON<8?1./]JXYO^UKMWA'^-EF!V4+!8?:S_ MR'1AA)=:8WT\\F&M#T:*V6]@WN@-R$;Q?[Y3_:$9YHR[8ZNLE(L#G@#@B>"\B#KHP^ 1Y?T'QVE>_A>A! M3'5DYSU9J VS3O9#V&XT#T.8\B1',)<\4HM*ED-*,@I9FD6I"$B&1&RSJ)SK M<&P+1"TO* 4&;8E[1T^=Q=R,KUTBZ9E[+P/1FCA-D7%$@F>[&Y303)7?)R?C M]WJD_II.ZTB;UCU!X_9GF@&LHXVQ<8:2%1P)+3+T9CJ+6#<]N 3+MTEV B>' M;I2F:/3+#=;5\' IP@S4V\D49O*\_6W<[GEG<\YVM_HI%I]^ZFZ6$\R0,AF" M #*,,,2"84BB"$$J@Y1G!.&4AZ9W=.>[&QLKE+*97UH9X'G^'L\M2N]S8GX% M2GE!+;!3!,TO ]TB.= 5X86(6MT=F@/4<:-HT,A@]XSF"K5O'RW>ZF5(J3VD MVB/.GU^LS:>]-\=&C]H8V#NC:7N86-E.^R 964P7X#. G=0!C7MSZ004?8VD M_>:&-(U.J+)G$)UZZM)+P:^;BVT64QRS)(524@IQ'&8P3X(,9C2+(T(2GH4] M[P*_CM558"MBWPN_KY9^ 1>",MSUGA\G@ [UG5_H?7V?B_\.%4]?WQT^>G%@ M>!FX<+=>+5=DIK=2DT1[_L@D@GG$]85_$,(,96J#PP0-LP2%26!9J>UD7V.; MY[N!X?_WOP4(O)"Z9.:_ Q0'5VK/I_]W)&B\CH(NELNU^DW'#LVWBOX[P,%5 M@K*K. _*S]2O<9A?Q6FDRVU^%JQDZ__Q?Z$D^)_J[T!_7\L'?ZBOTI'/KH#J M[$7H0W0Q?>L=I7XP^&;LY&A(/;/4;I1Z'0'6$M5+F/HI/-R'J1_T]%YAZJ=4 M[@A3/_E*_VH,GXLE,UUE3[XWHF_O3IT!+>1TKN/(7,ZCP(G1N2K00__GE557&2")0%(HT@ M$[$NRQ6'D&1)#&4N(H)0@F4<62V^%P@SNM59>S+H-;'\H27N%=@J5'YHN1Y> M,F"&"^9 P^![134>@1-/#5+5U0'6KE;K2T09=CEW -K!>N^B37N#H&56:,^4 M5[%XT^HP\^/%#J#.FT]N,/+,5RTA02,EL,', MRHPZ#TDO6ZJCV<$,JO.JM:TJ@Z?=%(O^1E;ZI[?K:3DR@BLZ^:%ZG8KF$YVB M\S\%6=S-Q$0&09J+#$,L%''/O'2BH'(C]!78* 2N]1E0J=+FXS*9 M[Q70:@&EUY##=%F=:V_#];YUL!T/V\7ULGO!;%E/VZZ/=ZVWW0N.<_6X^S7: M-\2&EW6 R/2>%/QV]HF\%"LRG>A2991+ 7$4J7]R$<*,1A'D&4,R0"'A-+>+ MDCG:S]A6JJV8X$7)"=6*Q2I);0-4CL-JMJ-W );O \0M3EI$G0'ZTQF<>@1V M=*+@+#;C>"\#AU=TJGH8(=']>-][NYFRIE>%XJ+/@JY:?%2YA^","9H)!(74 M=FXL,Y@')(821XAFA"84616&.=/?V*BA)2Z8S5>F+G:FZ)I>CCG#S/L%V18N M+6K+JO%0^]00%V<79=V]#7Q99J3ZX869V6N7^O94:0LG 44H)QF"<110B%$> MPYP$ >0\P4%"7>5.N_'L/=>SQK%V./G8D;_LX]OVD7;^LJJ:W383P++T MZ7W\269U9K,O\X44Q4K?-O]#%$\_]?9&$1%Y$K_K?$1Z9[-)>3K)A,1)+',8 ML50JUN QI!2%4*:(AP*'B6!6L?KC4&ML7-6Z7BN]D\!Z5N@+-4;45W2J,QU;B[*GT]#J6&+:@]#IU/K-DCDZZG MI;!2C6DA[F25GT'?NBMU%N*GTJC,"E3^M8G:YWD49#(B,(YQ#'$>Z5J>Q/G(DPLCSYL11@;Z56"ZGDH*FNP:%F#4NTV6.OPD.O#P]Y5 M\WJ,E^E1B\]1\'X80UCP M<*AW2W8LJ8O.B!E[FUS_\7F2$TPS03*81R2'.$F5I9 MK^9Z\]MVGN\T-\C,/:9 ,Q>/?M;SHK;,D' [^Z0S*"B3YA_%ZNMANN),8H0!E4_P801SF&1&($\Q0'6&F7Q-0J![M5[V.;KP]"KG?KLUG> MXEI!;WBGZPM0WS>\I=REZT>GD"1K9KS8POWG96O7"S=4-L%7?P]X']X'E MX':X5R,]3Y#83\'74Z',D.>7Z?Q-B!]B\5HP<>)\K/**4S_=2>T!_C33(=+W M8E',U7/+U?)1>]--,L8H3A&!6.H+YYP12) 0,%"DE^4DX FSHCTO4HZ-'H_6 ML-J>1^H"5EK#.@:]=CO2BEW5P0[@KU(OVZ,J+]\ PP.M]Q[7 :]L_ RI_9F8 M3\A=G9QYD7'8\S6?,!^2(B*"D2:G6(*"0X%3#+0XQ% M1B1B] (WQO$[+VHI+_)=O,1CRI@$291D5H?Q!GV. MC0MJD;5+CY:YJE@^+WTPJD.*52^711/TS2C#,::>":2!LQ:W1+/R:*DDO@*U MS.X(Q0(@1_1BTN.@9&,!P3[UV+PZ4N])7>VB,I8F6,:AH#JC&HEBB,,\@812 MH9-'(Y$Q$B,43V;B2<>1/8[(4W*K@M%/\J?HHMR?_/[/A,+.# MW(/LVS>CP?>AA>_U#KZ?E-5:K("NI>Y$AB3@<4AA(KE0E$4Q)'%$H.0QHB2,<9"C2;7O^;$BBY7Q M>?FYGFWFTG[__J;51S(MYP]1]K]X*F8SO7+/9;WSLSY1/PM_&'")) TA1TD. M,2,8YC%-=4JQC N29YBP&OX;]=[[@=_T/@CT0A]6^@/=^%+#)8S^KSB.NN?L M.4.=SO3>Y\;#%!]W]Q]G>QSZ-L04@B-W(\:O7G! >;\HF)BD 6)Q%L50)(CK M>"P" 4> M50?GT'16<_HT,)ZK3Q_I>!1UJ$\#8EJ1NJ.%@6\UZR/B5N;F6V7@%+-EP:IL M'(G@/&,LA1&F <1"1# /4J0V/BG#*8](P-#D52SHW/OUY3E9;>9K6V)_TW9S MG]0J"74%R-/3HKPK!44C?U5J:J!;R;-C[OD.TN4XCO_&.TF)7M_UB)EVOVO]?%LDPAW3AV5 78;V?E1PLA'A3/ M$UT34(OR.REF^JKPNUAM8EM)(!. :TG:"G: M\@&L=-4N?HVV^N*E_0W0"H,/6N7?KH#2VDNPM/_!<;0@>!1TT'7#/^#[R\L M/?9;A;[-7\N6;Y4\:E>@]@GWBSE?L]4_B-Y2K-ZN&5NLR?1A/IU^F2_T1F+" MDS @E##((QQ"C$@(2:BL>)(%,8EB2I/8J)[6!3*,;=UH5-!"K52KJJ\7L5B]U3&V<2Z3G*$,QE(DB@8E@SE'%$:9^B042$2!E95] MNJNQL=T]68FRK.^T8'MABG;1FME*FVX-X*K1)-EM]5]^%"7Q^^B96/^=<%Z8OZ]*; ME@P_\?K89F;WP4Q!USTY'Z'B>H$> 7]I04$IJ:,@KS,X M](KP.M7F8.%=9Y1JQW:=>]1^VGY;+::/8O&\O)./"WZ]6%C/W-,MC&WR?E/F M]J)0MF,IKCZ5/A*;:#Z=.Z [/Z/=H.;[:, $, _3_#PXO69Z1[.#3?;SJK7G MN\'3?;?CK#H))=-/\^?G^:ST=5A>KU:+@J[+6LV/\T/_AU8([X1SE"5Y@"$7 M/(:8Y012%D0PBD(29 3%RCZWV[9?*M+8^.9S,5V7Q0"%E&JKI.?/LI5\DF@R M;VG(,Y:[AF27QW3?IDO;F:OQ6(^JX315ULZP$JMU&+& M"K&<2))%B102DA2ENDY!"C,9AS")4<)HDA.183OO8].N;2;\,,[$S56&CA$7 M;=G!5 EOFRW=> C,&-8'K+ZW?BT\=X0N0^_!CM@. _$M@7(5BF_:[;#!^)9@ M'(3CV[[?XWR(_]?C7+O:7C^OC ^%6N^,S;A3LJV7JW+=5Q9"VX>X22IM<3#4 MQL;@-*@G++YYX"0BYP"Q.P,ZHGV_@Y]V0\.=]AP1?^>(Y]CG??-?+%=W\@>9 M-@7O)[E(L2PK!(11#G$D$DAY'L ((1E3G(H<)#DX]V-/!K)C- M%RW/M@FEDL=1G$(1!4C-9<1@GI49M]1$CG" @HC;F?3[78S/=/^N!DDGCIA/ MI_H4LG$BMIS6!U *%JCO&:,PSC.U.\J#0"?,1FJSE&9!&D:<4I%=.<@ =0IT& 0W5US0A2*U .**0XBR#*5=(!RB5C">V"7\N!]I_=I]. MF"_(]W, L-D*=0EDGA>HRH'WZN 0;@_!VW,!!/8NB"5?N-_\L,Z#)Y0[ M\ P\]9R].\_G.2OSJ-XW4TR79)]0KF8Y#RG,>$ T 2@3-,Z1HEZND_0D64 B M4W^>HSV,S01MA*S3'P,E)M!RFKOT' >R>Z([@,FJHKCUMX")FV-;0;O'F74P@,M M/7A=_EL9SE1I8'[B8P3I^9,@UVAZWWL: NG!I\ &JE['248=#';,9*-N^_C) MZCU[*KD78O'[8KY^N5TNUVKJ?IE9,TA'$V,C#BTJ*&4%M;"Z(L)\-9N;+O_G M,#M/$8[@\LP,74AY( ,#4'IQ0%>[@TU] ^7:,][D:6ZPN7E:E?:4 M['BJ;\[-\OKCBY+E6.+=^G(#11E+@SB$,J?Z')E3F*93I]4K!OB2&*X\XQMZWVN2PXS/-^TO3J,_J %H M/O53Y&.X,1M)/FA3J?^ELD-;#H7K7-&VW=LMBZ]D,?DF>,'(M#Y,('&$LSQ% M,,^%6KB2A,$\PA@R$88B)QG+S-Q\#UH>V])2"V>V,ASBU,W=%VGOF5UKNN N47V@\2.UV, !'C=>"DUA53JX]+]D5AF)<,?/C\(!QY4LR&Q4X_ MT,_\_E+,=*'"K\K4%YMB;=H[3]G[:IPG!&&"L4 PD8GV\$H$)$&0P(2%0S0ATBZ9G?&A!+4:^V MY1NOP%9<=Y:>(2Z.++1SO0UJ61FJOF\1F;[6-PG<)Z%/FJ>W,RY^_2_Q-L%A M2I( !1!E>08Q%P',"<=0BB"+!<*4)D9%Q4_V,#86J1.>U5*"4DR@Y+1-!+'G?P)X)OWC)2D: MV!LEKJHZ$UL]SH;BNZ@Q88&DO_H1)D*\=VT("Z ,ZC[8M-;SGNET!:.O2IK; ME7A>3@+%?B)3>UR)]%E;E")(\R2#648BQAB*>&Z5!LVDT[&M3)W5O2RO;4PP M-[QS<8RD[PN3+A#!7UID4,KL\D;> B)7]Q,F70Y[N6 !PL'-@,V[/7-\3,BLV[$QT>-< MYYUJ9UED[;M'44EMF>'+; #,2,D]K />XQY)=*@O9[LQM<_L9061J[Q>9IT. MF]7+"HB#G%YV;]N'>'R?SQ[64Z&H)48Z->WB>;;B7Z;DR332XV0#8V,5)2C4 MD@(M*D0[+@PZ/:^V2(5%(OC3R'63B#/0/'.&&5[@+RVVHXBNL[#T"A4YW>I@ M$2-G%6L'CIQ_N/>57[$27XM7P6]G*S66!9W6_G^_+^;+Y801$@0H4?#E*(,X MXU(MOR*"+$,R3L,L"9A1E1;3#L?&$*50X!-9+-[*@"B+!(#&&!O?\3E#SO\E MGQ(5EK*"K;"UV_(5*.5U>LMGA(R[:[[N[H:^YS-2_LA%G]E[O?/0Z\AR\JLV M1SZ*F9#%:A)@&F821S"E,8$X#@@D89Q!'8.6<())BJU"T4[T,S8:J;,?K,@O M\(%6(O[6;]-R"M@X%FD9Q_ M<,T8V@%@GHFY1DJ)V.SNP(=:RM-^*WT2VW?AX"Y;_=%>ADY!WZ7JD;SRG8_W MY=I798#/%V^:TY<_!?]]/N=?!!+L7@5RTF(,<(DXS#AH8"8*&..YHJ& MDR FG(9("&+)NV?['!L'-Y*")RVJ+3&^%+,C&FJSKM//=>#+U MV?I9\$^56UGUI&I%%*_ZS>6$I#EF<9S 3/ 8I1'4.T],&^%=,Z9WJTNPV,AX!6;"?8!M$S^1[WC=AJ#-HJ-S'!C=(' MP<&UWE>@UGRS&V\I[]6=PMM0^7.^<"_R>[MJ>!L$ \<.?WWW6\@^BV7Q5)Y8 M7R__0_"G\IIWN5J442UU'$TJXA 3SB!*9 IQG*D--DLBB 3-J?J)DCRP68<, M^AS;,K(5&9 EJ(4&6ZGMEA,3T%E&@X!&*912_8-)2)09H'_-!"5)$&5Y1NW. M,AS#/LRYQF>Q4%]T79]N"78'H4JHJ?Y>5671&MF6P# 9![-5V3&VGA?5<]]F M#\F*+ !RM)29]#CH2F0!P?Y"8O-JOW6@2DQ?E5[>SJH[7;KS\2>9/8KGE_F" M+-YNGU](L="?35@81C@.*,QIR"%F$L$LHS$,LI3'-$1(!%9..?8BC&V5J#0 MSU6%\&*CPQ4@Y9T9^'M1K%9B!N92VC%5C^$Q(RZ_H'OFL1KONB+[;0OO4@&P M4AJ C0I@JX,[7NN/GR.:ZR' H*S7'Z!]$KR@IRLM4G"2)I MED<$)E$:0ASF!!*2"ICK-),\2&3.XKYQP'M]C8WE=F. %UI8.)=PK7XAY>ZD M?_3O/LK&7@$NL//O$-".^GUH<%.B5L<0:I60:OS -6/KY_6T-,^NG[7K[7]W M^YI?%!)\ C /X<#[/;U;*/ )E;O"@$^]TI-8FBQCGXLEF\YU4K'E-MT?2Z,0 M!81#@=- V54BA6K'%\$H")#$,4,HLTLQT-7;Z,CE^O8!_'G]]8\;2Q;IA-20 M1UP!Y9M)-ED004M2QYGDK4!QQ1:=?0W+%R9J'S"&T4OV"9#^5Z%W>%/Q]A_S MF7A3_&-V.-'UZHB^SAL1P4;&'JE_3F)DG@7(!58#)00Z@IF;G$#G,.A(#W3R MU<$R!9T3OITTZ.RS_9;V[VO=R)V\>Q$+HH.FZB"JY20(XUAM&O39N:1JQT!R M2&0>08JH^JLD.!-6QK;DEX)6A4JUI%DY4W=O)$:+&NQ[=;[TSB;K?5. MT/-,C%O@-E*"'^?0LE[@SR+A:'$_W<^@"_M9=?<7]?,O]"T@YYAAZI$7.ED_84KP5?DRGH1*5'F9@]!"ZH$-.T M-'!QF#T%#NO"[#]@;RS_O_-BMOI3C82ROF]G/\B:%]<+0@O2%())$,D1C2#/ M]6VV]@_/PBB$D:2)I#DF<6HT)0WZ&MLD+<4%M;SJ>PI*B4$ELKFI?0[A\[L2 MA[AYGN&=D/78IIS#SGRWXA##@38M%V)IM8\Q1*=C.W.NA<%V-8:JM#X8HU['QKCMXB6["E1^XU4%*?H&?A?SIP5Y^5DP\%5_L:USRY@-BMGFR#G4 MGDGZ-+(^*[Y8H>3*J<6HSV'=6FQ@.'!LL7K9WAA4YN1ZN5H4FYS@210))' $ M@X#H\EE9#+,\4/P481DEC,LD-CJ%.=;XV,AG*Y^Y?7( V'EC[A(8/!/#5K0> MIMH!%.:VV260#&2,V4!C97F=TKW#U#IX93#;ZI2P;6/JY#,71BIN+XFVZW.0 MA52&0L(XD0)B%F&88_53%,:,IV$FLCCJ%:)XI+/1T=7W/V^^/]X]W-[\Z!F8 M> Q1,XO'%4[>^:P6LW7QZ^G>UP01UZ&'Q[IZGYC##J5/!AMVO6-ON1R)'?FQ M$B]EC,BR*)->G*2)3++22QA&DD$,4T2 M2"+.(8MS&F>4)9%,3*T>EX*-C8(V.6Y>2^\*M9%X68C78KY> E'YFA:U5H * M.5>3CVR5,;0/MO4;,,QD>#PW4FH&6P%>@]A)NM%-#V 0(BBM0:@@> MY^U7WFD@SRTN\$,:Q\@M8UR+^WW,^C/U!"_ M^<6F:WU+J#U'U?_S1_)K$M,@(RS#, @9T;$S 22I#J6)*,-8J.7:+G:FAPQC M6WMK%98]PO/[C BE&0A4_NK&,<0BSA6/X4"IASGC*KM%PZ(77REYS$8)MYR MX%$PVYUY1M:SG=*<16N"!(W\X&^E &@TT(F&:QU HX3.4.5N.W7TD M&'3S=P%$^WO"2YJR]R;2F8^OV6I-IM.W>U+P/]6J^$-,!5L)7M>:TGS([/ MJ_H"V,MWRJJCP5RK^JC?]KSJ];[]B99B0F7#K'2.U>_SE5@VB2XX"KE.K)SD MH80X00G,N*XQ$\5AG/,LQC(U/9LZWL7X^&DC)2C%-#]P.('A^3.@RY'QSB9[ MH/2XL3N!COG!RN4H#71$8OX5LCK:Z-:_XY#BQ(N#'3=T"]X^.#CS9+\C@*_S MV9-BCN?/@JX>51/7OXKE1&">YQ3%D$B.(,Y("HF0"41)'G$914D<605\'.MD M;-2F981:2*"EO ):3O"7EM1P&G=KQ?%<\WQ9V"3),9*2$LA2G*J9'D60LH! E/.(B31' M861TO7;0\MBF]T8XH*4S+]>\"U?W-+X(!,]SUU!_JZ+,1W7M58QYMZ7!BC ? M5:!=?/GX _U6VDV6E^IXORS_M+Q;KY8K,M,G*I.4L0SC-($AI3'$::Q6W2CF M$$6"LY0%0D96R0K/=3BV*;I-=U3=6%]5!>.68+Z5&7PH9O6?3Z>\[P>_V1+M M$E3/4WZ+YTV-9R4M:(GK;MTV!<;1&GZVNT'7/Z M/[J#5S+5T9_7J\99I,SX,,$TSE 6QS#-N;(!9(X@C9(0FS4FQW;&^%DB/*-^MS4-ZW M@F&?_.U>[K<"U*5AE[77R$(TWB>B*BI1RE G[YY$/* <,0P3[;BMJ(C 3$? M92B7$481%EDXF>F(%\$?S=<#&QF,)E9>3:P#23SNGK8N-TOM6TDW&I3>!OI/ M)8.16@T[^K(:)#,6X(Y.BR?' M*5DOP=41>_8285 6O02D?3:]J*V^D7^5+[+N5#'V1*99F!"6P2@43.=%2&&> M8 (YC7..A,0R-?)\.-'^* \'7K1[D)Y432"-;:C?+H1FI'4!,)[Y:!.[H$5K M>X%^(B_%BDRK$E?U0U>M/'#7;%6\EO6!7(;\'87)693?;NL#!_8=5>TPEN_X M8ST/#A5U+,1/Q1[%JZC*GI:&FF(;]5LUT/YN[IN^-+A09V?47!UI.=8NF$/__Q >W!, MZ*F;GBN#VJ(7JR^$Z1I_;Y_GSZ2837(1AXG:)\,T31#$088@B1""<1#2($#.)SCV'93@2=8!S"?3!$= M).2F$S!'T3;'^WC'0)M.I;MC;+I?[>^'_EA[N6K#I:H9/$D)3R1*")09QQ!3 M+&&.I( 9R8BDVN;(K*+-CW.SYBZ87'HFGZDD\&=TT\K>LP]O>/IR^L7-@7%W[:M_UB157GK M<2>K)PLRO9_7R3-^K?162>V OA;+U80&$6=Q$$ :B@CBF$4PQWD $YJJ34E$ M699:I:5S)MG8.&>OR-]&MRNPU4ZGLJGUTV<<&PU!HR+X:ZLDT%I:;H?3-;/Y>G]W.7VS?GV'LH_'B97.]6)M()G%U%)=UTT#.'NU@4 MK^K+^"J:^C;;@N++_Q!3/I$A#PG-">0\(LIHU,=15*202%V',L\$Q=PJ?_NY M'L?&Y=OR2RU!+9.RGT79C&&=8N>9.;>R*JX\!B'0 CM,PVZ*C:L4[&?[&S;] MNJGZ!ZG7C5_LQS"_DV*F;W/N9MMBW:V2K#D*,\H$@R0G'&*2J>VHWI.F- D" M*C,JD%5T='=W8^.6=ET(+?FR=#XO;[_$\C?M&/:-+/XIJANN'X*=VX?U&0$S MZG&'JV?>T8+6]X<:ORUH7HM F,'CB'K.=#8H[Y@IOD\ZAF_U8YQ_"%VE6_#K M5V5G/VUH[7,Q7:N_'L8J1B1AF-$,)F$F(0YUR%8@.)1A@F.:ABA. KL (DL) M;&;/,*%$M:3]74]MQR#) A:*((6AD"'$@J20"D[5,A QGF*)B5X&S'U:/([ M$#XK#?Y_UVH 4NGA-(C7=HS,%@J/R'M>.1K)02UZRVP]C/6] K5&[M:0GL@Y M6E1L>Q]TE>D)S?ZRT[<9^^O>+TK3^4P\"#97?;W=_'I17[6ZN-'M\XO.!%FP M>MMO??G;J_&QF;ZU$J#10M\\;/0HMXI[FIC?!_<#__SML'?ZE*Z_>6@T0U+DP4K^6*X_/T_0*0G<7>V$LP<'Q-;X@. M8VCZ-]6SM)*>^7?RCV5%UG=T1=1"H#C\YA?[J8/VU=[GJ$?%A- 8RS#G,,9( M46H2Q9"&E$&"0H$0BW"0QE8%EOI*,C9BU;XF.A!;U@Y."ZT8G$NX7C8; C"O MM=,5U42M7QFT/1-_@ZE6#TS[,F[_(37CW4$&RC/[/C1CHK2HF!;P580NA>N@EM#%#?;CWF_SF7BKO!"^*!OK(!$@ M24D6J&4>)FD:0\REA"2B(:1"X@#%+,28VC#LF?[&QJ.EN."YE!=H(]22!\_! M:\9V#D'SS&D57I6HH)35:VI%0V <<=.YW@9E($/5]WG&]+5^;++)7'+S2X>M MJ>TX79;&Y(0EC(>89C"B.($891@2$D8P"/*8Y"R+LMPJ"\[)GL;&(-MD+J*6 M]-_M*.0TIF;DX00IS[2Q!:D1$OS5B.EP(WD6"D=$<;J?02GBK+K[Y'#^!2^U M<[>'+D&>92E#!.*84X@#AB&5/(,RI2G5[NB2Y0X+YH[V7.SAYL^;[W_<@(>; M3W>_?[]]O+W[[K1*J^TQEP\^NSM=C=7S_W1>L82JOOM/!E"T8EC5671U! M'61=O5_,%1FNWN[5ETJ??.FLTR_ZD0E*J51[H@#2C"*(,4(PSV4 >2ZRC*=! M%),^"5#-)3":9,.G/;U7#?TD>NF>2_!2"W\%M)O"JCHN%HT&%Z9\/CTV9FSF M&.KW2_=\OT'Y?HORS5F4+T_V?!8P7ZF>3W?\OHF>SP)R-LWS^1;Z9*79*_!Z M_;PR3T%S^.[8S*23Q8>OG^=K4YHY"50WF;C R/OU7C]X+%/$G,:@9SZ8(PT. MF/SEM#J[F5XZGNN9R($4B_(0YD[N>CA,!,UC3JB$-(PRB!G.(<&YA#A'08A9 MG@J[:FQK;!+>P*9JK+@Y6/Q?S]9,N,,'TUWP)7LB;OJZT3*]P <%*ZR$9SL9]CL N?4/<@6 P#KB8_)GD(LS!%D*=)(I(X2@G*;2*[JV:M M)OU@108JOSE+ Z&"R= 2L%;>]Y+?K;']JKZCH*OENVITV'5Z1Y&#!7GW4_N# MN^N_R8(O/TWG2_$X_S9[*3X72W8[X]_56)D>X'6U,;9%5>Z68H)13^X,^%L]E&8QOW^]O@199?;!>Z$J/2O;BM>!K15&=0%J=ZYF@ MU.M\K[/AP<[Y3-1KG_<9/=^W8)BN4Z'SY>A;SJJZ^3>Q^CGGK>PY$T0QB72U M"!D$.<2,$*B6UAP&2*1YR@57=KA=&ANC?FTFQ##):YH:,E6-G_)Z7Y2RJTFR M$=NVWIC)")BMX(B!+Q?&6KE7?I>GM2VPWA0[U036OVPG<>' M+0TR5T\JT,S'TP_T]$6J,P&71T&41H@P%,.(J5TU1I2I:<=R2(*(DIAE89P9 M[0B.-3ZVF;=-J-WC,&T'-;.ENB\6GN>@*0SV;CQ']'7EJ--N>EA7G"-*'3C; M''NFY^1X1S M'E(FK')I=_0UMJG[<;Y8S/\N9D]+L)XI- &K2IJ1IX40/2SR+I@-)[<;\'S/ M]5K*C9MR(V=9KL7AU#^/ABLFZ.AI6&(XK_(!3QB\TO*OL0/L7@MF+@7BV+.Z\0H^H$JD%!DL.FG\L2+FJOO"A#YW4P_:?Y<@5:.KGT6A@&>&>.#Y[% M'=AW8ACP#]TO!NJWY]+SK L>_W>=*K*N-S-[TI-@.2@DH]SN5+FKN_$=)K>EU3Z0NH8@*);+=>FVP+30EBM %]J&[.T( M0=_,NP>=MI+ ;0/=IT[H[(G5 !-7I-C5U;"$9J#T 1F9O&-')*47]>)M\L>/ M"1()92E*(>$LAE@J4S.7"5<[7,Y"SD2>QD8[W&V38[,#_U#$JXR(LD*7X=1O MX=,]P?MI[7D:__']]O'F,_CQ>/UX\^/R"7NH8\35DW) M3:;MNQ?=Q/)/L5SI/(;5V<9>B9[?5?NKS\K4WC"AOO".PC1 $%$L(<8!@R1- M0QA1%HQN5]BD[H&_'#^(U-E>-5V&[ M1'"KU$2-T!7X<_/UJU"Z @>%VTJD@(8*;$U==^O0Z,;?T;(W'KT&767'H_:) M17U\ MH'K"A#Y+N8+^M=M6&$RLY+8UL>E7#P^\V=X8;@$(/NM>8B]3US?:.Y MPQ.#D^KVBB#9;6FPD)&C"K1C1(X_,+!!7D_]+_.%%,5*!PCI9%*_7HI%V<*R M88,)SS))<8AA$.M4,I2%,),DAA%"-,AED(J\3QX[[X(;S93AT]]]TM=>4UU3 M2VB9E;DR7VAO ZW,):66_7\1/%O%3L?U7\;:W=BS+;VK]'Q;S;=&[@B,5]MA M>F^CU%C>?PUCTQ9^9T:D=1?7'FU\K_2N=BIN9,H$KD2=1$"4\2"B4-!<0IT*M;$$:JW\" MA@*>"+4^7%A(U)?L8[."CY>=K+4'C?I70 -P!3:*E]6&J\#"TM^NI7SS][^V M^H,6 +8I5 ;\6IFMDR/]LGA>,4?T/7%1D]3WB/FK2.I-\O>N1^I[2 RJD7H7 MH=_2^G4^>U([G&?M@+=WQG,[4XN$6*X>E&QWZD\ZA\0DYCDB'&/(.>80YUQ M*@F%(1&$A91A@JU""BW[']L2=R.E8*N*<2II@187?"#*8->7'DP-JN6FS79( MS)86CT![7AZTY%"+7GJ)'CG2WX'^"I11R%H'=RS?$SQ'3&W;^Z!LVQ.:?<;L MVXRC4E.3!.&0)#R%L>3ZYAAQF.4X@0%+4")8+$6.;5*1'?1@Q5R#926;'Q28 MNK"^5-^Z4B/BF\-Z4AZ+2+GV3CEH_WV+1IWT13GY8,\3;_&DS:<'\:(]V&=/ MVQ17VVI%$4M#I)U#$A:IG3W7L=913&!.LHAG:8H$MXJP-NAS;.;*CYO?O]U\ M?P2WW[_+4?Y7PBRY_Z?_HB_95,*^_;QBM*?W ]X[M_:#U9'8LV@:6?1?5? M]?MTS4M6K.KV:I.GVF),9(Y0R)(,QK%$$$IC(2,4QL#95CQ MQV;]?!]J M7 ']+VAII$,=-D-^/NV]4*&R#PS\T0/Q61HQ76&P+L9?' A4<[M:( M]QE&1\O-P,(/NG*]S\#L+X+O)$6_]511LI;@?C%_+;C@']_^6&KWLTT4ZK4^ M9RL=US>I\K ,>, R!!F.$HC3/(8T1@',PHR1,"$B959UH>U%&)N!7]*4G,[_ MKI,"R49T0#:R6Y:0[C$N9FN07[1]^[F)5;4F-.)KEXX/6@-E3OP&-DJ K19> MJE+W!]$1B_<08% F[@_0/IM>T)(=([Z2Q>2;^+-8?A.\8&3Z8SY=E^X4U[_7 M?RZ=1&D2A'E(0DAPS"$.90@SQ7@P3H,TXA%&$:(F[&?6W=B8KA0-U"*#C>0?>/C#R.2N]S2NGB.'@W.EWW+ :+P%V M*%5TK]XI*1R%85[2N&$C@U"VG4(-/5N^U?=\F:T7@NO;J?J;G"0RBEA.(&)2 ML2\+.209)3 BG,L@1RR,B-UI\EX/8R/<6L#NW)*&X)D>$5\ B?<#X2T:'K(C MG%3=V5'O?OL#'^R>4._P&/?4@[W"C.[%_+N86P<:M5\;V[34 3?W-W?@^\V= M5;31#A3=\_%"%'SOQ+8 N \Z.J9SW["CG;:&##PZIL1>Z-'11_HME=_(XI]B MI6LFEY.WW!!-2"19'H@, M-Y)6^0&7&WGM%M&CL&91EDN>"O5=2R3$ZD68XU3!FF<41R)B- YM+H4NAG4P MQQ6OL)J9)Y>"Y7N+MT7HQWEPK"V4+NT=&2E'NQC43NE2/>^XCPWD&"LTW[0S=-Y/_SP1*G'>D]9?-0G;GO%IMV[5AQ,9#PE(B$ MYAD&$>049#EG@&4Q26F&$".AE<3C0&=+HX'6UN"I/G(_DEX+?FRUK"POVP\B M;<8+KO#S3 ][Z&H[;PZ*;+N;X)UK,3831%QI.@YU-:^6HX'39QJ.)N],J #, M__M0:$:JZUF9EOP]?FEI\[Z3R==5;(^SE U/L\]A&=_SF(R(YYG<#X:SJE^] M[D^KVONJI?G*]%YRX%5=WHL/3"W$^Z(&I-CL?B\V?WY8U]6 RO(W47V2GT4I M-B]J79ECA,)<"( A55_N)%)?;HD%2'FDONA$DAQ+FR^W09]+F\C:4K!:@^?& M5MM2N^,8FWVS'2/G><(?K+T)M+VU]$=C\4V@+Z(4,MA;[;+*KC%$SFKLCOV RC..486M&3^O]S>W@>MS<&1T5;GX&,(CB\3W8+GF2&'<'."BN>9;@J(\>0>=7IH6JN7CZ:T M^E8K#' M--(E>6,*&"1<[^!0H.8Z!!Q%DE,9HCB,["KR6O5O\PL^3XG>VJSI^MEVZ">< M1TQ"!$@J$A#Q. '!FOQ565^>Y"NDFH.0KT[/J>-?R;!,MI M4#BM$;NO#1>KQW^OJ^[RP4$W1W_3MN6C3$+.(%*?$PQ3$,4X C2".4"J&92) MD$>9D2KV6$=+8['&UOT-F2/YI\9<,[X:17>8FEQBYIF%IL)E3#BF6 SL)JDF M&EI1?^G89+3A68C#U+T]1Q@_/U'B2EN[KAJAX<^K\L\'U4Y[9Q8FF&10((!$ MHH*=)(L $3$"41C%'"8P0\SJ%N) 7TLCA5>F!MK60!L[\4KR$,AF,8LCZ#QS MPV34[%61QO%P)6$TT-.\>D/C+I^) QF\,E')1[52>AG9?P% M??1'*FF6\(P PC(=8NCMJ5S]$R$.XQ2)'"96A3(9]K M8#K3\KFJ,7>)L5_7JL,G?4] %X3X6)3E(TX$9)1+D&8H!Q'&"OJJ"I\+VYJ@A]F:LYQY1SS1WG@JZNPDZ MB^O".L&/VNC^'3@G":+]*'E,&;W0Z9LGD?8#89)6.O#VE?40FD(S]5Q@8^4_U>UC1-K(1R!:$8H M5T+CF3TZ5-JJ6JZ98L!]UV41CGIXF\((YR[VED:X\*BC;9R[W9U8LV]:0Z$^ MSX80T40B!,(\1"!B'(,\C1# 8:HBD2@6.8NOVLLYZ7!IP<:%K8F#O597!HP1 MG[BQYT?W>_K>LQ:"F2>X#9/"=6AXG_Y[(.ZN@L!<'W0Z%#-I@9I"8J7W>=GK 6W/DQ=FT_&\ M;.BQ9F?/$].+L=RN3R7L6W4[1H5(0K62B3.6@2C,",BS3/&1&L($81FJ",L-.*'QY4/DT@<5ALH[>KV4MCC#E] MJ9#%Z#O3F..S>%(88A$G'/ XB=6Z*)7-/>DX M)#*6.0P)0S;$,=#7TGBC-36H;0V.C)VT'AH"V8P]'$'GF3PFHV9-'09X.&*. MH9YF)0X#ET]YP^05^[S+^Y?G![TA:YI=N7]^:7/\GNR"EU(7LI+%YGLM#M65 MR3-/HCS ,3R3IR+A>S_)LKK M[S,G]J>N;?G&LOY"\%A""B$!*2<41"1&(.<\ @*K4)ZB3/#,:GMRL+>E3=*] M;9.^N\.XFGUYG:'E>2*; F6OQ6\"@"M=_L&^YM7H-W'[3*_?Z*4K2>+C(?$V MY2F$J4P!3#0SY%$.:$(48Z(8DQCBG&,K*=SS+A9'!WL+S9)S38&TI())\/B> M_W;(3*>!,^==S_V/;Y.LW.]@[RP_?]+^\*!.9*&DU%(IG9+A[6:CJTO6W$%W MW3,J7-,_N_V;;/BG6BBA_$4]62FV:0I6WF]63#R&1"#(* ,(8RUEQ2@@"*J5 MN^ R3"E"5&+3(P@?!BZ-5FH3U<)5Y^)]_?(^>!:;)B?/HHJ:EX$W'OC,34_Y'GKL9WIJ&C6,;8Z;_(Y .G5EZZG>WLRR=HQR=H7OMQE3%6 M[PPE,4-1+A) ,((@2E(5I\,0@3#-21A1FC,!KTL66^+^VH4[,6/[23:@&AZ[ M70V5[P,W>Y0<9(2-[,.Y20:;;Y_.S-'Q%# '>WF?JF]BHPEI([XI3EJ]B.XB M8ZU_^T#^=[FV_$'(- NS)(HH!%G*=84;HHBC9@\6BBPA,>7,*'IW9]+2J*7V M*&#'+DW(BG P5&8D-.\ >":L!OM7WKR^&7T0Y59>>1&3=0>GJ_O5UQLT[W5L M9P">W=YVU_($M;=6=^KKNGP6;"57@K>)Y#QC+$.( !EG'$02*S+5E1@9B1/$ M!8MD;,2H@[TLC20[D3.KQ/QA)(<)SQD^OG<5C*&Q4X ;<_T:%;C>MN=3@AMS M[Y4:W.C#$X]!](KN;F#5=[?K'KFPZ+OEO$XC)T_=.7=Y^)Y'""=IA$) ),0@ MRF .\BQ)0!8GG*>(\91:77GR:NWB"$=[ NK5]NNR/$?^!G07'#_7^AS43M\$ MK=LW0>?XT7T$R_C.[Z^*X9G14GX!YMBG!7>&8W\W8>R]A)*S#(^K S*OMLY[ MUC8'[&?'=K-T.O&KQKX)OGT2G^1[%1V_*,MTY+R70BX[/7[,4 1S(H"0-%*1 M;$) +F((:"SR+%/A+"5616I,.U[VE$53K0[!W(N!;H>M5GOJQ MWRC;NU(7:-J:EF:8/!+#-#;'('BF,V_X6]UYO@;$2?>C)W4XVUWJ:^ XOG=] M53O71VBTJC^$75 0HDQ*C#!(A-XVH"P&.4DA0#"/$TQ()F$Z-2H[[6QI1/K.HJ<_IH4BI]QW[Z*A>-Y;O MU")1,=.OZ^>57C):94WUM[ T F@L#6I3=6W>A]7W^DO[ZV_W'^PW[T;0&X]; MW #GF0Q,,7.;@34.S;3ZYOW-SE?L?-2U5Y7/QY^>(@.SKK>"?E]5W]YMRZKX M+C:?=?&"AZ(-5.XW!=^RJJZ6V_Y(\,' B,021*#3#()$B)C(?,X ME (^KL5_="KG@ZELS"13C"9(WDR0,X-\7I%21@:;O96-*.USXX#Z<;7=K$L5 MWF^T1EOU3>C;VZN"VXBP3!NX82[R/0ZS74^K/0BT"\'>AYN@]B)X*/;KJYN@ M]:2I!1T4>'G*M=?2P%=U]34 M?$(5XGXKGM0;I585J78?UNQIJVOIW.LB&L7ZMJHV*[JMU5Y?MFF,3L?/ M<*W]9J/B^3O7.%,KWS?N!*T_P;%#.D3O$) MHEYZ<5F6I-4P@Q%/,"49H&$(M=23+H=-,> $I5C21&34*D-EJ+.E<7'/A'92 M9\1*(LX5:)ZILI< G0O$F0#BM0+(6PC$F3AM5L_#B4#<+6/Z.*RIJ;;F>M_D MZS-72W\%81@F5K_@1FTMZ#>]LSL\\ * MAM,)8?=RW\PX'M./ZF\__;#_B?I#WU_]Z8?_ U!+ P04 " F@498BG3* MZM*S #+4 @ % '9A&UL[+UI=YM)RB*JN8U1>J2K&[W?,')58(;!&0 5$G^]1,)< %W+/GB3?E, MG^HJDJ*0D1%/QI:1$?_RO[Y?C7[YEJ:SX63\KW^B?R9_^B6-PR0.QY__]4^_ M7WX \Z?_]6__]$__\G\!_,>[\Y-?WD_"]54:SW\YG"8W3_&7/X;S+[_,OZ1? M_C:9_F/XS?WR:>3F>3*] OBWQ5\[G'S],1U^_C+_A1$F;G_M]D^G_\QRM%SE M"(E:!D)1#T9P"31G)@P),23Z_WS^9Q,3M\I$\(I)$%YE\,DJ2%PF%J5URI+% MAXZ&XW_\<_F7=[/T"VYO/%M\^Z]_^C*??_WG7W_]XX\__OS=3T=_GDP__\H( MX;_>_O:?;G[]^Y/?_X,O?IM::W]=_.G=K\Z&S_TB?BS]]3\^GER$+^G*P7 \ MF[MQ* O,AO\\6_SP9!+_EC_]]7"":$ Z%W]O_N-K^M<_ MS8977T?I]F=?IBG_ZY_P;^%RC%/&;%GL_U[^O5_OU_PZ33,$RF*/)_B#F[]> M%MEP_?1]GL8Q+3=T^_&C27CP2Z/"SLG=WQPYGT:+GPYB&@X6GWK@9_.I"_,! MI2Y3$SQP%B((FR5X*A6P0*3QV0NBV,/M%GIG2/""^[,4_OQY\NU7_.!?"P_* M%PMF+!CQ9+DE4[:C^_:X7>+O#FP.-CI& '&?0$3CP$0?\+CXB.?$!"K<3F2O MKO:0ZE5A'DS#+Y-I3%/4%[?+N6EX(MB'2+WYC5^_HKC'&":V8U4"LIJC_!/)!^0R!A11X9-0E4T7XCQ9>"P>L?1SLPL]&(/$I M38>3>#2.[]'R#H+1S$FO(8J F&8V@5&,0=3.*VV-D]17 <2#9=>" V\?#MOS MLA$P7$[=>#8LC+\!M%8!R8T*HB0"A#2HWI1"5REE[9Q$/TGP.M;AT7_DT';A@J20D0"$4U9M)X)G@8$G,AB5O M_- M7#Q><2T4R'91L!,'FY#^>?H\+$P8ST_=51I(3;0CW@"1'NFG%$EGR(T4M:2! M)Q+-;OK@N5770H%J'04[<+())!QC!#]%%;9@_ 7R/QU.KL?SZ8_#24R#G*7D M'KW?('$G(A1CYR4#[P+7-&0E5:P C%>)6 LGNG677@HII'2HU>-L$2 YB M1!',;OYS,APG.LB.9?2,+*B$5E((DHNI1";%1%%YFAB-K@"09Y9>"QRV=7#L MRM.6@'&(7YY-+R=_C >6.$NI8$!=R""4<>!3,F"]8T0P:B(-]6!QO_!ZJ2OR MDZ!B2X:VA(F%:3R;?II.O@W'(0U,-$8D1L'DB)8Q2PW..P]4&$>X-21(50\8 MCU9?#QT-9S:KL;8EB'R:S.9N]/\.ORY=)ZV](4Q#L@EWD2)&84EST)(Q8ZUF MS)-Z 'FP]GKP:#CA68FM/8.C:+V#:7(+NI6@63(M0.E(4>\Q@ZP( B2/))4@ MG?G=4IVKJZT'@(93G%NSKF>1EPO1T:Q/UYQ/=$WG,KLI0IE7 MK1,&29Q#4(%$H3P&1[OE*1ZON)[X&\YA[L3"GL5_.76EZ.3BQY6?C) #2%X* M&/VX&$O"G8)SS$$FR7+#$EC90&EF0DP<5/4:^CC PG%B@45*AN C*UD@E/+_Z>M!H/@59@;5- M0.1XC)^&[!A^2^_=W-UL:\!YUH;+B*&N8NCJH+MKG;$@B8XQ9F^%W:VHZ[75 MUX-(\XG("JQM B+E&G=ZZ.;I\V3Z8\"=LIH@N#'R081S(\ 0A_X0EX9S38)G MNSD3SRRZ7ME4\SG([1G9! XNKMQH].YZ-ARGV6R06#8B> WH !$D.DEP,A*P MBB7CC S2U;CX?+#H>CAH/MNX/2.;P,'159I^1I/WVW3RQ_S+X>3JJQO_&.!2 MWG)N0?N,:BWZ6)RC#"EHKRCA/.D:3L6SBZ^'B^;3C+LSM@E\7'Q)H]$M]9Z@ M$V302=8JE@<))H.EC$'V,GFMG/%58+&ZYGIH:#CGN",;FP !$GY5RC@FX1\7 M7Y!OL[/K>7FV42+K@9)&4Q<,*.HE[B8X\$*B'T1]DL8JG6P-V_$:#>N!I.'L M9&4V]PR:@ZLTCJ5N],/(?1Z0H PZ1PCOB) 7@J(UQ'\#<49Y34T.>K>W&0^6 M6P\*#6(^77'X:SX$9_3V[Z 7\R&W!!B!)10*(<@2N"!!,)@4BS8!@K M1;OCDZ(7%EX/"0VG+FLPM"E,+%\6+#=A7&!)&Z2:40\B"X4!$W7 #>.$":X2 MJ?-HY\G2Z^&BX71F'::VX5C@-J9N=#R.Z?N_IQ\#9XE2'MUC$LMK-&)#3OJBF>770\1[6KGWQIY?4PT7#:L@I+J\'B7WY]PL<3_,%V[[#/3M\?G5X< MO<N09K_=L M>YME*KSRWGEW.SX*OY[!9^>^#DH)_U5:5-$5:W,'R"!U]%QR"+%T);#$(W1D M!,*28&AA7'RU BV[F5^ Y6:=Y;E,H_GL]B?W!_0-4K;5.+YZ^I?%U^H"G M[W R7GSDWX;S+X?7LSDN-SWZ'D;7)?8ZF,T2_A,OW?;O%P,IN?Y=\FDS@[ M&,>+-/TV#&EV,1G%@1::J) B&*TP#/19@?5>@)>$)\TEZN[7$F_;H.YE:OIY M]]XEN"IQO@$,_3:=S&:?II,\G \$.@?4H?L?C-90^CE@G.@"4(^1 )Z($/AK MM>3;@&9E^7Z>PW>)DFUYNSTL)G,WJ@*+LZ^I/,4;?S[Z_C6-44/>,83HK*4@ MM)1 ^655O V. ]><2>JX3>FU2M)M0/(B,?T\E^\2,G7XWH!>.4=9( %?4#V^ M1TL\FGPM/+K9U4":B)Q@"I1>Y*:5 L<]!::E9,DRZLQK96G;.46O$-2O^U-) MZ$\C:8RL&N&6#N+5<+QX65XJ;&YW93AWUC@\:UPDW!4> M0DH&8!W(I &D/>'5P'%F!!<YZ6?IK.= F<*EQOP"[=TGUK5JFP MP3 ID-Y2..A15QH2!%!&O0M>4FMKQV&/2.BG\4RW6-F>QYM#Q"XA,DZ?2_?? MRWH>S/Q+FIY.QI.'*O-V4]Y%871"5U]("T)8 T[3DHZ@@>"!$-:]=D.VE85Z ME:)^NM)T:JSJ2: !S?/R1KAU(429 =4HJE!J+'CT"-$*$X][D3SPUUX#; .E MW5!4_?JU2Q35X7L3CL^MRW9[&S,<7^.F;GRZR7CV+N7)-"U_[])]3[.C[\@_ M%-IP[*8_CI&I,^1&*/6?%<[ _W^6E)X:^G2/O]V8WH 17EXC+<)>)UG@A!ET0TLG J(HF$0HI"R%5CPF M36I?T]VOWE-/GRX1LB5K&U HIVE^KUX/YO/IT%_/G1^ER\D+&C-BV**="R74 M51C1>(.H+QOD2E&)(8WFK_6?W,ICVY3(GKH&=>K*=2JHK9'X+4W]I%:4L+K% M 24J,) MLT]INGBI=,<1[7.(BRM(IDH?-5X0;\N.?#24;^/]<'0]3W' H@])4#Q3EI!2(T_ NL@@R M<9N8 3SZSDA3FNB^]JZ_(C)?(K%?8]P"-JL(KR(Z]_H,\/#LXZ?SH[_@[QS_ M]>CD[.+B^!1_=-3IF\ WU]S# \'-]EWIM>"=#W"6ET[!P3B6?C?3]"6-9\-O M-Q="=V#/3NN,:(.LRK-65VH#';7HD2;#(B=SE-"'O M+MWW9:,'_/DTN5EZGY;_O6.<\UE2[20HC.E!X/[ .5IF:EDM@C2>LT[J@':B MNE\+O4]L[EG"C6/ZPV2*#LMXV:,@_%C,%RW-55'NX[CX;K1$0?S/ZV6UYRV/ M!EF(,E\T #,)_6IK&%@6+1ABG3):RZQKZ])N=M+S(Z4]XW&#X[ G<#1P1)YA MP.U6\+OE@_9/I24U;G:=6T;B)*/E06H*/BYC3ILY6CTB9 B1*R9K7]-5WD*_ M#V/V:1#ZE'T#-XB;7Z$G49Z E(YGKJ@;D0@8GBE8GH76+E ;?HY:A\ZNJ?<) MWV[EU[9N'E!'"=7! --H7$0NC46H"* C8,FUWYRM0Y=NRJNT@%I?O^DEV:F4N0) M5%*H=HUG8$)6I=!(*.)$#*FVKGI(03/YISI(>*R3=F!W U9N2?U-K\"5R(XG M80Q2[NXGJ6D'ZALXMDGP7)+FQN "N';E:ZCY3_ M'/W7]?";&^%FT/<[=-/I#_3T_NI&UVF@K4ZT/-MF.N.FO G@,3 !6AI91K3^ M)M36JFL1U@*6=@+ 8U^HNC0:@-A!")-KW,9Y"@FWA.$$^G>WLY:,4YX298 ( M].M$Y!@[>/3UB$7=S1A'O5W[RN@U>OK-7=<'5#7>-X"CTB5@C+_R [3N& MZG.1AW[ HT&P)BAJ7II-RMG9)]P 1K W=V$'5^5^X+\7WPZXE49[U,1 M^=I6KOM=M>!C50D &P- ]JR=%O^8S@:#;SD3$KT&4)Y'RF2$^5*@(/WT5A" M!)[GVOZ$)H UFV;N-GQ^"#GX0B59II= M7/O9, [==)AFN-E)6/P4->G_G@S'\[_BKU^C' ?&2A:ESQ 6;3"U1Q)2CN2VP-8/3]S;)W+4WNCM] 1^)Y#AH=Y3)$6AB* M.\'(A\KD<]8QI5B[A D?J6E#IY&&@6M[5&]2E"_G24K J@>VUO T'W"I53LW 367))()?6@4WF) MY(A'$\\U:)6M-]X(KU)M[#Q'2+]=)&MB9F6L,%[0YL396J="/]ER&VBR@: M -7M5?*GBB5"))@;)%*\M0AJU3 R%$:YBTVMC:B:;G*6D&3#O) M^87Z@AV8W@9TIM>XZA,>#8A-)C*101I;YNJ&#,8R#"9Y=LS93$6H_3#M16+Z M-7;= :@"ZQO T,,P\G8_/VYW0P4+.0<&FJ%7*6@J=YO! /')!O0Y6:Y>0?DW2$IHI": !2)Y/QY\LTO7J?_%W-5A0\\1*G&'0@ ?>CP);7\%S+2"): M??0U:_M'3\GH]YJD(_#LRNX&$//<%.4GIT!;:H7)J%@#*=-O*;J+(GJ(UA-) M:%2\^F/K=>CJ][ZC(TQ5%T@#('O&5I5GJ6D&;>ZPR!_=Q$TH'=><.Y6-H1A@<&@(4(TY:Y8:04,)66'=RDY2-$PDP8')A'P2.6!4:E&U6\E#5@F/ M3O5KV!>I:<8-[Q!;=431 *A6-C%@WB:5C ;K?1F=ZQTX/ N0-%IPJZC@I/:= MV\KRS7C:>TEK;\3L!OREIQS9IG7,'1<-VG)GB$-OD6D0G&$$RZW%?TFG.<X.FG'KNT-KCR)O0#%^NEUWP8;%$]?5KK8F4L:RQW IRU( * QZJ0E= M"2>%-]0J4ST%_SI%??<^Z \K3Y][U1)< S \G%Q=3<;/;\4GKW,9I1$9P9 [ MNPS>8P1.'SHO@[1 MHQA0)H1*Z+*8:$M/;U4.$=H6%V+(64KT:VJ/"GB!E+Z[^#6#NAJB:@%Q]R_0 MUND;.J!.T2"#@T"H I&" &<]1E_9!Z6\2:SZS=.&)/;=J*\=A'8HV@:0>Y[F M;CA.\7:(T8.WE'D8AJ5QII:9$P**^9(;P+-H0!/'6H.>;8ZE?D4:"8:4<.):7*!ZW041E"#ZEHM_@N2'( M[2B@!O)"'X?CR73!PIO>JP;WSD3"@T%BQB,B&90JK6"Q=BKZ,0W] M/@)J"%X[":>)25%UF#E@*BCO0X;$*#(QDA)V"0H*/8M,K!""U^Y67H?R?M\F M-03E'H#0@'9]*\\[L$()R1?<+&UN=*(8W:%KPJ5)1$266=KW*YA^M>^^[W%V M%\O/WB'ZTT(N7])\&-SHX:9JMXM^N-1>>T>_LLM]-I*FJ"\1I1&47: +8P^; M8P+&O!.,:YYE[3>S>VDD/1I-_BB=B3Y,IN\GUWZ>KT=/FT0.9,13Y)("DCFZ M+]1S\!D-B$DI>\*\SJ9ZH[.U*.O[\J4R:6BZL RDV ,S=YG30RK_=+K96KZOA+I 51; MB*$!0*U<9;^H@)5Q+%.J($>%G*(L@,/X!Q2+.LA2\"@[F%#T%EE]WVIT#+': M@FD+:T_TL*&HA&-Y4F*U Q&U 2.%Q:T([FU(G%>O-WB%G+ZO+_:'K9T$T2*F M;M2PE2)[R3WD4-YNVZ# .X[ABM A>"H(\;7;+[Q 2M]W%?O&TA8":!%'#RH* M5;:D)+,%"0%$3KB-)"A0:Y3S@25.:S>'>8V>OJ\,]HVH;451#5:=YUTO+O'? M'X].+R_./EQ MH4=[>#^YH\J5Y=\2I!_=[P M5D--/::W@*"W7['<;,Q3AO_8#%R50:8,XP-'! 4F>3!)4,)H#T^3-D!69]>Z M]9#5B3":J'Q^_!KEEEN!,LID*@/7+(8. 3W 4+I(.!%(HE$*7_NV[7E*^KW# MK8:@"FQN0"D]7^U\LQ?FC8G4>XA)V5)V[< RYR'GQ!,QAE)5NU7!:_3T:]3J M.\O5>-\CCF;3^>!PJ4E1<1XA=6'^*4V'DWB6#^+DZT(Z)>RT.EHJC &O2"H% M,00#4!D@,-RGY5FAZ5X'2[C@"H[PNWL,K4M+(^5OVV=T.F%ZXR"Z.6^!,QZ( M4,!I4B!D].!LI)"3Q(W:C*IVK2NS'6'49YJG&^EO *TM1-$XN [B?UXO1_K= M:%]N?7!4)U N8H3J.1IP+@@H&827"7T&NE82>E=M]8BN=@&W#28VT6:["*@! M-^M.Z9^@RWB,7\X&Q#JFI H@N9<@T-:#88H >A2$"NY9J%Z9])2*1HIT*UYN M;,?@!B""0>>T]!M]GY;_/1X_O3P\1U?QPV3ZAYM&=!!E%"1R(+2T9T'4@Z4J M0_"9E_KB%*K7Y6Y(8B.W(%LBXLG4U^[$TP#Z*KV2I8Y@T(Q1B^.HD87%P^R8 M9Z!U2>K2Q'*LK]3V]ERZ,ZQV"JYNWD-O(NFM\?UUX0;@29[.NZ_&\X;IQ((L M#:Z0J80E,-0DB(0[FWBVJGH3VYVK\3J+4O>)R&I2:09GGZ:3/)R7GE2#C"Z, M"#8#2:7,ATL,Q[B38-#6!)DM$:QV.!^,XYX65VB7DTOWOQK.%P .UMWJ]['Q)U7RSE[PBN+6PT,/&4J4^V4KUY@ MN V=_;XSVZO&[5J*[0!VY8A>3EZHC%ELV#_>\'E"GL^&\W21IM^&(2VMTGD* MD\_CQ:NFQI;CP+&.1UIYL[V5._C^1Z4N#] MHZ,!)^6EJA[D=1I^'B^'SX4?EU,WGHT6?/C-#<:84HE<1A1,%N$@$*,DI^F@ZQNKYUMI[Z/>!WSY/0Z_2;\=DO!"/+ [T05@> M>]S[;"!9]F@2(Q 3/ @7PZ*W(CCEK2M!5K[/P&TG4BK 57\ ME&.+XSEP,1,6<@)'# -!A4$WC&O0BD8?)(8/LOY+KV=)62_[3_['@&Q'8>RJ MX%JZL7+*NIRX(LR&>JI,AGB#M7-*214A"!A I6? I!W!!9RDY M#TIU\#!E'=(:J>FM4VO2A3A^SJ8EAP<7?_EP2/V7T_'1VT8ZBADBS/%T1"\ BTB^6J-+!(O)2U.Q"]1L_.KUG2 MO'SFI^GDVQ Y]^['[[,4C\=W [T/PGSX;=E]_98#A.$IDMF!M=&!")R!8Y9 MM$QP55J6V=J3E3:GLI%*NET1].0!3+?B:B#T72E+D((+H= ,A%P*IE3,Q=\P MD$-0Z(H&@4Y"OX4@G0&H:SF_7 NR"=,;@,N#)'[)P(_#<)20??=#[BXGF[(R M([,T8Q1LR 0]$4; "A'!:),2$Z7==>TPH8M]].OA[1G"O0.A@5E>.DV:4L?Y(BT,T^=3#H05KO";G7]?C5>JW<+@YZ%447X]@_.:F>(B62RXY>>F^'WTONCJ]2^.$3G-AZO'5U\(O8;WV M(C&@@J+[HH+!P(XH\.A2>Q>85?P1)I\D7C9:L-\JX68@UYV0&E"#]\S\@!)8 MYN0_IOF7"6[U6[KA_V*,]_MAX?(XSLZF[X>SY>7.XNX[L21,-!*B,JCXDU/E MK)7W(%$[&A3/NH-GCSM2W6\=<3/8[@D&[=3C/+0CM\?\9.+&9]/AY^%X\0>(YYMFL&6NWF;+-7,RLQH[4!G$_KZK3%N#M.=B;9_]!:3 M5,KCSL:?KJ?A"X9X9_G=]6PX3K/9W47\>;I*;G8]+2*YK:4;2$ZR2.@.L9Q\ M28%8#/Y(*%T:HA+*^_3X>N%9'V*KQ?LM_6T&G_L17O\@O;; M@UT=H;6D[1X7/=UQ[N;-QQW;A#.)Q6A!"QJ0;<&#-RF R4E(9YATJC8JUZ>N MYP+>:!1EWG0%/=47EL$'UVFA-EH:B?>UZ&K MM28Q=3#Q)O1V%%#+VO+6#<%S.Z"4:R.T .6=!L%X E>NJY2DW#IE:5BOY]]. MH%LAJ+4&,'M"V[8B:1EFGZ;IJQO&VZS C<]Q,%[V'K^Y16 Y,.IE )9D!,&3 M00YBT!43(TH$DXBM75R[':6M=979$S"K"[%EQ-[J_$_NQT+A*X=!62 .3Z)6 MY=*5@?,T QY/:G+@5I#:#P3?)*JUOC)[-L?;B*95!W!ZC70,G1^.%C[TP. N M%AXSRU25UL7H-EM)(6;+O(L1X[/N=>%3NEKK![,_Q.TBH"9!=U@>B"&K2L.0 M0PS^,,R;WF[PQR!Y)D*. :C3LDQ IWBF$H>0@Q!)"Q7W8(M?);&U%B][@F(] ML36 RO6+2@*8(70H)*QI KZ=0CW7)K;D="V MA^,$3UN7<%S>R3_/2!F4-5QA;!:R+T-L%5@B\>@1Y*"F,9E8^_W0YE0V\C9P M3Z]G:HFK ?V('NYM0Z/2_F*:<*]XS.8_/HW<>(Z15RD=^5I^99!$L-)) 3)K M6M+W#KS2&AP/@F=!.+>U&T^O3UV3KV^JX>3)"-!.A-9_L'Q[DUYN \[&%VD^ M']VA_B'%RF4 M/UFD3K4E*1D)&MWLLENT++A-T-Q)ZE1,6770=WH;4IOT'CO3CGL09XN6^^6M MO4]^/G!!:Z5X !9*!V2B&9C2TR 335F.2I)4':V;D=AOLK%O&UY1? VIUL>[ M_.BF_TB+'D(K)\_R6'P4=$ULZ1.CM 3O) ')A(ZI9/0?V_#ZT'R.L'YSD7T# M$N2@Y!GP6PO1ZD",$5[:VO<]+XS5%(],N MW\\/K S/-4GLMPB\)X1V(;YV0+H^4P>*J" KZ+13?,S0[$EJ[=S@?AF,W#B]01B%MT$QZ*0(0DM#:@^V/)DL%<=)"ZW1 MH^[(FG]4H$UT&#]/7V_V>I9/)N//Z#1<$XW)(N%04L:]!.)I_0.&$L6!FC;Q+5Y/5/5V"L*Z)VO,I5AWG% MCU[XSL_PSG1DA^)K MP*:OS\T!5U9'9BE0%= WMXJ#*Y=71!L:+/&.D-HIH_6I:_).IRM,=B2T!F*> MLJWR_U)8\LV-EL[)[:S511YL'!_^8.4WES-VGA::WG1&./H>OKCQYW1>NJ_G MG% (ACMDB3;HZNORQ$,2Y [Z,7A029GB2F6L78JYWQWV>RPZB[4:ALG/?H@& MR65N/7$0"2L7P,R"B<: 45ERYKGWMG;J=2>"^[T\;1/B&PEQQ\$ER('IO '< M"D&B2\F#UR&CXV4M6!D%*.=#</V\[N6QO%[29";&3@SL7UUZ_+ M@D4WNF7E\3A/IE=+8=XRU7(EG#,9;%($'3[.,"; P" ;YB5WR9E8?=[T>J3U M>]G:&1*[$$P#$=OM#+0R#K@TH.-!Q&"0WL1R.3))@*.10TC,"2\S%QV\;WM M0L\C3;H0\Y/':]OSO G(W#2?78Y7+SLP4C&9?/$-T"T0&KT$##F1&UY;1;T* M6=8NA7M*1<^O>?8"G)TXWP!V[CILW=ZGCN-=GF$Q'NV.3RQ3[84O+=P5!V$2 M^IR*9\A!FJ2R49[4[O2S-G']5FMT=^?8B7 :0-T'-YPNAB6?Y64WCKOZIQP# M;L$PC&=RN<3/):B)!K@U99)R4IK6KIY\D9B>+PN[$?ZD"TDT.;+PXO>/'P_. M_W[VX>+XM]/C#\>'!Z>7!X>'9[^?7AZ?_O;I[.3X\/CHXN$6UII2N.8'[SZ8 M<)L=5)I%>#_8\M-D- RKJ6V#P%!9)]1HN[?I&: MG7N#3C^[\4TSZ,/)>(8?'Q??O'.SX>PL?UJ1W&W=YOLT"]/AUX4B&,>GM%VB M#-[A(O\81,M]L#& BEF5L9^F-!;D950W-2)Z:GSM.Y5.-]3S(*4ZF'S2:;09 M".QPJSWO2(F>'_WUZ/3WH_.CPS-409?'9Z=;*,QG/F1WY?@69944X7GZEL;7 MJ=P//]?1Y-X($^F28 8P1"PO6D(&%"]BD7BELG3>V]J#@=8D;??BFE>7N8=Z MX"HHFS'@H08C*6<)&&8-R.B)(UQH7CU"6)>V?A57%QAZ6E_3@92:].M.C@XN MMO+;;O[B[JKG.0HJJ9N3/,/#1<(@Q!:*1:[8C M$#U/3[]IS^H0JL#T)LW(^=')P>71^T\'YY=_OSP_.+TX."Q.Y#:&Y<6/JN'E MKD-E-5]W42C^R4WG/RZG;CQ#!)497O=H2LFI@J',A %1*A!<4*A$@N22>6$\ MJ_T Y2V:=O=NG__\]\-9&$UFU]-TCWFG@[ T:U#!82RG20+C; 07T6FR(0I6 M?3##!N3U[>-6Q,Y3Y[8;(36IF#X_E?/_5PQWM_* U_[HW177=KNHI,C>I^GP&U+\+1V/$7[7B[+N@W$L MO0 >%-#> ^C^/C H%I,D0((JCULC19PFB;#U,K)@H_6UWW[N0.[N4[0W7GHE MMT6LTX9%2+%4'S,,6CUW$0AN4%IB\">U]>$N]/:K(/>%R:?#N/HZ?:W?'*9]\#5GF,9T5P8$G&DQ+0WW#<4] 8W"J5DS35RZ5> M):A?G5,-%R]>&^\LA":UQO'I7X].+\_.M_.R5O_V[IKC15HJZ8Z[^8[/V!U! M:4"_.:+2-PZ$(!*_$@&4]C$059J_UA_A_2(YU0:./F?I1)94$:Z!JT3*5@-8 M30QNE3$>J7=4U[[5?HV>O@>8U<'$B[-$=Y5 DUKCM[.S]W\[/CG!,.?X]/+@ M]+?C=^6FX.+H>A'Z5EQ=$S M&/.&)T*9A1PKWXC 73716HNMY%IY8#JH #YK M#T(F"M:J#))P%E*F)K/:'MQF%/:KK;K#UF/]U:'C(1).)/"+0=?7QW?'JP[:79LQ]305&\25TEE7%;"G@XN?+#L7MXV8&^ M:K#1,Z"9B*4ONRC)UH9K*1*+2=1.0[Q&SZ[JXYG/?M:#M\8K&P0D3M'>$=RZ M]ZRT,=6>IF2#,;6+]]>CK%_E4@TICU5,!V)I4N.GIU>GI^=G* '@/'* MT?G1Q59!U4N?M+O>68O&2JJG/ TI-7Z3T:@\!KEYO7@'J1A$]CEP"(Z63,G?C]G.? [GVV0BO*% \,R"T]."L MR,"2MXP3E5SUN11KD-7_$Z)*.'FL>FJ+I$V]?CLXO_G)P MOLU%TO.?4T'GO$U?)8USY*9CA%!IKK/H&7F'H60ESYZ4JK)2J.RT <>= R)] MN;,DC,3:CLY+M.RJ91Y_[CV035(R\B2!!.O0;)H,7A$.TB;EB%>3L[\?H2=P=OCOGTX.MHJ4GOF0W77'6Y352JS< MV86SO-IC]J:BZW RF\\60O>E"^UM!\9[[SAD96.@8$,LP[04>L=<1M!)*>\# ME\I4ST_L1/'.B9IU5W^WNOK*B=%,\U@&?4LM2D- !4:@S96>,2D]=8;5SISO M2'+/B9_]X?-)@FB/HFY2.5X>_,?1Q=GIO0NSA6Y\^AF[J\8WZ*IV[W[3.^29 MO&-0R9?K"& F91!)&K"N#&W+02>)CKJI/G_B%7*J]:=Y+DC@U&(DD#5PX4N0 M0"QXC6>)"?R:!1,#ZZQ337,!6RU,O-BG9E<)-*E'+HY^^WA46B)\.#O_>+#E M&^5G/J1" XJ-TOIKJ_,3>^01PO\6/Y[I;Z>4H__M?0]2AKMM/+)BAY'#'H0T:#FS)&@$W$$6VOK@(07]SHSH"" [,+D!B-R, MM'AKY,7C&40+I3F( JVNM!(4#\@VFLNPN& @T>("HAJ5U8LC=J&WWT$173GG M^Q)@"V"=C$,JO?\6UXC#V3^6DS7+5P.NM-7*.DJ%48D-*#K:%)* MLK;+_@HY_39L[RX.K,+^!I"T[#I>W,''_E_RUB2-AIV$G$ PZL D9X%3PFE. M G5X;2/Y(C%KHKPS$;2A/&7P M/H@R@0_C">82E$Q;F:JJHZT-JO6I6R\52GXRF'4DG1YQ]\U-ET-?AK>C>].G MZ>3SU%T]WA -D3$C#814?%"B%L-9$^ >A0V)<63<&WEGRU[7H7S#2#H8N[&T4TCGH=X'>9_<].I&\]O\F<#3J1G)17"90YE8J<' M)Y0HL:^P,4=)26T8O4K0>ECZZ5+EU630 *"6[7>7?7!HCDOW M70Q,?0AHDCEAN)?D:.UKO5?(60],/UL^O!;_&X#2&\,!GER HWDV(1!0G)6[ M)+3=SCH&/HE@G"36\=JS=C>C<#W _6RI] ZEU &3],?*WQ#BX]?AL78O!=N M-(G2*@7!,=@HL\UL(F RXT!,#!R#$!)E[;[HO\4E2>H\(J@V<,*BTFP="(WAC+=)'#,J[V4\KNBOPN MPI<4KT=I.??SZ2W"@L4K>135"#+<\G/WCW8_R[P_(Q\GJ3#+)M;6"@N6L MO$7P BRAZ*U$(ZR(*?A,AYL\L1:7_T=T88T-EN!6$<[=B"H)@./IT-, MMPXR7ORH+D:M=A@\K#LL,SOJ$\>X-LN@RP53 &-":1428Y+!",)KIT#W-'#U M_7#F/G^>IL^WBGBY["/L*T-\)-$ HY:B6V ,V%3&M9M@N56&!5$[DEJ+L+[' M4-5'SS.-&RK+IP$C^2RW2F=C=$U?4K\T6$,([LXQ4SI09 D^$P)1<(5> !4Z M=_"X:%,R^PTD]@'(KF77I.E<#N'=VEP^^.NU1@)W:!8?S?4TUH9($"[&H+\C M0N*H7;B'Y+Q'L7(F>>U<4IW!P*6"9-DQ?06@=0Y15/T%ERYW1"\ MC)2A3D P*N.?):.H>T/.FZS7U/#?322\6I[3"7,;,% +]I3ZD$?;2%:QS+7$ M$-24?MHA@\W(+)>#9\@V(DWM;-8+I#0U^'<;^-1D=9,V8]VAE%M;E0T7V-^8 MS0XMTTZ##75BPBJ!FJ=X(=XH,,HX8)DY)1GEAM<^O#T.V[S/;SQ+Q$I>PT9T MSI@!SRD>7H-1A,F4 #SDS55%R#1C5^WV=IOG] MRX/"SC2[0+DNK_W/\K+8=[AXZ9DGTZM2^8M\O__Q9#95 EH!S5()+7'A)3129= ;H3K?6K]'O_SRT@YLV/8[;N:_;NQ2//J'B M+-H.G8)7)X]R+J@WP:!4$ROW1Q:,+M,O')>>.92,JGW=U^5$VOO#<+?*VO ML(&&)]YN@KN7-=Z^A=R F_";&Z*&GLW.QO>Z?L7I832+0)4#&:D%8:4"+ZP! M&JUTBJK,1>UDU.L4]6N4.\-@13$T *J/;OJ/-"_GXJ(F;E5G4S'D( MR2L0(J&?$H0!YUWFW 3+0JB>$)MVOE>'96SM@3S^CZE#O M#IVPU\8X'H[WOK?/=(H=H??&K MQQ4C+ECM% .NE2I!3P"30@ ??*:4^I!3[5OS=6GKN_5X':R\[#=5E$R3NN:5 MD=I;ZYZW/[/34> =ZJ8-AS9;X81 A\99H4%$M$&69 7)(&S09PZ*U.ZDM->! MX/>GY';9%2/,9 Z..4BB#/L(AH K$S^8YS%8I0UEU9NXOTS.3S7J>P/4O*RW M=I-( X[V2N@Z' _GZ63X+3UAWR-M+(W@1L@(F8?RN#!9W"(3@+H^QH#6P/ON M$K9KD]EOG-<'&+N18)/V]'[D^];F\\E'U!Q$W^F5ZK/CR 5)/M)L@;'2P(!: M"4[8 -0RXK4SWN?:/GLWX^A7K]/\8T>0:.*\) 1H&4+ L@J&*>IM M=5O_&CU]7WCNC(37[C)W8GX#INUV_.QRP-%2$2]^B M+:6ZY8_39VV]':]PUC=0#N16AMFK3?+XY/CRXN#L\^ MOCL^/=CIO5AE5>E\:,O;6A9 M<-8+ZV1W%G%].ONUE-50]+*][$AD3:JJT[/30SSUYV'IT?7>R0 MR7K]\RK,0E^?WDIJZW2"]FL\Q]7Q-S[?VK [R#'K*%/2(0((6D@?/1A+*"B/ MH9=*B1EC*A_:URG:I6+_^4]^9)YU5!KWEL$X:4#DJ,#$I$ I1BE+RL7'_2V> MK=9?9ZU^54U%R:]6[E=GCR?K+NIZ/SB[\4"/ M5RB%,@'#@??#T?4\QU7 M.57!T,L^4'=":U);'7W\='+V]R-T)GT+!/5$'H]%-+71Y61XFG\?#_T:B%@.6%I2NG"X5C0\R <8P$41@ M%*,:C4&&$HHRJK5-7;7-J;Z9GM.L^\/T*ZJU1W@TD,N]9\3S.[^8XZ;.OBX# M^^7#AL>/VH47T3A1Y%R5K:[ZIYMJ>XYO]L"\OB/Y TZ9!?'/WV\:@TLOUP=OYQMQN4%S^J0@O>M:BLY) _'MQZ MCT(FH\M"@B**E2;0$1V 9,NK ,6)=-;0ZAKA!5HJ:LY'*QR/%^\*BX#>_;CY MPY4J&.I,0PI:6ZDU5FN2SS$"R9,H M!2=<[:YEW;4@/[V^\FEZEL^^IM*W=?SYALFS@?>9*.D%1"K*+01/8(-QH''[ MQ'@:HZE]:?PB,=*[AM M"=J;!JS"L>Y5)+>*&D?P'/"$X4OD>$!B=,!+71=+V6?+?QH5^7Q_]8/YH9M. M?^!ZBW>5 ZXB#9KCF4TRHY^C+3AE/(004Q B".;W,ZO[$6'-JLY-,++>4.Y= M1+*U&OV6IGY2;XO$PP#'@B=&!>,NE#KC[$ M?1>"FYV8L*ORVH\(M\?K9.Y&O?J&MVV('\R4*+,DNO8!WUQX7[[>9ASHWJ?S MROI(;8 4W+Z!5$-:;\%H"U9WR**RD;>3Z[< M<#P07HG I )*2A<>#%? A:A ^NQ5TDE(UCF*[LEI#$7;BOQ-7;0=_UN TDN. MPL=4$HQEHE)*G%'0F9:*;Z7 <,. >>^4M$9&6KM'\ALD-0:I;47_&%(5Y= " MK)Z>O'=I'+YD_%L+NT"Y99312/;\^2W)LWB M3EAXDG2M+9@&T'83)L_.4TC#;T77W^W#R<@8 ZV1>B%+(U4C+$BA*T7GJ0)C>X;%J;M*9_G!'FX.C#56 M.T\S!")\Z="KP?@H@%%D%*41S7\-=+Q(0#\VJH9$)[79VR-&RFOO0S>>C#^F M. QN=/%C-D]7L\/)].MD>8(^3*:XJ]&/R\GLR]"[A[]WHR>]E,8*SH%9$4LN M5X+-+@*EQE"*,:E@C[#T['O[G0GI#U.5@##I2RH-.$%/]/;)<)R.RWX& ?VV M+)0!1S@>3QL81B8^ !?92-RABMWG,>^HZ7?@^3Y2 ]LQOD4(?4K3\@/W.=&! MM"%QX0R$G,L+\.#*?7? @R@($S;Z)&H7X+]&3V,QVI8R?PM*VPK@)RY&79F( MT76)P3-+[:NHX*U=[J$T5%+FA/$WO8^3X> M(R!Y\-(%0])/5!I:"G/F/SZF M^9=)O&?MV?Q+FEY^<>/+=%4L__3'\=57-YR6/QLD$3WCVH*19:ZJT@1\>53- M2?1.E:EDJK8^VYS*9LL/-D'/8RW7L; :,*3/#6/Y?3Q-;E3>^-]._QE0;H.B MZ&8D7_I+9>%P5UX!=2)9R4D2U2>$K4=9N_6F.\"N Z'\Q&;VXOKKU]$P39<# M'-.GZ>3SU%UU;G+?6'9O[SOS7J+IF;- M[";(>/)HMZ8@?F)-=S3^-IQ.QL6/<*/[[7>NZMY:=U^Z;J/]=Z_LLKHKNY)AO(_-S_+*X- ;#J=X.3E/PRM_C?@? ML*BI9Y%2XK%XL&^!;L,EFU5IF\A_-:';%;L;"!>06]-K M-_HPF3XXJ\4=+9?TR,4T+CP<*'1O@V,:D$<:PZ"LP91D$!=!DXB&(IG:%83K MTM9LR+ -WCH53,47COLWINA%Q.LP_YN;3MUX_J-K&_K"OLMGN+2:SF M0A,%C#F.3B Z:YZ7J8V&Y8!?<"T[./4=A0>/6'JKR9?MK0:.&A^<#Z"0)!#< M$+"1!4B669II5%'6'D#]*D'-6M%-,/%8J]430<_5&><.%?"B ,$$SUVV O4O M+7$2]V <*F%M3)0D:Y_"6C'E&]48=POVBXN* ISLRLT6('!S89^]C+$,GC76 MX<8)(>!M()"MEX*9%,QZG1_6 4'?!1-;"NNQN+?@7-^%>L/Q\.KZZH9P3CEU M2D1(WJ*CGS('ZRP'KV.05J/3GVJ<^P>+]BST;40VJ<&_O@7OOJ\0KF+2J.@8 M!,D)""$IN$ ]4B^I2+,[]O*/CJ(4XUP6_-OP8BY),C/MTD?LXGHY+\^0-_ ?6NY\Q*C=K691!1H\<5.,9>WDB= MD7>J>@/:+ M5I\?^2I%_2JWS@'Q^$:UGG2VQMK7Q8 0I&0ZWP/B;KX=IMGQ;':=XD H'P)! M/X'(LD>G#7@:T1D5+$:3A8_5AR%N1F&_"K M1.XDO>:UX>VLAH%5GF;M+3"; MD8$,PUEGC0,G'>6:AN"K5W*N1UF_#_G:PN)6TMH<@W:)P7%:W GOPR;GQ!SZ MN!RX+_O!(P9&,P>$6QYU"EFKVE<6%6QR9P]LVD+=1M+9T28?C5?Q5O-J]OSH MKT>GOQ^='QV>_79Z7(:0W/>??C^2K=G(N;ZS&LDXP!<=XJ*15QU=\5OD9/O\%(%UAYK.RJ2:/G7#XJ M[?G"2OR62E'JUR_E]>VRB0ZU28ED07."!L X- 4,-;TS_IR2)^75&+-!8,Q+ GA.*3@OF24A M6BEK-.IXN&J/H*@CPDD5?C:00SCZ>'1P0[EU!MW^TK&=:%2@RC.,/+D#K:6* MBBIC#:GLKMROWM_E<5U$[,C7OG7#;.@^N3#,PW!#O/::42(MZL8@06B$L_$N M0L8O"?Z?>[96^/Z6>GB\<#^YH8XTQ$Y<[1$2B_+*Z8_![Q>#$ -CT5.@I:>" ML.B6.\:<2>OX&"6PI\_3[[]>O.)2RCBD$U$T M *TW4@%'W\/H.I;9K+-9PG_BI?L^L*RX3U*"H;XF3S3JC[BRT)E_0OI9O/1]^_C(O:=;Y]71<=GTSUC!?C^/* [QN M,LT;+MYMYGD73NPY$^UB$,PX#MID=+P,\6"USD"5](0F]+^J#XO=4R;ZN<]> M"*8\_ R3;VEZB3)FMHWV_VUI!:4WX_E3&/R2L> MK868'2DS7P(81Q0$[1-U@DHK:O>QJ6O,N^RQW*0QWT1B56O!=H#CE_+R[WC\ MW";O7E?;.K@JUU#G:93<#-UEFD,R-.,6*?,@,&P#'YP!DK(-466CLMC69WQM MX9[#F,YAUKTT>BWX7W=[,0X7#10'W! 6&'+.%-]E,=_*B<1 $BN3%3H$LLYK MX4W6[#G^: 9B6\G@)[&A.BC]YAL=WO MFFOMM-+=\F+YE8:I3,LDDP2S B>&[P5/A0 M]*0KME=LG+P]BFZF*3R[F:RCU%PKD-*6T6^IM&(LLU"5IDSKY- H5\;0*^3T MW)&['H)JL;P!';1BT>]G&FEI8V *E"G CY2#C3*#BYPH1ZE2U5NJ/$-&OVBI M:*1V97$36N:ATKSS^@^OIX6; \)TR";0,M @+%&/_T]0E K4,,BWS$8QV8 TUP*W@&74I(WFM][-; M&JVMD-2='JJ,I&J<;\!VO7 J3B?C<+,AISU!]G!0A&L0W)O2QR5"]'A(G!,Q MAMHE$6\2U6^>:$^::4L9M*N<5C8D,[-6, U1Q;1\8^&XD!!T\N@T,FE8WH=^ MVA!2G67"]Z*BMN1_ UKJE6#AKE_"65[^UM"-/DUFBXNDHY)*FPW]"'DPFP], M%DERA;S,I2,5%0ZE[\_L78&'8?>PL;[!J] M4D>#), 512>5:HR)6;"@\2N3D_!>UPXHZU#>LV+M!KU[$F2K\+VW)!MLG/CL M I,,T \NV2*AP/*<06H;?,@L:K67F&0;XM<"L?Q90=RY.'^*J\F';GAYK.'& M<3%O-RTG!!ZZV9\@:FFD= R8-P:$HPZLCACR<<4$8@!$W@4TE6 M2FN$(EK;O,[0X9=7:.K.8!L(5&1@ _[70R#?-=PFW(04M0%2YCT)Z4H?0)$A MDR@%%_A36[LY[?.4-!65-NU.*)Y8S.BSH;^( MFXG@,J% LQ$IB.!-J%V$^BI!3<6&NX"G'MM[MCS%K_ODAO'#9'IW( [&<75_ MI1-I9,[&"#Q*"\)J 0:C6A")1Z:3%,SJ-6S0.FLU%7AM:XVJ,W5[D$S*I/,J M[; >YN_./#K_XQ2/,4P,B[+NU5RK>^L&:F@'"H&H8@OL660-F<)VM/IL*&=C@/$5]#,0* H*$!,;[!-RR MH%)R-%6?_+$UL6LA4_\/0>;NXNK9M.YP_!X9B_OMQZP)'KT(2?@R"04=4TN9 M \J,UY+2E,DZC30Z(&TM;)J&L=F"R*K9^;KM!4\.+H_>?SHXO_S[Y?G!Z<7! MX:*SWO'X6YK-B\<['*,/_,W-T^C'7](H'DZNOKKQCET%=UVS1C/!JONNUD-P M5-[(?G+3^8_+J1O/$._E#>4=]FT6*49E0;M2V*;*'"8\#!"M9I()XY--M0W: M&S3M/+SK)D]=.M0\O]*['P_^9#D<60?.1"G%DJ4?B:8*K%$16/(F!Y+*A.3* MC-B*T+Z[!U;$TY.Y7IT+KN^))G<;//JO:]3V']/\RR3>:XBG/TWIU%VEQ8 / MQG5Y>FI AXA6BND 7EL"+K! 1+)>2+8.0-\:>K(#C?UB]*61ZP95M;RJV=YMR(CFK, M(*WAR?-R0WBR,NMB$*QSZ_5X M!5Q(&>CW'/&#/J'84>?7'SK=[IT1];V?R";6]5^O7K[^&CX33O_X&O_Q)!Z'C4&A\BJ T7? M6#:6)Z\XBR"\O9&&RIX/UDU$.Z=:=W;GW/.9( M(_,'@JW+%W04X&WQ@$H'7I1%)LPNMWR#W3"RWCI#Y.9DHD7+ MHB!GRF$F#KP$%U.B,^62]BDX+5JW_]VGHL_@_J'Z?@16>PB_ _AL<^^N@C"> MKF8=+1TP1N^NQ@!>(Z^S:GR2BM/MWQI&#U/3#YSVT?/=[<-MA-X!?!XX9Y>& MOK!98I20/?U'1880O:*#9>A8I6*BP]:5VX^0,VT%;CRM;.%D%W Y&!K0(*!8Y+D4C+]6C*C M[V9M]PK.;OON:5M CAO,/UCV$V/G W[;7(X[A6_R]+FC$5C@H]TO*3S MQ%2RG"QZ20:^=R7G0.^NV:DL\0E [4S0="'BPW6^&%L!'<2/?PY^&Y9,KO-F MM95DLQE!UVG*'@KJ@$45'>^.,^\]43"2XAY-(0R18@<0N F/!V6)SFP@,N9) M!*P.""8^O##TSCIDZ6ZE9,\IA..H?C_I35U/>S6/YF/">5C.%NO+,7$6E";[ MS$FF07%Z9QTG8YNS.GNFCL;9+83R5*'LMB^?MAOPR!6P!TM_:OALZ/[G?/4- MTZS,,&].4LY1&IELW4M*)GZJX>U8- 3+B0N;;,RJ!80>(F#"@M;#E;IH+>%. M8/+[8HDIK,ZO[DF6/!EA%G+*-8'+$CA3=QEX'9T.43*VTY#2'3'R\[=/6?'< M1*5;0'* ?/N-M[Z9S?$UG:C5J8A*:U8<)!=<'?ULP?E %Z[4+.6<5 RM&XR> MHFG:#N%NPOO[Z:@#S&WO.;BN.7F/RU05^AE/1?+9%8L@BZC3@H.@=G6,QF]1ZCO=.A'4976Z#N/:*Z6)B_$.,>%V"0&T 62TH M<%F#+\@A%9^?1;;)CP.[BS'LKRKE=7K]Z56[]WBJ8D M;>J*X1S)EE4.(3!1:VB3S3&C$++U6J\!Y$U;EC$JUL924@?X.TEIS<3[\*-: MLEL%V:HRP4B>J6-<22?@1"Y M^?1I@PE'P<6>HIQZLMAVT;SZ^QLF^OUKIDYC#B0-'4!FGNK^%$4BRARTX9EG MQ2*[NW9I^[BP';]OVAE@HP%F%'%W8+Z\7^*W,,N5C_D*3^;YW?D77%[N?+UZ M4'E0B>N H%GM562.;#,9/= U*31&C=B\B6('LG8"FG]60!M+*5VNXOC]]=N3 MMR]?G[SY[=6'UW^=?'K]UZN/)V]_^\>KW_YX_?:/.F?MK]>?7M]>4/$;KB>M MS;[CZ_GJ?'FQ]E?WGR_7F(##A\V-*9%&D^>V?B$!]!^8ZP"#$SH$W]<;[7Z; MK=+98G6QQ)N!C-'PD*2')%0 %64MDB7#BW%18LP%;6S=!7@ N8=>K#=??9GA MX%Y9[NC@?=XJ MMC_";%Z#P2]^;*2W?HUJ;NUJLD"QS.9$9@=3F5Z'0.^$!!HHVFJ SQN86-3*,"\=CRI#,770@%5#=]D SA5.&/&"Q]; M9\(?)*875(V'A,48:ND 7V_Q_"89L>'J:AJ2]5EC,8#(5&VG*."E]5#(V/6" MW/,D6]]I#U,S+<(:J7LQBNP[0-&&^-]P-?L\#]==?U)4[ZO.TT)M:WB'@W>E MD(LF(PMD5F37.O^SG9)I4]4M7[T&DNX2+U==8:Y8(VL8D)!.N"<^@O4*,ITL MGY$Q.A>C(Z:'-ZV%GI^$SAY"[P \5PQ@/EEM>+IY]S?W)\;$O&<:?*HQH* # M!*1SAM:D@M$Q*5L/ -B!K-X@M8_^[UGA;971!;[NFY,?9JO_O#0:I4?EA09C MLZ_3AGE]ZCUP:8ID)$4CCN'H7=$S;;W,V.[<7E+O"D$O%_-U2.43_%U[ULAG^$!W[A5K5_WOT7L7C ;AK 3%180H!0-OI?(I,X&F]<;F'4GK M!62'8F$QOF(ZP-N-O&[2:URQR+F6@"S6*D4?Z37/%K(LVI)!6K)I[5)B_*[?";W4WTZF6,:8<)*0Z4%\Y,ORB*@A&B*19L"&R M\4#S %&]7$5[JOU!&+7005^@6E2EA+/+HM53+#8(93-P6^I>!E/ 1U? :!&4 M98)$U=ZCVTY++]&DYA#:7^*_2,7#9=_'!TR+S_/9?V.NW1^35T$,)FJ*RHC# M)-=!M82Q&G6V"H1Q=4*=\!!$82#H:YAQ&0-KO2^YHVH)3$FA5!DBXPQ4YAJ\ MK FQ0H?<^9 *MBXY^V6J)88@YZEJB2%ZZ.JUWN*^DYE!KX07D)&<*B7K?A:N M!/ABC2 ?7@G3.D%]<*CL:)4/@Q0])%0V1.I=(6B+;TY>5)32D,5::A84.?G- M00HPQ+LW>ZW$_;^H_N,[5LN"K6$"%=16E M8N"-\9"4+$)(JY1MC;%'R.G%:3W\^6LE\W[ALSEO3F/B(20H11M0'G4-W=12 M-9ZM8QF+:VU /4K0M%=3,[7O!J<]=- %H"YOUDTKR^92E2)P6]MB0HBUFDPH MB-)'L)(KR5,=:]@Z#KN5D"X!M(^B[T'H4*EW )UM<<5LLV$V1<"U:VLRUN8Z M <5[@Z@B#V6G"7Y'R/H>VGXP[@,FZ->[EXBM]_Q<"^]H=N1J6\S*L MOOQ^MOAWC9K@=0$VEL6R1@;/PFHU*[/-M3W/G\+?I\%%[QF=M>2Y(&$F"4'[ M6BG$HW269\];1]V:,M"+M;XGG!:]Z+:+\4B#V;_+^*4X*N\F..Y+3)!BG7(@ MZP#'1+P+%K22'@U'/36N'Z2^%U=A(E"WT>HODA&[T<8JG/\>9LN_PMD%3M,$ MO(V":;N GY1)!XDM85D.G#$0WG-0@MRB*)*%0M"5J7CKV7BIGS8)]Y8FL(HJD.\/AP Z*DDUB$KC.3> '% M(X=H3 1IG*DUB%;HG7;\#(#NL@,FO ,"^<$MF;W#J-\?S:@ >I>_.];(^@YM $?\NHUD'27>-D<)XO&!W+SP2>2C]*)1)-]!L54 MB3F%D,S_Z#;@07K>M0UXB- [ ,\NG://M0UXD/[W: ,>HHPNXL$OPEF8)_SX!?'G=+.*)B=T#(H2$I25'%R, MM;NBR*!=-+*TGBWV$"U]Y<8.>=*:2+N#>VD;'YL3EKQ4,3FR$EEM:%69DZ!R M(NLNN<0"H@NM]\<\3,VTMU ;;>\ H3U$WP&(+I,6EZ-'+^>0;BY1C\SS(@44 MZTD\NJ[RRG5\54Y>6V,-IM8]O@_1TA^ ]M'UUFS1@8+O!4!O%_-TRA*BZ=5[*T;B9Z_BT?@["P9\O'$,5T@+=M]4D^&I58 M,4"D,E"%#J0K*$A6J*7R/B;?VK';MTYVM-53XSQW^\FX*YA<5PB]NU4YM/8M M3K6R4;B2:UU%JC'>^T>IJN7"VE/Y3\(ID::Z!]=5U[& MCU,5!UE!N-G7=5H',G.6H)%HUW@B>QVGK)1MW%)3MIY&&8?!IRTAO M.]?K8MNC3E!Y^-NG*!_=418=E(XZ9D16P4(N]'"K+ 3XVF0NO5$6F<@H?N&9 M*,G&J'+M"%.UZ-R6.AE0*!!*F5A,2D&.-[_BF9>.#D'.4Z6C0_30P=/\?K&: M76[R<*ID7%_II\ !)[B+4#4'S\ MLEA>14#(.7:L" E&YE!GT)+S(42!4JS&R&3RJO4[>^OK^X##/EI,U.#80Q\( YX8L((M/0;.Y5STP??@@']= .!N]_9 MBQ^V_R-QD!0GU'[:T'QZ>OK.:>IEQE/]4#%VX!8^6O)A#>-&!ED7 M,8?J$M7D:M(@R2A6T20AS3%:^?M@IY5>=4@K0\IKQJB@@[@]/MBB;//\U=_IR]A_OEN[4ZP MA=OL'1CM/%W/=+%ZRPOP&(U0FAO5?$3EHP3U JA#];X82PD=(&I;YAUCD*7N M&B%#/(*21H%'>J^SQ>(\*L1'79Q?VE,B;H8Y4%H)JM% M5\L1K8=HBV3HC&-JO+SL'IN CEHH-4C)NVX"&B+Q/N>>G;S^\-?)FW^^>AN6 MRS6'!Y2?//A9#8I)=J.S46G(S>BRZP3^ZCJ#+SF3N90"-K "2M0-],%XR$** M5*3FJODHH\?H.=B,N?KLRZ:NDWG^J1,GU"_+[^8?L#J/M;IAGM\NYLNK'U^$ MU6QU>2T[19 UGH,N-65IR#H,0M/=+) ;([-*HKG)TXKX:>^K9GB[9QY-HMP. MWL@WB_EG^K2OOV%^AK<3LFT.#M< MPT] 9@]Q=P :\E"_X_)\1@>H,K)Q5#&+I'70X%4MZ^A60OJ"S#X:OMMJ=;"X.\#,QWKY8K[%@/ AHZWI?LV0_ YGP9=B(1B1$G/% M96S=O'"/B&FK8T; RF%B[@ GUT_[BQ_7O_S'#)=$U)C;%I$]6$8C:##GI"YD>.Z8OX^?YM#K")W M49' 2C)USTPB*X&Y#)EI9I54Z&SKR:V#".S$@&^(D(= V%Q=/6'Q]?S;Q?EJ M+3&^N?"3,")6H14N'%WX='*CK,MLDC;9.N[;SZ%ZA)Q.<-8>! _![4"-=#$; MK\4SB(Z."V MK7;ZIXV=?BV(4^:$H-.;(05+9UE9#C$H S9IM:9#M>O*S&V:_AO%QC&R8\=DIU )$[4Y37'M"7?(@K2PZ M!*YB',V9[#H;EES.*$R!(+.A0^C)(#(H02$>7L1BZUA5/X$*NP]-K:V N9,-;8[).PAK9>AU!P\!0U\_T'K#9+S T M1(<](7,G)S-XK:VL3F8IGIQ,S\#7 :&E%O093PZG'*WTXI<)# U"R$&!H2'J MZ@F+6\(04AE;!-:Q1TG6V40"G$BBSJ)-VCDE5?/R\%\D,#0(! ,"0T,TTBFX MQ(85(ZP.667@.=C+P5#?8PV1U4N MV.:E^$^0-"WN#M'V8CS13XBD[V%Y^G+Q]2LNTRRDA8D#@VFGC&.8/0+IG5J&Z"AG?@FQ\#RVV(9SO'%@L!\ MJEDT4N@(QKMUB9BKO4T"@JE=!")R)<-.BK_]J=,:0@.G@P_OGQC\5W M7,ZKAW'R^7(&U[I59/WRWKW#DF$\8BX@15*@9,H0:]^N$ 1>'A+WKG7!YB " MIYWDT? Q&4\M'6#N]?P[KLY_#D_?5,.<9NE23N3-&H'5>HL"8BITH )GA>2) M.K?>CO0X1=,NV&J(JH:"[P!&=W8YT=7K1(P!ZS(G6Y.F*H%CO(#-PF2'EBG7 MN@/^+@T[0<4\ Z@<)-PNP''YM62+?) M%IB"%)V3TH?"LVH.E<YQ#98'[*C^> M2^3%H6]]OVTAX_E7P[1)7QRJH0Y =G][*C%S:I(167L!VM;]J9E+",9$D-SX MB-$(YL?;:'N+D(F'"!VJWD<&QNXGZPX "$M M$,>*#I9SO/DHQA9T3YN.&?]J&UF3SZ5)_#)'7?.1-RYWTT[QQ[Y@E';QG3DZ M2L^XB%9S5P=PYT(.J)3@;5! , [(64[.MDY?'*5G_%;RX-7\?"WC3U_"^VR2,QSGIC7&8K7M2<@>O#!!; ,OLWUD.P$2%',E88 M#[:$\9*,G;&<_?=:@U=#-D5!),C*R&RN@"6O?K'>NX MOGM\28?.,UOJQ((,JNZ##\H42,P@&I^+9*W3 +O2-FWQZ>AP&T%!'0#O,"?H M)F=GBPHD6PU)>+)@!;?@ KE$,A>5#6:7<,39RH>0WDGF="(G= K]3]S9L2U: M>O)UL3R?_7_Z#G' M/_94_6(L/720.]O&T"G3@G,L="Z5JG7#'B%(IT%J\O=UUAQEZT;M;70\YUON M,*@UT\YSR6]=K4F^"&=_AO,-IT=(>^WQO:-DPP[E_QA),I^<]N3?D@$J"BC) M(GC.-$0D,U2QI(I_3DFRD^\DQBK:WQ?+C^%G"J<1#\W*GYDQT\KP?BK][M<>3*KM# MX_&:G[/UO\5\,L\?B<\SO/J3W^AW-\S_:W;^939_-\?_P+#\V=S1WFFN4@ I ME:W3KQU$PSVXY*W-UA:+N_08CTCBQ,,*I@7>$Z;K%"AX[H?AI! A)(5/7Y:+ MB\]??I]]7PODKAM@F.(+#KW-$ MVF.CP]/R,S-*8LZ6:V#H#+DWAMR;%#0XEXW6J3"?CQ=W&&_N1-<8W5\C'40@ M=A7M3;_&E0AC\2XYSFME)WG6D67P20DP7 =;!+G7HG7\=F]B.XEE3&57'Z:\ M#B_!W9Z%>OG3#A62/FC&Z+EA(H\+V <*> MA[W: XQ;:+:#C._6.+C6,0?I"UA5%[QBID,:O $IZF;U4"QK7@Z\=Y9BDQT@Z1:203-8.Q&.J@ M-((5)Y0QG6W(7OBH8N-C?I3>G)O/?E?6^<-;'>@_WB[.KUK03V[VGUZ63K 2 MM.9)DI4>R'.4WH.S7((626)DJI0TV@;F?8GN.*TP!%\/5J(<19D=/,1;^@"4 M-"YH'B"6]4A[1[PX](#!6&.#TM:V]L*[[[LD9HI/N4+6U#C)%$7DP M$K@)!A0+'*)0C&P-I8U)42KK1D79L^C)&:3WX3TY0Y30 :RV-X8D9K5A.8+% M2&:J"E@G9G)@4D0I'3&D_U]/SF!M[]23,T3T7>#GL480:11S228PZPI6;@P$ M(66=#2^,D%K(YG.5GW=/SF%X:J6*#G"UH_U'9&QRQK,%[^L,,Y,,&:%>@(_%2Z%* MPM)ZP&Z#9K INW,. UDS970 K=OAHS?U;U+_%;F.57 M?]?1^5CGR+X[_X++EQ?+*N#+X;)7,RF2]8'\7,@B$V?&%PC,T>DKR:,LEH?4 MVI[?G;II7\>1@#:2RAG42,^[86N\ Z%MK#001[&0=LHVL#OK4"+&0'1.C1.1&V:A; MWZ1[UWX<,^TT+AAVJ0(9HIDNNU-?O_WKU=M/[SZ\?O7QICJBQ@+FA-,?^Q=\ M[/:YA]=V[$%_HS*.FR^YP>-5EMUR;YG,&4+MB%N*#^_I&<\ZMNZ- M?(2<%@G+]4=_"/_^,Q :9^&L&A( M_3Z;SU;TD/RQ6.1[I\9EXHD#9T@LD8L$P44')*O =(X^Y]%N]8?)FCXW-2K$ M&NFC)X@1%Z)2RD"NMJA+P+ VQ(5:)N <^JRM;YU/O_W]T^>:1@7-4 EW M6:#]Q[MWO_WK]9LW)V]_>_WVT\G;/UZ_>//JY./'5Y\^UL/P[]G966VW+(OE MO\,R[V^J[_<]AYON#?AK9,I??1W92Z^)C_GGNF3C,ERV#:$J6UFW/4KTY$2B MB!!#EN!3B<9XD=&V]L8'$7CH/77E1[TK5U][&(&5:$WX\M-R]SUIHHH.'[WJIS8N+U6Q.EN)'_+P>,+9. MTIGB+#?%0LFL&HJU*]S7,KEHC7"8E'"M$YF/$C0MN)JH_"Z,FLF_!S!=TK[) MEOC(;$Z\3HA-!I26 ES)"K*74B0OE,/6A=(_$3 Q6-HI]BYD]I;RU&W!F&2;#V'D'BN8RV*/+WB&!BF-#VO+($+(M2U0QFYEF3MEQTT?/=SIXW;M%'R0;+J MX*:_>@!OTC<,>6VM]: Q1'+IM -O%:M3/&I)OXN^7WN*I1.,32Q(P"KK3HI40,2#(DC&Q$)E,8T'E%AE]."I[*O8!F.PK MY8Z 0C=AT9)95R= D%-6)U%Y8PT@O7M)E!PU:VTV7GUW'Y#86XD/@&*01/=& MPC=5,\D"1P]GE^62>5?GQ:AOGJ;*V3/^@!?K-8K4Y5K W2=6Y_ M,;6,)5B(DB2EZ>!PX2*9TZWCM;M3-^V;-!:F&FNEI_LG*2E9J.-'?(U(>\D@ M&$^&F?4B>Q%0FM95MX/NG]'21:/=/T,D>N#]\VJ>CQ_QOQ=I'"/<_]"7C!KK MWXFS20+]4A2AE WD)2D.*A5+CI=EP!3Z' .S=,7\&H'^FF0]QS>S[WCO:R_] M"REX%HDNVIRJ*'PF;Y0K!T;5-;^H4=Z=C=8P]O\4=7V85.TQ]7 ZH*F^.G@8 M'^'GQ8\_P_^W6+X\"ZO+L&9,F00H!' 5Z:;/AD/=10B::V\]B^CNQO0.+^/> MG;Q>L@=M$7*W+GLD=?6-Q!O&WH:O>!6;CJ &LD+S\YPO9WI M_9+X6I[_N!H $)+DW%HHT>DZ1--"8%H!.FW0!T:_VWY5_$/43-S??D2 -=+( MQ*F[EQ>K\\577%XM_UJ%Z^KTY0>\#.RLOLR^71V;B*B=MQD4ACI@U0@(Y.6# MR":Z.BS"\%UVB@S\VHG;[8Z JK%UT<$5]H@8;W(A7H42=9 0ZQ!,%7R!&(VO MFRRUT+((EX[H1W277YS*@=A/07V#[H]E#59;2Z=4$@,NU_2[RA:B=1)0%(N2 M;FWNCPBX-4W=&FE[HF!WF U72=\0.TGIXNMZ06O>[,=9J_&4N8"&"7H7O"QD M?)8$@40&0@14-NN08NL\^' JNS7E1H=A"[4-!Z:_!.8"BY]E95E\,:*-X)=)Q@Q%J/N>LU,\;6 M:^9\@*"EI%.4,T3N+' GM$F!*=M\#?*OF1D;@JD#,F-#]-6!R7=5V7^2_NMB MMII=C[:KU9[@!"4OV@C/>YM9U;D\2-?%0P!:JWP%. M^^MA\I:;OV:K%W6Z[WDBB5Y-*2]"U(L;(BO$A=)UCAV3D%WV5I4@N=]I)?2V M#^\/$ =G&4E??2-R:39$!C8M9@,BJT$%S$NBL.N!%95-B4%8=,4#[O&LY!D'E MP%J.(7I[9DG0;*5UCGMPK&A0!3DXQQ!J.DX;.M@R\AU>T3&2H-W4;@Q2_P%) MT"&ZZ.#V>[(L):'P/BM((450GCB)9+>2TVV\%UP%9UHOE&U1,M1-1<<^L!M# M-QU ;:=(-O>%:2L\).2UC5DX8DLM*Y5>YRB;A_5/1&P&$T= M'8#KRL=_N?@:9_,U4Q\P+3[/9_]- LPD\%F9A5MIW+7_GV_-HI[ABO[LXNM] M>:]G\G_Z$N;7S6N1V:!5E;O1'!2W ;SE 4I)*1CFZ#EIG4,X*H/=/NQMH-\O M6+H<.?[BW8Z) M"*/SHS303P5L1*L46F::3P1ZB):>,#-\M9TX*[230 MR6&@3*X-7++N*LU2)6=B]JTWQ3Y(3$_0V5?7BS$$/W%@_R/.9XOEF@/,;Q?G MUSP$DY+E1H$HIC:UL@C.QD".;PA"<<.5%4^8MX]]_K2N55,\-!-C!Y?)F\7\ M,WW:URJ@ND]Y?F6Q4BV7$*(#KE.O'CF6R^@VT9'3Y YW&(Y M6-(=HF5SB+@,7#H>P2I'KW)P#()+%HH5+DH>E>&MG:'ME$S[Z!RNX2<@LX>X M.P#-R\7\.R[/:ZBH,G(UX]69;&LI/_.1CI)+$:)1CMC)*K 8V3RLMQ@0H0@9Z,)-I5K^UBN(LB8>O>&Z"!V];OTFW2-B MV@=I!*P<)N8.I4^;HW2U=/IZ\)E$;WQ0P LCCT!R"U%;3L>@B&@S+Z;Y M[)!'R.G)C=Y3W5N,FA:R[Q-&IS[E0NZ^!E;J$!W+Z )UW@-&EFQ@GDG3.GJW MA8SIK9HF*GX:.H/DW0%D_@SGF]#1NW*;G6OY)%>Y?D433WYX6WNH*9:F#B@=]LL?/5W.KO(L_GGS>FXX?-RC$1PQ4CE M R#G 92(!7Q,M=;%BYQY(A/R3DIV:XQOP%=.>Q&UU?-B?*%W<$/]?-[J2"]2 MVOF'<([K+4[Y/2Y3U>%G/"T8BF:.SAQSU95T"7S2!9C5RG@ZAXR/:V4_1MVT MM]8HR!M911V [[:H_H6UTACSR7=<$BNWV7Q'O_5I]A5/I5$L!BZ GGIB3ZI8 MU[$FJ 4(CAR9E'WK'>X#29S6_QL5AF,JJP,L_GS*_CD/EX6CF&O-R^)B?OY^ MB5]G%U]/YNL RNO5ZB+,$[YY!GH4,-'I MY*JTQF@CTGN*7;0Q_*;0:1=0OOS:WV?SV^R<.L<,SU*#4TK1B?018J'+0)AH M4!AE6&Y=,/ *3W%.8X$BWO0/%Q'_4S8.E"BISDRQY(0$+6I:[]X39L5!YBX MI9?"")E:IX<.)+DG+WDJ!!]/YP8R> MZ:VG1J!J+OR]@?0=EW'1<-?&K6-R:KA'6S2=!"7J\N8BP1LF(656A_LKD67K MR.\=$J:/330&S"$B[MS8N562=EDW_4]B\*9RNL$,W/V_JZ4I=!"?XUI&0;GZ M1"$45>=TYQ(@_2C#E$U!V80%M+LFV*6)QBX%3EH5B$8.A7DF[MVL>3LVAM M^NS=WG#4ALQ!RMVEO6&(I#M$RZ;"5O%H@@IDHY4Z*E.2R>9R8,!1+N #3;Z^U#2H++1$?)UX7OI2Z\,$3<'6!F2V>SE88)NFAK]V@=Q:L5N!02!%M3YB87E5I?,GO. M"#AJQ]TA3]*!4NX.)[?:5I7-@B610!AF".^:G$,A-$CR& GQK!C3>@+LLYD1 M,$C'N\X(&"+PJ4>WWMR0MQN3!7D!RO@ Q:J:V:-#Y"4=K&*L-=P(CO9.1G7[ MA-:MG]X3"/;5VJ*I""<$P6IY?OHAS#]?-: R88J.P'D.H-!*"#I%,"$7H:*1 M3.XT/I4^]=8U03_=7!$_?>'T@;D6;\C^,NQ!\5>#@'-T(>D,0I=U,I]!( .) M?H69:^1^1YMB%]5/>0\K/E]+_$4DTYIN*E!> M!7 F"DA21\6M%+C;6I0G5/[3ETZL]'U4MF@AO^X,Q#?7)1=2A*0B4^"C)#8P M9_"!'BY'@HCJ22EM4NQG[R[@\WO(>')UUJ@=:JY094)^60@ MT2%214$4Y)FC"R78)#Q+8\QLW$9+3R;EGHI^%#Q[2KT[]#S1?H(HT&B(/'I0 M5C#BC"NPP63E9$G+]<),2\^ITD>2<(>.HY1DPE M@>6"3+Y@"@3C%6 ,S&=!'*K63;./D-.3!]0&5ZUDW]WE=8N9RU^NZDSLJBM^ M:G1Q:'TAQZ&N'5:>@1,N0V2UA9U,RI);A_!W)JXGJVJ,JZN57IX'X-XO9PGY MJ>2>!$>'* I/ABDF 8%^!L=9L4YH46+[;IP=B=L)>ND9<&\OJHO[ MKKSZKXO9^8^;O[(ZQ1*C,\Z"9;R.!"+;TWE.O"I;LI)D&(C6[^=P*G>"H/DE M(-A&4YTO57@9SLX^TF>&W+8 \.&/;5KKMR/UXY;U:88I1TMP(">10*#(BL= M9E@TG)%=1L99^]UHQRKK2TJDI(,"&<@Q4<5K<'75"?=&B$C>2V+CCLWOMZQO MB-YW*>L;(NKNGKC+R?!U-J'S"!(%78Q,6? F!BC2D8P3BL ]N%@5B4 6V-M5K8PE+K15;/IGYBD(YWK9\8 M(O ^ZR=4X3Y)NFVQ! XJ:0\AB RY:"8S,]G*769G/:OZB4%:>[I^8H@(.[@] MMA:\%JTXF=T(+MJZ@<0D"!@5!%629Q:CL:UOCN(ELT1LLDJ M[YT$+@JY:4P+""072,YH+6/@(8^-EQ[>F<,UO%OQ^!!Q=P":[=7,"5-BSBJZ M=KTCZUY&\&LG/S(236!)Z]83HYY/\?@@#>]4/#Y$W#U4=UU6N683?/8"F+%D MI=$Y F_KM!8MD9P_[?-NF=7G6]:WSX.SOPQ[4/P&K\2;"S$:2 P15*[;IG*L M<_2D8MS;PME.KN[S*NL;I*P'ROJ&2*ZOLKZ09&&USALKX!\NO +'APDI*T7ONZ[=G7ZD3%R('B/@.SRB6A?8BZ MI[461RWK:Q?IVD_>W<'FL90F64V2F81D\A!W"ET=R44N?BE!>G2).!TW6GIH MJOGX*R^&0&'O5/,0O?0,N(<3F%$DNKCIF ;G RBG([@B"_# LG>J2,>/5E5S M6*KY^!L/QH!@&TUU@,679V&U>E?^5;.Q\_-WRP]U(/6KOW&99BM<'Z_K/UQM M_G3%3U4A%H-R$&*N\Z^-)*O2.I FS>V[\7H3VY7VT0.;Z^ILXC;&-P M4X'[>IZ6&%;$XL?SY>P_-_S2F?P8SBY_.#4V%U>XA&@\!R5L(DZ- RU53H(Y M;?@=9&[/-QQ$14]FWF&P.[)&.J^]N;^^N&D-S@X?WW0$Z4!NQJW)\5D9M*56 MA+':?Z@$.(P62$X!%7DH]NY(SF=4D^,$V:-<>A#9>%"<_A,EUU"8(_O5%,V: MKZ=Z+C4Y0_2^2TW.$%%W8']MJ21 NBY#Y'17KN>\X+IFUAKPR25O@BXAC]N% MV&=-SB#%/EV3,T3*W>'D5K%!#%B,+W4Z T;R-U"3YV$M2"92R$I9AN/VBG5< MDS-(Q[O6Y P1^,2V]/T7?A/896@5ER9#YH($0U1#2'7V:F)U :2N-=$[6,D/ M?7Y/0-A7$:2/NE;"%@@:?:V/-\(X8H6/L0NL_\J< M0]Z;@R7=(5JN%J=CEB46 74-8_4BR9_DU9^TUO,@R+54K=NMGDUESB -[U:9 M,T3<'8!FGC'H'; O3(6,5ENSF\Y^"B3\ $W$Z#!V-)#AQ$&;0 MTGOMO"E) @MUEV.H [D#LR!4PLBD=NSNM;,5& .^LL]4Y;YH&4O6#2^2<3*3 M)ZL5GK\(*R)K$>9-LY)/?'3+C.00+L;-1@J4S@A1P!L;"( Z0%3< T9GDTW9 MEE&VCQ\G&ZF+2=S( B6Z0LSE]=Y: XQ^3B8A*C[NQ)Q^LY%#]+Y+-G*(J#NP MD%_25\ZJA3\[FYW_6,>TE%G/(@M0E*C#X44")^FNQ"*REB8+'5OGE^Y3,3U6 M#E+LW1JNPZ3<'4XV 2VMC"].&'#!DC,@R:TLIM1)YN,V\'1<+#-( MQ[L6RPP1^,1QFI^=S\?O36:=M-[G>@][DI40X#UY#5RBX%RE^F<[Q&D&?&5/ M<-E7OXOQA=W!Y;.U,L!K$>BY5A!$[0K2=?JNEH*<2^ECI->=VVZ6IQXUJ7G( M0W6PI#M$R^9<%>L4*R&!*'0C*UWY860!IHA&.U:;R5KGGYY-E]693-$ MW!V YG[Y!YTAEIQ&.D:)CE'*"AS3#K2(0463BY>MYR4]CRJ;09I]LLIFB)A[ M&'UR6966M*^+]L $1427NKW",04QA>1L=MR'XZ^R.^J0@WT>F?UEV(/B-WCU M01;T+H!AKII.T5Z."A-111T]-QA_P55V@Y3UP,R;(9*;>N;-;'YK9@LR43RS M J2N&0SG)?CL'%@;?%(F!F%WFA3PU,R;VU_:Q\R;02I;M)!?!Z; 0QET8[EE MY+0#T]K7TBP)](\1N [!B*RS#;*Q07!((>61=F"T#H[M)^\.8%,)?U?NN-N7 MLY]>+);+Q;^K,QZ^T9^<_SC%*#2)QM"1(+94W?,863"0>5:H8\F86F-I"'T] MA4;V!,1=+V4L[72*O)>+KU]GY^OB4L1;M7YUK(]+0M"-CG10+<_@I0P@,G=, ML)*8.0;P'B"OIZC_>+AKH9M.8?K4")','56A=I4XH^6>^4?L*P>O##^P/$ 8 KYD#<)YP[.T M'E7K7HS'Z)DVQCFU1[>?6CJ V/;[^=V_Y_0-7V;?;N40+-/6-GXKJSZO?$P^(8RND =>_#C_4"AD^+C?MS)<*K?G]G M"KWT)D PTH+R]*OHZ%&ER;DX#W4\$B@;%'A;+,2L8I3" M^""/D*/8E_QIW^31(#N5@CNX.+>P_B(L/Q,G[R^6Z4M88>7J Z;%Y_GLOS%O M)O!X=$$;LJ*UJG&@S#@$KCTP'8-"AE;;L0+_PRB=MASYF(AMK;9G",[UN+"U M15->S]/B*[Y;TC\EZK_@?#7[CI>_^:JFHE=UC].K^<577*X_]U2KR.KT*(@L M5K]PO22'Y".2MM9$>J5\:P/AB.Q-6X;9S3$X%D">3S-7F7!F=P?/ 05O/1+:ZB.:#JWZA\I8AZ#FX MO&6(JCJR,^ZFUX0HC0;CF2??E9F86N_=_#7*6P;I?\?R MEB'*Z!13/V?F,>82$"TH)4.=#"4AF%+WXTD,Q@G#+3\"NIY!>,B2P% $D>WKO%0D&[4P!SD9;%PDV3?,3W# MMJ 8F@,Y@M_PIG%\A/K3(R M!!O!.%[HSM$!0JWO2QJ%YR+*E%KG45K0W<OI:H/N3NOYYL-:0^)XQ]X MEC=/YJV/XZ>&8XG&%L@*23G(!#BC'/GNV7EO=!+J"&>F-5M]G*4IPX%' 42? M;O--A=CK3-J:E5E- OQ<#/3'8I'_/3L[.]E6%'3[\DJA>$9T \:Z\C)4L=%]$V/AN3 :%/NVH7<6P5P\NP^D)_4&^2[^&LAH)/ M34K&*./ RG5&S3!RM92!&)/*4LKHS!'"H@TYZLXSGPZ\;0[6&$CZU<[5Y3;; MR[])GX(D%/J7JU,FHU!"6K"Y]NNQ6ITL23!U,78JZ .*UHL:C\%7=T[_KWG& M6J#J%SMI9/Z&^>?9]5]^=_X%EY^^A/F5=D]9(UW?7_;][:@63GGL-1:4Z)2?1#>:3@^R=-LX5#/E.*>JN:=6) M..JCG;*G4]F7?@8A;OKC.L:5]G8Q3_?DLA;7:=$J6E%'H<5:YI0X^<]!>; Q M2HO":1N/$, ?@;.=CJ7YGW0L.T;6+WKL\/S4&B55MAK(2R:ON6@D6T$H2%D9 MY;0(SK5>]]J8A9T.DOU_!^FX6.DS=W8K+?.NO*$_J\XK9VPS3*S>%HOY.=%! MG_GY*JEX77UR&LG"8X$I\)G%RRLC8 EU&I3G&H7FIO44N.9,]&$.'B,_=D1E M'_H^3#H>*3M>G(B0(G.@E C@121K-$AON=7!ZR/DNEJ-1QK=8CH&[#\-F3P[[L'N>1:%# M(YAT.2GI[;NW+]^]_?3AW9LWK]_^\?KMIU,CN$@R83X+8J/4E3YH0&LGI+2:[I2Q$EM=S1YJH.0=!PP-D7BGP/EY M-DKTWMO:TN1\K=Z@XT2_DA%*9#DGKKUH?L\^TP%#@U0_>,#0$#WT,&#H3\RS M%,X^+LXN*C>KDS\VO[V>D1.40%-* FVB)UEY 5'2?V3UG%@6T;&=EVD]^DW] M0>4 M=X=/=1.QA/O+;I>'K ^2,');,DO 62Z+M&,"9S@"DP.+'$>N3$[U40] ML:;HIR^=MD:PW?MTF#1[@<'F<#BO+3,L@W9DS2G!(WBO$%C*)G 2@Q4[&;^[ M F'J!54'*&Z;^O>0XL0OQ_]9S.;G?Y&4+I;X>OXQ7.39R3+$6=A<:9Z%+!UZ MB%:3H:^#)U;([C<;FN4'$U7?:_@U,D;8Z*CF[>VN7IK('(4D)/P-B465&EA MTOR2*S@'H6#W%9Q#5-+#8WAOX*PV,KH4(FB)$520 5Q1$JP-LB9.M%1YU_>O MC]&]K;7VY,S>(2+L(&QW]VJ^R?#1,6#16@>!U0R?*QPBF0H0$B87%"]!M-Z_ M^2 QT[8=M(_YMI%ZA_#9LKOQQ8_W:RF?9N*KH&2@L,Y-C#Q!L+6Z03N9F$Y2 MQ];I^@'D]956V!,03\"LE7:>"_!^3O9=_I53)V0TVN6Z H\<'F?H@E;) #)7 MM(P>'6O=FKPWL7W%$H\(RH,UUP%$MX3L;UA\5_Y:G-_*0%]7N9PFYXQC-@/* M0++EA?AE=!H=2B<%YS;YL5KGAU':ET_9!IQ'T-G$AO]M=DYR7K,8SMY=G*_. MP[R.6_KXA>2_NBI,S*="(^><;-G@ MDYUB(XX@J,3,'4K'M(7S[3%W5+WTA\&3^?PBG'W VAY&[-75FCA?K?5Y2EZZ5,9G$!Y9 M36DC,>7(F9,YFI"S*'Z*N$>^==KR]J/@JY7,.[#?/N'7;XME6/ZXC!]= MWL^W+NS36(I@NDB(0A10(7IPG-A+(EM.K[ZQH77CZE,T35LQ/HY-UE0/'>!J M>[QZBQMTZM%D*Y('YB69 %HQ\'14(&=E$BO>>=DZ!+@U_D[BW=*3<:HT\RP;35RY&LH6 KS*$A"UY2$K*;%US>]>A.X$ M1?^\H#B^QIY3J\O-1NSM ;/K%X[6&+,7QT?JEU&LL!0R>$8^J6*U&C2@ M E]\#L$FIY0\RK70K%]F\7T]8_WU_.Y9_D!?^/MB^>^PS*>H>;;D#8$C8Q54 M]@X\=Q;(:+51%,,\;]X_LPMA???3#,#*O4!Q<[5T\!+?9>44HRE2D/U05+%$ MOT*@AR)"DI'%F$PF5WOD=,3$J:_V:GXBXS!(YGMCYALN9XO\\3PLS]O8<%B? M_\57K-LI3L[/E[-X<5XST9\6#S2^"LTMYTP!X\S7$(X$'WA-4[-@?=#.E>:- MC4.)G#C#-3KVQM7: 5W_C4"YEYF:'6J'(H)3FECTA4SD'"VPDE+2)F&6K0,G MXSD6XV6XQ@?GZ-J;."B\G<'+*7U?POPSKDZY)!>^E@(*B:7V1CB(W'FH-8"2 MYXA2[E+R]O0W39S0&@U,(\BY1SO-6E4K^B)(64U7DG M\S0[FZT_FYS\BZ]U ])B&>;Y-YPOOM;+=K$LB^6+L)JE^KNSLXOS]9"V2WOB M/1VMQ=>OB_DZ'GY .28Y#4(ETPFS4;!E5=A.:<[3P)!7:$&0QK:.M#]%RZ.5Y4YM_,C^?Y2KKV7?\6)."ZYD]K_ZN MJ[TP5PNC9@@O+F'PKMPEZ++2UFEADS5D @MO0"6K($8A(7!43AON6="-)=.6 M@VD=[":(NWM73ZCB#JR# WE^\6/[!ZQ[4P2)PEE!NC"11*'I!761["8O&"I2 M%&_OM8_(SK30GQ*EBSXAT^WIN=61$XTS0G$%09!?J6HS3E1!0I):&T?>@K*M M,PQ/T30MCKL!STZ@WE.3'2#S WD=RUDBR_#C^2+]YU4?L\?$E&- DHJ@G-#@ MHT"P64FZ#ER,N76X:BLA/6)P7UTO6@N^ _2\7,R_X_*\+D_Z#>/YC9 V[ @> M54%? %$BL<,#!)8\).:,S\4Y&5IO8GV"I&FC[Z,BJJ4R.L#6O^J@S/GYAGB; M3.8R1""*B?A8ZL&0Q(',43FOI8JMD?03 =,&QD?%S?Z"[@ E!]H);ZY+EV3P MW@A3P$A.-Z]E'GQ!!:(DH3T/MOU.EE:T3WNG_3H>QWY@Z. 0W+-^:\SO.NBA MI)$1;8"H8ZW<% :"\1(*XXGE'!+&UL&D1PGJT:@;&R-WRVZ;*:P#]/V4\#]U M)F5I(@/DA=X/H^G\9JF!(XN)>RZ+:5W!_1,!?44>#U#L8V45@Z3< 43^A;// M7\C5.2$#-7S&MQ?5U'A7[C4VK,5%)XMGRY2%G#(#E0WYYUE[X Z34:&V_0YM9QMZV$ M3.M>C >IPZ7>(70VJ=1K 4D=2$*:'"57Z]?JJ :G58 2R%VRQ0ALW[3T.$D] M1CDF-K$.45H'&/RYJO)[F)U=EE1N0^1, +?6>,R).]G:,3V^6H^L^@[ _H!EO#FZ]_NSF3,V"9M!:U$7<)&UY/TZC<.$MLAED*TG&@TD M<=K:W"Y@/*92.]@4^\#K=NH5YX(G!9SI DI9!0$U B^<>^^55[MMB#C<6IVV MNK<+#+904@?WXX&RW&S_M"4B8B[ G>,D2&X@)LY!)%8R<5R,;^U'-2%\VB$W M7>#X^ #HLIG_U9_OW[S[CU>O/GYZ]_+_OG]S\O;CFKU8S:#;@X%>_5U_>4 - M^YY?='@U>@L.&]65_S9;I;/%ZF*)[\KMK_Z 9W6_[\O%ZGQU0]S&"EU=>W?6 MYX!US7 1IG8=UK!6B00VQ0-G*%AI'K4YC.)V->JO"&&+'T@G=?E]EO#&5+]- MU,G9^B/7Y_5F6>W[=>_(FM++?&U.60?R3R$:1#JSBL28I*?G*G.-5KJ IK$8 M1V%DVE#$$;'\<%W[5+#HP("YC-5\)(6O'=0W&Q;7Y:)6"2S>"<#+N8")@U>) M7D@=I8_T*.GFM;F/D--+>?ED8+D?C&BBN7Y!>+6V2'M7;)8@@B86F!+@=+10 M,$65K<806L<4'B5H6B V4_MN<-I#!QT JAZQ=^5C.+NN 54\Z:*E A>RKKNO M- 2C)60Z;P%Y1#+[FQ?DWB&B2^#LH^![];>'2+L#N'P@31 !7TYJ#^EW/%M\ M6Z\5NK3D-RRYE(5Q"<'CND&950&Q1$ZBS-[J.O^M]4RH'UZH5X2TAFZP#-:8D[2I>YKI4GQ M] =:&LY4ZU*@001.FPT:#WCC:6EO"'['95RTJNAH8KS>A,Z8$TS[@)!JDA[\6MF!(A'=S2&\XV:;![C&_._RDS07-. M%HTU(=:WAX1KLP&;)>Y$=)PW MOAAZ":X_<-IO5;^\^'&_.*:.DMJ\6IB"D(J!3IY$)[4#;\F'E%P;)KTN3HT7 M4#^0^&<=1!^"V8>#Z,=4_\3KFC]4EM81-ZV4245*D"HE4%X4B"4$8%P+XZ-% M[UML9K[^PEZ"X$=5]N)0R?< EXW'R!(YH8%[T-D64#I[8CQKR"P$HWU,DN]T MR>T"F*F7,>^IK+OJWD-R$RO\S]E\]O7BZ]7X 4-P]HR!"E;5T88"?- %F,M% M6JE-P)WR%T^H_*_=)IP1C/%[RV_#D('3[Z)#SV)-_ZN\"ES2WXH/8,9E-4& MHB=+3- K:9*Q4XE@C:%33*1[I\SVB]=^=L%YK>'"BOGDPE60ZK# MH)0N##RY)2 <%ZH8ZZQN[3^/P\G$EOJ1\=CJ.+0#QZ]U1"Y[-$Z--,]GW_"W8!$B3 EZUR$B?CVL1VV?JRNT\N7&WNR&2& MDC+QOU^ DFU)EBA>0 /29*9JRI-+$SBGN]%H-!HI$(GYEW.H-'3=J\?Y)([4 M,!QJYGC&TD--@GGT9B@,7VPOK]E%L3Q(^%+9;B&0:!YSG0$H8F%;U)NM0\8P MT$+$1&$LF/,N!R-,PW. =7H6,U153F!M,31HE<\7]OIJ(<]__"0LY4E JH8TS[9N/9B4$L:0Z8FG* MA=KJ0K#S$;K&CQQIF#-,]]Q"[UF'=M\M?HLA/[RPU%C<<<99)%EF9HSKDE 3 M@4&9 :ET(JE,I#&K%FKG>EQ^DD&.5:4,A#?OJ9Q6",QX,P3+S7F^VC\L49 ( M(TU,4$;MZ2_&$0,4T1A AF3*A(")B%UH;X^Q^5GG/6KPV/R%[GD/3']M1\PV M=L2;B$"*-%8&$40R0T^2"D"A"6]BJ23!*4I$E+G0:">C]1-/>-3Q]^,-Y!N.(XHTNO'G./[BP MY+6-YG+^*DTBS$ED.ST;(B#E@*J$ "UQK"G"0JI#-R;&&->19MZ&[^B\$GP" MYSQK!K[5]G'3(1E?I%>^"&9:0@938*9# *82 TH1 8E"3$1"L50$7(+3>7IN9*7ZYYC='4]8Q*"P-\:UL(W_-&!:01"Q6"A-(X3C@ MZFJ9V,F4^ MHVBX'X/LI&[>LTFMP=E;U[NSW*,1(,&8IEHE0!%D2\X9,B32"% LS#]*I=#] M'<3WF]Z1GDD%:I.>U.X$5L>#52.-8)GHG5"=4L!D8K:HL4@!-?@ #;'9I:I8 M1\+U^QY>)WRDIWF!6FTPJGD"=MPZ[( 9S2@7!@<6 YP9]\;B) (Q2Q+-H.94 MN>Z6$E*4&UY>YCAM1LQY M6[GWF9K?MPB./*$SAOJ

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�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end XML 95 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 96 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 98 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 198 349 1 false 74 0 false 7 false false R1.htm 0000001 - Document - Cover Sheet http://www.varex.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited) Sheet http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 0000009 - Disclosure - REVENUE RECOGNITION Sheet http://www.varex.com/role/REVENUERECOGNITION REVENUE RECOGNITION Notes 9 false false R10.htm 0000010 - Disclosure - LEASES Sheet http://www.varex.com/role/LEASES LEASES Notes 10 false false R11.htm 0000011 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://www.varex.com/role/RELATEDPARTYTRANSACTIONS RELATED-PARTY TRANSACTIONS Notes 11 false false R12.htm 0000012 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES Sheet http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIES FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES Notes 12 false false R13.htm 0000013 - Disclosure - FAIR VALUE Sheet http://www.varex.com/role/FAIRVALUE FAIR VALUE Notes 13 false false R14.htm 0000014 - Disclosure - INVENTORIES Sheet http://www.varex.com/role/INVENTORIES INVENTORIES Notes 14 false false R15.htm 0000015 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETS GOODWILL AND INTANGIBLE ASSETS Notes 15 false false R16.htm 0000016 - Disclosure - BORROWINGS Sheet http://www.varex.com/role/BORROWINGS BORROWINGS Notes 16 false false R17.htm 0000017 - Disclosure - BUSINESS COMBINATIONS Sheet http://www.varex.com/role/BUSINESSCOMBINATIONS BUSINESS COMBINATIONS Notes 17 false false R18.htm 0000018 - Disclosure - NONCONTROLLING INTERESTS Sheet http://www.varex.com/role/NONCONTROLLINGINTERESTS NONCONTROLLING INTERESTS Notes 18 false false R19.htm 0000019 - Disclosure - NET (LOSS) INCOME PER SHARE Sheet http://www.varex.com/role/NETLOSSINCOMEPERSHARE NET (LOSS) INCOME PER SHARE Notes 19 false false R20.htm 0000020 - Disclosure - EMPLOYEE STOCK PLANS Sheet http://www.varex.com/role/EMPLOYEESTOCKPLANS EMPLOYEE STOCK PLANS Notes 20 false false R21.htm 0000021 - Disclosure - TAXES ON (LOSS) INCOME Sheet http://www.varex.com/role/TAXESONLOSSINCOME TAXES ON (LOSS) INCOME Notes 21 false false R22.htm 0000022 - Disclosure - SEGMENT INFORMATION Sheet http://www.varex.com/role/SEGMENTINFORMATION SEGMENT INFORMATION Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 26 false false R27.htm 9954473 - Disclosure - REVENUE RECOGNITION (Tables) Sheet http://www.varex.com/role/REVENUERECOGNITIONTables REVENUE RECOGNITION (Tables) Tables http://www.varex.com/role/REVENUERECOGNITION 27 false false R28.htm 9954474 - Disclosure - LEASES (Tables) Sheet http://www.varex.com/role/LEASESTables LEASES (Tables) Tables http://www.varex.com/role/LEASES 28 false false R29.htm 9954475 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables) Sheet http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESTables FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables) Tables http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIES 29 false false R30.htm 9954476 - Disclosure - FAIR VALUE (Tables) Sheet http://www.varex.com/role/FAIRVALUETables FAIR VALUE (Tables) Tables http://www.varex.com/role/FAIRVALUE 30 false false R31.htm 9954477 - Disclosure - INVENTORIES (Tables) Sheet http://www.varex.com/role/INVENTORIESTables INVENTORIES (Tables) Tables http://www.varex.com/role/INVENTORIES 31 false false R32.htm 9954478 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETS 32 false false R33.htm 9954479 - Disclosure - BORROWINGS (Tables) Sheet http://www.varex.com/role/BORROWINGSTables BORROWINGS (Tables) Tables http://www.varex.com/role/BORROWINGS 33 false false R34.htm 9954480 - Disclosure - BUSINESS COMBINATION (Tables) Sheet http://www.varex.com/role/BUSINESSCOMBINATIONTables BUSINESS COMBINATION (Tables) Tables http://www.varex.com/role/BUSINESSCOMBINATIONS 34 false false R35.htm 9954481 - Disclosure - NONCONTROLLING INTERESTS (Tables) Sheet http://www.varex.com/role/NONCONTROLLINGINTERESTSTables NONCONTROLLING INTERESTS (Tables) Tables http://www.varex.com/role/NONCONTROLLINGINTERESTS 35 false false R36.htm 9954482 - Disclosure - NET (LOSS) INCOME PER SHARE (Tables) Sheet http://www.varex.com/role/NETLOSSINCOMEPERSHARETables NET (LOSS) INCOME PER SHARE (Tables) Tables http://www.varex.com/role/NETLOSSINCOMEPERSHARE 36 false false R37.htm 9954483 - Disclosure - EMPLOYEE STOCK PLANS (Tables) Sheet http://www.varex.com/role/EMPLOYEESTOCKPLANSTables EMPLOYEE STOCK PLANS (Tables) Tables http://www.varex.com/role/EMPLOYEESTOCKPLANS 37 false false R38.htm 9954484 - Disclosure - SEGMENT INFORMATION (Tables) Sheet http://www.varex.com/role/SEGMENTINFORMATIONTables SEGMENT INFORMATION (Tables) Tables http://www.varex.com/role/SEGMENTINFORMATION 38 false false R39.htm 9954485 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details) Sheet http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details) Details 39 false false R40.htm 9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) Sheet http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashandCashEquivalentsandRestrictedCashDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) Details 40 false false R41.htm 9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details) Sheet http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details) Details 41 false false R42.htm 9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investments (Details) Sheet http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESInvestmentsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investments (Details) Details 42 false false R43.htm 9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Supplier Finance Programs (Details) Sheet http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSupplierFinanceProgramsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Supplier Finance Programs (Details) Details 43 false false R44.htm 9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Environmental Obligations (Details) Sheet http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEnvironmentalObligationsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Environmental Obligations (Details) Details 44 false false R45.htm 9954491 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) Sheet http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details) Details 45 false false R46.htm 9954492 - Disclosure - REVENUE RECOGNITION - Schedule of Disaggregation of Revenue (Details) Sheet http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails REVENUE RECOGNITION - Schedule of Disaggregation of Revenue (Details) Details 46 false false R47.htm 9954493 - Disclosure - REVENUE RECOGNITION - Schedule of Right of Return Assets and Refund Liabilities (Details) Sheet http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails REVENUE RECOGNITION - Schedule of Right of Return Assets and Refund Liabilities (Details) Details 47 false false R48.htm 9954494 - Disclosure - LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details) Sheet http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details) Details 48 false false R49.htm 9954495 - Disclosure - LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details) Sheet http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details) Details 49 false false R50.htm 9954496 - Disclosure - RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies (Details) Sheet http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies (Details) Details 50 false false R51.htm 9954497 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivative Instruments (Details) Sheet http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivative Instruments (Details) Details 51 false false R52.htm 9954498 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Income Recognized From Derivative Instruments (Details) Sheet http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Income Recognized From Derivative Instruments (Details) Details 52 false false R53.htm 9954499 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives at Fair Value (Details) Sheet http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives at Fair Value (Details) Details 53 false false R54.htm 9954500 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Balance Sheet Hedges (Details) Sheet http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Balance Sheet Hedges (Details) Details 54 false false R55.htm 9954501 - Disclosure - FAIR VALUE - Narrative (Details) Sheet http://www.varex.com/role/FAIRVALUENarrativeDetails FAIR VALUE - Narrative (Details) Details 55 false false R56.htm 9954502 - Disclosure - FAIR VALUE - Schedule of Fair Value Inputs (Details) Sheet http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails FAIR VALUE - Schedule of Fair Value Inputs (Details) Details 56 false false R57.htm 9954503 - Disclosure - FAIR VALUE - Schedule of Marketable Securities (Details) Sheet http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails FAIR VALUE - Schedule of Marketable Securities (Details) Details 57 false false R58.htm 9954504 - Disclosure - FAIR VALUE - Schedule of Contractual Maturities of Marketable Securities (Details) Sheet http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails FAIR VALUE - Schedule of Contractual Maturities of Marketable Securities (Details) Details 58 false false R59.htm 9954505 - Disclosure - FAIR VALUE - Schedule of Balance Sheet Marketable Securities (Details) Sheet http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails FAIR VALUE - Schedule of Balance Sheet Marketable Securities (Details) Details 59 false false R60.htm 9954506 - Disclosure - INVENTORIES - Schedule of Inventory (Details) Sheet http://www.varex.com/role/INVENTORIESScheduleofInventoryDetails INVENTORIES - Schedule of Inventory (Details) Details 60 false false R61.htm 9954507 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details) Sheet http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details) Details 61 false false R62.htm 9954508 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Sheet http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) Details 62 false false R63.htm 9954509 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) Details 63 false false R64.htm 9954510 - Disclosure - BORROWINGS - Schedule of Debt (Details) Sheet http://www.varex.com/role/BORROWINGSScheduleofDebtDetails BORROWINGS - Schedule of Debt (Details) Details 64 false false R65.htm 9954511 - Disclosure - BORROWINGS - Schedule of Interest Expense (Details) Sheet http://www.varex.com/role/BORROWINGSScheduleofInterestExpenseDetails BORROWINGS - Schedule of Interest Expense (Details) Details 65 false false R66.htm 9954512 - Disclosure - BORROWINGS - Convertible Senior Unsecured Notes Narrative (Details) Notes http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails BORROWINGS - Convertible Senior Unsecured Notes Narrative (Details) Details 66 false false R67.htm 9954513 - Disclosure - BORROWINGS - Call Spread Narrative (Details) Sheet http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails BORROWINGS - Call Spread Narrative (Details) Details 67 false false R68.htm 9954514 - Disclosure - BORROWINGS - Senior Secured Notes Narrative (Details) Notes http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails BORROWINGS - Senior Secured Notes Narrative (Details) Details 68 false false R69.htm 9954515 - Disclosure - BORROWINGS - Asset-Based Loan Narrative (Details) Sheet http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails BORROWINGS - Asset-Based Loan Narrative (Details) Details 69 false false R70.htm 9954516 - Disclosure - BUSINESS COMBINATIONS - Narrative (Details) Sheet http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails BUSINESS COMBINATIONS - Narrative (Details) Details 70 false false R71.htm 9954517 - Disclosure - BUSINESS COMBINATIONS - Schedule of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails BUSINESS COMBINATIONS - Schedule of Assets Acquired and Liabilities Assumed (Details) Details 71 false false R72.htm 9954518 - Disclosure - NONCONTROLLING INTERESTS - Narrative (Details) Sheet http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails NONCONTROLLING INTERESTS - Narrative (Details) Details 72 false false R73.htm 9954519 - Disclosure - NONCONTROLLING INTERESTS - Schedule of Noncontrolling Interest (Details) Sheet http://www.varex.com/role/NONCONTROLLINGINTERESTSScheduleofNoncontrollingInterestDetails NONCONTROLLING INTERESTS - Schedule of Noncontrolling Interest (Details) Details 73 false false R74.htm 9954520 - Disclosure - NET (LOSS) INCOME PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net Income Per Common Share (Details) Sheet http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails NET (LOSS) INCOME PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net Income Per Common Share (Details) Details http://www.varex.com/role/NETLOSSINCOMEPERSHARETables 74 false false R75.htm 9954521 - Disclosure - EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) Sheet http://www.varex.com/role/EMPLOYEESTOCKPLANSSharebasedCompensationExpenseDetails EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details) Details 75 false false R76.htm 9954522 - Disclosure - EMPLOYEE STOCK PLANS - Stock Option Activity (Details) Sheet http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails EMPLOYEE STOCK PLANS - Stock Option Activity (Details) Details 76 false false R77.htm 9954523 - Disclosure - EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details) Sheet http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details) Details 77 false false R78.htm 9954524 - Disclosure - TAXES ON (LOSS) INCOME (Details) Sheet http://www.varex.com/role/TAXESONLOSSINCOMEDetails TAXES ON (LOSS) INCOME (Details) Details http://www.varex.com/role/TAXESONLOSSINCOME 78 false false R79.htm 9954525 - Disclosure - SEGMENT INFORMATION - Narrative (Details) Sheet http://www.varex.com/role/SEGMENTINFORMATIONNarrativeDetails SEGMENT INFORMATION - Narrative (Details) Details 79 false false R80.htm 9954526 - Disclosure - SEGMENT INFORMATION - Income Statement Information (Details) Sheet http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails SEGMENT INFORMATION - Income Statement Information (Details) Details 80 false false R9999.htm Uncategorized Items - var-20231229.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - var-20231229.htm Cover 81 false false All Reports Book All Reports var-20231229.htm var-20231229.xsd var-20231229_cal.xml var-20231229_def.xml var-20231229_lab.xml var-20231229_pre.xml var-20231229_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 101 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "var-20231229.htm": { "nsprefix": "var", "nsuri": "http://www.varex.com/20231229", "dts": { "inline": { "local": [ "var-20231229.htm" ] }, "schema": { "local": [ "var-20231229.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "var-20231229_cal.xml" ] }, "definitionLink": { "local": [ "var-20231229_def.xml" ] }, "labelLink": { "local": [ "var-20231229_lab.xml" ] }, "presentationLink": { "local": [ "var-20231229_pre.xml" ] } }, "keyStandard": 310, "keyCustom": 39, "axisStandard": 31, "axisCustom": 0, "memberStandard": 52, "memberCustom": 18, "hidden": { "total": 24, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 18, "http://xbrl.sec.gov/ecd/2023": 1 }, "contextCount": 198, "entityCount": 1, "segmentCount": 74, "elementCount": 656, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 768, "http://xbrl.sec.gov/dei/2023": 29, "http://xbrl.sec.gov/ecd/2023": 10 }, "report": { "R1": { "role": "http://www.varex.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R3": { "role": "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R4": { "role": "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R5": { "role": "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-30", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-30", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R8": { "role": "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.varex.com/role/REVENUERECOGNITION", "longName": "0000009 - Disclosure - REVENUE RECOGNITION", "shortName": "REVENUE RECOGNITION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.varex.com/role/LEASES", "longName": "0000010 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.varex.com/role/RELATEDPARTYTRANSACTIONS", "longName": "0000011 - Disclosure - RELATED-PARTY TRANSACTIONS", "shortName": "RELATED-PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIES", "longName": "0000012 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.varex.com/role/FAIRVALUE", "longName": "0000013 - Disclosure - FAIR VALUE", "shortName": "FAIR VALUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.varex.com/role/INVENTORIES", "longName": "0000014 - Disclosure - INVENTORIES", "shortName": "INVENTORIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETS", "longName": "0000015 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.varex.com/role/BORROWINGS", "longName": "0000016 - Disclosure - BORROWINGS", "shortName": "BORROWINGS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.varex.com/role/BUSINESSCOMBINATIONS", "longName": "0000017 - Disclosure - BUSINESS COMBINATIONS", "shortName": "BUSINESS COMBINATIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.varex.com/role/NONCONTROLLINGINTERESTS", "longName": "0000018 - Disclosure - NONCONTROLLING INTERESTS", "shortName": "NONCONTROLLING INTERESTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.varex.com/role/NETLOSSINCOMEPERSHARE", "longName": "0000019 - Disclosure - NET (LOSS) INCOME PER SHARE", "shortName": "NET (LOSS) INCOME PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.varex.com/role/EMPLOYEESTOCKPLANS", "longName": "0000020 - Disclosure - EMPLOYEE STOCK PLANS", "shortName": "EMPLOYEE STOCK PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.varex.com/role/TAXESONLOSSINCOME", "longName": "0000021 - Disclosure - TAXES ON (LOSS) INCOME", "shortName": "TAXES ON (LOSS) INCOME", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.varex.com/role/SEGMENTINFORMATION", "longName": "0000022 - Disclosure - SEGMENT INFORMATION", "shortName": "SEGMENT INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables", "longName": "9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.varex.com/role/REVENUERECOGNITIONTables", "longName": "9954473 - Disclosure - REVENUE RECOGNITION (Tables)", "shortName": "REVENUE RECOGNITION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.varex.com/role/LEASESTables", "longName": "9954474 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "var:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "var:AssetsAndLiabilitiesLesseeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESTables", "longName": "9954475 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables)", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.varex.com/role/FAIRVALUETables", "longName": "9954476 - Disclosure - FAIR VALUE (Tables)", "shortName": "FAIR VALUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.varex.com/role/INVENTORIESTables", "longName": "9954477 - Disclosure - INVENTORIES (Tables)", "shortName": "INVENTORIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSTables", "longName": "9954478 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.varex.com/role/BORROWINGSTables", "longName": "9954479 - Disclosure - BORROWINGS (Tables)", "shortName": "BORROWINGS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.varex.com/role/BUSINESSCOMBINATIONTables", "longName": "9954480 - Disclosure - BUSINESS COMBINATION (Tables)", "shortName": "BUSINESS COMBINATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.varex.com/role/NONCONTROLLINGINTERESTSTables", "longName": "9954481 - Disclosure - NONCONTROLLING INTERESTS (Tables)", "shortName": "NONCONTROLLING INTERESTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "var:NoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "var:NoncontrollingInterestTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.varex.com/role/NETLOSSINCOMEPERSHARETables", "longName": "9954482 - Disclosure - NET (LOSS) INCOME PER SHARE (Tables)", "shortName": "NET (LOSS) INCOME PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.varex.com/role/EMPLOYEESTOCKPLANSTables", "longName": "9954483 - Disclosure - EMPLOYEE STOCK PLANS (Tables)", "shortName": "EMPLOYEE STOCK PLANS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.varex.com/role/SEGMENTINFORMATIONTables", "longName": "9954484 - Disclosure - SEGMENT INFORMATION (Tables)", "shortName": "SEGMENT INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails", "longName": "9954485 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": null }, "R40": { "role": "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashandCashEquivalentsandRestrictedCashDetails", "longName": "9954486 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-46", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R41": { "role": "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails", "longName": "9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Customer Concentration Risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-47", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESInvestmentsDetails", "longName": "9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investments (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSupplierFinanceProgramsDetails", "longName": "9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Supplier Finance Programs (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Supplier Finance Programs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:SupplierFinanceProgramObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:SupplierFinanceProgramObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEnvironmentalObligationsDetails", "longName": "9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Environmental Obligations (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Environmental Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-4", "name": "var:PercentageOfLiabilitiesObligatedToReimburse", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "var:PercentageOfLiabilitiesObligatedToReimburse", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails", "longName": "9954491 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Product Warranty (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StandardProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:StandardProductWarrantyAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails", "longName": "9954492 - Disclosure - REVENUE RECOGNITION - Schedule of Disaggregation of Revenue (Details)", "shortName": "REVENUE RECOGNITION - Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-54", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R47": { "role": "http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails", "longName": "9954493 - Disclosure - REVENUE RECOGNITION - Schedule of Right of Return Assets and Refund Liabilities (Details)", "shortName": "REVENUE RECOGNITION - Schedule of Right of Return Assets and Refund Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerRightToRecoverProduct", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ContractWithCustomerRightToRecoverProduct", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails", "longName": "9954494 - Disclosure - LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details)", "shortName": "LEASES - Schedule of Lease Right-of-Use Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R49": { "role": "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails", "longName": "9954495 - Disclosure - LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details)", "shortName": "LEASES - Schedule of Operating Lease Cost and Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails", "longName": "9954496 - Disclosure - RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies (Details)", "shortName": "RELATED-PARTY TRANSACTIONS - Investment in Privately-Held Companies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:AccountsPayableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-67", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R51": { "role": "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "longName": "9954497 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivative Instruments (Details)", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-75", "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "unitRef": "instrument", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-75", "name": "us-gaap:DerivativeNumberOfInstrumentsHeld", "unitRef": "instrument", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails", "longName": "9954498 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Income Recognized From Derivative Instruments (Details)", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Income Recognized From Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-76", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-76", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails", "longName": "9954499 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives at Fair Value (Details)", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Derivatives at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-80", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-80", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails", "longName": "9954500 - Disclosure - FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Balance Sheet Hedges (Details)", "shortName": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES - Schedule of Balance Sheet Hedges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-88", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-88", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.varex.com/role/FAIRVALUENarrativeDetails", "longName": "9954501 - Disclosure - FAIR VALUE - Narrative (Details)", "shortName": "FAIR VALUE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-89", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-89", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails", "longName": "9954502 - Disclosure - FAIR VALUE - Schedule of Fair Value Inputs (Details)", "shortName": "FAIR VALUE - Schedule of Fair Value Inputs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-96", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-96", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails", "longName": "9954503 - Disclosure - FAIR VALUE - Schedule of Marketable Securities (Details)", "shortName": "FAIR VALUE - Schedule of Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "var:MarketableSecuritiesAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-101", "name": "var:MarketableSecuritiesAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R58": { "role": "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails", "longName": "9954504 - Disclosure - FAIR VALUE - Schedule of Contractual Maturities of Marketable Securities (Details)", "shortName": "FAIR VALUE - Schedule of Contractual Maturities of Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-4", "name": "var:MarketableSecuritiesMaturityAllocatedAndSingleMaturityDateRollingWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "var:MarketableSecuritiesMaturityAllocatedAndSingleMaturityDateRollingWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails", "longName": "9954505 - Disclosure - FAIR VALUE - Schedule of Balance Sheet Marketable Securities (Details)", "shortName": "FAIR VALUE - Schedule of Balance Sheet Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:MarketableSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-113", "name": "us-gaap:MarketableSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R60": { "role": "http://www.varex.com/role/INVENTORIESScheduleofInventoryDetails", "longName": "9954506 - Disclosure - INVENTORIES - Schedule of Inventory (Details)", "shortName": "INVENTORIES - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails", "longName": "9954507 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Goodwill Rollforward (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R62": { "role": "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "longName": "9954508 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "longName": "9954509 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-142", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R64": { "role": "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "longName": "9954510 - Disclosure - BORROWINGS - Schedule of Debt (Details)", "shortName": "BORROWINGS - Schedule of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R65": { "role": "http://www.varex.com/role/BORROWINGSScheduleofInterestExpenseDetails", "longName": "9954511 - Disclosure - BORROWINGS - Schedule of Interest Expense (Details)", "shortName": "BORROWINGS - Schedule of Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "var:InterestExpenseDebtContractualInterestCoupon", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "var:InterestExpenseDebtContractualInterestCoupon", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "longName": "9954512 - Disclosure - BORROWINGS - Convertible Senior Unsecured Notes Narrative (Details)", "shortName": "BORROWINGS - Convertible Senior Unsecured Notes Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-146", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-152", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R67": { "role": "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "longName": "9954513 - Disclosure - BORROWINGS - Call Spread Narrative (Details)", "shortName": "BORROWINGS - Call Spread Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-154", "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-156", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R68": { "role": "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails", "longName": "9954514 - Disclosure - BORROWINGS - Senior Secured Notes Narrative (Details)", "shortName": "BORROWINGS - Senior Secured Notes Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-4", "name": "var:LongtermDebtExcludingCurrentMaturitiesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-159", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R69": { "role": "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "longName": "9954515 - Disclosure - BORROWINGS - Asset-Based Loan Narrative (Details)", "shortName": "BORROWINGS - Asset-Based Loan Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-162", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-162", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "longName": "9954516 - Disclosure - BUSINESS COMBINATIONS - Narrative (Details)", "shortName": "BUSINESS COMBINATIONS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-166", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": null }, "R71": { "role": "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "longName": "9954517 - Disclosure - BUSINESS COMBINATIONS - Schedule of Assets Acquired and Liabilities Assumed (Details)", "shortName": "BUSINESS COMBINATIONS - Schedule of Assets Acquired and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-167", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-167", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R72": { "role": "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "longName": "9954518 - Disclosure - NONCONTROLLING INTERESTS - Narrative (Details)", "shortName": "NONCONTROLLING INTERESTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-168", "name": "us-gaap:MinorityInterestOwnershipPercentageByParent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R73": { "role": "http://www.varex.com/role/NONCONTROLLINGINTERESTSScheduleofNoncontrollingInterestDetails", "longName": "9954519 - Disclosure - NONCONTROLLING INTERESTS - Schedule of Noncontrolling Interest (Details)", "shortName": "NONCONTROLLING INTERESTS - Schedule of Noncontrolling Interest (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:MinorityInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-30", "name": "us-gaap:MinorityInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R74": { "role": "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails", "longName": "9954520 - Disclosure - NET (LOSS) INCOME PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net Income Per Common Share (Details)", "shortName": "NET (LOSS) INCOME PER SHARE - Reconciliation of Numerator and Denominator for Basic and Diluted Net Income Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R75": { "role": "http://www.varex.com/role/EMPLOYEESTOCKPLANSSharebasedCompensationExpenseDetails", "longName": "9954521 - Disclosure - EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details)", "shortName": "EMPLOYEE STOCK PLANS - Share-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails", "longName": "9954522 - Disclosure - EMPLOYEE STOCK PLANS - Stock Option Activity (Details)", "shortName": "EMPLOYEE STOCK PLANS - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R77": { "role": "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails", "longName": "9954523 - Disclosure - EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details)", "shortName": "EMPLOYEE STOCK PLANS - Restricted Stock and Performance Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true, "unique": true } }, "R78": { "role": "http://www.varex.com/role/TAXESONLOSSINCOMEDetails", "longName": "9954524 - Disclosure - TAXES ON (LOSS) INCOME (Details)", "shortName": "TAXES ON (LOSS) INCOME (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R79": { "role": "http://www.varex.com/role/SEGMENTINFORMATIONNarrativeDetails", "longName": "9954525 - Disclosure - SEGMENT INFORMATION - Narrative (Details)", "shortName": "SEGMENT INFORMATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": null }, "R80": { "role": "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails", "longName": "9954526 - Disclosure - SEGMENT INFORMATION - Income Statement Information (Details)", "shortName": "SEGMENT INFORMATION - Income Statement Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-193", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "var-20231229.htm", "unique": true } }, "R9999": { "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "longName": "Uncategorized Items - var-20231229.htm", "shortName": "Uncategorized Items - var-20231229.htm", "isDefault": "false", "groupType": "", "subGroupType": "", "menuCat": "Cover", "order": "81", "firstAnchor": null, "uniqueAnchor": null } }, "tag": { "currency_AUD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AUD", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Australian Dollar", "label": "Australia, Dollars" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdateExtensibleList", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Update [Extensible List]", "label": "Accounting Standards Update [Extensible Enumeration]", "documentation": "Indicates amendment to accounting standards." } } }, "auth_ref": [ "r205", "r206", "r207", "r208", "r209", "r264", "r265", "r266", "r340", "r341", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r386", "r509", "r510", "r511", "r521", "r522", "r530", "r531", "r532", "r548", "r549", "r550", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r579", "r580", "r584", "r585", "r586", "r587", "r597", "r598", "r602", "r603", "r604", "r615", "r616", "r617", "r618", "r619", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r986" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25", "r864" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r806" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net of allowance for credit losses of $0.6\u00a0million and $0.6\u00a0million at December\u00a029, 2023 and September\u00a029, 2023, respectively", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r337", "r338" ] }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccrualForEnvironmentalLossContingencies", "crdr": "credit", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEnvironmentalObligationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrual for environmental losses", "label": "Accrual for Environmental Loss Contingencies", "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies." } } }, "auth_ref": [ "r394", "r839", "r953", "r954", "r1009", "r1010" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities and other current liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r36", "r37", "r146", "r222", "r654", "r687", "r691" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive (Loss) Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r11", "r37", "r552", "r555", "r619", "r682", "r683", "r971", "r972", "r973", "r983", "r984", "r985" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r914" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r137", "r864", "r1055" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r509", "r510", "r511", "r704", "r983", "r984", "r985", "r1029", "r1057" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r920" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r920" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r920" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r920" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares withheld on vesting of restricted stock", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r77", "r78", "r475" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r885", "r896", "r906", "r931" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r888", "r899", "r909", "r934" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r920" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r927" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r892", "r900", "r910", "r927", "r935", "r939", "r947" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r945" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r505", "r512" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r223", "r339", "r358", "r359", "r360", "r1050" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "srt_AmericasMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AmericasMember", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Americas", "label": "Americas [Member]" } } }, "auth_ref": [ "r1059", "r1060", "r1061", "r1062" ] }, "us-gaap_AmortizationOfDeferredLoanOriginationFeesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDeferredLoanOriginationFeesNet", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of deferred loan costs", "label": "Amortization of Deferred Loan Origination Fees, Net", "documentation": "The net increase(decrease) in interest income during the period representing the allocation of deferred loan origination fees less deferred loan origination costs using the effective interest method over the term of the debt arrangement to which they pertain taking into account the effect of prepayments." } } }, "auth_ref": [ "r979", "r990" ] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.varex.com/role/BORROWINGSScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r151", "r429", "r600", "r979" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r63", "r67" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive shares (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r292" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r49" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r49" ] }, "srt_AsiaPacificMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "AsiaPacificMember", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "APAC", "label": "Asia Pacific [Member]" } } }, "auth_ref": [ "r1059", "r1060", "r1061", "r1062" ] }, "var_AssetBasedLoanRevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "AssetBasedLoanRevolvingCreditFacilityMember", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-Based Loan", "label": "Asset-Based Loan Revolving Credit Facility [Member]", "documentation": "Asset-Based Loan Revolving Credit Facility" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r187", "r218", "r255", "r301", "r322", "r328", "r347", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r536", "r540", "r583", "r653", "r738", "r864", "r876", "r1016", "r1017", "r1037" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails", "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "var_AssetsAndLiabilitiesLesseeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.varex.com/20231229", "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "presentation": [ "http://www.varex.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Balance Sheet Information", "label": "Assets And Liabilities, Lessee [Table Text Block]", "documentation": "Assets And Liabilities, Lessee [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r212", "r225", "r255", "r347", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r536", "r540", "r583", "r864", "r1016", "r1017", "r1037" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets measured at fair value", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r119" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostBasisRollingMaturityAbstract", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Costs", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Rolling Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r942" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r943" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r938" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r938" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r941" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r940" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r939" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r939" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r106", "r111" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r528", "r856", "r857" ] }, "var_BusinessAcquisitionAnnualRecurringCompensation": { "xbrltype": "perShareItemType", "nsuri": "http://www.varex.com/20231229", "localname": "BusinessAcquisitionAnnualRecurringCompensation", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual recurring compensation (in euros per share)", "label": "Business Acquisition, Annual Recurring Compensation", "documentation": "Business Acquisition, Annual Recurring Compensation" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r79", "r82", "r528", "r856", "r857" ] }, "var_BusinessAcquisitionCumulativePercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://www.varex.com/20231229", "localname": "BusinessAcquisitionCumulativePercentageOfVotingInterestsAcquired", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative percentage of voting interests acquired (as a percent)", "label": "Business Acquisition, Cumulative Percentage Of Voting Interests Acquired", "documentation": "Business Acquisition, Cumulative Percentage Of Voting Interests Acquired" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r528" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of voting interests acquired (as a percent)", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r80" ] }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "crdr": "credit", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Noncontrolling interest in MeVis Breastcare", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date." } } }, "auth_ref": [ "r85" ] }, "us-gaap_BusinessCombinationBargainPurchaseGainRecognizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationBargainPurchaseGainRecognizedAmount", "crdr": "credit", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on purchase of business", "negatedLabel": "Bargain purchase gain", "label": "Business Combination, Bargain Purchase, Gain Recognized, Amount", "documentation": "In a business combination in which the amount of net identifiable assets acquired and liabilities assumed exceeds the aggregate consideration transferred or to be transferred (as defined), this element represents the amount of gain recognized by the entity." } } }, "auth_ref": [ "r86", "r87", "r88", "r89", "r90", "r91" ] }, "us-gaap_BusinessCombinationBargainPurchaseGainRecognizedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationBargainPurchaseGainRecognizedStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Bargain Purchase, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Business Combination, Bargain Purchase, Gain, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes gain from bargain purchase in business combination." } } }, "auth_ref": [ "r534" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Fair value of total consideration transferred", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r1", "r2", "r9" ] }, "us-gaap_BusinessCombinationConsiderationTransferredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredAbstract", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combination, Consideration Transferred [Abstract]", "label": "Business Combination, Consideration Transferred [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "crdr": "credit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total of consideration paid and fair value of previous equity interest", "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination", "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination." } } }, "auth_ref": [ "r9", "r16" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS COMBINATIONS", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r179", "r529" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r84" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "crdr": "debit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r84" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts payable", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r84" ] }, "var_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilitiesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilitiesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accrued liabilities and other current liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities And Other Current Liabilities", "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Current Liabilities, Accrued Liabilities And Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r84" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total identifiable net assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r83", "r84" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other long-term liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other", "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r84" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest", "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree." } } }, "auth_ref": [ "r84" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recognized amounts of identifiable assets acquired and liabilities assumed", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "crdr": "credit", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of previous equity interest at acquisition date", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages." } } }, "auth_ref": [ "r17" ] }, "var_BusinessCombinationStepAcquisitionEquityInterestInAcquireePriorToAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePriorToAcquisition", "crdr": "credit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of previous equity interest before acquisition", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Prior To Acquisition", "documentation": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Prior To Acquisition" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "crdr": "credit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement gain", "verboseLabel": "Remeasurement gain recorded on previous equity interest", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination." } } }, "auth_ref": [ "r81" ] }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainLossNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainLossNetAbstract", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remeasurement of previous equity interest", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combinations [Abstract]", "label": "Business Combinations [Abstract]" } } }, "auth_ref": [] }, "currency_CNY": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CNY", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chinese Renminbi", "label": "China, Yuan Renminbi" } } }, "auth_ref": [] }, "var_CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "CanonMedicalSystemsCorporationFormerlyToshibaMedicalSystemsMember", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canon Medical Systems Corporation", "label": "Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member]", "documentation": "Canon Medical Systems Corporation (Formerly Toshiba Medical Systems) [Member]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashandCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashandCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r43", "r214", "r821" ] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents, Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r44", "r186" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashandCashEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashandCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period", "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period", "totalLabel": "Total as presented in the Condensed Consolidated Statements of Cash Flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r43", "r160", "r253" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r160" ] }, "var_CashPaidForOperatingAndFinanceLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "CashPaidForOperatingAndFinanceLeases", "crdr": "credit", "calculation": { "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash paid for amounts included in the measurement of lease liabilities", "label": "Cash Paid For Operating And Finance Leases", "documentation": "Cash Paid For Operating And Finance Leases" } } }, "auth_ref": [] }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ChangeInContractWithCustomerLiabilityAbstract", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refund Liabilities", "label": "Change in Contract with Customer, Liability [Abstract]" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r918" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise price (in USD per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r438" ] }, "var_ClassOfWarrantOrRightPercentIncreaseOfStrikePriceOverSalePrice": { "xbrltype": "percentItemType", "nsuri": "http://www.varex.com/20231229", "localname": "ClassOfWarrantOrRightPercentIncreaseOfStrikePriceOverSalePrice", "presentation": [ "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percent increase of strike price over sale price", "label": "Class Of Warrant Or Right, Percent Increase Of Strike Price Over Sale Price", "documentation": "Class Of Warrant Or Right, Percent Increase Of Strike Price Over Sale Price" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r919" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r919" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails", "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r171", "r870", "r871", "r872", "r873" ] }, "var_CommercialPaperReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "CommercialPaperReceivable", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper Receivable", "documentation": "Commercial Paper Receivable" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r69", "r807" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r866", "r867", "r868", "r870", "r871", "r872", "r873", "r983", "r984", "r1029", "r1053", "r1057" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value per share (in USD per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r136" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r136", "r726" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r136" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, outstanding (in shares)", "periodStartLabel": "Common stock, shares, outstanding, beginning balance (in shares)", "periodEndLabel": "Common stock, shares, outstanding, ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r12", "r136", "r726", "r744", "r1057", "r1058" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $.01 par value: 150,000,000 shares authorized Shares issued and outstanding: 40,618,590 and 40,529,573 at December\u00a029, 2023 and September\u00a029, 2023, respectively", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": [ "r136", "r726" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r924" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r923" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r925" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r922" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive (loss) income attributable to Varex", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r38", "r233", "r235", "r241", "r650", "r664" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive (loss) income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r99", "r182", "r233", "r235", "r240", "r649", "r663" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r51", "r53", "r120", "r121", "r336", "r806" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r51", "r53", "r120", "r121", "r336", "r692", "r806" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r51", "r53", "r120", "r121", "r336", "r806", "r961" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r130", "r199" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r806" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (as a percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r51", "r53", "r120", "r121", "r336" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r50", "r51", "r53", "r54", "r120", "r185", "r806" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r51", "r53", "r120", "r121", "r336", "r806" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r95", "r829" ] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Right of Return Assets and Refund Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r1020" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r440", "r441", "r460" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with customer, liability, revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r461" ] }, "us-gaap_ContractWithCustomerRefundLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerRefundLiability", "crdr": "credit", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Contract with Customer, Refund Liability", "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer." } } }, "auth_ref": [ "r1022" ] }, "var_ContractWithCustomerRefundLiabilityAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "ContractWithCustomerRefundLiabilityAdditions", "crdr": "credit", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additions to refund liabilities", "label": "Contract With Customer, Refund Liability, Additions", "documentation": "Contract With Customer, Refund Liability, Additions" } } }, "auth_ref": [] }, "var_ContractWithCustomerRefundLiabilityAmountReleased": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "ContractWithCustomerRefundLiabilityAmountReleased", "crdr": "debit", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Release of refund liability included in beginning of year refund liability", "label": "Contract With Customer, Refund Liability, Amount Released", "documentation": "Contract With Customer, Refund Liability, Amount Released" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerRightToRecoverProduct": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerRightToRecoverProduct", "crdr": "debit", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning of period", "periodEndLabel": "Balance at end of period", "label": "Contract with Customer, Right to Recover Product", "documentation": "Amount of right to recover product from customer on settling refund liability." } } }, "auth_ref": [ "r1022" ] }, "us-gaap_ContractWithCustomerRightToRecoverProductAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerRightToRecoverProductAbstract", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of Return Assets", "label": "Contract with Customer, Right to Recover Product [Abstract]" } } }, "auth_ref": [] }, "var_ContractWithCustomerRightToRecoverProductCostsRecovered": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "ContractWithCustomerRightToRecoverProductCostsRecovered", "crdr": "debit", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Costs recovered from product returns during the period", "label": "Contract With Customer, Right To Recover, Product Costs Recovered", "documentation": "Contract With Customer, Right To Recover, Product Costs Recovered" } } }, "auth_ref": [] }, "var_ContractWithCustomerRightToRecoverProductRightOfReturnAssetFromShipments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "ContractWithCustomerRightToRecoverProductRightOfReturnAssetFromShipments", "crdr": "debit", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofRightofReturnAssetsandRefundLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of return assets from shipments of products subject to return during the period", "label": "Contract With Customer, Right To Recover Product, Right Of Return Asset From Shipments", "documentation": "Contract With Customer, Right To Recover Product, Right Of Return Asset From Shipments" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r172", "r408", "r409", "r419", "r420", "r421", "r425", "r426", "r427", "r428", "r429", "r840", "r841", "r842", "r843", "r844" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes", "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r1023" ] }, "var_ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "ConvertibleNotesMember", "presentation": [ "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes", "label": "Convertible Notes [Member]", "documentation": "Convertible Notes" } } }, "auth_ref": [] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails", "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate notes/bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "var_CorporateBonds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "CorporateBonds", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate notes/bonds", "label": "Corporate Bonds", "documentation": "Corporate Bonds" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenues", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r154", "r633" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenues", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r257", "r258", "r411", "r437", "r625", "r826", "r828" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CrossCurrencyInterestRateContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CrossCurrencyInterestRateContractMember", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cross currency swap contracts", "label": "Cross Currency Interest Rate Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates." } } }, "auth_ref": [ "r1023", "r1028" ] }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]" } } }, "auth_ref": [ "r207", "r263", "r269", "r275", "r351", "r357", "r509", "r510", "r511", "r521", "r522", "r551", "r552", "r553", "r555", "r556", "r557", "r562", "r565", "r567", "r568", "r617" ] }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption [Axis]", "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "auth_ref": [ "r207", "r263", "r269", "r275", "r351", "r357", "r509", "r510", "r511", "r521", "r522", "r551", "r552", "r553", "r555", "r556", "r557", "r562", "r565", "r567", "r568", "r617" ] }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption [Domain]", "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "auth_ref": [ "r207", "r263", "r269", "r275", "r351", "r357", "r509", "r510", "r511", "r521", "r522", "r551", "r552", "r553", "r555", "r556", "r557", "r562", "r565", "r567", "r568", "r617" ] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [ "r1032" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer concentration risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r52", "r336" ] }, "var_CustomerContractsandSupplierRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "CustomerContractsandSupplierRelationshipsMember", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer contracts and supplier relationship", "label": "Customer Contracts and Supplier Relationships [Member]", "documentation": "Customer Contracts and Supplier Relationships [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.varex.com/role/BORROWINGS" ], "lang": { "en-us": { "role": { "terseLabel": "BORROWINGS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r170", "r254", "r407", "r413", "r414", "r415", "r416", "r417", "r418", "r423", "r430", "r431", "r433" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r23", "r132", "r133", "r188", "r189", "r259", "r408", "r409", "r410", "r411", "r412", "r414", "r419", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r601", "r840", "r841", "r842", "r843", "r844", "r981" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price (in USD per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r173", "r410" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion ratio", "label": "Debt Instrument, Convertible, Conversion Ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r31", "r71", "r175", "r176", "r410" ] }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "presentation": [ "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of equity instruments for convertible debt (in shares)", "label": "Debt Instrument, Convertible, Number of Equity Instruments", "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity." } } }, "auth_ref": [ "r31", "r71", "r175", "r176", "r410" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r123", "r125", "r408", "r601", "r841", "r842" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Interest Rate (as a percent)", "verboseLabel": "Contractual interest rate (as a percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r30", "r409" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r259", "r408", "r409", "r410", "r411", "r412", "r414", "r419", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r601", "r840", "r841", "r842", "r843", "r844", "r981" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r32", "r259", "r408", "r409", "r410", "r411", "r412", "r414", "r419", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r601", "r840", "r841", "r842", "r843", "r844", "r981" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r32", "r71", "r72", "r122", "r123", "r125", "r129", "r174", "r176", "r259", "r408", "r409", "r410", "r411", "r412", "r414", "r419", "r420", "r421", "r422", "r424", "r425", "r426", "r427", "r428", "r429", "r432", "r601", "r840", "r841", "r842", "r843", "r844", "r981" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "calculation": { "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r124", "r419", "r434", "r841", "r842" ] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNetAbstract", "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized issuance costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net [Abstract]" } } }, "auth_ref": [] }, "var_DebtRedeemedFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "DebtRedeemedFaceAmount", "crdr": "debit", "presentation": [ "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt redeemed", "label": "Debt Redeemed, Face Amount", "documentation": "Debt Redeemed, Face Amount" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationPlanAssets", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred compensation plan", "label": "Deferred Compensation Plan Assets", "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } }, "auth_ref": [ "r966" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails": { "parentTag": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r124", "r1019" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r515", "r516" ] }, "var_DeferredIncomeTaxExpenseBenefitCashImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "DeferredIncomeTaxExpenseBenefitCashImpact", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred taxes", "label": "Deferred Income Tax Expense (Benefit), Cash Impact", "documentation": "Deferred Income Tax Expense (Benefit), Cash Impact" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "crdr": "credit", "presentation": [ "http://www.varex.com/role/TAXESONLOSSINCOMEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities of undistributed foreign earnings", "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences." } } }, "auth_ref": [ "r1025" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r68" ] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r542" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r227", "r228", "r582", "r706", "r707", "r708", "r710", "r711", "r713", "r714", "r715", "r717", "r718", "r732", "r733", "r786", "r791", "r792", "r793", "r794", "r795", "r828", "r868", "r1054" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r715", "r718", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r757", "r758", "r759", "r760", "r763", "r764", "r765", "r766", "r786", "r788", "r792", "r794", "r866", "r868" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets fair value, gross", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r19", "r109", "r145", "r226", "r828" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Derivative liabilities fair value, gross", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r19", "r109", "r145", "r226", "r828" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r107", "r110", "r112", "r114", "r715", "r718", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r757", "r758", "r759", "r760", "r763", "r764", "r765", "r766", "r786", "r788", "r792", "r794", "r828", "r866", "r868" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIES" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCIAL DERIVATIVES AND HEDGING ACTIVITIES", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r184", "r546", "r558" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r13", "r107", "r112" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liabilities", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r227", "r228", "r582", "r706", "r707", "r708", "r710", "r713", "r714", "r715", "r717", "r718", "r739", "r741", "r742", "r788", "r789", "r791", "r792", "r793", "r794", "r795", "r828", "r1054" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r542" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r558" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional Value", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1026", "r1027" ] }, "us-gaap_DerivativeNumberOfInstrumentsHeld": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNumberOfInstrumentsHeld", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Instruments", "label": "Derivative, Number of Instruments Held", "documentation": "The number of derivative instruments of a particular group held by the entity." } } }, "auth_ref": [ "r102", "r103", "r717", "r786", "r787", "r790", "r868" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r13", "r100", "r101", "r103", "r105", "r108", "r112", "r115", "r116", "r118", "r558" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "verboseLabel": "Derivatives Designated as Net Investment Hedges", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r13" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired existing technology", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r180" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r459", "r846", "r847", "r848", "r849", "r850", "r851", "r852" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r459", "r846", "r847", "r848", "r849", "r850", "r851", "r852" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue by Geographic Location", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1021" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "EMPLOYEE STOCK PLANS", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r473", "r478", "r506", "r507", "r508", "r859" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r880" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r913" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "var_DpiXHoldingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "DpiXHoldingMember", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "dpiX Holding", "label": "dpiX Holding [Member]", "documentation": "dpiX Holding [Member]" } } }, "auth_ref": [] }, "var_DpiXLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "DpiXLLCMember", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dpi X LLC", "label": "Dpi X LLC [Member]", "documentation": "Dpi X LLC" } } }, "auth_ref": [] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EMEAMember", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "EMEA", "label": "EMEA [Member]", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": [ "r1059", "r1060", "r1061", "r1062" ] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "EUR", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per common share attributable to Varex", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in USD per share)", "terseLabel": "Basic net (loss) income per share attributable to Varex (in USD per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r242", "r267", "r268", "r269", "r270", "r271", "r277", "r279", "r289", "r290", "r291", "r295", "r568", "r569", "r651", "r665", "r831" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per share - basic", "label": "Earnings Per Share, Basic [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in USD per share)", "terseLabel": "Diluted net (loss) income per share attributable to Varex (in USD per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r242", "r267", "r268", "r269", "r270", "r271", "r279", "r289", "r290", "r291", "r295", "r568", "r569", "r651", "r665", "r831" ] }, "us-gaap_EarningsPerShareDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDilutedAbstract", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income per share - diluted", "label": "Earnings Per Share, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "NET (LOSS) INCOME PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r276", "r292", "r293", "r294" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r878" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r878" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r878" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r952" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r878" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r878" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Smaller Reporting Company", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r878" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r878" ] }, "us-gaap_EnvironmentalCostsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EnvironmentalCostsPolicy", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Environmental Obligations", "label": "Environmental Costs, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for obligations that resulted from improper or other-than normal operation of a long-lived asset in the past. This accounting policy may address (1) whether the related remediation costs are expensed or capitalized, (2) whether the obligation is measured on a discounted basis, (3) the event, situation, or set of circumstances that generally triggers recognition of loss contingencies arising from the entity's environmental remediation-related obligations, and (4) the timing of recognition of any recoveries." } } }, "auth_ref": [ "r387", "r388", "r396", "r838", "r955" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r12", "r207", "r236", "r237", "r238", "r260", "r261", "r262", "r265", "r272", "r274", "r296", "r351", "r357", "r439", "r509", "r510", "r511", "r521", "r522", "r551", "r552", "r553", "r554", "r555", "r557", "r567", "r590", "r591", "r592", "r593", "r594", "r596", "r619", "r682", "r683", "r684", "r704", "r769" ] }, "us-gaap_EquityMethodInvesteeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvesteeMember", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investee", "label": "Equity Method Investee [Member]", "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor." } } }, "auth_ref": [ "r637", "r639", "r641", "r643", "r645", "r647", "r1034", "r1035" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r344", "r345", "r346" ] }, "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment", "crdr": "debit", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment, amount written off", "label": "Equity Method Investment, Other than Temporary Impairment", "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment." } } }, "auth_ref": [ "r992" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest (as a percent)", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r344" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r311", "r343", "r965", "r993" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable equity securities", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r219", "r581", "r823" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r921" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r885", "r896", "r906", "r931" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r882", "r893", "r903", "r928" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r927" ] }, "var_ExercisePriceRangeRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.varex.com/20231229", "localname": "ExercisePriceRangeRollForward", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price Range", "label": "Exercise Price Range [Roll Forward]", "documentation": "Exercise Price Range [Rollforward]" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.varex.com/role/FAIRVALUENarrativeDetails", "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r572", "r573", "r577" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.varex.com/role/FAIRVALUENarrativeDetails", "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r572", "r573", "r577" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.varex.com/role/FAIRVALUENarrativeDetails", "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r421", "r464", "r465", "r466", "r467", "r468", "r469", "r573", "r627", "r628", "r629", "r841", "r842", "r853", "r854", "r855" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r572", "r573", "r574", "r575", "r578" ] }, "us-gaap_FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureAssetAndLiabilityNotMeasuredAtFairValueLineItems", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value", "label": "Fair Value Disclosure, Asset and Liability, Not Measured at Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r576" ] }, "us-gaap_FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosureOfAssetAndLiabilityNotMeasuredAtFairValueTable", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "label": "Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table]", "documentation": "Disclosure of information about fair value of asset and liability not measured at fair value." } } }, "auth_ref": [ "r576" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.varex.com/role/FAIRVALUE" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r571" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.varex.com/role/FAIRVALUENarrativeDetails", "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Level 1", "terseLabel": "Quoted Prices in Active Markets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r421", "r464", "r469", "r573", "r627", "r853", "r854", "r855" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r421", "r464", "r469", "r573", "r628", "r841", "r842", "r853", "r854", "r855" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r421", "r464", "r465", "r466", "r467", "r468", "r469", "r573", "r629", "r841", "r842", "r853", "r854", "r855" ] }, "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareLineItems", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share", "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareTable", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]", "label": "Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Table]", "documentation": "Disclosure of information about investments in certain entities that calculate net asset value per share or equivalent measured at fair value on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r20" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.varex.com/role/FAIRVALUENarrativeDetails", "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r421", "r464", "r465", "r466", "r467", "r468", "r469", "r627", "r628", "r629", "r841", "r842", "r853", "r854", "r855" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r571", "r578" ] }, "us-gaap_FairValueOfAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfAssetsAcquired", "crdr": "debit", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases of property, plant, and equipment financed through accounts payable", "label": "Fair Value of Assets Acquired", "documentation": "The fair value of assets acquired in noncash investing or financing activities." } } }, "auth_ref": [ "r46", "r47", "r48" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities (current)", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r607" ] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": [ "r608" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease liabilities (non-current)", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r607" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability." } } }, "auth_ref": [ "r608" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails": { "parentTag": "var_CashPaidForOperatingAndFinanceLeases", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing cash flows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r609", "r613" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r606" ] }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset." } } }, "auth_ref": [ "r608" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r216", "r377" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r375", "r376", "r377", "r378", "r634", "r635" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r169", "r635" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r634" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r64", "r66" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r169", "r634" ] }, "us-gaap_FiscalPeriod": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiscalPeriod", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal Year", "label": "Fiscal Period, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed." } } }, "auth_ref": [ "r92" ] }, "var_FixedCostCommitmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "FixedCostCommitmentsMember", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fixed Cost Commitments", "label": "Fixed Cost Commitments [Member]", "documentation": "Fixed Cost Commitments [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeContractMember", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Exchange Contract", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": [ "r828", "r853", "r862" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r889", "r900", "r910", "r935" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r889", "r900", "r910", "r935" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r889", "r900", "r910", "r935" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r889", "r900", "r910", "r935" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r889", "r900", "r910", "r935" ] }, "us-gaap_GainLossOnInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestmentsTextBlock", "presentation": [ "http://www.varex.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gains and (Losses) on Marketable Securities", "label": "Gain (Loss) on Securities [Table Text Block]", "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security." } } }, "auth_ref": [ "r974", "r975" ] }, "var_GainLossOnSettlementOfHedgeInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "GainLossOnSettlementOfHedgeInvestingActivities", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on settlement of cash flow hedge", "label": "Gain (Loss) On Settlement Of Hedge, Investing Activities", "documentation": "Gain (Loss) On Settlement Of Hedge, Investing Activities" } } }, "auth_ref": [] }, "var_GainOnPurchaseOfBusinessIncludingRemeasurmentGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "GainOnPurchaseOfBusinessIncludingRemeasurmentGainLoss", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on purchase of business", "label": "Gain on Purchase Of Business Including Remeasurment Gain (Loss)", "documentation": "Gain on Purchase Of Business Including Remeasurment Gain (Loss)" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Balance at September 29, 2023", "periodEndLabel": "Balance at December 29, 2023", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r215", "r363", "r648", "r836", "r864", "r997", "r1004" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r168" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r370" ] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r836" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "terseLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r152", "r255", "r301", "r321", "r327", "r330", "r347", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r583", "r833", "r1016" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r13", "r545" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r13" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r13" ] }, "currency_INR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "INR", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indian Rupee", "label": "India, Rupees" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails", "http://www.varex.com/role/TAXESONLOSSINCOMEDetails" ], "lang": { "en-us": { "role": { "totalLabel": "(Loss) income before taxes", "terseLabel": "(Loss) income before taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r147", "r193", "r301", "r321", "r327", "r330", "r652", "r659", "r833" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Income (loss) from equity investments", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r8", "r148", "r192", "r308", "r343", "r658" ] }, "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income from equity method investments", "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions", "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSSharebasedCompensationExpenseDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r379", "r389", "r753" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSSharebasedCompensationExpenseDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r389", "r753" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.varex.com/role/TAXESONLOSSINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "TAXES ON (LOSS) INCOME", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r256", "r514", "r518", "r519", "r520", "r523", "r525", "r526", "r527", "r698" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails", "http://www.varex.com/role/TAXESONLOSSINCOMEDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax (benefit) expense", "verboseLabel": "Income tax (benefit) expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r196", "r203", "r273", "r274", "r309", "r517", "r524", "r667" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid, net of (refunds)", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r45" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities and other current and long-term liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenues", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r632", "r978" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dilutive effect of share-based awards and other (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r280", "r281", "r282", "r291", "r477" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r892", "r900", "r910", "r927", "r935", "r939", "r947" ] }, "var_IndustrialMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "IndustrialMember", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Industrial", "label": "Industrial [Member]", "documentation": "Industrial [Member]" } } }, "auth_ref": [] }, "var_IndustrialSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "IndustrialSegmentMember", "presentation": [ "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Industrial", "label": "Industrial Segment [Member]", "documentation": "Industrial [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r945" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r881", "r951" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r881", "r951" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r881", "r951" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r62", "r65" ] }, "us-gaap_IntellectualPropertyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntellectualPropertyMember", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patents, licenses and other", "label": "Intellectual Property [Member]", "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights." } } }, "auth_ref": [ "r22" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 }, "http://www.varex.com/role/BORROWINGSScheduleofInterestExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofInterestExpenseDetails", "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "totalLabel": "Total interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r124", "r195", "r239", "r305", "r599", "r754", "r874", "r1056" ] }, "var_InterestExpenseDebtContractualInterestCoupon": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "InterestExpenseDebtContractualInterestCoupon", "crdr": "debit", "calculation": { "http://www.varex.com/role/BORROWINGSScheduleofInterestExpenseDetails": { "parentTag": "us-gaap_InterestExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofInterestExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual interest coupon and other", "label": "Interest Expense, Debt, Contractual Interest Coupon", "documentation": "Interest Expense, Debt, Contractual Interest Coupon" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseMember", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Expense", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r18" ] }, "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock", "presentation": [ "http://www.varex.com/role/BORROWINGSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Interest Expense", "label": "Interest Income and Interest Expense Disclosure [Table Text Block]", "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r247", "r250", "r252" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.varex.com/role/INVENTORIES" ], "lang": { "en-us": { "role": { "terseLabel": "INVENTORIES", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r361" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.varex.com/role/INVENTORIESScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/INVENTORIESScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r167", "r824" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.varex.com/role/INVENTORIESScheduleofInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/INVENTORIESScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r224", "r822", "r864" ] }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "crdr": "debit", "calculation": { "http://www.varex.com/role/INVENTORIESScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/INVENTORIESScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials and parts", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments." } } }, "auth_ref": [ "r167", "r969" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.varex.com/role/INVENTORIESScheduleofInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/INVENTORIESScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r167", "r825" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory write-down", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r362" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r156", "r304" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments and Marketable Securities", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r666", "r693", "r694", "r695", "r696", "r778", "r779" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails", "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment Type [Axis]", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r707", "r709", "r710", "r713", "r716", "r775", "r777", "r781", "r784", "r785", "r796", "r797", "r799", "r800", "r801", "r802", "r803", "r868" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails", "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments [Domain]", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r707", "r709", "r710", "r713", "r716", "r775", "r777", "r781", "r784", "r785", "r796", "r797", "r799", "r800", "r801", "r802", "r803", "r868" ] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury bills", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": [ "r572" ] }, "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in privately-held companies", "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures", "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate." } } }, "auth_ref": [ "r967" ] }, "var_JointVentureInSaudiArabiaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "JointVentureInSaudiArabiaMember", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joint Venture In Saudi Arabia", "label": "Joint Venture In Saudi Arabia [Member]", "documentation": "Joint Venture In Saudi Arabia [Member]" } } }, "auth_ref": [] }, "var_KimberleyHoneysettMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "KimberleyHoneysettMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Kimberley Honeysett [Member]", "documentation": "Kimberley Honeysett" } } }, "auth_ref": [] }, "var_LeaseCostFinanceLeaseCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "LeaseCostFinanceLeaseCosts", "crdr": "debit", "presentation": [ "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total finance lease costs", "label": "Lease, Cost, Finance Lease Costs", "documentation": "Lease, Cost, Finance Lease Costs" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.varex.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Lease Cost and Supplemental Cash Flow Information", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1033" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.varex.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r605" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r611" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.varex.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r605" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r27", "r255", "r347", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r537", "r540", "r541", "r583", "r725", "r832", "r876", "r1016", "r1037", "r1038" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails", "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Liabilities", "terseLabel": "Liabilities:", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r141", "r191", "r657", "r864", "r982", "r994", "r1031" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and stockholders' equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r29", "r213", "r255", "r347", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r537", "r540", "r541", "r583", "r864", "r1016", "r1037", "r1038" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities measured at fair value", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r119" ] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Used capacity, commitment fee percentage", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r26" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r26" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt outstanding, net", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r23", "r189", "r420", "r435", "r841", "r842", "r1048" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 }, "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r220" ] }, "us-gaap_LongTermDebtCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrentAbstract", "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of long-term debt", "label": "Long-Term Debt, Current Maturities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.varex.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r221" ] }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective Interest Rate (as a percent)", "label": "Long-Term Debt, Weighted Average Interest Rate, over Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time." } } }, "auth_ref": [] }, "var_LongtermDebtExcludingCurrentMaturitiesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "LongtermDebtExcludingCurrentMaturitiesGross", "crdr": "credit", "calculation": { "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total non-current maturities of long-term debt:", "verboseLabel": "Long-term debt excluding current maturities, gross", "label": "Long-term Debt Excluding Current Maturities, Gross", "documentation": "Long-term Debt Excluding Current Maturities, Gross" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails", "http://www.varex.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r32" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails", "http://www.varex.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r32", "r70" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r336", "r848", "r1021", "r1051", "r1052" ] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails": { "parentTag": "var_MarketableSecuritiesAmortizedCost", "weight": 1.0, "order": 1.0 }, "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails", "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails", "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total marketable debt securities", "totalLabel": "Total marketable debt securities", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r128", "r968" ] }, "var_MarketableSecuritiesAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "MarketableSecuritiesAmortizedCost", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails", "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total marketable debt securities", "label": "Marketable Securities, Amortized Cost", "documentation": "Marketable Securities, Amortized Cost" } } }, "auth_ref": [] }, "var_MarketableSecuritiesMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "MarketableSecuritiesMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughFive", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails": { "parentTag": "us-gaap_MarketableSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Marketable Securities, Maturity, Allocated and Single Maturity Date, After Year One Through Five", "documentation": "Marketable Securities, Maturity, Allocated and Single Maturity Date, After Year One Through Five" } } }, "auth_ref": [] }, "var_MarketableSecuritiesMaturityAllocatedAndSingleMaturityDateRollingAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "MarketableSecuritiesMaturityAllocatedAndSingleMaturityDateRollingAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails": { "parentTag": "var_MarketableSecuritiesAmortizedCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Marketable Securities, Maturity, Allocated and Single Maturity Date, Rolling After One Through Five Years, Amortized Cost", "documentation": "Marketable Securities, Maturity, Allocated and Single Maturity Date, Rolling After One Through Five Years, Amortized Cost" } } }, "auth_ref": [] }, "var_MarketableSecuritiesMaturityAllocatedAndSingleMaturityDateRollingWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "MarketableSecuritiesMaturityAllocatedAndSingleMaturityDateRollingWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails": { "parentTag": "var_MarketableSecuritiesAmortizedCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due within one year", "label": "Marketable Securities, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Amortized Cost", "documentation": "Marketable Securities, Maturity, Allocated and Single Maturity Date, Rolling Within One Year, Amortized Cost" } } }, "auth_ref": [] }, "var_MarketableSecuritiesMaturityAllocatedAndSingleMaturityDateYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "MarketableSecuritiesMaturityAllocatedAndSingleMaturityDateYearOne", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails": { "parentTag": "us-gaap_MarketableSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofContractualMaturitiesofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due within one year", "label": "Marketable Securities, Maturity, Allocated And Single Maturity Date, Year One", "documentation": "Marketable Securities, Maturity, Allocated And Single Maturity Date, Year One" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.varex.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Marketable Securities", "label": "Marketable Securities [Table Text Block]", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesUnrealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities credit loss", "label": "Marketable Security, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in marketable security." } } }, "auth_ref": [ "r150" ] }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MaturitiesOfLongTermDebtAbstract", "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current maturities of long-term debt:", "label": "Maturities of Long-Term Debt [Abstract]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails", "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r392", "r393", "r395", "r396", "r471", "r631", "r679", "r717", "r718", "r776", "r780", "r782", "r783", "r798", "r817", "r818", "r835", "r845", "r858", "r865", "r1018", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044" ] }, "var_MeVisBreastcareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "MeVisBreastcareMember", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MeVis Breastcare", "label": "MeVis Breastcare [Member]", "documentation": "MeVis Breastcare" } } }, "auth_ref": [] }, "var_MeVisMedicalSolutionsAGMeVisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "MeVisMedicalSolutionsAGMeVisMember", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MeVis Medical Solutions AG (MeVis)", "label": "MeVis Medical Solutions AG (MeVis) [Member]", "documentation": "MeVis Medical Solutions AG (MeVis) [Member]" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r919" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r919" ] }, "var_MedicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "MedicalMember", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical", "label": "Medical [Member]", "documentation": "Medical [Member]" } } }, "auth_ref": [] }, "var_MedicalSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "MedicalSegmentMember", "presentation": [ "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical", "label": "Medical Segment [Member]", "documentation": "Medical [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails", "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r392", "r393", "r395", "r396", "r471", "r631", "r679", "r717", "r718", "r776", "r780", "r782", "r783", "r798", "r817", "r818", "r835", "r845", "r858", "r865", "r1018", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/NONCONTROLLINGINTERESTSScheduleofNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Noncontrolling interests", "periodStartLabel": "Noncontrolling interests, at beginning of period", "periodEndLabel": "Noncontrolling interests, at end of period", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r35", "r190", "r255", "r347", "r398", "r400", "r401", "r402", "r405", "r406", "r583", "r656", "r728" ] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTS" ], "lang": { "en-us": { "role": { "terseLabel": "NONCONTROLLING INTERESTS", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r181" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestLineItems", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest, ownership percentage by noncontrolling owners (as a percent)", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Majority voting rights (as a percent)", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestTable", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r35", "r94", "r96", "r153" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r938" ] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_MovementInMinorityInterestRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInMinorityInterestRollForward", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSScheduleofNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest", "label": "Equity, Attributable to Noncontrolling Interest [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_MovementInStandardProductWarrantyAccrualRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInStandardProductWarrantyAccrualRollForward", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Movement in Standard Product Warranty Accrual", "label": "Movement in Standard Product Warranty Accrual [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r946" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r336", "r848", "r1021", "r1051", "r1052" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r920" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r249" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r249" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r160", "r161", "r162" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income attributable to Varex", "terseLabel": "Net (loss) income attributable to Varex - basic", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r149", "r162", "r194", "r211", "r232", "r234", "r238", "r255", "r264", "r267", "r268", "r269", "r270", "r273", "r274", "r287", "r301", "r321", "r327", "r330", "r347", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r569", "r583", "r662", "r746", "r767", "r768", "r833", "r874", "r1016" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited", "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/NONCONTROLLINGINTERESTSScheduleofNoncontrollingInterestDetails", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Less: Net income attributable to noncontrolling interests", "terseLabel": "Less: Comprehensive income attributable to noncontrolling interests", "netLabel": "Net income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r98", "r183", "r232", "r234", "r273", "r274", "r661", "r973" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net (loss) income attributable to Varex - diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r243", "r278", "r283", "r284", "r285", "r286", "r288", "r291" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativeInstrumentsDetails", "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r104" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Standards or Updates Not Yet Effective", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r919" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r889", "r900", "r910", "r927", "r935" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r917" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r916" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r927" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r946" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r946" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental non-cash activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Abstract]", "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "crdr": "credit", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.varex.com/role/NONCONTROLLINGINTERESTSScheduleofNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisitions", "label": "Noncontrolling Interest, Increase from Business Combination", "documentation": "Amount of increase in noncontrolling interest from a business combination." } } }, "auth_ref": [ "r10", "r73", "r85" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r93", "r439", "r983", "r984", "r985", "r1057" ] }, "var_NoncontrollingInterestOtherChanges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "NoncontrollingInterestOtherChanges", "crdr": "credit", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSScheduleofNoncontrollingInterestDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Noncontrolling Interest, Other Changes", "documentation": "Noncontrolling Interest, Other Changes" } } }, "auth_ref": [] }, "var_NoncontrollingInterestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.varex.com/20231229", "localname": "NoncontrollingInterestTableTextBlock", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Noncontrolling Interest", "label": "Noncontrolling Interest [Table Text Block]", "documentation": "Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Interest and other expense, net", "terseLabel": "Interest and other expense, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r157" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.varex.com/role/SEGMENTINFORMATIONNarrativeDetails", "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r989" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r301", "r321", "r327", "r330", "r833" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r612", "r863" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current operating lease liabilities", "verboseLabel": "Operating lease liabilities (current)", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r607" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "verboseLabel": "Operating lease liabilities (non-current)", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r607" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "calculation": { "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails": { "parentTag": "var_CashPaidForOperatingAndFinanceLeases", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r610", "r613" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/LEASESScheduleofLeaseRightofUseAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease assets", "verboseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r606" ] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "netLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r163", "r164", "r165", "r181" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r217" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax", "crdr": "debit", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency translation adjustments", "label": "OCI, Foreign Currency Transaction and Translation Gain (Loss), Arising During Period, Tax", "documentation": "Amount of tax expense (benefit), before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5", "r6", "r588", "r589", "r595" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Amount of Loss Recognized in OCI on Derivative", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r229", "r230", "r543", "r544", "r547" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofIncomeRecognizedFromDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of Gain Recognized in Income on Derivative (Amount Excluded from Effectiveness Testing)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r202", "r230", "r231" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [ "r106", "r117" ] }, "us-gaap_OtherDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherDebtSecuritiesMember", "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other debt", "label": "Other Debt Obligations [Member]", "documentation": "Investments in debt securities classified as other." } } }, "auth_ref": [ "r995", "r1023", "r1030" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r33" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r162" ] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofDerivativesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense), net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r158" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r919" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r887", "r898", "r908", "r933" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r890", "r901", "r911", "r936" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r890", "r901", "r911", "r936" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ParentMember", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Total Varex Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r915" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r958", "r976" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Taxes related to net share settlement of equity awards", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r246" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of marketable debt securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r39", "r244", "r342" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Purchase price", "terseLabel": "Cash", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r40", "r533" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions of businesses, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r40" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of marketable equity securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r991" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property, plant, and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r159" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r918" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r918" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r917" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r927" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r920" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r916" ] }, "var_PercentageOfAdditionalOutstandingSharesPurchased": { "xbrltype": "percentItemType", "nsuri": "http://www.varex.com/20231229", "localname": "PercentageOfAdditionalOutstandingSharesPurchased", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of additional outstanding shares purchased (as a percent)", "label": "Percentage Of Additional Outstanding Shares Purchased", "documentation": "Percentage Of Additional Outstanding Shares Purchased" } } }, "auth_ref": [] }, "var_PercentageOfFixedCosts": { "xbrltype": "percentItemType", "nsuri": "http://www.varex.com/20231229", "localname": "PercentageOfFixedCosts", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fixed costs", "label": "Percentage Of Fixed Costs", "documentation": "The percentage of fixed costs as defined in the agreement and determined at the beginning of each calendar year that the entity is required to pay." } } }, "auth_ref": [] }, "var_PercentageOfLiabilitiesObligatedToReimburse": { "xbrltype": "percentItemType", "nsuri": "http://www.varex.com/20231229", "localname": "PercentageOfLiabilitiesObligatedToReimburse", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESEnvironmentalObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of liabilities obligated to reimburse", "label": "Percentage of Liabilities Obligated To Reimburse", "documentation": "Percentage of Liabilities Obligated To Reimburse" } } }, "auth_ref": [] }, "var_PercentageOfManufacturingCapacity": { "xbrltype": "percentItemType", "nsuri": "http://www.varex.com/20231229", "localname": "PercentageOfManufacturingCapacity", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of manufacturing capacity", "label": "Percentage Of Manufacturing Capacity", "documentation": "The percentage of manufacturing capacity that the entity has the guaranteed right to purchase up to." } } }, "auth_ref": [] }, "us-gaap_PositionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PositionAxis", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Position [Axis]", "label": "Position [Axis]", "documentation": "Information by position taken for a security." } } }, "auth_ref": [] }, "us-gaap_PositionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PositionDomain", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Position [Domain]", "label": "Position [Domain]", "documentation": "Indicates position taken for a security." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in USD per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r135", "r436" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r135", "r726" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r135", "r436" ] }, "us-gaap_PreferredStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $.01 par value: 20,000,000 shares authorized, none issued", "label": "Preferred Stock, Value, Outstanding", "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders." } } }, "auth_ref": [ "r135", "r726" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r970" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings under credit agreements", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ProceedsFromHedgeInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromHedgeInvestingActivities", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement of net investment hedge", "label": "Proceeds from Hedge, Investing Activities", "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation." } } }, "auth_ref": [ "r251", "r958" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r959", "r977" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities of marketable debt securities", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r244", "r245", "r991" ] }, "us-gaap_ProductWarrantyLiabilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyLiabilityLineItems", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Warranty Liability", "label": "Product Warranty Liability [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ProductWarrantyLiabilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyLiabilityTable", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Warranty Liability [Table]", "label": "Product Warranty Liability [Table]", "documentation": "Disclosure of information about product warranty liability, including, but not limited to, reductions in the liability for payments made under the warranty, changes in the liability for accruals related to product warranties issued, and changes in the liability for accruals related to preexisting warranties." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSSINCOMEUnaudited", "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net (loss) income", "terseLabel": "Net (loss) income", "verboseLabel": "Net (loss) income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r211", "r232", "r234", "r248", "r255", "r264", "r273", "r274", "r301", "r321", "r327", "r330", "r347", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r535", "r538", "r539", "r569", "r583", "r652", "r660", "r703", "r746", "r767", "r768", "r833", "r860", "r861", "r875", "r973", "r1016" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant, and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r962", "r1007" ] }, "var_PurchasesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "PurchasesMember", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases", "label": "Purchases [Member]", "documentation": "Purchases" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r915" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r915" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails", "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r392", "r393", "r395", "r396", "r463", "r471", "r501", "r502", "r503", "r630", "r631", "r679", "r717", "r718", "r776", "r780", "r782", "r783", "r798", "r817", "r818", "r835", "r845", "r858", "r865", "r868", "r1008", "r1018", "r1040", "r1041", "r1042", "r1043", "r1044" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "http://www.varex.com/role/BORROWINGSCallSpreadNarrativeDetails", "http://www.varex.com/role/BORROWINGSConvertibleSeniorUnsecuredNotesNarrativeDetails", "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails", "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r392", "r393", "r395", "r396", "r463", "r471", "r501", "r502", "r503", "r630", "r631", "r679", "r717", "r718", "r776", "r780", "r782", "r783", "r798", "r817", "r818", "r835", "r845", "r858", "r865", "r868", "r1008", "r1018", "r1040", "r1041", "r1042", "r1043", "r1044" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r882", "r893", "r903", "r928" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r470", "r623", "r624", "r720", "r721", "r722", "r723", "r724", "r743", "r745", "r774" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction, amounts of transaction", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r127", "r623" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r623", "r624", "r1036" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "var_RelatedPartyTransactionExpectedFixedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "RelatedPartyTransactionExpectedFixedCost", "crdr": "debit", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related party transaction expected fixed cost", "label": "Related Party Transaction Expected Fixed Cost", "documentation": "Related Party Transaction Expected Fixed Cost" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r749", "r750", "r753" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r470", "r623", "r624", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r720", "r721", "r722", "r723", "r724", "r743", "r745", "r774", "r1036" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED-PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r620", "r621", "r622", "r624", "r626", "r699", "r700", "r701", "r751", "r752", "r753", "r772", "r773" ] }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermLinesOfCredit", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of borrowing under credit agreements", "label": "Repayments of Long-Term Lines of Credit", "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r42" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r257", "r258", "r411", "r437", "r625", "r827", "r828" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r131", "r513", "r1045" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r883", "r894", "r904", "r929" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r884", "r895", "r905", "r930" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r891", "r902", "r912", "r937" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashandCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofCashandCashEquivalentsandRestrictedCashDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r964", "r980", "r1046", "r1049" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based awards and other", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r49" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r138", "r177", "r655", "r686", "r691", "r697", "r727", "r864" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r207", "r260", "r261", "r262", "r265", "r272", "r274", "r351", "r357", "r509", "r510", "r511", "r521", "r522", "r551", "r553", "r554", "r557", "r567", "r682", "r684", "r704", "r1057" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues, net", "verboseLabel": "Revenues, net", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r302", "r303", "r320", "r325", "r326", "r332", "r334", "r336", "r458", "r459", "r633" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCustomerConcentrationRiskDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from contract with customer", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r336", "r960" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r204", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r819" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITION" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE RECOGNITION", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r204", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r462" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "calculation": { "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails": { "parentTag": "var_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityAndFinanceLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash finance right-of-use assets obtained in exchange for new lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r614", "r863" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails": { "parentTag": "var_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityAndFinanceLeaseLiability", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash operating right-of-use assets obtained in exchange for new lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r614", "r863" ] }, "var_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityAndFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.varex.com/20231229", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityAndFinanceLeaseLiability", "crdr": "debit", "calculation": { "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/LEASESScheduleofOperatingLeaseCostandSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total right-of-use assets obtained in exchange for new lease liabilities", "label": "Right-Of-Use Asset Obtained In Exchange For Operating Lease Liability And Finance Lease Liability", "documentation": "Right-Of-Use Asset Obtained In Exchange For Operating Lease Liability And Finance Lease Liability" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r946" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r946" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario, Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r472", "r987" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Domain]", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r275", "r472", "r956", "r987" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r49" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/BUSINESSCOMBINATIONSScheduleofAssetsAcquiredandLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r79", "r82", "r528" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r79", "r82" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.varex.com/role/BORROWINGSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Instruments", "label": "Schedule of Derivative Instruments [Table Text Block]", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r13", "r100", "r101", "r103", "r105", "r108", "r112", "r115", "r116" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r988" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r76" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.varex.com/role/BUSINESSCOMBINATIONSNarrativeDetails", "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails", "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r344", "r345", "r346" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.varex.com/role/FAIRVALUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r572", "r573" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSIntangibleAssetsDetails", "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r64", "r66", "r634" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r64", "r66" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r836" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r836", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.varex.com/role/INVENTORIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory, Current", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r24", "r142", "r143", "r144" ] }, "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Investment Hedges", "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position." } } }, "auth_ref": [ "r113" ] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Product Warranty Liability", "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": [ "r397" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r126", "r127", "r749", "r750", "r753" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restrictions on Cash and Cash Equivalents", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r21", "r186", "r1049" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r58", "r59", "r60", "r61" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.varex.com/role/SEGMENTINFORMATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r58", "r59", "r60", "r61" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r474", "r476", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r14", "r15", "r75" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Customers with a Significant Portion of Revenue", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r50", "r51", "r53", "r54", "r120", "r185" ] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.varex.com/role/BORROWINGSAssetBasedLoanNarrativeDetails", "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails", "http://www.varex.com/role/FAIRVALUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r877" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r879" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r298", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r336", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r390", "r391", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r836", "r963", "r1051" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r334", "r335", "r708", "r712", "r714", "r777", "r781", "r785", "r799", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r820", "r847", "r868", "r1021", "r1051" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.varex.com/role/SEGMENTINFORMATION" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT INFORMATION", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r301", "r313", "r324", "r328", "r329", "r330", "r331", "r332", "r333", "r336" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r314", "r315", "r316", "r317", "r318", "r319", "r334", "r834" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general, and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r155" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSSharebasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Selling, general, and administrative", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "var_SeniorSecuredNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "SeniorSecuredNotesMember", "presentation": [ "http://www.varex.com/role/BORROWINGSScheduleofDebtDetails", "http://www.varex.com/role/BORROWINGSSeniorSecuredNotesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Secured Notes", "label": "Senior Secured Notes [Member]", "documentation": "Senior Secured Notes" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restricted stock units, canceled or expired in period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r495" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units, canceled or expired (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r495" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units, grants in period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r493" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units, grants in period (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r493" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Restricted stock units, nonvested, beginning balance (in shares)", "periodEndLabel": "Restricted stock units, nonvested, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r490", "r491" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number\u00a0of\u00a0Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Restricted stock units, nonvested, beginning of period (in USD per share)", "periodEndLabel": "Restricted stock units, nonvested, end of period (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r490", "r491" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted\u00a0Average Grant-Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Restricted stock units, vested in period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r494" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSRestrictedStockandPerformanceStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units, vested in period (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r494" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r474", "r476", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r484" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, exercisable, weighted average exercise price (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r484" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Canceled, expired or forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r1024" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled, expired or forfeited (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1024" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r486" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options, outstanding, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r74" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning balance (in shares)", "periodEndLabel": "Outstanding, ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r482", "r483" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding beginning balance (in USD per share)", "periodEndLabel": "Options outstanding ending balance (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r482", "r483" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in USD per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r486" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in USD per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r74" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, exercisable, weighted average remaining contractual term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r74" ] }, "var_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.varex.com/20231229", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingPrice", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding at period beginning (in USD per share)", "periodEndLabel": "Outstanding at period ending (in USD per share)", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price", "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Outstanding, Price" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Options, outstanding, weighted average remaining contractual term, (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r178" ] }, "var_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisablePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.varex.com/20231229", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisablePrice", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in USD per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Price" } } }, "auth_ref": [] }, "var_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeituresandExpirationsinPeriodPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.varex.com/20231229", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeituresandExpirationsinPeriodPrice", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canceled, expired or forfeited (in USD per share)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Price" } } }, "auth_ref": [] }, "var_SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsGrantsinPeriodPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.varex.com/20231229", "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsGrantsinPeriodPrice", "presentation": [ "http://www.varex.com/role/EMPLOYEESTOCKPLANSStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in USD per share)", "label": "SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsGrantsinPeriodPrice", "documentation": "SharebasedCompensationArrangementsbySharebasedPaymentAwardOptionsGrantsinPeriodPrice" } } }, "auth_ref": [] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Shares withheld on vesting of restricted stock (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShortMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortMember", "presentation": [ "http://www.varex.com/role/FINANCIALDERIVATIVESANDHEDGINGACTIVITIESScheduleofBalanceSheetHedgesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short", "label": "Short [Member]", "documentation": "Indicates the sale of a borrowed security or written option." } } }, "auth_ref": [] }, "us-gaap_StandardProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyAccrual", "crdr": "credit", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Accrued product warranty, at beginning of period", "periodEndLabel": "Accrued product warranty, at end of period", "label": "Standard Product Warranty Accrual", "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability. Does not include the balance for the extended product warranty liability." } } }, "auth_ref": [ "r1012", "r1015" ] }, "us-gaap_StandardProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyAccrualPayments", "crdr": "debit", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Product warranty expenditures", "label": "Standard Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard product warranty. Excludes extended product warranties." } } }, "auth_ref": [ "r1013" ] }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New accruals charged to cost of revenues", "label": "Standard Product Warranty Accrual, Increase for Warranties Issued", "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties." } } }, "auth_ref": [ "r1014" ] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Product Warranty", "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r1011" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.varex.com/role/GOODWILLANDINTANGIBLEASSETSGoodwillRollforwardDetails", "http://www.varex.com/role/SEGMENTINFORMATIONIncomeStatementInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r210", "r298", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r336", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r380", "r390", "r391", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r836", "r963", "r1051" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r12", "r34", "r207", "r236", "r237", "r238", "r260", "r261", "r262", "r265", "r272", "r274", "r296", "r351", "r357", "r439", "r509", "r510", "r511", "r521", "r522", "r551", "r552", "r553", "r554", "r555", "r557", "r567", "r590", "r591", "r592", "r593", "r594", "r596", "r619", "r682", "r683", "r684", "r704", "r769" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r334", "r335", "r708", "r712", "r714", "r777", "r781", "r785", "r799", "r805", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r820", "r847", "r868", "r1021", "r1051" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r260", "r261", "r262", "r296", "r633", "r693", "r705", "r719", "r720", "r721", "r722", "r723", "r724", "r726", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r743", "r745", "r747", "r748", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r769", "r869" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario [Axis]", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r275", "r472", "r956", "r957", "r987" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r260", "r261", "r262", "r296", "r633", "r693", "r705", "r719", "r720", "r721", "r722", "r723", "r724", "r726", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r743", "r745", "r747", "r748", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r769", "r869" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r886", "r897", "r907", "r932" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued upon vesting of restricted shares (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r12", "r177" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Business acquisitions", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r12", "r34", "r177" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total Varex stockholders' equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r136", "r139", "r140", "r166", "r728", "r744", "r770", "r771", "r864", "r876", "r982", "r994", "r1031", "r1057" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity", "periodStartLabel": "Stockholders' equity, outstanding, beginning balance", "periodEndLabel": "Stockholders' equity, outstanding, ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r93", "r94", "r97", "r207", "r208", "r237", "r260", "r261", "r262", "r265", "r272", "r351", "r357", "r439", "r509", "r510", "r511", "r521", "r522", "r551", "r552", "r553", "r554", "r555", "r557", "r567", "r590", "r591", "r596", "r619", "r683", "r684", "r702", "r728", "r744", "r770", "r771", "r804", "r875", "r982", "r994", "r1031", "r1057" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsPolicyPolicyTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for reporting subsequent events." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierFinanceProgramObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplierFinanceProgramObligation", "crdr": "credit", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSupplierFinanceProgramsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts due for supplier finance program", "label": "Supplier Finance Program, Obligation", "documentation": "Amount of obligation for supplier finance program." } } }, "auth_ref": [ "r381", "r382", "r383", "r384", "r385", "r837" ] }, "var_SupplierFinanceProgramPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.varex.com/20231229", "localname": "SupplierFinanceProgramPolicyTextBlock", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Finance Programs", "label": "Supplier Finance Program [Policy Text Block]", "documentation": "Supplier Finance Program" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r926" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.varex.com/role/NONCONTROLLINGINTERESTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary equity, shares outstanding (in shares)", "label": "Temporary Equity, Shares Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r134" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r918" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r925" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r945" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r947" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.varex.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r948" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r949" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r947" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r947" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r950" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r948" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.varex.com/role/REVENUERECOGNITIONScheduleofDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails", "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government agencies", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r830", "r853", "r1047" ] }, "us-gaap_USGovernmentAgenciesSecuritiesAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesSecuritiesAtCarryingValue", "crdr": "debit", "calculation": { "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofFairValueInputsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government agencies", "label": "US Government Agencies Securities, at Carrying Value", "documentation": "Debt securities issued by a United States government agency such as Government National Mortgage Association (Ginnie Mae), Federal Home Loan Mortgage Corporation (Freddie Mac), and Federal National Mortgage Association (Fannie Mae), which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "us-gaap_USTreasuryBillSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryBillSecuritiesMember", "presentation": [ "http://www.varex.com/role/FAIRVALUEScheduleofBalanceSheetMarketableSecuritiesDetails", "http://www.varex.com/role/FAIRVALUEScheduleofMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury bills", "label": "US Treasury Bill Securities [Member]", "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government." } } }, "auth_ref": [ "r1047" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r944" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r55", "r56", "r57", "r197", "r198", "r200", "r201" ] }, "var_VECImagingGmbHCo.KGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.varex.com/20231229", "localname": "VECImagingGmbHCo.KGMember", "presentation": [ "http://www.varex.com/role/RELATEDPARTYTRANSACTIONSInvestmentinPrivatelyHeldCompaniesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VEC Imaging GmbH & Co. KG", "label": "VEC Imaging GmbH & Co. KG [Member]", "documentation": "VEC Imaging GmbH & Co. KG [Member]" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r866", "r867", "r870", "r871", "r872", "r873" ] }, "var_WarrantyTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.varex.com/20231229", "localname": "WarrantyTerm", "presentation": [ "http://www.varex.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESProductWarrantyDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warranty term", "label": "Warranty Term", "documentation": "Warranty Term" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r278", "r291" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.varex.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "http://www.varex.com/role/NETLOSSINCOMEPERSHAREReconciliationofNumeratorandDenominatorforBasicandDilutedNetIncomePerCommonShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Basic weighted average shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r277", "r291" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "44", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-3" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-4" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "30", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-5" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "30", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-6" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-12" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r187": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r188": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r189": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r190": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r191": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r192": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r193": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r194": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r195": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479468/405-50-50-4" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//410-30/tableOfContent" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480627/815-20-45-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2E" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-9" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-5" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-21" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477128/405-50-55-5" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481899/410-30-55-14" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481899/410-30-55-16" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r953": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r954": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r955": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-8" }, "r956": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r957": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481655/310-20-35-2" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-7" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 102 0001681622-24-000009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001681622-24-000009-xbrl.zip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